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Abstract
Over the past 15 years, a number of prognostic and treatment predictive signatures
for breast cancer have been reported and utilised in the clinic. These signatures, for
most part, are dominated by genes that reflect tumour proliferation, and provide limited
insight into the biological pathways that drive tumour growth. Large gene expression
datasets from primary tumours and well annotated clinical follow-up data have the po-
tential to identify pathways correlated with treatment response and outcome. Rewiring
of cellular metabolism is vital to meet the proliferative demands of tumours. To date,
very little is known about how tumour metabolism influences patient outcome. This
study sought to identify and characterise the metabolic features of tumours which asso-
ciate with survival in breast cancer patients.
Cox regression and gene set enrichment analyses were performed on gene expression
data from 973 breast cancer patients. High expression of a signature comprised of 19
genes involved in fatty acid oxidation (FAO) was correlated with better disease-specific
survival. The prognostic performance of this signature was validated using independent
datasets from breast and several other cancer types. Analysis of the FAO signature
in tumour-normal gene expression data revealed decreased expression in tumours com-
pared to normal counterparts, which was exacerbated in advanced disease, compared to
primary tumour tissues. The FAO signature was downregulated in various models of
EMT induction in cell and organoid systems, independently of proliferation. Addition-
ally, activation of MAPK and Wnt signalling pathways were observed to downregulate
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expression of the FAO signature in gene expression datasets from in vitro and in vivo
systems.
Overexpression of CPT1A in MDA-MB231 breast cancer cells decreased the prolif-
eration and wound healing rates. No significant differences were observed in transwell
migration rates, or colony formation in soft agar between basal and CPT1A overexpress-
ing cells. MCF7 breast cancer cells with CPT1A knockdown did not alter proliferation
rates or colony formation in soft agar, compared to basal expression control. Modulation
of CPT1A expression did not alter oxygen consumption in response to exogenous palmi-
tate. Transcriptome analysis suggested that transcriptional activity of EMT, MAPK
and Wnt pathways was increased in MCF7 cells with CPT1A knockdown suggests a
trend towards increased transcriptional activity of these pathways in this cell system.
In summary, this work suggests that cancer cell proliferation and migration processes
decreases the FAO signature expression, which is associated with poor patient progno-
sis. Alterations in the rate-limiting enzyme of this pathway alters proliferation and
migration rates in MDA-MB231 cells, and increases expression of genes corresponding
to key oncogenic pathways in MCF7 cells. These findings warrant further investigation
of this pathway in breast and other cancer cell types. Understanding of how FAO affects
tumour biology could help advance therapies that modulate this pathway.
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1.1 Clinically significant prognostic and predictive mark-
ers in breast cancer
1.1.1 Prognostic factors
Prognostic factors are defined as features that correlate with the natural course of the
disease, independently of treatment. Therefore, these factors reflect the inherent char-
acteristics of a primary tumour. In breast cancer, established prognostic factors include
nodal status, tumour grade and size, histological subtype, and demographic variables
such as age, menopausal status and ethnicity (Cianfrocca and Goldstein, 2004). It is
worthwhile noting, however, that prognostic and predictive markers are not mutually
exclusive. Some markers such as oestrogen receptor (ER), progesterone receptor (PgR),
and human epidermal growth factor receptor 2 (HER2), provide both prognostic and
predictive information (Taneja et al., 2010). Selected clinical prognostic factors are
briefly mentioned below.
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1.1.1.1 Axillary lymph node status
In primary breast cancer, axillary lymph node involvement is the most powerful prog-
nostic factor (Jatoi et al., 1999). Cancer cells detected in axillary lymph nodes indicate
disseminated disease. Additionally, removal of involved nodes has little impact on sur-
vival, which supports node involvement as an established surrogate of advanced disease
(Jatoi et al., 1999). A strong, linear relationship exists between outcome and the num-
ber of nodes involved (Hilsenbeck et al., 1998). The disease-free- and overall survival
decreases with each additional node involved. The 5-year relapse-free survival for pa-
tients with no tumour cells in the lymph node or node-negative is 80% (Hilsenbeck
et al., 1998). The relapse-free survival decreases to approximately 75% when 1-3 nodes
are involved; 55% with 4-9 nodes involved and 30% when 10 or more nodes are positive
(Cianfrocca and Goldstein, 2004).
1.1.1.2 Tumour size
Tumour size is another important prognostic factor, especially in node-negative patients
(Cianfrocca and Goldstein, 2004). As with node involvement, there is a direct relation-
ship between tumour size and outcome. Patients with tumours less than 1 cm had an
overall survival of nearly 99%(Rosen et al., 1993). This figure drops to 89% for tumours
1-3 cm in size, and 86% for tumour sizes between 3 to 5 cm. For node-negative patients,
tumour size is the most powerful prognostic factor (Cianfrocca and Goldstein, 2004).
Data from large studies have shown that tumours less than 1 cm in size in node-negative
patients have a 20 year relapse-free survival of 90%, compared to approximately 72%
for tumours more than 1-2 cm in size (Rosen et al., 1989). Futhermore, there is an
inverse correlation between tumour size and median time to metastasis (Rosen et al.,
1993; Koscielny et al., 1984; Carter, Allen, and Henson, 1989).
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1.1.1.3 Histologic and nuclear grade
Several histological features of primary breast tumours have been associated with risk
for distant relapse (Bloom and Richardson, 1957). However, histologic grading is sub-
ject to interobserver variability and lack of agreement, and therefore, has been criticised
for poor reproducibility (Gilchrist et al., 1985). Additionally, several systems for de-
termining the tumour grade exists, which may further confound the reliability of this
feature as a prognostic factor. Nonetheless, when conducted in a centralised institution
by experienced pathologists, the tumour grade has a strong relationship with clinical
outcome (Contesso et al., 1987).
The two most common methods of tumour grading are the Scarff-Bloom-Richardson
classification and Fishers nuclear grading system (Bloom and Richardson, 1957). The
Scarff-Bloom-Richardson method considers three features of the tumour; (i) degree of
differentiation, (ii) pleomorphism and (iii) mitotic index. Differentiation assesses the
extent of similarity of the tumour to normal, differentiated features such tubular, glan-
dular and papillary formations. Pleomorphism assesses the shape and size of the cell
and nuclei. Mitotic index measures the number of mitosis per high power field, and is an
indication of the proliferation rate of the tumour. Each of these components are given
a score of 1-3, and finally categorised as grades 1, 2 or 3. With increasing grade, the
tumours are less differentiated, have less consistent cell morphology and more distorted
nuclei structures such as multi-nucleated and aneuploid chromosomes; and have higher
rates of proliferation. A study by Doussal et. al. found a positive correlation between




1.1.2.1 Oestrogen receptor as a prognostic and treatment predictive marker
The oestrogen receptor (ER) exists as two isoforms - ER alpha (ERα) and ER beta
(ERβ) - each encoded by different genes (Kumar et al., 2011). Both isoforms medi-
ate the physiological effects of oestrogen and have different tissue-specific distribution
(Gustafsson, 1999). ERα and ERβ reside mainly in the cytoplasm, where they are both
sequestered in an inactive state. In this thesis, ER will be mentioned and discussed in
the context of ERα.
Patients with ER-positive tumour have a better disease-free survival compared with ER-
negative patients, particularly over shorter period of time post-diagnosis (Hilsenbeck et
al., 1998). The prognostic advantage of ER gradually diminishes with increasing follow-
up period. This time-dependent effect suggests that ER expression is associated with
slower proliferation, rather than the metastatic potential of a tumour.
A large meta-analysis by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
that included approximately 70,000 women from at least 56 randomised trials conclu-
sively proved that ER status is a significant predictor of benefit for 5 years of treatment
with the anti-oestrogen tamoxifen (EBCTCGb, 2005). The annual recurrence risk and
death was significantly lower for ER-positive compared to ER-negative disease. The
degree of benefit from tamoxifen is directly correlated to the ER levels of the tumour.
Patients with tumours with ER levels of >100 fmol/mg protein have a much-lowered re-
currence rate from 5 years of tamoxifen compared to patients with lower ER levels. This
is supported by the NSABP-14 biomarker trial that found quantitative measurement of
ER by quantitative polymerase chain reaction to be predictive of tamoxifen benefit.
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Up to 60% of ER-positive tumours respond to endocrine therapy, whereas only 10% of
ER-negative benefit from the same treatment (Ellis et al., 2001). In the latter case, it
is possible that assays for ER expression yielded false-negatives, or some level of het-
erogeneity in ER expression is present within the tumour. Additionally, the extent of
benefit from endocrine therapy is positively correlated with of ER expression (Dowsett et
al., 2008). Tumours with high ER expression benefit the most from treatment, whereas
tumours with low ER expression have a poorer response to endocrine therapy, possibly
due to the activation of alternative signalling pathways.
There is evidence to suggest that breast cancer patients with ER/PgR-positive tumours
benefit less from various chemotherapy regimes (Henry and Hayes, 2007). Furthermore,
studies that show benefit from chemotherapy regardless of ER status may be confounded
by the ovary ablating effects of chemotherapy. For instance, in a trial that compared
taxotere, adriamycin and cyclophosphamide (TAC) versus a 5-fluorouracil, adriamycin
and cyclophosphamide combination, TAC was interpreted as being superior regardless
of ER status (Martin et al., 2005). However, more than half of the patients were pre-
menopausal and a greater incidence of chemotherapy-induced amenorrhea was reported
in the TAC arm. Therefore, the beneficial effect observed in TAC-treated patients may
be due to the indirect endocrine therapy. This effect of ER on chemotherapy response
is supported by data from neoadjuvant trials. Pathological complete response, where
no residual tumour can be visualised by imaging after a short course of treatment, was
more commonly achieved in ER-negative (20%) compared to ER-positive (5%) tumours
(Mazouni et al., 2007).
1.2 Pharmacotherapy of ER-positive breast tumours
Approximately 70-80% of breast cancers are ER-positive, and therefore depend on oe-
strogen for tumour growth and survival. Surgery is the main intervention to remove
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the primary, localised tumour. Additionally, pre-menopausal women may have an
ovariectomy while post-menopausal women may undergo adrenalectomy (Johnston and
Dowsett, 2003). These procedures surgically deplete the body of oestrogen, and there-
fore, block the growth of the hormone-sensitive breast tumour.
Pharmacologically, the dependence of ER-positive tumours is targeted by two main
mechanisms; (i) antagonism of ER and (ii) depriving ER of its ligand, oestradiol. Two
common drugs utilised to achieve this are tamoxifen - a selective oestrogen receptor
modulator (SERM), and aromatase inhibitors (Fig 1.1).
Figure 1.1: Tamoxifen and aromatase inhibitor inhibit oestrogen signalling
by different mechanisms. Aromatase inhibitors block the aromatisation of testos-
terone or androstenedione precursor, thereby inhibiting oestrogen synthesis, while ta-
moxifen competitively antagonise the ER. Both mechanism result in the decreased ex-
pression of oestrogen-responsive genes, including those involved in proliferation. E2=
oestradiol. Figure adapted from Johnston and Dowsett, 2003.
1.2.1 Tamoxifen
Tamoxifen functions as a SERM due to its selective agonistic and antagonistic nature
that varies between cell types (Grese et al., 1997). The balance between the two func-
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tions depends on molecular events that mediate ER signalling, such as recruitment of
co-activators or co-repressors, and cross-talk with other signalling cascades (Dutertre
and Smith, 2000). The large side chain of another SERM, raloxifene, stabilises helix 12
of ER and maintains the receptor in an inactivated state, incapable of interacting with
co-activators (Brzozowski et al., 1997).
Large, randomised clinical trials have established that 5 years of adjuvant tamoxifen
treatment in early stage breast cancer patients reduces the relative recurrence and mor-
tality rates by 47% and 26% respectively (EBCTCG, 1998). Furthermore, the recurrence
and mortality rates were substantially lower 10 and 15 years after diagnosis respectively
(Davies et al., 2011). Therefore, 5 years of tamoxifen has a carry-over beneficial effect
for at least 10 years post-diagnosis.
1.2.2 Aromatase inhibitor (AI)
To avoid the possible oestrogenic-like activity of SERMs, agents that block the synthe-
sis of oestrogen were developed. Oestrogen is synthesised from the aromatisation of
androgens catalysed by the rate-limiting enzyme aromatase. Aromatase - a member of
the cytochrome (CYP) P450 family of enzymes - first converts androgens into oestrone,
which is then reduced to oestrogen by 17-hydroxysteroid dehydrogenase I. Aromatase
is expressed at high levels in the placenta and granulosa cells of the ovaries, under
the temporal control of gonadotropin stimulation (Johnston and Dowsett, 2003). Af-
ter menopause, non-endocrine tissues such as subcutaneous fat, liver, muscle, brain and
normal breast continue to synthesise residual amounts of oestrogen (Smith and Dowsett,
2003).
AIs can be classified into steroidal or non-steroidal depending on their aromatase bind-
ing site. Steroidal AIs are androstenedione analogues that bind and are converted into
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reactive intermediates that covalently associate with the aromatase active site. In con-
trast, the nitrogen within the triazole of non-steroidal agents bind reversibly to the
heme-center of aromatase, therefore disrupting the catalytic cycle of the enzyme (Kelly
and Buzdar, 2010).
Third generation AIs such as anastrozole, letrozole and exemestane were developed in
the early 1990s. On average, third-generation AIs inhibit at least 97% of aromatase
activity, although a small trial found letrozole to suppress aromatase more than anas-
trozole (Geisler et al., 2002). Several clinical trials in the neoadjuvant and adjuvant
setting have been conducted to assess the efficacy of different AIs or between AIs and
tamoxifen in post-menopausal women.
1.2.2.1 Efficacy of AIs versus tamoxifen
Two large adjuvant trials, Breast International Group (BIG) 1-98 and Arimidex, Tamox-
ifen and in combination (ATAC) compared the efficacy of third generation non-steroidal
AIs, letrozole and anastrozole respectively, against tamoxifen (Thurlimann et al., 2005;
Cuzick et al., 2010). BIG 1-98 had four treatment arms: (1) monotherapy of tamox-
ifen or (2) letrozole; (3) tamoxifen for 2 years followed by 3 years of letrozole; and (4)
letrozole for 3 years followed by tamoxifen for 2 years. The ATAC trial had a simpler
treatment stratification, 5 years of either anastrozole or tamoxifen, and a combination
of both agents for a similar time span.
In BIG 1-98, patients in the letrozole-only treatment arm had a decreased risk for a
disease-free survival (DFS) event as compared to tamoxifen (hazard ratio (HR) 0.82,
p=0.0002). Furthermore, the hazard ratio for secondary endpoints - overall survival,
distant relapse-free interval and disease-free interval - were all consistently lower in the
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letrozole monotherapy group as compared to tamoxifen.
The results of the ATAC trial parallels that of BIG 1-98. Patients in the 5 year anastro-
zole treatment arm exhibited an absolute reduction in recurrence by 2.7% and 4.3% at
5- and 10 years respectively. Furthermore, distant-relapse was also lower in the anastro-
zole group, with an absolute difference of 2.6% at 10 years. As oestrogen is involved in
maintaining bone health, patients on anastrozole had an increased risk for fracture (odds
ratio 1.33, p<0.0001). Additionally, the incidence of endometrial cancer was four times
lower in the anastrozole treated group (odds ratio 0.25, p=0.001). Taken together, the
data from these trials suggest that early-stage ER-positive breast cancer patients that
received AI may gain a modest improvement in remaining disease-free, as compared to
patients that received tamoxifen.
1.2.2.2 Treatment outcome and survival
A meta-analysis by the EBCTCG provided strong evidence for the positive effect of both
endocrine and chemotherapy on survival (EBCTCGb, 2005). However, currently, only
a handful of clinicopathologic factors such as ER/PgR and HER2 status, tumour grade
and node involvement are used to aid treatment decisions and estimate prognosis. Such
factors, however, do not capture the extensive heterogeneity of tumours, which may have
therapeutic implications. For instance, a common treatment regime for node-positive
patients is the combination of anthracycline and taxanes, followed by an endocrine agent
in the case of ER-positive tumours. However, patients that are treatment responsive
may still be administered suboptimal drug doses and receive unnecessary combination
of other toxic agents. As such, with current treatment guidelines, chemotherapy is ad-
ministered to approximately 60% of patients with early-stage breast cancer, from which
only up to 15% may derive benefit, leaving the rest at risk of toxic side effects. These
figures, therefore, suggest an urgent need to identify predictors of response to hormone-
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or chemotherapy that (i) improve outcome by ensuring optimal treatment for a given
patient and (ii) decrease complications from unnecessary exposure of toxic treatments.
1.3 Molecular risk stratification of breast cancer
Meta-analysis of clinical trials that compared tamoxifen to AI treatment for five years
suggests that approximately 20% of women have a recurrence based on 8 year follow-up
data (Dowsett et al., 2010). This suggests a need to identify patients that are likely to
have a poor prognosis when designing, or prior to starting, adjuvant treatment. Molecu-
lar profiling of tumours using high throughput technologies has generated a rich volume
of clinically meaningful data (Cross and Burmester, 2004; Wesolowski and Ramaswamy,
2011). To date, several comprehensive genomic characterisation of tumours including
gene expression-, single nucleotide polymorphism- and copy number profiling, and DNA
sequencing have been performed in several large cancer genomic studies (Koboldt et al.,
2012; Curtis et al., 2012; Gatza et al., 2014).
1.3.1 Genomic technologies and data analysis methods
The general objective of gene expression profiling experiments is to identify genes that
are differentially expressed between different sample groups or subgroups. As this
methodology measures a large number of transcripts per assay, statistical and machine
learning methods have been increasingly utilised to interpret data from this technology.
The more common analysis methods can be divided into unsupervised and supervised
approaches. Unsupervised methods require only the microarray data to discover pat-
terns based on the similarities of gene expression profile between samples. Common
methods in unsupervised analysis include hierarchical clustering, k-means clustering,
self-organising maps, singular value decomposition and principal component analysis.
Supervised methods, on the other hand, attempts to identify patterns or relationships
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in the data based on pre-defined labels applied. Most of the early microarray-based
studies performed on primary breast tumours utilised either approach, and the focus
of these studies were to derive treatment predictive or prognostic molecular features to
facilitate assessment of disease outcome independently of traditional clinico-pathological
parameters (Symmans et al., 2010; Liedtke et al., 2009; Hatzis et al., 2011; Vijver et al.,
2002; Goncalves and Bose, 2013).
1.3.1.1 Molecular intrinsic subtyping of breast tumours
Perhaps the most enduring progress made from the early days of breast tumour molecu-
lar profiling is based on work by Perou et. al. (Perou et al., 2000). Using an array-based
and hierarchical clustering approach, the authors identified four molecular subtypes of
breast cancers: luminal, HER2-enriched, basal-like and normal - each with distinct prog-
nosis. This work was then followed up by another study from the same group (Sorlie
et al., 2001). Subsequently, Parker et. al. developed a 50-gene (PAM50) risk-of-relapse
model based on the molecular subtypes defined by Perou et. al. (Parker et al., 2009).
These intrinsic subtypes were also reproduced more recently in a comprehensive se-
quencing effort by The Cancer Genome Atlas (Koboldt et al., 2012), and features of the
various subtypes are briefly described below.
1.3.1.1.1 Luminal A Luminal tumours can be subclassified into luminal A and lu-
minal B. Luminal A is the most prevalent subtype, representing up to 60% of all breast
cancers. Tumours of this subtype express low levels of proliferation genes and high lev-
els of GATA3, a transcription factor involved in regulating luminal cell differentiation
in the mammary gland. Using immunohistochemistry, luminal A tumours are charac-
terised by the expression of ER, PgR, Bcl-2, and cytokeratins CK8 and CK18 (Eroles
et al., 2012). Luminal A tumours also have a lower proliferation rate as compared to
luminal B, which is reflected in lower levels of the cell division marker Ki67. Patients
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of this subtype have a good prognosis, with a relapse rate of slightly over 25%, which
is significantly lower compared to other subtypes (Kennecke et al., 2010). Furthermore,
with a median survival period of 2.2 years from the time of relapse, luminal A subtype
patients generally survive longer following relapse relative to other subtypes. Of clinical
significance, luminal A tumours have a higher tendency (19%) to metastasise to the
bones as compared to other anatomic locales such as the brain, lung and liver (2-, 7-
and 8% respectively) (Kennecke et al., 2010).
1.3.1.1.2 Luminal B Luminal B tumours represent between 10 to 20% of breast
cancers, and are more aggressive than luminal A. Luminal B tumours present with a
higher histological grade and proliferation rate, which may explain the poor prognosis of
this subtype. In addition to increased expression of proliferation genes such as cyclin B
and Ki67, luminal B tumours may also express growth factor receptors such as the epi-
dermal growth factor receptor (EGFR) and HER2. This presents alternative signalling
pathways, apart from oestrogen signalling to trigger cell growth and division.
1.3.1.1.3 HER2-enriched Approximately one-fifth of breast cancer cases are pos-
itive for HER2 expression. Amplification of the gene - which codes for the HER2
protein - and overexpression of its associated amplicon are common features of this
subtype (Koboldt et al., 2012). HER2-positive tumours are highly proliferative, with
three-quarter of cases presenting with high histological grade and a substantial number
of cases harbour mutations in TP53. HER2-positive patients have a bleak prognosis,
but the development of anti-HER2 therapies have substantially improved the outcome
of women in this subtype (Dawood et al., 2010). Additionally, due to the high prolif-
erative nature of HER2-positive tumours, 43% of patients have a complete response to
chemotherapy, which is higher than that of luminal subtype patients.
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1.3.1.1.4 Basal-like Basal-like tumours generally do not express ER, PgR or HER2,
and therefore, are referred to as triple-negative. However, three-quarters of tumour de-
fined as basal-like by intrinsic subtyping are clinically triple-negative while the remainder
comprise of other molecular subtypes. Clinical characteristics of basal-like tumours in-
clude earlier age onset, a larger tumour size and, higher grade and node positive disease
(Bosch et al., 2010). Basal-like tumours display high frequency of TP53 mutations, in
agreement with pathway analysis which revealed loss of TP53 in almost all basal-like
cases. Furthermore, loss of function in other genes involved in maintaining genome in-
tegrity such as RB1 and BRCA1 are common features of this subtype (Herschkowitz et
al., 2008; Turner and Reis-Filho, 2006). PIK3CA, while commonly mutated, was para-
doxically observed to have the highest pathway activity among all subtypes (Koboldt
et al., 2012). Some possibilities that may account for this increased PIK3CA activity
include loss of function in the phosphatases PTEN and INPP4B, which negatively reg-
ulate this pathway.
1.3.1.2 Integrative clustering based molecular stratification of breast cancer
The intrinsic subtype/PAM50-based classification is based primarily on the gene ex-
pression profile of a particular tumour. Recently, a collaborative effort by the Molecular
Taxonomy of Breast Cancer International Consortium (METABRIC) analysed the copy
number abberations, single nucleotide variants, and gene expression profiles from over
2000 primary breast tumours, and proposed an alternative molecular classification sys-
tem (Curtis et al., 2012). This study identified ten integrative clusters, based on the
genomic and transcriptomic correlates of tumours. The features of each cluster are suc-
cinctly summarised by Dawson et. al. (Dawson et al., 2013). Clusters 2, 5 and 10 were
associated with poor prognosis (Fig 1.2). These clusters had intermediate to high ge-
nomic instability, different copy number aberrations such as amplifications in 11q13/14,
8q gain, and HER2 amplification, and patients diagnosed younger with higher grade
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and large tumours, and lymph-node positive disease. Clusters with good prognosis in-
cluded tumours from patients that were older at diagnosis, low grade tumours and low
genomic instability, and negligible to low copy number aberrations, compared to the
poor prognosis clusters.
.
Figure 1.2: Multi-platform molecular risk stratification of breast cancer pa-
tients . Kaplan-Meier survival curve of patients in different integrative cluster as defined
by the METABRIC investigators. Clusters 2 (green line), 5 (brown line) and 10 (dark
purple line) have poorer disease-specific survival compared to other clusters. Patients
in cluster 10 exhibit poor outcome at earlier time points, but otherwise remain event-
free after approximately 60-70 months, which suggests time-dependency in this cluster.
Figure adapted from Curtis et al., 2012
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1.3.2 Commercially-available prognostic signatures
Several of the gene expression studies conducted earlier have resulted in prognostic
signatures that are commercially available and utilised in the clinic to determine the
prognosis and tailoring adjuvant treatment to each patient.
1.3.2.1 Oncotype DX
This signature comprises of 16 classifier and 5 reference genes from which a recurrence
score is derived that categorises patients into three groups: low (<18), intermediate
(18-30), and high (>31). This signature comprises of proliferation and invasion asso-
ciated genes, as well as genes correlated with oestrogen signalling and HER2 expres-
sion. Retrospective analysis of samples from the National Surgical Adjuvant Breast
and Bowel Project B-14 (NSABP-14) trial, in which ER-positive, node-negative pa-
tients were treated with tamoxifen, demonstrated a significant difference between low
and high risk for distant recurrence at 10 years (6.5% vs 30.5% respectively; p <0.001)
(Paik et al., 2004).
This Oncotype DX signature is also predictive of benefit from adjuvant chemotherapy
based on retrospective analysis of the NSABP B-20 and Southwest Oncology Group
8814 trials (Albain et al., 2010). High-risk patients derived more benefit from the com-
bination of chemotherapy with tamoxifen, compared to low-risk patients (HR 0.26, 95%
confidence interval 0.13-0.53) (Paik et al., 2006). Therefore, the Oncotype DX can




The PAM50-based signature Prosigna, which has been approved by the United States
Federal Drug Agency (FDA), is based on the expression levels of 50 classifier genes,
and categorises patients into one of four intrinsic subtypes with associated prognostic
significance (Parker et al., 2009). A sub-study from the ATAC trial found the PAM50
risk-of-relapse (ROR) score to be more prognostic than the Oncotype DX recurrence
score (Dowsett et al., 2013). The ROR score could also better stratify patients with an
intermediate recurrence risk as determined by the Oncotype DX assay. This was sup-
ported by the findings of Kelly et. al., whom were able to classify about half of patients
in the intermediate risk group by Oncotype DX into low-risk luminal A subtype using
the PAM50 classifier (Kelly et al., 2012).
1.3.2.3 MammaPrint
Mammaprint, another FDA-approved signature, was developed at the Netherlands Can-
cer Institute in 2002 using tumour samples from relatively young, node-negative breast
cancer patients (Veer et al., 2002). This microarray-based 70-gene assessment assigns pa-
tients as having either a high or low 5-year risk for distant relapse. A validation analysis,
by the same group, was conducted on retrospectively collected samples, which included
both node-negative and node-positive patients. This validation exercise, however, has
been criticised for including 61 patients from the original study and 130 patients that
received either adjuvant chemotherapy or hormonal therapy. Consequently, the result-
ing data would be inaccurate in terms of assessing the prognostic performance of this
signature. Nonetheless, another independent study done in patients that did not receive
systemic therapy confirmed the original findings by Veer et. al. (Vijver et al., 2002;
Wittner et al., 2008).
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1.3.3 Limitations of first-generation molecular signatures
1.3.3.1 Performance of first-generation molecular signatures
While many molecular signatures have been reported in the literature, there is little
overlap of genes that make up these signatures (Haibe-Kains et al., 2008). Prat et.
al. compared the concordance of six signatures in their recurrence prediction perfor-
mance (Prat et al., 2012). All six signatures were strongly prognostic in node-negative
patients. Furthermore, in this patient subset, all of the signatures were also able to
identify patients with very favourable prognosis with 88-96% relapse-free at 5- and 8.5
years post-diagnosis. In contrast, in node-positive patients, the prognostic performance
of most signatures was limited. Moreover, none of the signatures analysed could identify
node-positive patients with 90% distant relapse-free survival following adjuvant tamox-
ifen treatment. If all six signatures had similar prognostic performance, could it be
driven by a common underlying biological process?
1.3.3.2 Proliferation as a key hallmark of prognostic signatures
To investigate the question above, Wirapati et. al. conducted a meta-analysis of pub-
lished prognostic signatures, and demonstrated that proliferation was the driving force
of many prognostic signatures (Wirapati et al., 2008).
First, they mined a large multi-platform gene expression dataset and found 524 genes
that were significantly associated with outcome. Of these, 71% were highly coexpressed
with AURKA - a kinase involved in mitosis - while 26% were coexpressed with ESR1
and 2% coexpressed with HER2. Therefore, these findings suggest that in their dataset,
most genes associated with outcome were correlated with proliferation. Additionally,
when analysing individual signatures, the authors found that many of the genes were
also strongly correlated with proliferation, but not with ESR1 and HER2. Furthermore,
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when the signatures were divided into proliferative and non-proliferative constituents,
overall prognostic performance was not affected using only proliferation-associated genes.
In contrast, when only non-proliferation genes were applied, the prognostic performance
of the signatures decreased. These findings were supported by the work of Desmedt et.
al., who demonstrated proliferation to be the strongest prognostic factor in ER+/HER2-
tumours (Desmedt et al., 2008). Taken together, these findings suggests that most of
the prognostic performance of molecular signatures are driven by genes involved in pro-
liferation.
In a seminal study by Venet et. al., the authors demonstrated that adjusting for the
proliferating cell nuclear antigen (PCNA) metagene - which comprises of the top 1%
of genes positively correlated with PCNA in 47 published signatures - resulted in a
dramatic drop in association with outcome in multiple breast cancer datasets (Venet,
Dumont, and Detours, 2011). This study also reported that several signatures of no
biological significance in breast cancer, such as a signature associated with social defeat
in mice, had significant prognostic performance. Taken together, the implications of the
findings from Wirapati et. al., Desmedt et. al. and Venet et. al. are threefold; (i) many
signatures invariably contain proliferation-associated genes; (ii) established signatures
may consist of genes that weaken their prognostic performance; and (iii) random signa-
tures, by virtue of correlation with proliferation, may be significantly associated with
outcome in breast cancer patients.
1.3.3.3 Biology-driven signatures
Another critical shortcoming of first-generation gene signatures is that they are not in-
formative with regards to the pathways and processes driving the disease (Yao et al.,
2012). As mentioned above, proliferation/cell-cycle associated genes are components of
many signatures. Since proliferation is strongly prognostic in ER-positive, but not ER-
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negative disease, many of these signatures are therefore prognostic only in ER-positive
tumours (Weigelt and Reis-Filho, 2009). However, is it surprising that many published
gene signatures from tumours identify features that are correlated with proliferation?
The more pertinent question should be: can one identify pathway enrichments in these
features that could be targeted clinically?
There are two implications for biology-driven signatures. Firstly, it extends the cur-
rent appreciation of tumour biology by identifying clinically significant networks that
have yet to be reported. Secondly, pathways corresponding to these biology-driven sig-
natures may then be targeted for with approved drugs, or initiate the development of
novel agents that could improve patient prognosis.
1.4 Metabolic reprogramming as a key feature in cancer
biology
The transformation of a cell from one that complies with homeostatic decrees to a rogue
entity involve alterations in cellular processes, including metabolism. Indeed, in a follow
up to their first perspective, Hanahan and Weinberg considered altered cellular energet-
ics as an emerging hallmark of cancer (Hanahan and Weinberg, 2011). The nomination
of altered metabolism as a tenet of cancer biology is not unexpected, as proliferating
cells require energy and biomass to synthesise DNA, proteins and lipids. Cultures of
mouse fibroblast cells revealed that the energetic requirements for the genesis of a new
cell is approximately 50% higher (assuming glucose as the primary substrate) than that
required for homeostatic needs (Kilburn, Lilly, and Webb, 1969). What this suggests,
then, is that the accumulation of biomass to synthesise an entire daughter cell - or the
doubling of one cell - is more likely to be limiting than the energetic status per se. But
how are these lofty energetic and anabolic requirements met by a proliferating cell? How
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do oncogenic and tumour suppressive pathways orchestrate these metabolic rewiring to
influence disease progression and prognosis? The sections below introduces the early
in-roads made in cancer metabolism in the early-mid 20th century, and then review the
questions above in light of the literature.
1.4.1 A brief history of cancer metabolism
Altered cellular energetics is an emerging hallmark of cancer. Tumours - a perverse,
corporeal microcosm of its host - are highly dependent on internal and external sources
of nutrients to fuel their rampant growth. The insatiable proliferation of cancer cells de-
mands adequate supply of molecules to meet energetic, anabolic and redox requirements.
This link between proliferation and enhanced glycolysis in cancer was first observed by
a German physiologist by the name of Otto Warburg, who noticed that rat liver cancer
cells do not take up more oxygen than normal liver tissue, but instead, produce lactic
acid in the presence of oxygen (Koppenol et al., 2011). This somewhat contradicts the
Pasteur effect, which states that cells stop fermenting in the presence of oxygen. The
increased lactic acid generation was also observed in throat, intestine, skin, penis and
nose carcinomas (Koppenol et al., 2011). Seigo Minami, an academic guest at Warburg’s
Kaiser Wilhelm Institute, observed that while the respiration of rat liver carcinoma cells
was approximately one-fifth less than normal tissues, the cancer cells metabolised glucose
an order of magnitude higher than could be accounted for by mitochondrial respiration
(Minami, 1923). Warburg followed up Minami’s finding by showing that cancer cells
produce 100 fold more lactic acid than normal tissues (Koppenol et al., 2011).
Cori and Cori reported that in vivo, the levels of lactic acid produced by mouse and
rat tumours were substantially lower than those reported by Warburg (Koppenol et al.,
2011). Venous blood exiting a Rous sarcoma tumour implanted in one wing of a chicken
had higher lactic acid and lower glucose concentrations, compared to venous blood of
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the other normal wing (Koppenol et al., 2011). This is likely explained by removal of
the lactic acid by fresh blood supply to the tumour. Furthermore, Warburg and col-
leagues also showed that in venous blood of sarcoma transplanted into the stomach,
the concentration of glucose was up to 70% lower compared to arterial blood supply
the tumour (Koppenol et al., 2011). In contrast, the glucose concentration from the
veins of the control organs was 18% lower than the arterial blood. Additionally, lactic
acid concentrations between arterial and venous blood from the tumour suggests that
approximately two-thirds of glucose is metabolised to lactic acid. Taken together, these
findings strongly suggests increased consumption of glucose by the tumour, compared
to normal tissues.
If oxygen was not able to suppress lactic acid production and promote respiration in
cancer cells, does that indicate some form of mitochondrial dysfunction in these cells?
Indeed, Warburg reasoned that impaired or defective mitochondrial function caused the
increased glycosis and lactic acid generation in tumours (Koppenol et al., 2011). This
was rebutted by Sidney Weinhouse, who demonstrated, alongside work from Chance
et. al., that cancer had normal functioning mitochondria, and are not the root of the
enhanced lactic acid generation (Weinhouse, 1956, Koppenol et al., 2011). Even if Wein-
house was right then, as we know he is to a large extent today, Weinhouse had a minor
hurdle to overcome: he was up against the reputation of a Nobel Prize winner in Warburg
(ironically awarded for the discovery of cytochrome c oxidase, an essential component
of mitochondrial respiration), and some of Warburg’s contemporaries, including Dean
Burke, one of the duo that derived the Lineweaver-Burke equation to study enzyme
kinetics.
Studies conducted over the past 50-60 years have contributed a body of knowledge of
cancer cell metabolism, and the sections below will review key metabolic pathways im-
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plicated in disease initiation and progression.
1.4.2 Why do cancer cells have a sweet tooth?
As mentioned earlier, cancer cells have high glucose consumption. However, the metabolism
of glucose is an inefficient source of ATP (two molecules of ATP per molecule of glu-
cose), compared to the complete mitochondrial oxidation of pyruvate, which generates
36 molecules of ATP. Surely, then, this would be a bottleneck for rapid cell doubling?
Rather, computational modelling by Pfeiffer et. al. suggests that assuming the supply
of glucose - the most abundant nutrient in the human circulation - is not limited, then
high rates of glycolysis is sufficient for a thriving cellular population (Pfeiffer, Schuster,
and Bonhoeffer, 2001; Hay, 2016). If this is so, what other purpose could increased
glycolytic flux serve for a proliferating cell?
1.4.2.1 Glycolysis is not the main source of ATP during proliferation
Glycolysis is not the major producer of ATP in the majority of cancer cells - oxygen
consumption (surrogate of oxidative ATP production) and lactate secretion (surrogate
of glycolytic ATP production) analysis in a panel of cancer cell lines and tumour tis-
sues indicate that on average, 17% of ATP is derived from glycolysis (Zu and Guppy,
2004). Furthermore, estimates suggest that ATP is not likely to be limiting for macro-
molecule synthesis to generate a new cell (Kilburn, Lilly, and Webb, 1969). In fact,
ATP consumption is vital for key rate-limiting glycolytic reactions that are inhibited
by a high ATP:ADP ratio (Lunt and Vander Heiden, 2011). For example, phosphofruc-
tokinase catalyses a committed step in glycolysis, and is sensitive to the ATP:ADP ratio.
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1.4.2.2 Glycolytic intermediates are important building blocks of macro-
molecules
Proliferating cells require precursors to synthesise macromolecules such as nucleotides
and different lipid species. An overview of this pathway is provided in Fig 1.3. Each
pyrimidine and purine nucleotide comprises 9 and 10 carbon atoms respectively, half of
which are derived from a downstream intermediate of ribose-5-phosphate (R5P). R5P
is generated from glucose-6-phosphate through the non-oxidative arm, or through the
oxidative arm via fructose-6-phosphate or glyceraldehyde-3-phosphate of the pentose
phosphate pathway. In mouse lymphocytes stimulated with mitogen, an exponential
increase in lactate was observed 50 hours post-stimulation, and the decrease in lactate
release mirrored the decreased thymidine incorporation into DNA (Wang, Marquardt,
and Foker, 1976). In support of this finding, increasing glucose concentration in rat
thymocytes stimulated with mitogen also resulted in enhanced thymidine incorporation
(Hume et al., 1978). Additionally, activity of glycolytic enzymes, lactate acid generation
and DNA synthesis peaked during the S phase of the cell cycle (Marjanovic, Wielburski,
and Nelson, 1988). Taken together, these findings suggest an important role for glycol-
ysis is to generate nucleotides required for DNA replication.
Glycolysis also generates important precursors for various lipid species required for cel-
lular growth (Fig 1.3). Levels of glycerol and glycerol-3-phosphate (G3P) were increased
in human peripheral lymphocytes in response to mitogen stimulation (Lunt and Van-
der Heiden, 2011). Dihydroxyacetone phosphate (DHAP) - the product from the fourth
glycolytic reaction and a precursor of glycerol-3-phosphate - is necessary for the biosyn-
thesis of phospholipids and triacylglycerol, which are important structural lipids in cell
membranes (Lunt and Vander Heiden, 2011). DHAP is also a precursor for cardi-
olipin, a component of mitochondrial membrane. Another glycolytic intermediate -
3-phosphoglycerate - is the precursor for sphingolipids, which serve as membrane com-
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Figure 1.3: Brief schematic of glycolysis, glutamine oxidation and fatty acid
synthesis pathways. Substrates for the pathways are indicated in red (glycolysis),
navy blue (glutamine oxidation) and brown (fatty acid synthesis) and pathways that
various intermediates can feed into are indicated in blue. Enzymes catalysing each
reaction are italicised. Figure adapted from Hay, 2016,Altman, Stine, and Dang, 2016,
and Rohrig and Schulze, 2016.
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ponents and in cell signalling (Lunt and Vander Heiden, 2011).
Amino acids constitute a large proportion of cell mass in a proliferating cell, and there-
fore, would be in large demand prior to cell division (Hosios et al., 2016). Synthesis of
some non-essential amino acids uses glycolytic precursors. 3-phosphoglycerate provides
carbons required for cysteine, glycine and serine synthesis, while pyruvate supplies ala-
nine synthesis. Apart from cell mass requirements, serine is also essential in folic acid
metabolism, NADPH generation, phosphatidylserine synthesis and is the precursor of
ethanolamine, and choline, as well as other phospholipid head group molecules (Yang
and Vousden, 2016).
1.4.3 Glutamine metabolism
The second most commonly consumed substrate in proliferating cells is the amino acid
glutamine (DeBerardinis and Cheng, 2010) (Fig 1.3, highlighted in brown). Glutamine
is the most abundant non-essential amino acid and constitutes approximately one-fifth
of free amino acids in the human circulation, and 40% in muscle (Mayers and Vander
Heiden, 2015; Bergstrom et al., 1974). As such, glutamine can be a convenient source
of carbon and nitrogen atoms to meet the energetics and biosynthetic needs for prolifer-
ating and cancer cells. Glutamine is transported into cells via the SLC1A5 transporter,
and is converted by mitochondrial glutaminase into glutamate and an ammonium ion.
There are two isoforms of glutaminase: the kidney type (GLS) and liver-type (GLS2).
GLS is expressed in a broader range of tissues and is more relevant in several cancers,
compared to GLS2, whose expression is restricted to the liver, brain, pituitary gland and
pancreas (Ardlie et al., 2015). The GLS mRNA can be alternatively spliced to generate
glutamine C (GAC) or kidney-type glutaminase (KGA) isoforms. The expression and
activity of GAC is higher than KGA, and is increased in several cancer types, which
suggests that alternative splicing may be essential in the higher glutamine metabolism
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observed in cancer cells (Heuvel et al., 2012; Jacque et al., 2015).
1.4.3.1 Contribution of glutamine to cancer cell physiology
Why are many cancers dependent on glutamine? Several lines of evidence suggest that
glutamine provides precursors for a wide variety of metabolites required for cell division
(Yang, Venneti, and Nagrath, 2017). The nitrogen derived from converting glutamate
to alpha-ketoglutarate can be used to synthesise amino acids such as proline, alanine
and aspartate. In vitro, tracer analysis suggests that at least 50% of non-essential amino
acids used for protein synthesis can be derived from glutamine (Alberghina and Gaglio,
2014).
Since most of the pyruvate from glycolysis is converted to lactate, this decreases the
fraction of citrate generated from acetyl CoA via pyruvate dehydrogenase. Glutamine
metabolism can provide an alternative source of citrate via reductive carboxylation of
alpha-ketoglutarate to citrate (Metallo et al., 2011). The citrate molecule is then ex-
ported out of the mitochondria into the cytosol, where it is cleaved to generate acetyl
CoA as a precursor for lipid synthesis, and oxaloacetate. This reaction is particularly
prevalent in hypoxic cancer cells, or in tumours with constitutive hypoxia inducible fac-
tor (HIF) 1A activity (Gameiro et al., 2013; Wise et al., 2011; Metallo et al., 2011).
The de novo synthesis of nucleotides also utilises nitrogen atoms from glutamine. Can-
cer cells that are deprived of glutamine undergo cell cycle arrest which can be rescued
by exogenous nucleotides, but not citric acid cycle intermediates such as oxaloacetate
(Gaglio et al., 2009). Furthermore, aspartate derived from transamination of glutamate
is an important carbon source for purine and pyrimidine synthesis, and aspartate sup-
plementation can rescue cell cycle arrest due to glutamine deprivation (Patel et al., 2016;
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Sullivan et al., 2015; Birsoy et al., 2015).
1.4.4 Fatty acid metabolism
Rapid cell division in cancer cells requires fatty acids for synthesis of organelle and cell
membranes, as well as generation of lipid signalling molecules. The cell membrane is
composed primarily of phospholipids such as phosphatidylethanolamine, phosphatidyl-
choline, and other lipids including sterols and lysophospholipid. As compared to normal
cells that prefer to utilise exogenous fatty acid, tumours often engage the fatty acid
synthesis pathway and generate lipids de novo (Rohrig and Schulze, 2016).
Fatty acid synthesis is catalysed by a series of enzymes whose expression is regulated
by the sterol response element binding protein (SREBP) family of transcription factors
(Horton, 2002) (brief schematic of fatty acid synthesis in Fig 1.3, highlighted in navy
blue). Fatty acid synthesis is a reductive process and requires large amounts of NADPH,
and SREBP regulates expression of genes that regenerate NADPH such as the oxidative
arm of the pentose phosphate pathway, malic enzymes, and isocitrate dehydrogenases
(Shimano et al., 1999; Shechter et al., 2003).
1.4.4.1 What is the role of fatty acid synthesis in cancer cells?
What are the fates of the lipids generated de novo by cancer cells? As mentioned earlier,
proliferating cells require fatty acids for membrane assembly. The enzyme ATP-citrate
lyase (ACLY), cleaves citrate to oxaloacetate and acetyl CoA; the latter being the start-
ing point for fatty acid synthesis (Zaidi, Swinnen, and Smans, 2012). Additionally,
inhibition of ACLY disrupted cell growth of immortalised haemotopoietic stem cells
stimulated with growth factor (Hatzivassiliou et al., 2005).
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Cardiolipins (CL) are structural phospholipids that are primarily localised to the inner
mitochondrial membrane, and regulate mitochondrial respiration and signalling dur-
ing apoptosis induction (Claypool and Koehler, 2012). CLs have four acyl chains that
are constantly remodelled through the activity of phospholipases and acyltransferases,
and hence are sensitive to alterations in cellular fatty acid composition (Chicco and
Sparagna, 2007). The function of CL in the inner mitochondrial membrane, in partic-
ular, to bind cytochrome c - which is involved in electron transfer from complex III to
complex IV - is dependent on the length and saturation of the CL acyl chains (Schug and
Gottlieb, 2009). Hence, alterations in fatty acid composition can directly affect cellular
bioenergetics. For example, the CL profile of mouse brain tumours were substantially
different compared to normal tissue, and was correlated with impaired activity of en-
zymes involved in the electron transport chain (Kiebish et al., 2008).
Some signalling proteins require post-translational modification such as acylation for
their function. Hence, the function of such proteins may be affected by the abundance
and saturation levels of different cellular lipid species. The WNT proteins, which acti-
vate a signalling cascade that is frequently deregulated in cancer, are modified through
attachment of a palmitoleoyl chain (Nile and Hannoush, 2016). Inhibition of the enzyme
that catalyses this reaction - O-acyltransferase porcupine - effectively blocked growth
of cancers that are dependent on WNT (Proffitt et al., 2013; Liu et al., 2013).
Fatty acids are also precursors of lipid signalling molecules, such as sphingosine-1-
phosphate (S1P) and lysophosphatidic acid (LPA), which regulate inflammation, migra-
tion and survival (Wymann and Schneiter, 2008; Pyne and Pyne, 2010). LPA can induce
proliferation, migration, inflammation and angiogenesis via autocrine and paracine sig-
nalling that involves endothelial, immune and cancer cells (Park et al., 2012). Fatty
acids also have a role in synthesis of lipid second messengers such as inositol-1,4,5-
triphosphate and phospatidylinositol triphosphate (Griner and Kazanietz, 2007). These
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signalling lipids are derived from membrane phospholipids, which are actively remod-
elled and synthesised, and hence their composition is strongly correlated with cellular
fatty acid availability.
Activation of de novo fatty acid synthesis shifts the saturation levels of membrane lipids
towards saturated and monounsaturated species, and a reduction of dietary polyun-
saturated species (Hilvo et al., 2011). This serves to protect cells from peroxidation
of polyunsaturated lipids due to ROS generation (Rysman et al., 2010). Nonetheless
lipid peroxidation has a role in the synthesis of eicosanoids such as prostaglandins,
leukotrienes, and thromboxanes, which are derived from polyunsaturated fatty acids.
Eicosanoids have diverse roles in tumourigenesis from modulating inflammation and im-
mune response to remodelling the tumour microenvironment (Wang and Dubois, 2010).
1.4.4.2 Fatty acid oxidation in cancer
Compared to other metabolic pathways such as glycolysis and glutamine metabolism,
the relevance of fatty acid oxidation in cancer is less understood (Carracedo, Cantley,
and Pandolfi, 2013). However, in the past few years, several reports have began to
unravel the role of fatty acid oxidation in different cancers. The subsections below will
briefly introduce the fatty acid oxidation pathway, before mentioning key literature re-
garding this metabolic pathway in cancer.
1.4.4.2.1 Fatty acid uptake and activation Fatty acid oxidation occurs primarily
in the mitochondria, although other it can also occur in the peroxisomes and microsomes.
Several transport and modification of fatty acids are required prior to being oxidised
in the mitochondrial matrix. A brief schematic of this pathway is provided in Fig 1.4.
Cellular uptake of long- and very long chain fatty acids is facilitated by fatty acid trans-
port proteins (FATP). Long chain acyl-CoA synthetase (ACSL) or FATP, which also
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has acyl-CoA synthetase activity, converts fatty acids in acyl-CoA, thereby activating
the fatty acid molecule for oxidation.
Figure 1.4: Key steps in the fatty acid beta oxidation pathway. Upon uptake
into the cell via CD36/FATP, fatty acids are activated to form acyl-CoA in the cytosol.
CPT1 then attaches a carnitine group to acyl-CoA to generate acyl-carnitine, which is
then transported through the intermembrane space into the mitochondrial matrix, where
it is dissociated into acyl-CoA and carnitine by CPT2. Acyl-CoAs are first metabolised
by ACAD with different length specificities (very long chain ACAD (VLCAD) C14-C18;
medium chain ACAD (MCAD) C6-C12; and short chain ACAD (SCAD) C4). The next
step is catalysed by the mitochondrial trifunction protein (MTP) which has hydratase,
hydroxyacyl-CoA-dehydrogenase, and thiolase activity, which generates an acetyl-CoA
molecule and acyl-CoA two carbons shorter after each oxidation cycle. Figure adapted
from Houten and Wanders, 2010.
1.4.4.2.2 Carnitine shuttle While fatty acid oxidation occurs in the mitochondrial
matrix, the mitochondrial membrane, however, is impermeable to acyl-CoAs. The im-
port of acyl-CoA into the mitochondria is facilitated by the carnitine shuttle. Acyl-CoA
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is first converted to acylcarnitine by carnitine palmitoyl transferase 1 (CPT1), located
on the outer mitochondrial membrane. The acylcarnitine molecule is then transported
into the mitochondrial matrix through the mitochondrial intermembrane space. In the
mitochondrial matrix, CPT2 - located in the inner mitochondrial membrane - dissoci-
ates acylcarnitine to acyl-CoA and carnitine molecules again.
1.4.4.2.3 Beta oxidation of acyl-CoA In the mitochondrial matrix, acyl-CoA is
oxidised through a cycle of four reactions to generate acetyl-CoA and the reducing equiv-
alents FADH and NADH. Briefly, in the first reaction, the acyl CoA is dehydrogenated by
acyl CoA dehydrogenase (ACAD) to generate trans-2-enoyl-CoA. The resulting double
bond is then hydrated by enoyl-CoA hydratase, generating 3-hydroxyacyl-CoA, before it
dehydrogenation to yield 3-keto-acyl-CoA. In the final step, thiolytic cleavage of 3-keto-
acyl-CoA generates an acyl-CoA that is shortened by two carbons, and an acetyl-CoA
molecule. The acetyl-CoA then enters the citric acid cycle where it is oxidised further
to generate reducing equivalents, which is eventually oxidised in the electron transport
chain to generate ATP.
1.4.4.3 Fatty acid oxidation in cancer
At the time this thesis was written, analysis of the literature suggests a contentious role
of fatty acid oxidation in cancer (Carracedo, Cantley, and Pandolfi, 2013). In two differ-
ent studies, fatty acid oxidation was found to be important for cancer cell survival, but
in different contexts. Schafer et. al. demonstrated that loss of attachment of MCF10A
mammary epithelial cells resulted in decreased ATP generation due to decreased glu-
cose uptake, as well as generation of reactive oxygen species, which suppressed fatty
acid oxidation (Schafer et al., 2009). Antioxidant supplementation activated fatty acid
oxidation, which resulted in increased ATP generation, without increased glucose up-
take. In breast cancer, Carracedo et. al. demonstrated a role for the putative tumour
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suppressor promyelocytic leukemia (PML) protein in activating fatty acid oxidation via
peroxisome proliferator activated receptor (PPAR) signalling and showed this prevented
anoikis - cell death through loss of attachment (Carracedo et al., 2012). PML expres-
sion was expressed highly in ER-negative breast cancer, and was associated with poorer
patient survival. Hence, the authors concluded that targeting both PML and fatty acid
oxidation in advanced ER-negative tumours may confer clinical benefits in this disease
subset. Treatment of MDA-MB231 breast cancer cell line with unsaturated fatty acid
promoted its proliferation; but saturated fatty acid treatment resulted in apoptotic cell
death. Additionally, cell death was exacerbated when cells were treated etomoxir - a
CPT1A inhibitor - likely due to accumulation of fatty acids. Furthermore, Padanad et.
al. show that KRAS mutant lung cancer promotes the activity of ACSL3, which in-
crease synthesis of acyl-CoA for fatty acid oxidation. Blocking ACSL3 activity resulted
in depletion of ATP and death of lung cancer cells (Padanad et al., 2016).
Metabolomics performed on a mouse model of inducible MYC-overexpression ER-negative
breast tumour found increased levels of fatty acid oxidation intermediates, such as acyl-
carnitines - the product of the rate-limiting step in fatty acid oxidation, compared to
basal MYC expression control (Camarda et al., 2016). Furthermore, the expression
of the majority of genes from a fatty acid metabolism geneset was downregulated in
ER-negative, compared to ER-positive tumours from the TCGA cohort. However, the
expression of PPARGC1A - a key regulator of fatty acid oxidation - was upregulated in
ER-negative, compared to ER-positive tumours. Based on this, the authors concluded
that ER-negative tumours have higher fatty acid oxidation activity, although it was not
entirely evident from their PCG1A immunoblot on a panel of breast cancer cell lines
that expression of this protein correlated with ER status (Camarda et al., 2016).
On the other hand, activation of fatty acid oxidation has been shown to be detrimen-
tal in different cancer cell systems. Treatment of selected lung and breast cancer cell
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lines with pioglitazone - an agonist of the nuclear receptor PPARG - increased fatty
acid oxidation and induced cell cycle arrest (Srivastava et al., 2014). In conducting a
bioinformatics screen, Torrano et. al. reported that increased expression of peroxisome
proliferator gamma coactivator 1A (PGC1A) in prostate tumours was associated with
good prognosis (Torrano et al., 2016). Importantly, overexpression of PGC1A in PC3
prostate cancer cell line increased fatty acid oxidation flux, and decreased the prolifera-
tion rate and colony formation of cells. Taken together, the literature suggests that the
role of fatty acid oxidation in cancer is conflicting, and merits further investigation.
1.4.5 Oncogene and tumour suppressor activity, signalling pathways
and cancer metabolism
Since genetic aberrations drive tumourigenesis, do these mutations also influence the
metabolism necessary to meet the demand of rapidly proliferating cells?
1.4.5.1 Oncogenes and tumour suppressors associated with cancer metabolism
One of the earliest pieces of evidence that oncogenes regulate tumour metabolism was
the observation that the transcription factor MYC activates glycolysis via upregulating
the expression of LDHA and most glycolytic enzymes (Shim et al., 1997; Osthus et al.,
2000). MYC also has a role in the transcriptional activation of genes involved in mito-
chondrial biogenesis and glutamine metabolism (Li et al., 2005; Wise et al., 2008). In line
with its role in supporting the metabolic requirements of cell proliferation, MYC regu-
lates the synthesis of nucleotides and lipids required for cell division (Vazquez, Markert,
and Oltvai, 2011; Morrish et al., 2010).
The PI3K-Akt-mTOR signalling axis is one of the most commonly activated pathways
in cancer (Liu et al., 2009). Increased AKT activity recruits glucose transporters to the
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cell surface, and enhances hexokinase 2 and phosphofructokinase 1, two of the three en-
zymes that catalyse committed steps in glycolysis (Hay, 2016). The negative regulator
of the PI3K pathway - the phosphatase PTEN - also has roles in cancer metabolism.
Loss of PTEN activates glycolysis in leukemia cells, while increased PTEN expression in
mice was found to shift cellular metabolism from glycolysis to mitochondrial respiration
(Tandon et al., 2011; Garcia-Cao et al., 2012). The mammalian target of rapamycin
(mTOR) protein - a serine/threonine kinase downstream component of PI3K signalling
- activates anabolic pathways. mTOR regulates HIF1A and SREBP1 to activate gly-
colysis and the pentose phosphate, and lipid synthesis pathway (Duvel et al., 2010).
The HIF1 and HIF2 complexes are transcription factors that facilitate the molecular re-
sponse to low oxygen conditions (Nakazawa, Keith, and Simon, 2016; Schofield and Rat-
cliffe, 2004). These complexes consist of HIFα and HIF1β subunits, which are stabilised
during hypoxia. Under normal oxygen tension, the HIFα subunits are hydroxylated in
an oxygen-dependent manner, which is recognised by the E3 ligase von Hippel-Lindau
(VHL) for proteosomal degradation (Schofield and Ratcliffe, 2004). In cancer, the HIF
complex can be activated by hypoxia, mutations in VHL, succinate dehydrogenase,
fumarate hydratase, and PI3K signalling (Nakazawa, Keith, and Simon, 2016). Upon
stabilisation, HIF1 transcriptionally activates a retinue of genes, including glucose trans-
porters and the majority of glycolytic enzymes (Schofield and Ratcliffe, 2004). HIF1
also activates the pyruvate dehydrogenase kinase, which phosphorylates and inactivates
the pyruvate dehydrogenase complex, thereby uncoupling glycolysis from mitochondrial
metabolism (Nakazawa, Keith, and Simon, 2016).
1.4.5.2 Wnt and MAPK signalling pathways and cancer metabolism
Two of the most frequently activated oncogenic signalling pathways in cancer are the
mitogen activated protein kinase (MAPK) and the Wnt signalling cascades (Burotto
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et al., 2014; Polakis, 2012).
Adenomatous polyposis coli (APC ) inactivation occurs in approximately 80% of colorec-
tal tumours (Muzny et al., 2012a). APC is a cardinal regulator of the Wnt signalling
pathway by forming a multi-protein complex with Axin, casein kinase 1 and glycogen
synthase kinase-3β to sequentially phosphorylate and ubiquitinate β-catenin for proteo-
somal degradation (Duchartre, Kim, and Kahn, 2016). Furthermore, gain-of-function
mutations in CTNNB1 and TCF4 have been reported in colorectal cancers without
APC inactivation, which suggests a positive selection for Wnt signalling activity in this
tumour type (Fukushima et al., 2001). Activation of Wnt signalling has been shown
to result in the Warburg effect in colorectal cancer cells and osteoblasts (Esen et al.,
2013; Pate et al., 2014). Additionally, expression of monocarboxylate transporter 1,
which catalyses lactate efflux, was decreased in response to dominant-negative lym-
phoid enhancer binding factor 1 (LEF1) expression in two colorectal cancer cell lines
(Sprowl-Tanio et al., 2016).
The RAS-RAF-MEK/ERK signalling axis is frequently activated across several cancers
(Roberts and Der, 2007). This is due to abberant activation of receptor tyrosine kinases
or gain-of-function mutations in downstream components of this pathway. Oncogenic
mutations in the RAS genes are common in several cancers: KRAS mutations occur
in colon, pancreatic and lung cancers; NRAS mutations in melanoma and acute lym-
phoblastic leukaemia; and HRAS mutations have been observed in bladder- and head
and neck cancers (Muzny et al., 2012a; Hammerman et al., 2012; Hodis et al., 2012;
Neri et al., 1988; Guo et al., 2013; Agrawal et al., 2011; Bailey et al., 2016).
Oncogenic mutations in RAS and BRAF can alter cellular metabolism (Gaglio et al.,
2009; Chiaradonna et al., 2006; Ying et al., 2012; Parmenter et al., 2014; Haq et al.,
2013). Mouse fibroblasts transformed with RAS exhibit enhanced glycolysis and glu-
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taminolysis, and culture of the transformed fibroblasts or MDA-MB231 breast cancer
cells in 1 mM glucose dramatically reduced proliferation compared to 25 mM glucose
(Gaglio et al., 2009; Chiaradonna et al., 2006). In pancreatic ductal adenocarcinoma,
KRAS G12D promotes glucose uptake to generate intermediates for the hexosamine
biosynthesis pathway and reducing equivalents for redox homeostasis (Ying et al., 2012).
KRAS mutation in colorectal cancer cell lines and tumour tissues was associated with
increased uptake of aspartate and conversion to asparagine (Toda et al., 2016). This
was achieved via increased asparagine synthetase expression, through KRAS activation
of PI3K-Akt signalling. Treatment of BRAF V600E mutant melanoma cell lines with
vemurafenib decreased glucose uptake and lactate production, and increased oxidative
phosphorylation (Parmenter et al., 2014; Haq et al., 2013).
Staying within the theme of BRAF V600E-induced rewiring of metabolism, vemu-
rafenib treatment of BRAF-mutant melanoma cell lines resulted in increased oxida-
tive metabolism via activation of PGC1A (Haq et al., 2013). Expression of PGC1A,
is in turn, positively regulated by the micropthalmia associated transcription factor
(MITF)(Haq et al., 2013). The transcription factor MITF is pertinent in normal
melanocyte development and melanomagenesis (Garraway et al., 2005). MITF protein
expression is exquisitely regulated, and a rheostat model has been proposed to recon-
cile MITF expression and the multifarious fates associated, ranging from melanoma cell
cycle arrest and senescence (low), invasiveness (low to intermediate) and proliferation
(intermediate) to differentiation of melanocytes (high) (Wellbrock et al., 2008; Goding,
2011). However, the metabolic correlates of different MITF expression levels is poorly
understood.
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1.4.6 Metabolic features associated with epithelial-to-mesenchymal tran-
sition and cellular differentiation
Epithelial-to-mesenchymal transition (EMT) is a transdifferentiation process during
which cancer cells lose cell-to-cell adhesion, adopt a mesenchymal phenotype, and ac-
quire migratory and invasive properties to metastasise (Nieto et al., 2016). In breast
and cervical tumours, acquisition of mesenchymal properties is associated with aggres-
siveness, and disease progression and survival (Imani et al., 2016; Rojas-Puentes et
al., 2016). EMT induction in human mammary epithelial cells induced expression of
stem cell markers, and culture of stem-like mammary cells formed mammospheres, a
property of mammary stem cells, and expressed similar markers of mammary epithelial
cells that have undergone EMT (Mani et al., 2008). Additionally, a subpopulation of
CD44high/CD24low cells - markers of cancer stem cells, albeit controversially - from oral
cancer cell lines not only express stem-related proteins (SOX2, NANOG, OCT4), but
also exhibit EMT characteristics such as decreased expression of CDH1, and increased
expression of VIM (Ghuwalewala et al., 2016).
1.4.6.1 EMT and metabolism
Because of the role of EMT in cancer dissemination, understanding its metabolic alter-
ations during this process may help delay metastasis, and reduce distant recurrence rates.
1.4.6.1.1 Glycolysis and EMT Several enzymes in glycolysis have been impli-
cated in EMT: breast cancer stem cells have increased HK2 expression, and treatment
with 2-deoxyglucose resulted in a dose-dependent inhibition of the stem cells under-
going EMT (Bacci et al., 2016). Overexpression of phosphoglucoisomerase in breast
cancer cells results in EMT via activation of nuclear factor kappa B, increased expres-
sion of several EMT transcription factors and downregulation of miR-200, resulting in
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decreased E-cadherin expression (Ahmad et al., 2011). Upregulation of aldolase A in
lung squamous carcinoma cells induced migration and EMT via decreased E-cadherin
expression and increased vimentin and fibronectin expression, while silencing of enolase
in a non-small cell lung cancer cell line disrupted EMT induction (Du et al., 2014; Fu
et al., 2015). The preferred PKM2 isoform in cancer, and transforming growth factor
beta-induced EMT in the SW480 colorectal cell line resulted in nuclear translocation
of PKM2 to form a complex with homeobox 2, to effect epigenetic changes and down
regulate E-cadherin expression (Hamabe et al., 2014).
In MCF7 cells, overexpression of the transcription factor distal-less homeobox 2 resulted
in increased glycolysis, glutamine metabolism and EMT induction (Lee et al., 2015; Lee
et al., 2016). Genetic or pharmacologic inhibition of GLS1 abrogated EMT induced by
Dlx2 expression, transforming growth factor beta, Wnt3 and Snail1 (Lee et al., 2016).
Furthermore, knockdown of GDH in LoVo and SW480 cells resulted in decreased ex-
pression of ZEB1 and vimentin, while expression of E-cadherin was increased (Liu et al.,
2013).
1.4.6.1.2 Fatty acid metabolism and EMT Substantial effort in characteris-
ing the role of fatty acid metabolism in EMT focused mainly on the anabolic aspect.
Lipidomics performed on DU145 prostate cancer cells treated with tumour necrosis fac-
tor alpha to induce EMT revealed increased fatty acid synthase (FASN) expression and
triacylglycerol synthesis (Dalmau et al., 2015). Further supporting the role of FASN in
EMT, MCF7 cells treated with osthole - which suppresses FASN expression - inhibited
EMT induction (Hung et al., 2011). Overexpression of acyl-CoA synthetase (ACSL)
and stearoyl CoA desaturase (SCD) - enzymes that are involved in priming fatty acid
synthesis and remodelling to unsaturated species, respectively - promoted EMT, while
glycolysis and proliferation was not affected (Sanchez-Martinez et al., 2015a). Acti-
vation of AMPK - a master energy sensor of the cell which promotes catabolic and
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represses anabolic reactions during energetic stress - reversed the EMT phenotype in
response to transgenic expression of ACSL and SCD (Sanchez-Martinez et al., 2015a).
It is worthwhile mentioning that in A549 lung cancer cell line, knockdown of FASN
induced EMT, and TGFβ treatment increased respiration (Jiang et al., 2015). This
suggests that metabolic adaptations during EMT may be dependent on cell type and
genetic background.
What does increased fatty acid synthesis and remodelling during EMT achieve? In a
panel of breast cancer cell lines with knockdown expression of CerS6, which encodes
ceramide synthase isoform 6, affected the fluidity of the cell membrane to promote cell
migration (Edmond et al., 2015). In NMuMG murine mammary gland, HCV29 bladder
cancer and MCF7 cell lines, inhibition of glycosphingolipid synthesis resulted in down
regulation of E-cadherin, and increased expression of N-cadherin, fibronectin and vi-
mentin, as well as adoption of fibroblastic morphology and enhanced motility (Guan,
Handa, and Hakomori, 2009). TGFβ-induced EMT of HCV29 and NMuMG cell lines
also resulted in similar decreases in several glycosphingolipid species. Supplementation
with ganglioside M2 and ceramide Gg4, but not GM1 or GM3 prevented the EMT in-
duction in all three cell lines. Indeed, a recent study by Tisza et. al. showed that
reorganisation of the cell membrane constituents, with a particular involvement of lipid
raft destabilisation (Tisza et al., 2016). This destabilisation was essential to maintain a
stem cell phenotype and relay EMT-related signalling from the cell membrane. Exoge-
nous supplementation with docosahexanoic acid, an omega 3 fatty acid, stabilised the
lipid raft, and reduced migration and mammosphere formation. Taken together, these
data suggest that increased fatty acid anabolism may have a role in providing substrate
for remodelling lipid species to effect EMT.
As compared to fatty acid synthesis, lesser is known with regards to the role of fatty
acid oxidation in EMT. Very recently, metabolomic analysis of the D492 breast epithe-
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lial cells and its mesenchymal derivative - D492M - found that fatty acid oxidation was
increased in the mesenchyme line, compared to its epithelial parental (Halldorsson et
al., 2017). In this study, the mesenchyme line was generated from spontaneous EMT
of D492 cells co-cultured three-dimensionally with endothelial cells. Importantly, the
authors show that while fatty acid oxidation was increased in the mesenchymal line, the
proliferation rate was slower compared to the epithelial parental line. This finding is
particularly crucial, given that this thesis has reported a negative correlation between
a fatty acid oxidation gene signature and tumour proliferation (details in Section 3.3.6,
Table 3.5). Nevertheless, how different modalities of inducing EMT such as treatment
with transforming growth factor beta (Xu, Lamouille, and Derynck, 2009), mutations
in isocitrate dehydrogenase and fumarate hydratase (Grassian et al., 2012; Sciacovelli
et al., 2016), in different cell systems, affect fatty acid oxidation remains unclear and
requires investigation.
1.4.6.2 Stem cell differentiation and metabolism
Both stem cells and EMT share an underlying theme of cellular differentiation, and
cellular dedifferentiation has been proposed as one facet of cancer (Harris, 2005). Fur-
thermore, the transcriptional program that governs stem cell renewal and maintaining
an undifferentiated state has been suggested to also be exploited in cancer (He, Nakada,
and Morrison, 2009). As such, one may suggest that the metabolic proclivities in cancer
are not only a reflection of rapid cell proliferation, but also maintenance of an un-
differentiated state, compared to the cell of origin.
Several examples warrant this point: proliferating stem cell progenitors of the tadpole
Xenopus laevis rely heavily of glycolysis for ATP, but differentiation into neurons re-
sults in increased mitochondrial respiration (Love et al., 2014). Importantly, this was not
due to limited oxygen availability or respiratory defects, which suggests a cell-intrinsic
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mechanism controlling differentiation and metabolism (Fiske and Vander Heiden, 2012;
Agathocleous et al., 2012). Secondly, embryonic stem cells had higher unsaturated
metabolites compared to differentiated cardiomyocytes and neurons, and inhibition of
eicosanoid metabolism - which involves oxidation of unsaturated metabolites - delayed
differentiation and maintained a pluripotent state (Yanes et al., 2010). Thirdly, nuclear
reprogramming of mouse embryonic fibroblasts to a pluripotent state resulted in a shift
from oxidative metabolism to glycolysis (Folmes et al., 2012). Inhibiting glycolysis with
2-deoxyglucose or bromopyruvate; or promoting oxidative metabolism via dichloroac-
etate decreased the reprogramming efficiency of the mouse embryonic fibroblasts to a
pluripotent state.
1.4.6.2.1 Link between EMT-associated factors and mammary stem cell
differentiation Mammary epithelial cell (MEC) differentiation is a step-wise, hier-
archical process, starting from mammary stem cell to a bipotent progenitor, and then
leading to either myoepithelial or luminal progenitors (Visvader and Stingl, 2014). The
basal cells from the mammary stem population express EMT genes such as SNAI2 and
TWIST1 ; and knockout of SNAI2 in this basal population led to expression of differ-
entiated luminal cell markers such as GATA3 and ER. This suggests that SNAI2 is
essential to maintain a less differentiated basal stem cell population of mammary stem
cells (Nassour et al., 2012). Importantly, studying mammary stem cells also provides a
system to identify molecular processes that are relevant in both cellular differentiation
and EMT.
1.4.7 Tumour microenvironment and metabolism
Thus far, most of this introduction focuses on the cell autonomous role of cancer
metabolism. It is important to note that tumour metabolism may also be influenced by
factors external to the tumour (i.e., tumour microenvironment). Two examples from the
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literature support this point. Primary cultures established from lung tumours in mice
showed increased lactate secretion from glycolysis, and greater glutamine anaplerosis,
compared to the primary tumours they were derived from (Davidson et al., 2016). When
these cultured cells were re-implanted into mouse lungs, the tumours exhibit metabolic
features similar to the original tumour. Secondly, co-culture of breast cancer cells with
adipocytes promote lipolysis and drives cancer cell proliferation and invasion (Balaban
et al., 2017).
1.4.8 Prognostic association of cancer metabolic pathways
In breast cancer, prognosis is determined based on clinical factors such as ER status,
tumour size, grade, and lymph node involvement. Apart from the association of some
of these factors such as tumour grade with proliferation, in general, little can be gleaned
about the biology of a tumour from these metrics. As mentioned earlier, many molec-
ular gene signatures in breast cancer also inevitably capture mainly the proliferative
component of tumours. While the central role of metabolism in tumour initiation and
progression is recognised, little is known regarding the association of metabolic pathways
opted by tumours and patient survival. Nonetheless, several studies have made early
attempts to understand the metabolic dysregulation in primary breast tumours and its
association with disease (Haider et al., 2016; Gaude and Frezza, 2016; Leoncikas et al.,
2016), and two of them will be briefly discussed below.
Haider et. al. analysed mutation, mRNA and copy number data from over 6000 tumour-
normal samples from 10 different cancer types and identified 44 metabolism-associated
genes whose mRNA expression were increased due to copy number gains or amplifica-
tions (Haider et al., 2016). These 44 genes were enriched in hypoxic tumours, which
suggests a core metabolic program enrichment in response to low oxygen tumour mi-
croenvironment. Of these 44 genes, 25 of them were prognostic in several cancers, and
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the authors focused on SQLE - which encodes squalene oxidase - an enzyme involved the
cholesterol synthesis pathway. While SQLE was co-amplified with MYC, it was prog-
nostic in the METABRIC breast cancer cohort independently of MYC amplification.
Small molecule inhibition of SQLE resulted in a dose-dependent decrease in viability in
two of three cell lines with SQLE amplification. Additionally, clonogenic assays per-
formed in hypoxic conditions in seven cell lines revealed decreased number of colonies
in response to SQLE inhibition, compared to non-treated controls. Taken together, this
study suggests the prognostic and potential translation value of targeting SQLE in a
subset of cancer patients.
More recently, Gaude et. al. analysed gene expression data, with a particular focus on
metabolism related genesets, from 20 tumour types using data from TCGA (Gaude and
Frezza, 2016). The authors found that cancers converge toward a common metabolic
phenotype: the downregulation of genes involved in mitochondrial metabolism such as
the citric acid cycle and oxidative phosphorylation. Importantly, this down regulation
of mitochondrial metabolism was associated with poor patient survival. Ten out of 15
cancers exhibited a downregulation of at least one mitochondrial metabolic pathway,
with 60% of tumours showing decreased expression of genes encoding subunits I and
IV of the electron transport chain. Furthermore, the downregulation of mitochondrial
metabolism was correlated with increased expression of genes involved in EMT, hypoxia
and angiogenesis. In comparing primary and metastatic melanoma, expression of the
oxidative phosphorylation geneset was decreased further in disseminated disease, com-
pared to the primary tumour.
Taken together, these studies suggest that dysregulation of certain metabolic pathways
are clinically relevant and can influence patient survival. The extensive metabolic net-
work in tumour warrants more in-depth analysis and characterisation, and the accu-




This thesis set out to identify features associated with prognosis in breast cancer pa-
tients, with a particular focus on metabolic pathways that were informative of patient
outcome. The hypothesis of this thesis is that increased expression of an FAO gene
signature is correlated with good response to endocrine therapy and is associated with
favourable prognosis.
Therefore, the overall aims were to:
(i) identify the genes and pathways involved in metabolism that are associated with
prognosis in breast cancer patients
(ii) explore the consequences of manipulating the fatty acid oxidation pathway on key
cancer hallmarks including proliferation and migration in breast cancer cell systems
1.5.1 Thesis outline
Chapter 3 describes the generation and validation of a prognostic gene signature in-
volved in fatty acid oxidation in breast, as well as other cancer types. The expression of
this signature between tumour and normal tissues from different cancer types will also
be explored. In light of findings by Gatza et. al, this thesis will highlight the potential
co-amplification of genes encoding cyclin D1 and CPT1A, and discuss the implication
of this finding based on the literature.
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Chapter 4 explores how the fatty acid oxidation gene signature is associated with
epithelial-to-mesenchymal transition, a key process understood for cancer cells to metas-
tasise. Furthermore, how cellular differentiation - a component of tumour grade in breast
cancer - affects expression of the fatty acid oxidation will also be analysed.
Chapter 5 highlights how activation of two key oncogenic signalling pathways - Wnt and
MAPK - affects expression of the fatty acid oxidation signature expression.
Chapter 6 describes the generation and characterisation of breast cancer cell systems
with stable CPT1A overexpression and knockdown. Characterisation experiments in-
clude assessing the proliferation, migration, anchorage-independent growth and oxygen
consumption analysis. Findings from this chapter will be discussed in light of what is
known based on current literature.
Chapter 7 assesses the global transcriptomes of the transgenic cell systems described in
the previous chapter, with a particular focus on identifying pathways that are signifi-
cantly altered in response to CPT1A modulation.
Finally, Chapter 8 concludes by bringing together the findings from Chapters 3 to 7.
This chapter will also highlight the clinical implication of findings from this thesis, and




2.1 Cell lines and complete media
The basic features of the cell lines utilised in this study are summarised in Table 2.1.
MCF7, MDA-MB231, and MCF10A cell lines were obtained from the American Type
Culture Collection (ATCC) or Sigma. MDA-MB231 and MCF7 cells were maintained
in RPMI1640 media, supplemented with 10% foetal bovine serum (FBS). MCF10A cells
were maintained in DMEM/F12, supplemented with 5% horse serum, 20 ng/mL epider-
mal growth factor, 0.5 mg/mL hydrocortisone, 100 ng/mL cholera toxin and 10 µg/mL
insulin (conditions recommended by Professor Joan Brugge’s lab, Department of Cell
Biology, Harvard Medical School).
Table 2.1: Cell lines used in this study.
Cell line Company Catalog number Tissue Morphology
MDA-MB231 ATCC HTB-26 Breast; metastatic pleural effusion Epithelial
MCF7 ATCC HTB-22 Breast; metastatic pleural effusion Epithelial
MCF10A Sigma CLLS1042 Breast; fibrocyst Epithelial
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2.1.1 Cell culture maintenance
Cells were grown in complete media in a humidified incubator at 37 ◦C and 5 % carbon
dioxide. Cells were passaged at subcultivation ratios and media replaced as recom-
mended by the ATCC for each cell line. To trypsinise cells, media was aspirated and
cells rinsed with phosphate buffered saline (PBS) once, before 1 and 3 mL of 0.05%
trysin was added to T25 or T75 flasks, respectively. Flasks were incubated at 37 ◦ C
until all cells were detached, and trypsin inactivated with complete media. Cells were
collected in a 15 mL Falcon tube, and centrifuged at 500 revolutions per minute (rpm)
for 5 mins. For MCF7 and MDA-MB231 cell lines, media was replaced and cells were
re-seeded into new flasks at respective subcultivation ratios. For MCF10A cells 1 million
cells were re-seeded into a T75 flask.
2.2 Expression plasmids and primers
The bacterial strains and expression plasmids used in this study are summarised in Table
2.2. All primers used in this thesis are provided in Table 2.3 and were purchased from
Integrated DNA Technologies.
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Table 2.2: Plasmids used in this study.
Plasmids Relevant features
pTET-ON
CMV promoter drives rtTA expression, neomycin- and
ampicillin resistance genes
pTRE Cloning site downstream of Tet response element (TRE)
pTRE-luc Firefly luciferase cloned downstream of TRE
pTRE-CPT1A CPT1A cloned downstream of TRE
pBabe-puro Empty backbone plasmid that expresses puromycin resistance gene
pTRIPZ
Lentiviral vector for expression of shRNA and
RFP downstream of TRE
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5’ ACCGCGGATGGCAGAAGCTCACCAAGC 3’ 5’ GCGTCTAGATTACTTTTTGGAATTAGAACTG 3’
Sequencing
CPT1A Internal 5’ CAGGCCGAAAACCCATGTTG 3’ 5’ AGGAGTGTTCAGCGTTGAGG 3’
Vector 5’ CCACGCTGTTTTGACCTCC 3’ 5’ CCCTGAAAACTTTGCCCCCT 3’
Quantitative PCR
CPT1A 5’ ATCAATCGGACTCTGGAAACGG 3’ 5’ TCAGGGAGTAGCGCATGGT 3’
GAPDH 5’ TGCACCACCAACTGCTTAGC 3’ 5’ GGCATGGACTGTGGTCATGAG 3’
49
2.3 Preparation of RNA samples
Total RNA was extracted from MCF10A cells using the Quick RNA Mini-Prep kit
(Zymo) and all reagent formulations are propietary. Cells were lysed in 600 µL of Lysis
Buffer and gently pipetted or vortexed intermittently for one minute. The lysate was
cleared by centrifugation at 10,000 rpm for one minute. The supernatant was transferred
into a Spin-Away Filter column and centrifuged at 10,000 rpm for one minute to remove
excess genomic DNA. One mL of absolute ethanol was added to the flow through and
transferred into a Zymo-Spin IIICG column, centrifuged for 30 seconds (sec) and flow-
through discarded. To remove residual genomic DNA, in-column DNase treatment was
performed. Four hundred µL of RNA Wash Buffer was added to the column, centrifuged
and flow-through discarded. Eighty µL of DNase I reaction mixture was added to the
column matrix and incubated for 15 min at room temperature, and then centrifuged for
30 secs. Next, 400 µL of RNA Prep buffer was added to the column, centrifuged for
one minute, and flow-through discarded. The RNA was washed twice with the RNA
wash buffer and centrifuged first for 30 sec, and then 2 mins to ensure complete removal
of the wash buffer. Finally, total RNA was eluted in an RNase-free tube by adding 35
µL of DNase/RNase-free water to the column and centrifuged at 13,000 rpm for 30 sec.
The quality and quantity of the RNA preparation was measured using the NanoDrop
ND1000 spectrophotometer and stored at -80 ◦C.
2.3.1 Reverse transcription
Complementary DNA (cDNA) from total RNA prepared as described in section 2.3 was
obtained by performing reverse transcription using the PrimeScript First Strand cDNA
synthesis kit. Volumes and concentrations of reaction mix are summarised in Table 2.4.
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Table 2.4: Reverse transcription mix components per reaction.
Reagent Sample (µL) Standard (µL)
Sample
no RT control (µL)
5X Primescript buffer 2 2 2
PrimeScript RT enzyme 0.5 0.5 0
oligo dT primers 0.5 0.5 0.5
Random 6mers 0.5 0.5 0.5







Reaction mixtures were made up in PCR tubes, gently pipetted several times to mix
and collected by briefly centrifuging, and placed in the Biorad C1000 Thermal Cycler.
The reaction was incubated at 37 ◦C for reverse transcription for 15 mins, and then
heated at 85 ◦C to inactivate the RT enzyme.
2.4 Polymerase chain reaction of CPT1A cDNA
From the resulting cDNA, CPT1A was selectively amplified using conventional poly-
merase chain reaction. Primers were designed against CPT1A RefSeq NM01876.3
A standard reaction consisted of 500 ng of cDNA (prepared as above), 0.005 units of Q5
High Fidelity polymerase (New England Biolab catalog no. M0491), 200 µM dNTPs,
0.5 µM of both forward and reverse primers and 5 µL of 5X Q5 Reaction Buffer, and
topped up to 25 µL with milliQ water. Negative control was set up as the reaction
mixture above but cDNA replaced with milliQ water. The PCR cycling conditions are
summarised in Table 2.5.
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Table 2.5: PCR protocol for CPT1A cDNA amplification.
Step Temperature (◦C) Duration Cycles
Initial denaturation 95 3 min Hold
Denaturation 95 30 secs 35
Annealing 72 30 secs 35
Extension 72 2.5 min 35
Additional extension 72 5 min Hold
2.5 Preparation and ligation of DNA fragments
To prepare for ligation, digested PCR products, which is approximately 2.2 kb in size,
and plasmid vectors were resolved on a 0.8% agarose gel, visualised under minimal ultra-
violet radiation (approximately 5-10 seconds), and the product of expected size excised.
The gel fragment was then column purified (Macherey-Nagel, Norrie Biotech, NZ cata-
log no. 740588.10), quantitated and added to the ligation reaction mixture.
A 10 µL ligation reaction was prepared that consisted of the pTRE digested plas-
mid, CPT1A insert, T4 ligase, ligation buffer, and milliQ water, and left in the fridge
overnight at approximately 4 ◦C. To estimate self-ligation of digested pTRE digested
plasmid, a vector only ligation mix was prepared similarly, but milliQ water added in-
stead of the CPT1A insert.
2.5.1 Heat shock transformation of competent bacteria with ligated
products
DH5alpha E.coli competent bacteria were thawed on ice, and split into two 100 µL vol-
umes in 2 mL tubes. Five µL of the pTRE-CPT1A or pTRE-only ligation mixes were
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added to each tube, and placed on ice for 30 min. The suspensions were then placed at
42 ◦ C (heat shock step) for 5 mins, and then placed on ice. No positive control was
performed for this transformation step. One mL of LB media without ampicillin was
added to each tube and incubated with gentle shaking (200rpm) for one hour. Fifty µL
of this suspension was inoculated on an LB agar plate (with 10 µg/mL ampicillin). The
remainder of the suspension was spun down at 5000 rpm for 5 mins, and supernatant
removed until approximately 50 µL was left, which was innoculated on an LB agar plate
(with 10 µg/mL ampicillin). The agar plates were incubated at 37 ◦ C overnight.
2.5.2 PCR screen for positive transformants
The following day, colonies were picked using a sterile pipette tip, and dipped in 15 µL
of milliQ water, before the tip was displaced into 2 mL of LB media with ampicillin
in a 15 mL Falcon tube. The PCR tubes were topped up to 20 µL of PCR master
mix (Thermo Scientific catalog no. 10342020; in a 20 µL reaction: 10X buffer 2 µL, 10
µM forward and reverse primers 0.5 µL each, DNA polymerase 0.5 µL, 200 µM dNTP
0.5µL, 50 mM magnesium chloride 0.6 µL, DNA 25 ng, top up with milliQ water to
20 µL) and PCR was performed to identify colonies that had taken up the CPT1A
insert. Positive clones in LB/ampicillin (10 µg/mL) media were cultured at 37 ◦ C for
approximately 16 hours. Glycerol stocks were prepared by mixing 500 µL and 500 µL
of glycerol. The pTRE-CPT1A plasmids were prepared using the Qiagen Plasmid Mini
Kit (BioStrategy, NZ, catalog no. 12125) and Sanger sequencing performed (Genetic
Analysis Service, University of Otago) to verify that no mutations were present in the
CPT1A transgene.
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2.6 Generation of double-stable, inducible MDA-MB231
cell line
2.6.1 Transfection of pTetOn plasmid into MDA-MB231 cell line
To generate the first stable MDA-MB231 constitutively expressing the reverse tetracy-
cline transactivator protein (rtTA), MDA-MB231 cells were transfected with the pTetOn
plasmid (Clontech catalog no. 631018) using Lipofectamine LTX (Thermo Scientific,
NZ, catalog no. A12621). Cells were plated in a 24 well plate at a density of 125,000
cells per well in a total of six wells, and left overnight to adhere. Based on optimisa-
tion experiments, 1.25 µL of Lipofectamine LTX reagent and 0.25 µL of Plus reagent
were used for pTetOn transfection. The transfection mix was prepared in serum-free
media and added for six hours to cells grown in serum, then media replaced and cells
incubated overnight. The following day, cells were trypsinised, total cells from the six
wells resuspended in 6 mL media, and plated in 10- and 15 cm dishes at three different
densities (1 mL of cells into each of two 15 cm dishes, 1 mL of cells into each of two 10
cm dishes, 0.5 mL of cells into each of two 15 cm dishes, and 0.5 mL of cells each into
10 cm dishes. Media was made up to 8 mL in the 10 cm dish, and 15 mL in the 15 cm
dish.
2.6.2 Selection and isolation of stable pTetOn transfectants
Selection of stable clones was commenced at 24 hours post-seeding into dishes using
800 µg/mL of G418. Media was replaced every two days with G418-containing condi-
tioned media. Once single colonies were observed, media replacement was performed
every four days, until colonies of approximately 50 cells were observed. To isolate these
individual clones, media was removed and cells were rinsed with PBS. Sterile, punch-
holed Whatman papers dipped in trypsin were placed over individual colonies, and left
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for two minutes. Upon completion of trypsinisation, each colony was transferred to a
well of a 24-well plate. The Whatman papers were left for up to 72 hours and cells
were cultured in conditioned, selective media until sufficient cell numbers were avail-
able to be frozen. MDA-MB231 cells were frozen in complete media (RPMI + 10%
serum) in 5% dimethyl sulfoxide in cryotubes (approximately 1 million cells in 1 mL
of media per tube). Cryotubes were then transferred into Mr Frosty and placed in -80
◦C overnight, before being transferred to liquid nitrogen container for long term storage.
2.6.3 Preparation of doxycycline hydrochloride and puromycin stock
solutions
Doxycycline hydrochloride (Dox) (Sigma-Aldrich, catalogue no. D3447) was prepared
as a 2 mg/mL stock in sterile milliQ water, filter sterilised through a 0.2 micron mem-
brane, aliquoted into Eppendorf tubes and stored at -20 ◦C. Once thawed, stocks were
used for no more than two weeks.
Puromycin dihydrochloride (Sigma-Aldrich, catalogue no. P8833) was prepared as a
10mg/mL stock in sterile milliQ water. This stock solution was added at required vol-
ume to the RPMI1640 culture media achieve the working concentration, which was then
sterile filtered as above.
2.6.4 Luciferase-based screening of single transfectant clones
Putative single stable transfectant clones were plated in duplicates in a 24-well plate
and transiently transfected with pTRE-luciferase. Transfection was set up similar to
that described in Section 2.6.1. One well was induced with 2 µg/mL of Dox, and the
same volume of milliQ water added to the uninduced well, for 48 hrs. Cells were lysed
in 50 µL of cell culture lysis buffer (Promega catalogue no. PME1500), vortexed, and
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whole cell lysates frozen at -20 ◦C until assayed. Prior to conducting the assay, whole
cell lysates were centrifuged at 4 ◦C for five mins and 10 µL of supernatant added to 100
µL of substrate reagent solution in a white-walled, flat bottom 96-well plate. The plate
was then placed in the ClarioStar plate reader (BMG LabTech, Thermo Fisher Scien-
tific), and luminescence measured for 10 secs. Clones with at least 20-fold induction
were independently screened again, and the clone with the highest inducibility taken for
further downstream analysis.
2.6.5 Co-transfection of pTetOn single transfectant cell line with
pTRE and pBabe puro
Upon generation of a single, stable pTetOn MDA-MB231 cell line, a second round of
co-transfection was performed with 450 ng of a doxycycline-inducible plasmid carry-
ing the CPT1A transgene, and 50 ng of a plasmid conferring puromycin resistance.
Briefly, 125,000 cells were plated in a 24-well plate and left overnight to adhere. The
following day, each well was transfected with 450 ng of pTRE-CPT1A and 50 ng of
pBabe puro using 1.25 µL Lipofectamine LTX per well. A total of six wells were trans-
fected. Twenty four hours post transfection, cells were trypsinised and plated into 10
cm dishes. Puromycin selection (1 µg/mL) was commenced the following day, and cells
were maintained in 80% complete media with 400 µg/mL G418 and 20% conditioned
media obtained from pTetOn MDA-MB231 cells every 24 hours. Once colonies were
observed, colony lifts were performed as described in section 2.6.2. A PCR screen was
performed to determine if the puromycin-resistant colonies had stably integrated the
pTRE plasmid. Positive colonies were further expanded to conduct experiments mea-
suring the inducibility of CPT1A.
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2.6.6 Assessing CPT1A mRNA induction in putative overexpression
clones
To measure the inducibility of CPT1A, 250,000 cells per colony were plated in duplicate
in a six well plate and left overnight to adhere. One of the wells was induced with 2
µg/mL of Dox for 48 hours and total RNA extracted as described in section 2.3. Expres-
sion of CPT1A in the putative overexpression clones were assayed by quantitative PCR
(qPCR). A 10.2 µL reaction consisted of 5 µL of KAPA SYBR FAST qPCR Master
Mix Universal (Kapa Biosystems, catalogue no. KK4601), 20 ng of cDNA, 0.2 µL of
forward and reverse primers, 0.2 µL ROX High reagent. No reverse transcriptase con-
trol samples from cDNA synthesis were assayed for genomic DNA contamination during
RNA preparation, and no template control assayed to ensure no contamination of assay
reagents. As this is a screen, only one reference gene - GAPDH - was assayed to nor-
malise CPT1A expression. Each condition was plated in three technical replicates, and
only one biological replicate was conducted for screening. Reactions were plated into
a 384-well plate, sealed, spun and placed in the 7900HT Fast Real-Time PCR system
(Applied Biosystems). Melt curves were also performed to verify a specific product. The
reaction cycling protocol summarised in Table 2.6. Standards were derived from cDNA
prepared from 2 µg of total RNA from MCF7 breast cancer cells, and diluted in milliQ
water to achieve concentrations of 100-, 20-, 2-, 0.2- and 0.02 ng in 4.5 µL per well.
These standards were assayed in three technical triplicates. The qPCR assay data was
analysed using the SDS 2.4 software (Applied Biosystems) and quantifying the amount
of CPT1A mRNA based on the standard curve performed.
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Table 2.6: qPCR cycling protocol.
Step Temperature (◦C) Duration Cycles
Enzyme activation 95 3 mins Hold
Denaturation 95 5 secs 40
Annealing/extension 60 30 secs 40
2.7 Establishing stable MCF7 and MCF10A cell lines for
CPT1A knockdown
2.7.1 Cloning of shRNA constructs into pTRIPZ vector
The pTRIPZ (GE Healthcare, Dharmacon) plasmid is an inducible, lentiviral vector
that expresses shRNA against a target gene in response to Dox treatment. The ma-
ture antisense shRNA sequence was obtained from the Dharmacon website and reverse
engineered to generate the coding sequence of four shRNA constructs against CPT1A.
PCR was performed using ultramers that prime off each other to generate a fragment
encoding each shRNA (Rangasamy, Tremethick, and Greaves, 2008). Four unique pairs
of ultramers were amplified, giving rise to four shRNA constructs, and the sequence is
provided in Table 2.7. The cycling conditions are summarised in Table 2.8.
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Table 2.7: Ultramer sequences for amplifying shRNA sequence against CPT1A.
CPT1A shRNA ultramer Forward Reverse
Construct 1
5’ gct cga gaa ggt ata ttg ctg ttg aca gtg agc g
CA AAG AAG TTC ATC AGA TTC AA
tag tga agc cac aga tgt a
T TGA ATC TGA TGA ACT TCT TTT
tgc cta ctg cct cgg aat tcg 3’
3’ cga gct ctt cca tat aac gac aac tgt cac tcg c
GT TTC TTC AAG TAG TCT AAG TT
atc act tcg gtg tct aca t
A ACT TAG ACT ACT TGA AGA AAA
acg gat gac gga gcc tta agc 5’
Construct 2
5’ gct cga gaa ggt ata ttg ctg ttg aca gtg agc g
CG CCA TGA AGC TCT TAG ACA AA
tag tga agc cac aga tgt a
T TTG TCT AAG AGC TTC ATG GCT
tgc cta ctg cct cgg aat tcg 3’
3’ cga gct ctt cca tat aac gac aac tgt cac tcg c
GC GGT ACT TCG AGA ATC TGT TT
atc act tcg gtg tct aca t
A AAC AGA TTC TCG AAG TAC CGA
acg gat gac gga gcc tta agc 5’
Construct 3
5’ gct cga gaa ggt ata ttg ctg ttg aca gtg agc g
GT ACA GTG GTA TTT GAA GTT AA
tag tga agc cac aga tgt a
T TAA CTT CAA ATA CCA CTG TAA
tgc cta ctg cct cgg aat tcg 3’
3’ cga gct ctt cca tat aac gac aac tgt cac tcg c
CA TGT CAC CAT AAA CTT CAA TT
atc act tcg gtg tct aca t
A ATT GAA GTT TAT GGT GAC ATT
acg gat gac gga gcc tta agc 5’
Construct 4
5’ gct cga gaa ggt ata ttg ctg ttg aca gtg agc g
GC TGG ACT TCA TTC CTG GAA AA
tag tga agc cac aga tgt a
T TTT CCA GGA ATG AAG TCC AGA
tgc cta ctg cct cgg aat tcg 3’
3’ cga gct ctt cca tat aac gac aac tgt cac tcg c
CG ACC TGA AGT AAG GAC CTT TT
atc act tcg gtg tct aca t
A AAA GGT CCT TAC TTC AGG TCT
acg gat gac gga gcc tta agc 5’
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Table 2.8: PCR protocol for shRNA ultramers amplification.
Step Temperature (◦C) Duration Cycles
Initial denaturation 94 2 min Hold
Denaturation 94 30 secs 29
Annealing 50 30 secs 29
Extension 72 2.5 min 29
Additional extension 72 5 min Hold
Digested plasmid ( 13 kilobase) and PCR products ( 150 base pairs) were resolved on a
1.2% agarose gel for 25 min at 100V. Gels were visualised under a UV lamp and bands
corresponding to purified, digested plasmid and PCR products were excised. DNA from
gel extracts was eluted using a column (NucleoSpin Gel and PCR Clean-up). Ligation
was performed as per section 2.5 overnight at 4 ◦C using a 1:2 vector-to-insert ratio.
This translates into 100 ng of plasmid and 8 ng of insert. To estimate background re-
ligation of vector without insert, a vector only control ligation of identical setup was
performed, with water used in place of purified shRNA construct. The following day,
5 µL of the ligation reaction was transformed into STBL3 E.Coli strain using the heat
shock method (42 ◦C, 5 mins) , and recovered in LB for one hour at 37 ◦C. No positive
control was performed for this transformation step. The culture was then pelleted and
50 µL inoculated on an ampicillin-containing (10 µg/mL) agar plate, and incubated
overnight at 37 ◦C.
The following day, colonies were picked and PCR screened for uptake of shRNA con-
structs using construct specific primers. Positive colonies were grown for approximately
16 hours in 3 mL of LB/ampicillin (10 µg/mL) media and plasmids prepared. All shRNA
constructs were sequence verified by Sanger sequencing (Genetic Analysis Service, Uni-
versity of Otago).
60
2.7.1.1 Assessing knockdown efficiency of shRNA constructs
To compare knockdown efficiencies of the different constructs, a transient knockdown
experiment was performed using MCF7 cells. Two hundred thousand cells were plated
in triplicates in a six well plate for each construct, including a non-silencing construct
control and left to adhere overnight. Cells were transfected with 2 µg of respective
constructs using FuGENE HD (Promega) according to manufacturers recommendation.
The transfection mix was prepared in serum-free media, and transfection performed on
cells grown in serum. Six hours post-transfection, 2 µg/mL Dox was added to induce
shRNA expression. The following day, cells were visualised for RFP expression to esti-
mate transfection efficiency, which was approximately 40-60%. Cells were then selected
with 2 µg/mL of puromycin for 72 hours. After 72 hours, total RNA was prepared
and expression of CPT1A was determined using qPCR based on a standard curve, as
described in section 2.6.6. Expression of CPT1A was normalised to the GAPDH ex-
pression as reference.
2.7.1.2 Lentivirus particle production
Lentivirus particles were produced using the second generation system (Wang and Mc-
Manus, 2009). This is achieved by transfecting HEK293FT cells with three plasmids
that consist of the transfer plasmid pTRIPZ carrying the shRNA of interest, the psPAX2
packaging plasmid and the VSV-G envelope plasmid.
Cells were seeded at a density of 5.6 million cells/mL in a T75 flask and allowed to
adhere overnight. The following day, a transfection mix of 18.6 µg of pTRIPZ, 9.6 µg of
psPAX2, and 4.8 µg of VSVG plasmid was prepared in serum-free RPMI 1640 media to
a final volume of 1 mL, and filtered into another 15 mL Falcon tube containing 55.7 µL
of Lipofectamine 2000 in 944.3 µL of RPMI 1640. This mix was incubated for 20 min
at room temperature, and added drop-wise into the flask while gently tilting to facili-
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tate equal distribution of the mix. Transfection was done in cells grown in serum. The
flasks were incubated overnight and replaced with complete media the following day.
Fourty-eight hours post-transfection, supernatants from the flasks were recovered, and
centrifuged at 3,000 rpm for 15 min. The supernatant containing the lentiviral particles
were filtered through a 0.45 µm PVDF filter to remove debris and frozen at -80 ◦C as
500 µL aliquots.
2.7.1.3 Determining viral transducing unit
Both MCF7 and MCF10A cells were plated in triplicates in a clear bottom, black-walled
96 well plate at a density of 4,000 cells/well. The following day, serial dilutions of the
viral stock were prepared from ranging from 2 to 64 fold, together with 2µg/mL of
doxycycline. Media was replaced with 100µL of respective dilutions, and left for 48
hours. To determine the transducing units, cells were fixed in PBS with 0.25% (v/v)
paraformaldehyde and 0.075% (v/v) saponin and stained with 2 µg/mL DAPI, and
plates wrapped in tin-foil for at least one hour and imaged using the Cytell imaging
system using the DAPI and TRITC filters. Images were imported in CellProfiler and
ratios of DAPI-to-RFP cells determined.
2.7.1.4 Lentiviral shRNA infection of MCF7 and MCF10A cells
MCF7 and MCF10A cells were plated at a density of 150,000 cells/well in a six well
plate and left overnight to adhere. While tittering of the viral stock was conducted as
above, this method proved to yield unrealiable viral concentrations. The following day
post-seeding, cells were transduced with 50- or 100 µL of viral supernatants carrying the
shRNA constructs. Six hours post-transduction, 2µg/mL Dox was added to each well
to induce RFP expression to estimate transduction efficiency. Fourty eight hours post-
transduction, approximately 20-30% of the transduced wells expressed RFP. MCF10A
and MCF7 cells were selected with 1.5- and 1 µg/mL of puromycin respectively to gen-
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erate stable polyclonal populations.
2.7.1.5 Screening for stable shRNA knockdown clones in MCF7 and MCF10A
To select for clones that show the best knockdown of CPT1A, total RNA was prepared
from the polyclonal populations of MCF10A and MCF7 cells and qPCR performed.
MCF10A cells (20,000 cells/well) and MCF7 cells (80,000 cells/well) were plated in six
well plates and induced with 2- or 4µg/mL of doxycycline for 5 days, with fresh media
replaced on day 3.
qPCR analysis was performed to determine the expression of CPT1A, and clones that
showed at least 50% mRNA decreased expression after 5 days of knockdown were taken
forward for immunoblotting.
2.7.1.6 Immunoblot analysis of inducible cell systems
2.7.1.6.1 Induction of CPT1A transgene in MDA-MB231 pTRE-CPT1A
cell lines For CPT1A induction analysis of putative overexpression clones, 150,000
cells were seeded for each clone in duplicate in six well plates, and one of the wells in-
duced with 2 µg/mL Dox for 48 hours. Cells were lysed and scraped in ice cold radio im-
munoprecipitation assay buffer (50 mM Tris pH8.0, 150 mM NaCl, 0.1% sodium dodecyl
sulfate, 1% w/v sodium deoxycholate, 0.01% NP40), transferred into 1.5 mL Eppendorf
tubes, and placed on ice for at least 15 mins with intermittent vortexing. Whole lysates
were frozen at -80 ◦C until analysed. For time course experiments, 100,000 cells were
seeded into 10 mm dishes and induced with 2 µg/mL Dox for up to 120 hours. For 96-
and 120 hr time points, media was replaced at 72 hours. Lysates were prepared as above.
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2.7.1.6.2 Induction of CPT1A shRNA expression in MCF10A and MCF7
cells To determine CPT1A knockdown in MCF7 and MCF10A cell lines, 50,000- and
25,000 cells, respectively, were seeded in six-well plates and induced with 2 µg/mL Dox
for one week, and lysates prepared.
2.7.1.6.3 Immmunoblot procedure Cell lysates were thawed and spun at 13,000
rpm for 10 mins at 4 ◦C. The bicinchoninic acid assay was performed to quantitate the
amount of protein in each sample. Samples were diluted 10 fold in RIPA buffer, and a 2
mg/mL stock solution of bovine serum albumin was diluted to give a range from 0.025-
to 2 mg/mL to generate a standard curve. Twenty-five µL of standards and samples
were plated in triplicates, 200 µL of working reagent added and incubated at 37 ◦C, and
absorbance at 562nm measured. Protein quantity were measured using the standard
curve, taking into account the dilution factor.
Ten % sodium dodecyl sulfate (SDS) polyacrylamide gels were poured and set in the
fridge overnight. The resolving gel consisted of 6.6 mL 30% acrylamide, 5 mL 1 M
Tris-hydrochloride (pH 8.8), 200 µL 10% SDS, 100 µL 10% APS, 20 µL TEMED and
8.9 mL milliQ water. The resolving gel was poured into the Bio-Rad Mini Protean 3
system (Bio-Rad Laboratories) gel cast, layered with isopropanol, and allowed to set.
Stacking gel consisted of 1.16 mL 30% acrylamide, 1.26 mL Tris-hydrochloride (pH 6.8),
50 µL SDS, 5 µL TEMED, 25 µL 10% APS, and 3 mL milliQ water.
For all immunoblot analysis, 20 µg of proteins were resolved at 100V for approximately
2 hours. Proteins were transferred onto a PVDF membrane at 90V for 90 minutes, and
blocked with 5% (w/v) milk for one hour at room temperature. Blots were then rinsed
in Tris-buffered saline with 0.1% Tween 20 (TBST) and incubated with anti-CPT1A
(88kDa, 1:1000, or 1 µg/mL from 1 mg/mL stock, Abcam catalogue 128568 mouse
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monoclonal) overnight at 4 ◦C. Blots were washed with TBST thrice for 10 minutes per
wash, and incubated with sheep anti-mouse secondary antibody linked to horseradish
peroxidase (1:10,000, Amersham catalogue NA931) for 1 hour. Blots were washed as
previously described, and enhanced chemiluminescence reagent (Pierce ECL Plus West-
ern Blotting Substrate, catalog no. 32132) added for 1 minute and imaged using the
LiCor Odyssey under the ’Chemi’ channel for 2 mins. Since CPT1A and alpha-tubulin
of different sizes, blots were not stripped, but rinsed and re-probed with alpha-tubulin
(50 kDa, 1:5000, Sigma catalogue TA6199 mouse monoclonal) , and subsequent washes,
secondary antibody incubation, and development performed as previous.
2.7.1.6.4 Soft agar assay For the base agar, a 1.2 % agarose solution was prepared
using sterile milliQ water. The agar was left to cool on a heat block to approximately 55
◦C, before equal volumes of the agarose solution and 2 x RPMI/20% FBS mixture was
prepared. Two mL of this final 0.6% agarose solution in 1x RPMI/10% FBS was added
to six well plates and left to cool at room temperature, before leaving at 4 ◦C overnight.
The following day, a 0.6% agarose solution was prepared and incubated on a 37 ◦C heat
block. Cells were prepared at a density of 300,000- (MDA-MB231) and 120,000 cells
(MCF7) in 3 mL of 2 x RPMI/20% FBS, and added to 3 mL of 0.6% agarose. Two
mL of this solution was plated above the base agar, to give a final concentration of
50,000- (MDA-MB231) or 10,000 (MCF7) cells in 0.3% agar. This mixture was allowed
to set, and complete media added the following day, with or without 2 µg/mL Dox. One
mL of fresh media was replaced every 2-3 days. After three weeks, the agar was fixed
and stained with 20% methanol at room temperature and 0.05% crystal violet (which
binds to protein and DNA, thereby indicating colonies) solution for 30 mins and plates
wrapped in tin-foil. Stains were washed several times with milliQ water and colonies
from 9 random fields (4x magnification) counted using a phase-contrast microscope.
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2.7.1.6.5 Boyden chamber assay MDA-MB231 TetOn or pTRE-CPT1A clone 3
cells were induced with 2 µg/mL Dox for 5 days. Cells were resuspended to a final
concentration of 1 million cells/mL in serum-free media, and 200 µL of this suspension
was added to the transwell insert overlaying 600 µL of complete media in the bottom
well, careful to avoid bubble formation between the media in the bottom well and in-
sert. Cells seeded in the transwell were supplemented with 175 µM of BSA-palmitate
and 0.5 mM carnitine. Carnitine (50 mM stock) was prepared diluting 0.15 g of car-
nitine (Sigma catalog. C0283) in 15 mL of milliQ water, filter sterilised (0.2 micron
filter), aliquoted into 1 mL volume in sterile Eppendorf tubes, and frozen at -80 ◦C
until required. BSA-palmitate was prepared according to protocol provided by Seahorse
Biocsciences. Briefly, 1g of fatty acid-free BSA (Sigma catalog no. A8806) was dissolved
in 44 mL of milliQ water in a 250 mL beaker and stirred. This BSA solution was then
placed in a 600 mL beaker with pre-warmed (37-40 ◦C) distilled water, and continued
to stir until all the BSA dissolved. From this solution, 22 mL was removed in the tissue
culture flow hood, and diluted with 22 mL of 150 mM sodium chloride to generate 44
mL of 0.17 mM BSA stock solution. The remainder 22 mL of undiluted BSA solution
was used to conjugate to sodium palmitate (Sigma catalog no. P9767). Palmitate solu-
tion was prepared by adding 30.6 mg of sodium palmitate to 44 mL of 150 mM sodium
chloride solution in a 100 mL beaker. This beaker containing the palmitate solution
was then placed in a one litre beaker containing distilled water, and the temperature
slowly raised to 70 ◦C on a stir plate, and the palmitate continuously stirred until a
clear solution was obtained. From this solution, 17.6 mL was transferred into the 22 mL
of undiluted BSA solution and continued to stir not beyond 40 ◦C, for approximately
two hours, until a clear solution was obtained. A further 4.4 mL of 150 mM sodium
chloride was added to this solution to generate 44 mL of 1 mM conjugated palmitate
stock solution, before adjusting the pH to 7.4 with 1 M sodium hydroxide. The 0.17
mM BSA and BSA-palmitate conjugate solution was then aliquoted (4mL volume) into
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sterile universal glass vials, wrapped with tin foil, and stored at -20 ◦C until use.
Migration experiment was conducted for 48 hours, following which cells that had mi-
grated and adhered to the bottom well were fixed in PBS with 0.25% (v/v) paraformalde-
hyde and 0.075% (v/v) saponin and stained with 2 µg/mL DAPI, and plates wrapped in
tin-foil for at least one hour, and nuclei count performed using the Cytation 3 imaging
system (Biotek Instruments).
2.7.2 Real time FAO flux analysis using the Seahorse XF extracellular
flux technology
The Seahorse XF analyser measures the oxygen consumption rate (OCR) and extracel-
lular acidification rate (ECAR) as a proxy for mitochondrial respiration and glycolysis,
respectively. Changes in concentrations of dissolved oxygen due to mitochondrial res-
piration and free protons due to lactate secretion can be measured using solid state
sensor probes. These probes are suspended 200 microns above a cell monolayer and
measure the OCR in pmol/min and ECAR at mpH/min at 2-5 min intervals. Baseline
OCR/ECAR measurements are measured up to five times before cells are treated with
inhibitors, substrates, or other small molecules through an injection port.
In these series of experiments, three mitochondrial inhibitors, which are provided as part
of the MitoStress test assay kit (In Vitro Technologies, NZ catalog no. SEA103015100):
oligomycin, carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP) and antimycin
A, that bind to different components of the electron transport chain (ETC), were utilised.
These compounds were reconstituted according to manufacturer’s instructions.
Oligomycin binds to the oligomycin-sensitive conferring protein on ATP synthase, thereby
inhibiting ATP synthesis. Hence, the cells require an alternative source of ATP, which
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is primarily achieved from increased glycolysis.
FCCP is a lipid soluble, weak acid that facilitates proton permeability across the mi-
tochondrial matrix and intermembrane space, thereby abolishing the obligatory proton
gradient required for oxidative phosphorylation. This results in decreased ATP produc-
tion, thereby increasing citric cycle activity and generation of reducing equivalents such
as NADH and FADH2. Oxygen is the terminal electron acceptor from oxidation of these
reducing equivalents, hence explaining the marked increase in oxygen consumption in
the presence of a mitochondrial uncoupler.
Antimycin A inhibits cytochrome c oxidoreductase and prevents the oxidation of ubiquinone.
This prevents the transfer of electrons from NADH and succinate to oxygen, thereby
resulting in decreased demand and consumption of oxygen. The compounds, their tar-
gets and effects on OCR are summarised in Table 2.9.
Table 2.9: Mitochondrial inhibitors utilised in real time FAO flux analysis.
Compound Target Effect on OCR
Oligomycin ATP synthase Decrease
FCCP Inner mitochondrial membrane Increase
Antimycin A Complex III Decrease
2.7.2.1 Induction of CPT1A expression and knockdown in cell systems
MDA-MB231 TetOn and pTRE-CPT1A overexpressing clones were seeded at a density
of 200,000 cells/well in a six well plate. Three wells were induced with 2µg/mL Dox for
5 days. Media was replaced on day 3. MCF10A cells were seeded at 20,000 cells/well
and MCF7 cells were seeded at 50,000 cells/well in a six well plate and induced with
2µg/mL Dox for 7 days.
68
2.7.2.2 Optimisation of FCCP required to achieve maximal OCR in cell
systems
The FAO assay workflow uses BSA, which can bind to FCCP and thereby decrease the
effective concentration available to cells. As such, the concentration of this compound
requires optimisation to achieve maximal OCR in the presence of BSA for each cell line.
MDA-MB231 TetOn and pTRE-CPT1A overexpression clones were plated at a density
of 60,000 cells/well in 100 µL of substrate-limited media and left at room temperature for
30 mins to allow even dispersion prior to a 4 hr incubation at 37 ◦C to allow adherence.
A further 150 µL of substrate-limited media was added to each well and cells incubated
overnight. The same setup was performed for MCF7 and MCF10A knockdown systems,
with cells seeded at a density of 40,000 cells/well. These cell densities were selected
to achieve approximately 80-90% confluence post-seeding and also within the manufac-
turer’s recommended baseline range for ECAR (20-120 mpH/min) and OCR (50-400
pmol/min). A standard MitoStress assay was carried out, with FCCP concentrations
ranging from 0.5- to 4 µM and assayed for maximal OCR.
2.7.2.3 FAO assay set up
MDA-MB231 TetOn and pTRE-CPT1A overexpression clones were plated at a density
of 60,000 cells/well in 100 µL of media and left at room temperature for 30 mins for
even dispersion prior to a 4 hr incubation at 37 ◦C to allow adherence. A further 150 µL
of substrate-limited media was added to each well and incubated overnight. The same
setup was performed for MCF7 and MCF10A knockdown systems, with cells seeded at
a density of 40,000 cells/mL. These cell densities were selected to achieve approximately
80% confluency post-seeding and also within the manufacturer’s recommended baseline
range for ECAR (20-120 mpH/min) and OCR (50-400 pmol/min).
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The following day, cells were rinsed once, and media replaced with 375 µL of FAO as-
say media and incubated at 37 ◦C without carbon dioxide for 30 min. Mitochondrial
inhibitors oligomycin, FCCP and antimycin A were prepared for injection into respec-
tive ports. The concentrations of compounds used in each cell line are summarised in
Table 2.10. Unused, free ports were filled with assay media. Fifteen minutes prior to
the start of assay, 37.5 µL of 400 µM etomoxir (approximately 40 µM final) was added
into designated wells. Prior to loading of the plate to be assayed, 87.5 µL of BSA- or
BSA-palmitate was added into designated wells.
Table 2.10: XF24 Fatty oxidation instrument run protocol.
Command Number of loops Time (mins)
Calibrate:
Mix, wait, measure
5 3, 2, 3
Inject oligomycin (1 µM) :
Mix, wait, measure
3 3, 2, 3
Inject FCCP (1-2 µM):
Mix, wait, measure
3 3, 2, 3
Inject antimycin A (10 µM):
Mix, wait, measure
3 3, 2, 3
2.8 Bioinformatics analysis methods
2.8.1 Cox proportional hazards regression to identify features signif-
icantly associated with outcome
To identify genes that were significantly associated with disease specific survival (DSS),
univariate Cox regression was performed using the gene expression as the dependent vari-
able. This analysis was performed on the gene expression data from the METABRIC
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training cohort coxph() function from the ’survival’ package in RStudio (RStudio Team,
2015). To account for multiple comparison tests, p-values from the Cox regression were
adjusted using the false-discovery rate method using the p.adjust function. Multivariate
Cox regression analysis was performed using the coxph() function, and including other
co-variates for respective analysis.
2.8.2 Collapsing multiple probesets to unique genes
In many microarray platforms, a gene can be represented by multiple probesets and
may have different sensitivities to measure expression levels of a particular transcript.
Therefore, prior to performing Cox regression analysis, the expression matrix was col-
lapsed so that each probeset represented a unique gene using the collapseRows package
(Miller et al., 2011). Collapsing the matrix also ensures that the adjusted p-values are
not confounded by multiple probesets to represent each gene.
2.8.3 Gene set enrichment analysis
To identify pathways that were enriched from the Cox regression, gene set enrichment
analysis (GSEA) was performed using the GSEA software (versions 2.2.0 and 2.2.3)
available from the Broad Institute. Genes were pre-ranked based on their adjusted p-
value in ascending order. The gene set database was obtained from Kyoto Encyclopaedia
of Genes and Genomes (KEGG) or Reactome.
2.8.4 Kaplan-Meier survival analysis
Kaplan-Meier survival curves were plotted to determine the association of a gene expres-
sion signature or clinico-pathologic variable with outcome. This analysis was performed
using the survplot() function, and statistical significance between curves was calculated
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using the log-rank test using the survdiff () function from the ’survival’ package.
All signature expression scores were generated based on mean expression value of genes
comprising the signature. Unless stated otherwise, the dichotomous cut-off for gene ex-
pression signatures are based on being below (Low group) or above (High group) median
signature expression score of the cohort.
2.8.5 Accessing publicly available gene expression datasets
Publicly available gene expression datasets were accessed from the Gene Expression Om-
nibus or ArrayExpress repositories. Datasets were normalised by contributing authors
prior to submission. Normalisation procedures aim to balance hybridisation intensities
to ensure meaningful biological comparisons can be made between arrays (Quackenbush,
2002). Potential sources of variability that normalisation serves to reduce include dif-
ferences in starting RNA amount, differences in the labelling or detection efficiencies
with regards to the fluorescent dye utilised, and systematic biases of gene expression
measurements. All datasets from The Cancer Genome Atlas were accessed from the
Cancer Browser hosted by University of California Santa Cruz. Of note, where survival
analyses were performed, many A summary of the datasets analysed in this thesis is
provided in Table B.59-B.64.
2.8.6 RNA-Seq analysis of CPT1A overexpressing and knockdown
cell lines
To investigate for genes and pathways that were differentially expressed in response
to overexpression of CPT1A in MDA-MB231 and knockdown in MCF7 cells, RNA-
sequencing transcriptome analysis on the Illumina HiSeq platform using the services of
New Zealand Genomics Limited. TetOn and CPT1A overxpression clones 3 and 17 were
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seeded in six well plates and induced for 5 days with 2µg/mL Dox. MCF7 non-silencing
and CPT1A shRNA1 and shRNA2 lines were seeded in six well plates and induced with
2µg/mL Dox for 7 days. Total RNA was extracted as described in section 2.2. Two bio-
logical replicates from the overexpression and knockdown experiments were prepared for
transcriptome analysis. The services of New Zealand Genomics Limited was employed
for RNA sequencing and alignment.
Differential analysis expression was performed using the ’limma’ package in RStudio,
and codes were adapted from the package user manual (Ritchie et al., 2015; Phipson
et al., 2016; Liu et al., 2015). Geneset enrichment analysis was performed using the
Enrichr online software (Chen et al., 2013; Kuleshov et al., 2016). For targeted analysis,
the Wnt target signature was derived from Van der Flier et. al. (Flier et al., 2007). The
MAPK signature was derived from the Reactome database (ERK MAPK TARGETS),
and the EMT signature was obtained from Groger et. al. (Fabregat et al., 2016; Croft





associated with breast cancer
treatment response and prognosis
3.1 Background
A multitude of prognostic gene expression signatures have been identified through the
application of transcriptomic technologies to breast tumour tissues and clinical data
(Gyorffy et al., 2015). While there is little overlap in the genes that make up these
different signatures, most of them quantify two key processes in breast cancer: ER
signalling and proliferation (Venet, Dumont, and Detours, 2011; Wirapati et al., 2008;
Weigelt and Reis-Filho, 2009). This leaves the potential for substantial gains to be made
in utilising data from gene expression studies to identify the biological processes that
sustain tumour growth during treatment. Furthermore, potential molecular processes
identified can also be analysed in other tumour types, which may facilitate a broader
understanding of how the particular pathway contributes to tumourigenesis or disease
progression. Therefore, the aim of this chapter is to identify the molecular processes
associated with survival in ER-positive breast cancer patients that received adjuvant
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hormone- and/or radiotherapy.
The METABRIC study, conducted in the United Kingdom, Canada and Norway, anal-
ysed gene expression and copy number aberrations from over 2000 primary breast tu-
mours (Curtis et al., 2012). When this section of this thesis was undertaken, this study
was the best resource for gene expression analysis with regards to sample size and com-
pleteness of clinical data. Importantly, the size of the METABRIC study allows for
subgroup analysis (e.g., ER-positive patients, adjuvant treatment). The clinicopatho-
logic information of patients in the METABRIC training cohort for analysis in this
chapter is summarised in Supplementary Table B.1.
3.2 Objectives
The objectives of this chapter are to:
(i) identify pathways that are associated with prognosis in a breast cancer training
cohort of patients that received radiation and/or endocrine therapy
(ii) select and validate one pathway of interest in independent breast cancer datasets
(iii) explore the association of the selected pathway with prognosis in other cancer types
(iv) investigate whether the expression of the selected pathway differs between normal
and cancer tissues of different anatomical origins.
3.3 Results
3.3.1 Gene signatures significantly associated with breast cancer disease-
specific survival
To identify genes and pathways that were associated with disease-specific survival (DSS)
in the METABRIC training data (n=973), Cox regression was performed on gene ex-
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pression data from patients that received either adjuvant endocrine therapy only, or
a combination of endocrine- and radiation therapy. Genes were pre-ranked from most
to least significantly associated with DSS based on their FDR adjusted p-value, and
geneset enrichment analysis was then performed using the KEGG database to identify
pathways that were enriched from the Cox regression analysis.
Table 3.1 summarises the KEGG pathways that are significantly associated with DSS in
the METABRIC training cohort. Several of these genesets including base excision repair,
DNA replication, pyrimidine metabolism and meiosis include genes that are involved in
proliferation, which is known to be highly prognostic in breast cancer (Bianchini et al.,
2013; Diest, Wall, and Baak, 2004). Therefore, these genesets provide assurance that
the analysis is sound, and warrants further investigation of previously unreported prog-
nostic genesets.
A 19-gene signature associated with fatty acid oxidation (FAO) was amongst the en-
riched candidate genesets (nominal p = 0.002 , FDR adjusted p=0.038) (Fig 3.1, Table
3.1). Furthemore, the key genes in this pathway is highlighted (red circles) from the
KEGG ’Fatty Acid Degradation’ pathway, which was previously known as the ’Fatty
Acid Metabolism’ before the software was updated (Fig 3.2). Examination of the liter-
ature suggests that while fatty acid synthesis in cancer is well-defined, the role of fatty
acid oxidation is unclear, and may be context-dependent (Carracedo et al., 2012; Currie
et al., 2013). Since altered cellular energetics is a hallmark of cancer, metabolic path-
ways such as FAO could therapeutically targeted in cancer. Based on this reasoning,
the 19-gene FAO signature was selected for further investigation (Table 3.2).
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KEGG VALINE LEUCINE AND
ISOLEUCINE DEGRADATION 0.53 1.74 0 0.032
KEGG BASE EXCISION REPAIR 0.55 1.71 0 0.03
KEGG PYRIMIDINE METABOLISM 0.48 1.68 0 0.03
KEGG DNA REPLICATION 0.52 1.66 0 0.03
KEGG GLYOXYLATE AND
DICARBOXYLATE METABOLISM 0.58 1.64 0.002 0.03
KEGG OOCYTE MEIOSIS 0.45 1.62 0 0.03
KEGG GLYCINE SERINE AND
THREONINE METABOLISM 0.51 1.61 0.002 0.03
KEGG PROTEASOME 0.48 1.58 0.002 0.04
KEGG FATTY ACID METABOLISM 0.48 1.59 0.002 0.04
Figure 3.1: Enrichment plot of KEGG Fatty Acid Metabolism pathway.
Black lines in the middle of the plot indicate genes in the KEGG Fatty Acid Metabolism
geneset. Genes from left to right indicate the position of each gene in the pre-ranked
list after Cox regression was performed on the training data. While the geneset had a
total of 42 genes, only 19 were defined as core-enriched in the analysis.
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Figure 3.2: FAO genes in the KEGG Fatty Acid Degradation/Metabolism
pathway. Circled in red are some genes such as ACSL5, CPT1A, ACAD, HADH and
ACAA, all key genes in the FAO pathway.
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Table 3.2: 19-gene signature involved in FAO associated with disease-specific
survival in METABRIC training cohort. Genes are sorted according to their
adjusted p-values.
Gene symbol Gene name
ACAA1 acetyl-CoA acyltransferase 1
CPT1A carnitinepalmitoyl transferase 1A
ACADM acyl-CoA dehydrogenase, C-4 to C-12 straight chain
GCDH glutaryl-CoA dehydrogenase
ACADS acyl-CoA dehydrogenase, C-2 to C-3 short chain
ACAT2 acetyl-CoA acetyltransferase 2
ECI2 enoyl-CoA delta isomerase 2
ACAT1 acetyl-CoA acetyltransferase 1
ACADSB acyl-CoA dehydrogenase, short/branched chain
CYP4A11 cytochrome P450 family 4 subfamily A member 11
ACADVL acyl-CoA dehydrogenase, very long chain
ADH1A alcohol dehydrogenase 1A (class I), alpha polypeptide
CPT2 carnitine palmitoyl transferase 2
HADHB
hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/
enoyl-CoA hydratase (trifunctional protein), beta subunit
ADH1B alcohol dehydrogenase 1B (class I), beta polypeptide
ALDH9A1 aldehyde dehydrogenase 9 family member A1
ACSL5 acyl-CoA synthetase long-chain family member 5
ADH4 alcohol dehydrogenase 4 (class II), pi polypeptide
ALDH3A2 aldehyde dehydrogenase 3 family member A2
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3.3.2 High FAO signature expression is associated with better disease-
specific survival in training dataset
To visualise the FAO signature expression distribution in the METABRIC training co-
hort, a cluster analysis was performed. As shown in Fig 3.3, approximately three clusters
could be visually determined from the heatmap: patients in cluster 1 have higher ex-
pression of the FAO signature compared to patients in cluster 3; while patients in cluster
2 exhibit more heterogenous expression of the FAO signature.
Expression of ADH1A and ADH1B genes contributed a large extent to the high FAO
signature expression in cluster 1 (orange arrows). Both ADH1A and ADH1B are lo-
cated next to each other on chromosome 4q23, encode enzymes that oxidise alcohol
into aldehyde. At the moment, there is no evidence in the literature that ADH1A or
ADH1B is involved in regulation of FAO. Additionally, cBioPortal analysis revealed no
significant copy number alterations in ADH1A and ADH1B using the METABRIC and
TCGA breast cancer cohorts.
Tumours from patients in cluster 3 were observed to have increased CPT1A and ACAT2
expression (black arrows), although the remainder 17 genes were generally expressed
lower relative to cluster 1 tumours. Of note, the emphasis in this analysis is to show
that constructing a metagene from the average expression of the 19 genes is a reasonable
measure of the FAO pathway in the tumour from each patient. This is important for
the survival analyses that is described in the sections below.
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Figure 3.3: Cluster analysis of genes in the FAO signature in the METABRIC training cohort. The distribution of expression of the FAO
signature in the METABRIC training cohort was visualised by cluster analysis. The distance metric was Euclidean, and complete linkage was selected as
the clustering method. Red indicates higher relative expression, while blue indicates lower relative expression of genes. Columns represent each patient
(n=973), while rows represent each gene as indicated on the right. The average FAO signature score is denoted on top of the heatmap, with a similar
colour scale used for the cluster analysis. Black arrows indicate genes expressed higher in cluster 3, while orange arrows indicate genes expressed higher
in cluster 1.
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To assess how the FAO signature expression is correlated with DSS, a Kaplan-Meier
survival curve was plotted using the METABRIC training data. Patients were stratified
into two groups - low (below median cut-off) and high (above median cut-off), based
on their average expression of the 19-gene signature. Statistical significance between
curves was assessed using the log-rank test (Bland and Altman, 2004). As shown in Fig
3.4, patients with high expression of the FAO signature had better survival compared
to those in the low group (log-rank test p=4.4-e06).
Figure 3.4: FAO signature is significantly associated with DSS of
METABRIC training data. Average expression level of the signature was calcu-
lated for each patient. Based on their signature score, patients were stratified into two
groups - low (below median) and high (above median cut-off). Statistical significance
between curves was determined using the log-rank test.
3.3.3 FAO signature expression is prognostic in independent breast
cancer cohorts
To investigate whether the prognostic performance of the FAO signature expression was
reproducible in independent datasets, survival analysis was performed on seven inde-
pendent, publicly available datasets. Of note, these datasets included those generated
on different platforms (e.g. Agilent, Affymetrix, Illumina HiSeq), in addition to the Illu-
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Table 3.3: FAO signature expression is associated with survival in multi-
ple breast cancer datasets. RFS, relapse-free survival; DRFS, distant relapse-free






(Low vs High) Hazard ratio 95% CI
FDR adjusted
p value
GSE42568 104 0.00562 (RFS) 2.24 1.25 - 4.03 0.007
104 9.58E-05 (OS) 4.05 1.84 - 8.66 0.000311
GSE20685 327 0.0118 (DMFS) 1.98 1.26 - 3.11 0.003
0.00243 (OS) 1.75 1.12 - 2.27 0.013
GSE46563 94 0.000543 (DMFS) 5.46 1.86 - 16.1 0.002
GSE25066 508 5.98E-06 (DRFS) 2.43 1.64 - 3.62 1.17E-05
TCGA breast cancer cohort 776 0.00387 (RFS) 2.08 1.25 - 3.47 0.0047
1096 0.097 (OS) 1.31 0.95 - 1.81 0.097
GSE22219 216 0.00753 (DRFS) 1.82 1.17 - 2.85 0.0085
BRCA2116 672 6.51E-05 (DRFS) 2.02 1.42 - 2.88 9.10E-05
mina BeadChip used to derive the training data. As summarised in Table 3.3, the FAO
signature expression was significantly associated with distant relapse-free survival and
overall survival in several breast cancer datasets. Notably, in all datasets analysed, the
hazard ratio for the ’Low’ group were all > 1, which suggests increased risk for an event
for this group, compared to the ’High’ group. Taken together, this analysis supports
the concept that downregulation of genes involved in fatty acid oxidation is associated
with poor survival outcomes in breast cancer. Of note, the BRCA2116 dataset - which
was previously compiled and published by Associate Professor Michael Black (Nagalla
et al., 2013) - was used to specifically validate the findings in the training data. In this
dataset, only patients that were ER-positive and received endocrine therapy (n=672)
was used to validate the performance of the FAO signature.
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3.3.4 Low FAO signature expression is correlated with clinical fac-
tors associated with poor prognosis
To determine the correlation of the FAO signature expression with established prognos-
tic factors, boxplots of the FAO signature expression compared to tumour grade and
molecular subtype was performed. As shown in Figure 3.5a and b, the FAO signature
expression was lower in ER-negative, compared to ER-positive tumours. In two indepen-
dent datasets, grade 1 had higher expression of the FAO signature compared to grade 3
tumours. (Fig 3.5c,d). Furthermore, the FAO signature was expressed higher in luminal
A, compared to basal/HER2-enriched molecular subtypes (Fig 3.5e-g). Therefore, the
data suggests that the FAO signature expression is significantly correlated with clinical
features associated with poor prognosis.
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Figure 3.5: FAO signature expression higher in ER-positive, Grade 1 and
luminal molecular subtype. FAO signature expression higher in (a, b) ER-positive
compared to ER-negative tumours; (c,d) grade 1 compared to grade 3 tumours and (e,
f, g) Luminal A compared to basal molecular subtype tumours. Wilcoxon-rank sum test
p**≤0.01.
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Table 3.4: FAO gene signature is an independent prognostic factor in breast






GSE25066 (n=466) (DRFS) Grade, ER status 1.62 0.0592
BRCA2116 (n=660) (DRFS) Grade, size, lymph node status 1.5 0.09
GSE42568 (n=104) (RFS) Grade, size, lymph node status 2.55 0.009
GSE22219 (n=216) (RFS) ER status, age, size, lymph node status 1.91 0.014
GSE46563 (n=94) (DRFS) Grade, ER status, size 5.54 0.009
GSE20685 (n=327) (DRFS) Age 1.7 0.009
TCGA breast cancer (RFS) ER status 1.61 0.09
3.3.5 FAO signature expression is prognostic independently of stan-
dard histopathological features in breast cancer
To determine whether the FAO signature is an independent prognostic factor, multi-
variable Cox regression was performed by including other established clinical prognostic
covariates in the model. This analysis was conducted on eight datasets and is sum-
marised in Table 3.4. After adjustment for available clinical factors, in most datasets,
the FAO signature was a significant, or trended towards an independent prognostic fac-
tor, with hazard ratios ranging from 1.3 to 5.5.
3.3.6 FAO signature expression is inversely correlated with prolifer-
ation gene signature
High expression of the FAO signature is associated with better survival, and low tumour
proliferation is also associated with good prognosis. Therefore, the assocation between
the FAO signature and proliferation was explored. An 12-gene proliferation signature
known as the mitosis kinome score (MKS) was used as a molecular readout of cell pro-
liferation (Bianchini et al., 2013). As summarised in Table 3.5, the FAO signature has
a significant negative correlation with proliferation in all datasets analysed.
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Table 3.5: FAO signature expression is negatively correlated with the MKS
proliferation signature in breast cancer datasets. All p values are FDR adjusted.
Dataset n Spearman’s rho p
GSE42568 104 -0.27 5.174E-03
GSE20685 327 -0.44 <3.85E-16
GSE46563 94 -0.403 7.70E-05
GSE25066 508 -0.45 <3.85E-16
GSE22219 216 -0.6 <3.85E-16
TCGA breast cancer 1215 -0.59 <3.85E-16
3.3.7 High FAO signature expression is associated with good response
to neoadjuvant aromatase-inhibitor treatment
In the METABRIC and BRCA2116 datasets, tamoxifen was the main anti-oestrogen
administered to patients who received endocrine therapy. To investigate whether the
FAO signature is also correlated with clinical response to aromatase inhibitors (AI),
gene expression datasets from the FAIMoS neoadjuvant AI trial was analysed.
Tumours with higher FAO signature expression pre- two-week AI treatment were cor-
related with complete or partial response as determined by the RECIST guideline (Fig
3.6). In contrast, tumours from patients with stable or progressive disease had lower
FAO signature expression before treatment.
3.3.7.1 ESR1 knockdown in MCF7 decreases FAO signature expression rel-
ative to basal expression control
Two lines of evidence suggest an association between oestrogen signalling and the FAO
signature: (i) the signature expression was higher in ER-positive compared to ER-
negative tumours and (ii) patients with good response neoadjuvant AI treatment had
increased FAO signature expression.
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Figure 3.6: High FAO signature expression is associated with good response
to short-term neoadjuvant AI treatment. FAO signature expression in 102 pre-
treatment breast tumour samples with different responses to short term oestrogen with-
drawal treatment (Progress n=7; complete response n=7; stable disease n=41; partial
response=47). Disease progression vs complete response t-test p = 0.039.
To investigate how alterations in oestrogen signalling and proliferation affects the FAO
signature expression, transcriptome data from MCF7 cells with ESR1 knockdown and
basal expression was analysed to compare the FAO signature expression between the
two conditions (Al Saleh, Al Mulla, and Luq, 2011).
As shown in Fig 3.7, a trend between ESR1 knockdown and decreased FAO signature
expression was observed (t-test p=0.07), which achieved statistical significance when
one outlier value (cirled in blue) from the ESR1 knockdown triplicate was removed (t
test p=0.0036). In this system, the MKS proliferation signature was increased, while the
expression of an oestrogen responsive geneset was decreased, which suggests oestrogen-
independence in ESR1 knockdown, relative to their basal expression counterparts. In-
deed, the authors of this dataset reported increased proliferation of this MCF7 cell
system in their study (Al Saleh, Al Mulla, and Luq, 2011). Taken together, these data
suggest that increased proliferation due to adaptation to decreased oestrogen signalling
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Figure 3.7: ESR1 knockdown decreases FAO signature expression in MCF7
cell line. (a) FAO, (b) MKS and (c) oestrogen-responsive signature expression in MCF7
cells transfected with plasmid encoding ESR1 shRNA. Control line was established from
transfected cells that retained sensitivity to oestrogen and tamoxifen, most likely due to
null shRNA generation. In panel (a), value circled in blue is the proposed outlier value.
t-test p*≤0.05.
decreases the FAO signature expression.
3.3.8 Low FAO signature expression is correlated with better neoad-
juvant chemotherapy response
To determine whether the FAO signature expression was correlated with response to
neoadjuvant chemotherapy, logistic regression was performed on breast tumour gene
expression datasets from neoadjuvant chemotherapy clinical trials. All datasets used in
this analysis are summarised in Table B.60 under ’Neoadjuvant chemotherapy’.
The average FAO signature expression score was computed for each patient, and re-
sponse was defined as having achieved pathological complete response (pCR). As shown
in the forest plot in Fig 3.8, low FAO signature score was associated with higher odds
of achieving pCR. Since the signature is correlated with molecular subtypes, this find-
ing is consistent with that of Bonnefoi et. al. who reported greater pCR rates for
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Figure 3.8: Low FAO signature expression is associated with neoadjuvant
chemotherapy pCR. The n/N indicates the number of patients that achieved pCR
(or not) out of the total sample size and the odds ratio gives a point estimate of the
odds of achieving pCR in each trial from patients in the Low FAO signature expression
group.
HER2+/non-luminal tumours, relative to luminal A tumours (Bonnefoi et al., 2014).
3.3.9 CPT1A is likely to be co-amplified with CCND1 in multiple
cancers
Thus far, the FAO signature expression has been shown to be correlated with good
prognosis and expressed higher in tumours with favourable clinical features (e.g., ER-
positive and grade 1). Gatza et. al. analysed the copy number and gene expression
from highly proliferative breast luminal tumours and identified CPT1A as one of the
essential genes for tumour proliferation (Gatza et al., 2014). CPT1A - a member of the
19-gene FAO signature - is the rate-limiting enzyme for FAO, and its amplification can
be interpreted as an important feature for tumour growth. However, CPT1A is located
in the cytogenetic band 11q13.3, which is also the cytogenetic location of CCND1 (Fig
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Figure 3.9: Cytogenetic locations of CCND1 and CPT1A in 11q13. Genomic
location of CPT1A relative to CCND1 is indicated. Figure was derived from the UCSC
Genome Browser.
3.9) - a key oncogene that is amplified and overexpressed in many cancers (Musgrove
et al., 2011). The chromosomal proximity between these two genes begs the question:
is CPT1A frequently co-amplified with CCND1 in breast cancer?
To test this hypothesis, analysis of copy number data was conducted using data ob-
tained from cBioPortal (Cerami et al., 2012; Gao et al., 2013). Three genes: FGF3,
FGF4, and CTTN that have been shown to be co-amplified with CCND1 were in-
cluded in this analysis as ’positive’ controls for 11q13 amplicon amplification (Zaharieva
et al., 2003). Conversely, three genes on other chromosomes: ERRB2 (chromosome
17q12), and MELTT6 and FGD5 (chromosome 3p25) known to be amplified at differ-
ent frequencies in breast cancer were used as ’negative’ controls for intra-chromosomal
amplification. As observed in Fig 3.10, the amplification frequency of CPT1A is lower
than CCND1. If CCND1 is the primary amplicon driver, it is possible that genes lo-
cated a substantial distance away (e.g., CPT1A) may not be co-amplified in some cases.
Hence in most cases, when CPT1A is amplified, so is CNCD1 ; but the reverse is rarely
true.
Using the METABRIC copy number data, 16% of the cohort had CCND1 amplification,
while 9% had a CPT1A amplification (Fig 3.10a). Both amplifications had a significant
tendency to co-occur (odds ratio >3, Fisher’s exact test p=<0.001). Similar observa-
tions were also made in the breast TCGA cohort (Fig 3.10b). Furthermore, analysis of
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Figure 3.10: CPT1A is likely to be co-amplified with CCND1 in breast
cancer. cBioPortal copy number analysis of CPT1A and CCND1 in (a) METABRIC
and (b) TCGA cohort. In both panels, red bars indicate amplification events. In panel
(b) the blue bars indicate deletion events. Of note, each column represents a single
patient. This is particularly more obvious in panel (b).
other cancer types found frequent co-amplification of CPT1A and CCND1, which sug-
gests a positive selection of this amplicon across multiple cancers (Table 3.6). Analysis
performed on copy number data from the Cancer Cell Line Encyclopaedia found 73 cell
lines with CCND1 and CPT1A co-amplification, and is summarised in Supplementary
Table B.2. Taken together, findings from these analyses suggest that CPT1A is likely
to be co-amplified with CCND1 within the 11q13 locus in a small subset of cancers.
3.3.10 FAO signature is prognostic in multiple cancers
To investigate whether the prognostic capacity of the FAO signature could be extended
to other cancers, survival analysis based on the FAO signature expression was per-
formed using datasets available from the KMplotter online software (www.kmplot.com)
or accessed from public repositories. As shown in Fig 3.11, the FAO signature was asso-
ciated with overall survival in lung and gastric cancers, and TCGA clear cell renal cell
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Table 3.6: CPT1A is likely to be co-amplified with CCND1 in multiple
cancers. This table was derived from the output from cBioPortal. The log odds ratio
calculates the odds of co-occurence of amplifications between CCND1 and CPT1A. The











(TCGA, provisional) 35 20 >3 <0.001
Head and neck (n=279)
(TCGA, Nature 2015) 28 15 >3 <0.001
Neuroendocrine prostate cancer (n=114)
(Trento/Cornell/Broad 2016)
27 27 >3 <0.001
Lung squamous (n=504)
(TCGA, provisional)
14 6 >3 <0.001
Bladder urothelial carcinoma (n=413)
(TCGA, provisional)
12 7 >3 <0.001
Cholangiocarcinoma (n=36)
(TCGA, provisional) 11 6 >3 <0.001
Pancreatic (n=109)
(UTSW, Nature Commun 2015) 9 7 >3 <0.001
Ovarian serous (n=606)
(TCGA, provisional)
7 6 >3 <0.001
Stomach adenocarcinoma (n=295)
(TCGA, Nature 2014)
7 6 >3 <0.001
Cutaneous melanoma (n=479)
(TCGA, provisional)
7 5 >3 <0.001
Hepatocellular carcinoma (n=442)
(TCGA, provisional) 7 4 >3 <0.001
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Figure 3.11: FAO signature expression is associated with overall survival in
different cancers. The prognostic performance of the FAO signature was assessed in
(a) lung adenocarcinoma (n=720) and (b) gastric cancer (n=876) using the KMplotter
online software. (c) FAO signature expression is associated with overall survival in
TCGA ccRCC cohort (n=588).
carcinoma (ccRCC) (Szasz et al., 2016; Creighton et al., 2013). Furthermore, the signa-
ture expression was a significant prognostic factor in ccRCC after adjusting for tumour
size and stage (HR 1.77, p=0.0002). In melanoma, higher FAO signature expression
was correlated with better survival. In the GSE65904 dataset reported by Cirenajwis
et. al., high FAO signature expression was associated with better disease-free survival
(Fig 3.12a), while in the TCGA cohort, the FAO signature expression was significantly
associated with overall survival (Fig 3.12b) (Cirenajwis et al., 2015; Akbani et al., 2015).
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Figure 3.12: FAO signature expression is associated with melanoma sur-
vival in different datasets. The FAO signature is associated with (a) disease-specific
survival (GSE65904, n=177) and (b) overall survival (TCGA cohort, n=396).
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3.3.11 FAO signature expression is down-regulated in tumour com-
pared to normal tissues
To investigate how the FAO signature expression compares between normal and tumour
tissues, gene expression datasets from multiple cancers with associated normal tissues
were analysed. As shown in Fig 3.13 and 3.14, the FAO signature was down regulated
in 11 different tumour types compared to their normal counterparts. Additionally, in
prostate- (Fig 3.13d), oral- (Fig 3.14d) and bladder (Fig 3.14e) cancers, there was a
clear downregulation of the FAO signature expression from healthy, normal tissues to
increased disease states. Of note, the scales on the y-axis vary between different datasets
due to different normalisation methods (e.g., robust multichip average or MicroArray
Suite 5.0) performed by authors that deposit these datasets. Regardless of this method-
ological difference, the trend of decreased FAO signature expression in tumour tissues
was consistent across all cancer types analysed.
Figure 3.14: (a-e) FAO signature is downregulated in tumours compared to
normal tissues. FDR-adjusted p **≤0.01.
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Figure 3.13: (a-f) FAO signature is downregulated in tumours compared to
normal tissues. FDR-adjusted p **≤0.01; NS = non-significant.
3.3.11.1 Androgen-deprivation increases FAO signature expression in prostate
cancer
Apart from breast cancer, prostate cancer is another hormone-driven malignancy: over
95% of prostate tumours express the androgen receptor (Leav et al., 2001). Castration
- a means of depriving prostate cancer cells of androgen - is the first line treatment
for androgen-dependent tumours, analogous to oestrogen-withdrawal treatment in ER-
positive breast cancer. To investigate whether the findings observed between the asso-
ciation of the FAO signature and inhibition of oestrogen signalling demonstrated earlier
could also be extended to prostate cancer, gene expression datasets from mouse tumour
xenografts post-castration were analysed.
In the GSE33316 dataset generated by Sun et. al. (Sun et al., 2014), surgical castration
of mice with LuCaP35 xenografts resulted in the decreased expression of an androgen-
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responsive geneset, which indicates decreased androgen signalling (Fig 3.15c). Conse-
quently, proliferation was lowered in castrated mice, compared to the sham-treated coun-
terparts (Fig 3.15b). Notably, the FAO signature expression was significantly increased
in castrated, compared to sham-treated mice (Fig 3.15a). In an independent dataset
using tissue from KuCaP2 xenograft (Terada et al., 2010), castrate-resistant tumours
reacquired their androgen signalling and proliferation to levels similar to androgen-
dependent tissue (Fig 3.15f). The FAO signature was significantly down regulated in
the castrate-resistant, compared to androgen-dependent tissue (Fig 3.15d).
3.4 Discussion
3.4.1 FAO signature expression is prognostic independently of stan-
dard histopathological features in breast cancer
The FAO signature is one of several genesets that are associated with adjuvant endocrine
treatment resistance. However, the signature expression was also found to be correlated
with outcome in the adjuvant or neoadjuvant settings in several breast cancer cohorts,
of which some were from chemotherapy clinical trials. In the endocrine- or chemother-
apy treated adjuvant setting, high FAO signature expression was observed to correlate
with better recurrence-free or overall survival in multiple breast cancer datasets. After
adjusting for prognostic clinical factors, the signature expression remained significantly
associated with survival.
In the neoadjuvant setting, the FAO signature expression was higher in post-, compared
to pre-treatment biopsies of patients that had good response to short term AI treatment.
In contrast, no significant difference in the FAO signature expression was observed in
poor responders when comparing the pre- and post-treatment biopsies. In neoadju-
vant chemotherapy trials, low signature expression in the primary biopsies was observed
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Figure 3.15: FAO signature expression is altered in castrated or androgen-
independent prostate xenografts in mice. (a-c)(a) FAO, (b) MKS and (c)
androgen-responsive signature expression in LuCaP35 xenografts inoculated subcuta-
neously for one month, and then tumours harvested one month post castration or sham
surgery. n=5 for both conditions. (d-f) (d) FAO, (e) MKS and (f) androgen-responsive
signature expression in KuCaP2 xenografts established in mice and tissues harvested
at various stages pre- (androgen-dependent) and post-castration (regressed, androgen-
independent). n=4 for all conditions.
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to be significantly associated with achieving a complete pathological response. Given
that the FAO signature was negatively correlated with the MKS proliferation signature,
these findings suggest an association between proliferation and FAO in primary tumours.
The FAO signature expression was higher in ER-positive and grade 1, compared to
ER-negative, grade 3 breast tumours. What evidence is available currently that could
possibly explain the inverse relationship between tumour ER status and the FAO signa-
ture expression? Using isotope-labelling and mass spectrometry metabolome analysis,
Louie et. al. demonstrated the different fates of exogenous palmitate in a panel of
cancer cell lines, including breast cancer (Louie et al., 2013). The ER-negative, highly
invasive MDA MB231 cell line incorporated exogenous palmitate into structural and sig-
nalling lipid molecules, while the ER-positive, poorly invasive MCF7 cell line directed
exogenous fatty acids to generate acylcarnitine, a precursor of β-oxidation. As such,
the different fates of palmitate between these two cell lines could explain why the FAO
signature expression differs between ER-positive and negative tumours. Additionally,
since FAO occurs in the mitochondria, one cannot discount a general decreased mito-
chondrial respiration in cancer cells. Indeed, oxygen consumption analysis on a panel of
breast cancer cells indicate that MDA-MB231 cells have a higher extracellular acidifi-
cation rate (ECAR)-to-oxygen consumption rate (OCR), which suggests higher aerobic
glycolysis in MDA MB231, relative to MCF7 cells (Pelicano et al., 2014). In contrast,
MCF7 cells have a higher OCR:ECAR ratio, which suggests more active mitochondrial
oxidative metabolism.
3.4.1.1 ESR1 knockdown decreases FAO signature expression in MCF7 cell
line
Based on the observation that patients with good response to AI treatment - which
blocks oestrogen signalling - had increased FAO signature expression, the relationship
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between ESR1 expression and FAO signature expression was explored. It should be
noted that the increased expression of the FAO signature expression in patients that
respond or achieved complete response to short term oestrogen withdrawal therapy is
likely due to decreased tumour proliferation.
In MCF7 cells, knockdown of ESR1 decreased the FAO signature expression, while
expression of the MKS proliferation signature was increased. One possibility for the
increased proliferation is that this particular population of cells could have engaged
alternative signalling pathways to bypass decreased oestrogen signalling, and there-
fore, phenocopies endocrine-treatment resistance. As such, the decreased FAO signa-
ture expression observed in oestrogen-independent MCF7 cells complements the finding
of increased signature expression in patients with good response to neoadjuvant anti-
oestrogen treatment. These results do not imply that genes involved in FAO are directly
regulated by ER. More likely, these findings suggest the decrease in the FAO pathway
in proliferating cells. Instead, these findings suggests that the alterations in other path-
ways brought about by oestrogen dependence (or independence) may indirectly rewire
expression of genes involved in FAO.
3.4.2 CPT1A is co-amplified with CCND1 in multiple cancers
An unexpected, but intriguing finding in this chapter is the observation that CPT1A
is co-amplified with CCND1 in several cancers. This analysis was motivated the find-
ings of Gatza et. al., who reported CPT1A as an essential gene in a subset of highly
proliferative breast luminal tumours (Gatza et al., 2014). CCND1 is located within the
same cytoband as CPT1A, and is more commonly amplified in ER-positive, compared
to ER-negative breast tumours (Elsheikh et al., 2008). Analysis of copy number data
in multiple cancers suggests CPT1A is most likely co-amplified with CCND1. This may
explain why tumours with CPT1A amplification were highly proliferative. Furthermore,
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FGF3 and FGF4 were amplified at similar frequency as CCDN1. The FGF family is
associated with tumour initiation and progression, and phase I/II trials that inhibit
FGF receptor signalling was shown to exhibit antitumour response (Dieci et al., 2013;
Turner and Reis-Filho, 2006; Jing et al., 2016).
Of all the amplified genes that were associated with high proliferation identified by Gatza
et. al. (Gatza et al., 2014), only CPT1A expression was not associated with survival
in two independent datasets. However, several reports have interpreted the increased
expression or amplification of CPT1A per se as an important oncogenic event. Using
the cBioPortal database, Balaban et. al. found ER-positive tumours with CPT1A al-
terations to have worse overall survival than what was defined as ’normal’ expression
(Balaban et al., 2017). It was not clear how the cut-offs were defined, and this finding
was not reproduced in an independent dataset. It is tempting to speculate that patients
with ’alterations’ in CPT1A may also have CCND1 amplification. In their review, Deep
et. al. mentioned 22% of patients from a cohort of neuroendocrine prostate tumours
(Trento/Cornell/Broad dataset) that were resistant to anti-androgens had amplifications
in CPT1A, which were likely to drive the resistance phenotype (Deep and Schlaepfer,
2016). Based on this, the authors proposed inhibiting FAO as a second-line treatment
in these androgen-independent tumours. As shown in Table 3.6, in this dataset, CCND1
and CPT1A were co-amplified at a frequency of 27%. It was not apparent whether Deep
et. al. were aware of CCND1 and CPT1A co-amplification in these tumours.
Experimental evidence is required to demonstrate that amplification of CPT1A is indeed
oncogenic, and not a passenger event of CCND1 amplification. If CPT1A amplification
is a selected trait, this should make the cancer cells more sensitive to CPT1A small
molecule inhibition such as etomoxir, compared to cells that are not amplified at that
locus. Similarly, cells with CCND1 amplification would be more sensitive to CDK4/6
inhibition (e.g., palbociclib), relative to non-amplified cells. If the latter, but not for-
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mer, is true, then a case with experimental evidence can be made against CPT1A as an
oncogene in subset of cancers with 11q13 amplification.
3.4.3 FAO signature expression is lower in tumours, compared to
normal tissues; and is prognostic in several cancer types
Even though the FAO signature was generated using gene expression data from breast
cancer, the prognostic association of this signature was also observed in gastric, lung
and kidney cancers, and melanoma. The subsections below provide a discourse of the
FAO signature in terms of its prognostic capacity and expression between tumour and
normal tissues, taking the literature into consideration.
3.4.3.1 Gastric cancer
In gastric cancer, the survival curves for both high and low FAO signature expression
groups showed a steep initial decline, which is characteristic of advanced disease due to
late diagnosis. Nonetheless, the signature significantly risk-stratified patients. In addi-
tion, the FAO signature was found to be down regulated in tumour, compared to normal
tissues. This finding is in agreement with a pilot study by Enjoji et.al, who reported
decreased expression of genes involved in fatty acid β-oxidation in gastric tumours, com-
pared to normal tissues (Enjoji et al., 2016). On the other hand, the authors observed
increased expression of genes involved in lipid synthesis (e.g., ACC1, FAS, SREBP1C )
in cancer relative to normal gastric tissues. These findings are consistent with the known
mutually exclusive activity between fatty acid catabolic and anabolic reactions.
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3.4.3.2 Lung cancer
The lung cancer dataset used in the KMplotter analysis comprised both squamous and
adenocarcinoma cases. Analysis of both histological subtypes combined showed a sub-
stantial separation of the Kaplan-Meier curves. When analysed as individual histological
subtypes, the signature was strongly prognostic in the adenocarcinoma only cohort, but
no significant difference in survival was observed in the squamous cell only cohort. This
could be due to squamous cell lung cancer having very low fatty acid oxidation activity,
such that it is not feasible to stratify patients further based on this pathway. This is
supported by the lower FAO signature expression in squamous, compared to adenocar-
cinoma of the lung (Supp Fig A.1).
Treatment of lung adenocarcinoma cell lines with pioglitazone - an agonist of the nu-
clear receptor PPAR agonist - resulted in increased fatty acid oxidation (Srivastava et al.,
2014). The increased oxidative metabolism resulted in the generation of reactive oxygen
species, leading to the activation of the retinoblastoma tumour suppresor protein and
cell cycle arrest. Furthermore, the increased FAO in response to pioglitazone treatment
resulted in decreased glutamine oxidation, a key anaplerotic pathway utilised by cancer
cells. Therefore, the Srivastava et. al. study suggests that pharmacologically induced
increase in FAO can halt the cell cycle of lung cancer cells, and rewire the metabolic
state toward a less proliferative state.
3.4.3.3 Clear cell renal cell cancer
In ccRCC, inactivation of VHL occurs in approximately 90% of tumours, which conse-
quently stabilises the transcription factor HIF1A (Nickerson et al., 2008). This results
in the transcriptional activation of genes involved in glycolysis and lactate efflux such
as GLUT1, LDHA and MCFT4, and anaplerotic pathways (Pinthus et al., 2011). How-
ever, the role FAO in this extensive metabolic rewiring observed in this disease remains
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poorly characterised.
The FAO signature was expressed higher in normal kidney, compared to ccRCC tu-
mours. This finding is a more relevant extension of that reported by La Gory et. al,
whom observed a decreased expression of a geneset involved in FAO in 786-O ccRCC
cell line compared to normal kidney cells (LaGory et al., 2015).
Survival analysis using the ccRCC TCGA cohort found that patients with high FAO
signature expression had better overall survival, compared to patients in the low group.
Notably, the FAO signature expression was an independent prognostic factor after ad-
justing for tumour grade and stage. ccRCC can be classified into two molecular subtypes:
ccA and ccB (Brannon et al., 2014). The ccA subtype had increased expression of genes
involved in FAO, angiogenesis, and decreased expression of cell cycle and EMT-related
genes, relative to the ccB subtype. Importantly, patients assigned the ccA subtype had
better disease- and overall survival, compared to the ccB subtype. In another study,
combined proteomics and metabolomics of ccRCC tissues revealed decreased abundance
and activity of enzymes involved in the FAO pathway with increasing tumour grade.
Taken together, findings in this chapter corroborate and extend those in the literature
(Brannon et al., 2014; LaGory et al., 2015), and show for the first time, a prognostic
association between FAO and survival in ccRCC.
3.4.3.4 Colorectal cancer
In colorectal tumour-normal analysis, the FAO signature was down regulated as the
disease progressed from normal tissue to benign adenoma to adenocarcinoma, which
suggests the reprogramming of FAO during disease progression. Laser capture microdis-
sected tumours had lower FAO signature expression compared to bulk tumour sections,
which suggests the alteration is mainly from tumour, rather than stromal cells (Supp
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Fig A.2). These findings are in agreement with that of Wisnieswki et. al., who reported
decreased protein abundance of most of the enzymes involved in FAO, including CPT1A,
CPT2 and ACAD (Wisniewski et al., 2015).
3.4.3.5 Prostate cancer
In prostate tumours, the signature expression was lower in tumours, relative to normal
prostate tissues. Furthermore, castrate-resistant tumours had lower signature expres-
sion compared to benign and local disease. Analysis of xenograft studies showed that
the FAO signature was increased upon castration, and castrate-resistant tumours had
decreased signature expression relative to androgen-dependent tissues. Furthermore,
the MKS and FAO signatures were inversely expressed in these prostate cancer stud-
ies, which supports the negative correlation between both signatures observed in breast
cancer.
The findings from the analysis above corroborates several recent studies reported in the
literature regarding the role of FAO in prostate cancer. By performing a bioinformatics
screeen on several prostate tumour datasets, Torrano et. al. identified low peroxi-
some proliferator gamma co-activator 1 alpha (PGC1A) - a key oxidative metabolism
transcriptional co-regulator - expression to be associated with poor prognosis (Torrano
et al., 2016). Overexpression of PGC1A in DU145, PC3 and LNCaP prostate cancer
cell lines promoted beta-oxidation, decreased growth rates of all three cell lines; and
lowered anchorage-independent growth and bromodeoxyuridine incorporation in PC3
cells. In another study, FAO flux analysis using the Seahorse XF system in syngeneic
RWPE-1 normal prostate epithelial cells with increasing degree of invasiveness found
highly invasive clones to have decreased FAO flux, relative to the parental epithelial and
pre-malignant counterparts (Vayalil and Landar, 2015). Additionally, Dueregger et. al.
showed that RWPE-l cells were more capable of utilising exogenous lipid for energetic
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purposes, compared to prostate cancer cell lines (Dueregger et al., 2015).
3.5 Summary, strengths and limitations
To summarise, the 19-gene FAO signature expression is:
1. prognostic in breast and several other cancer types
2. associated with response to neoadjuvant endocrine or chemotherapy in breast cancer
3. expressed lower in tumour, compared to normal tissues in 11 different cancers
An overarching finding in this chapter is the inverse correlation between the FAO and
MKS proliferation signatures. This raises two questions: (i) why is FAO decreased in
proliferating cells, and (ii) what is the effect of modulating FAO on cancer cell prolif-
eration? Answering these questions in experimental systems might shed new insights
on how an important metabolic pathway intersects with proliferation, and may reveal
potential therapeutic opportunities.
The strength of this chapter is that the validation exercise robustly reproduced the prog-
nostic performance of the FAO signature in seven independent breast cancer datasets, as
well as on datasets from other cancer types. Furthermore, tumour-normal analysis of the
FAO signature expression was also performed across a panel of cancer types. In short,
the comprehensive analyses in term of sample size and range of tumour type undertaken
and described in this chapter provides strong statistical support for observations made.
There are also limitations to this analyses presented in this chapter. Firstly, all of the
analyses conducted were based on mRNA expression. Establishing a correlation between
gene and protein expression of metabolic enzymes in tumour tissues is not trivial, given
that many factors, including tissue type, contexts such as hypoxia and locale of a partic-
ular biopsy relative to the whole tumour, need to be considered. Furthermore, metabolic
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pathway flux is regulated by a minority of rate-limiting enzymes, relative to all enzymes
involved in the pathway. Therefore, deriving a pathway surrogate from the average score
of all 19 genes from the FAO signature may not fully represent its activity level. How-
ever, proteogenomic correlation analysis of TCGA colorectal and breast cancer cohorts
found a correlation between mRNA and protein expression levels (Spearman’s rho = 0.47
for colorectal cohort, FDR p= 9.42e-5 for colorectal, rho = 0.5-0.75 for breast cohort,
p=0.009), supporting studies such as this as a ’first-pass’ to evaluate pathway activity
(Mertins et al., 2016; Zhang et al., 2014). Furthermore, proteome analysis of metabolic
enzymes between normal colon, adenoma and laser microdissected tumours found a de-
creased expression of enzymes involved in beta-oxidation in tumours, relative to healthy
colon tissue (Wisniewski et al., 2015). Therefore, these data suggest that, in colorectal
and breast cancer at least, there is some correlation between mRNA and protein ex-
pression of genes involved in FAO. However, proteome analysis of other tumours would
be required to further substantiate the mRNA-protein correlation in other tumour types.
Secondly, it is possible that other mechanisms (e.g., post-translational phosphorylation,
acetylation, epigenetic) could affect the activity of a particular metabolic enzyme regula-
tion, which would not be observed at the mRNA level. Thirdly, metabolic pathways do
not occur in silos, but rather, as highly organised networks. Therefore, changes in FAO
may also inevitably alter the flux through other pathways. Since no other key pathways
involved in central carbon metabolism (e.g., glycolysis, oxidative phosphorylation) were
significantly enriched from the Cox regression analysis on breast tumours, it is not clear





differentiation alters the FAO
signature expression
4.1 Background
Epithelial-to-mesenchymal transition (EMT) is a transdifferentiation process during
which cancer cells lose cell-to-cell adhesion, adopt a mesenchymal phenotype, and ac-
quire migratory and invasive properties to metastasise (Nieto et al., 2016).
Both stem cells and EMT share an underlying theme of cellular differentiation. For
instance,and as mentioned in the Introduction, basal population of mammary stem cells
(MaSC) expresses key EMT effectors such as SNAI2 and TWIST1 ; and knockout of
SNAI2 in the basal population of MaSC led to expression of luminal markers such as
GATA3 and ER, which suggests that SNAI2 is essential to maintain the less differen-
tiated basal stem cell population (Nassour et al., 2012). With regards to metabolism,
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Folmes et. al. show that as stem cell differentiates, oxidative metabolism increases
(Folmes et al., 2012). However, how FAO contributes to cell fate acquisition remains
unclear. This chapter will explore how changes in the morphological and differentiation
cell states affect the FAO signature expression.
This chapter aims to address two related question:
(i) Since low expression of the FAO signature is associated with prognosis in certain
cancers, and EMT is understood to be important for tumour metastasis; is there an
association between these two processes?
(ii) As mentioned above, EMT is associated with loss of an epithelial phenotype. Since
cancer cells typically lose their differentiation status (Jogi et al., 2012), what is the re-
lationship between cellular differentiation and the FAO signature expression?
4.2 Objectives
The two overarching objectives of this chapter are to use published gene expression
datasets to:
(i) investigate the association between the FAO signature expression and EMT induced
by different methods such as TGFβ treatment, 2-hydroxyglutarate accumulation, and
transgenic expression of key EMT transcription factors;
(ii) gain insight into how cellular differentiation from a mammary stem cell to ma-




4.3.1 FAO signature expression and EMT in cell systems
4.3.1.1 Transforming growth factor beta-induced EMT decreases FAO sig-
nature expression in cell systems
Treatment of selected cell lines with transforming growth factor beta (TGFβ) is an
established model to study EMT (Xu, Lamouille, and Derynck, 2009). To explore an
association between the FAO signature and EMT, microarray datasets of human and
mouse mammary epithelial cells treated with TGFβ were accessed. In these studies,
MCF10A or mouse NMuMG mouse mammary glands cells were treated with TGFβ
at different concentrations and time points to study EMT (Deshiere et al., 2013; Shao
et al., 2016; Chang et al., 2013). The EMT signature comprises of 65 genes that were
upregulated during EMT, and was derived from Groger et. al. (Groger et al., 2012).
As shown in Fig 4.1a and 4.1d, treatment of MCF10A cells with TGFβ significantly down
regulated the FAO signature expression, relative to untreated control. As expected, an
EMT geneset was up regulated in the TGFβ treated cells, relative to untreated cells (Fig
1b,e). Similar results were observed in mouse mammary gland cells treated with TGFβ
to induce EMT (Fig 1g,h). Notably, TGFβ treatment followed by a 13 day withdrawal
resulted in the recovery of the FAO signature expression, which suggests that TGFβ
signalling suppresses expression of genes involved in FAO. TGFβ treatment either had
no significant influence (Fig 4.1c,f) or decreased proliferation (Fig 4.1i) based on the
MKS proliferation signature expression.
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Figure 4.1: TGFβ treatment of MCF10A or NMuMG mammary epithelial
cells induces alterations in FAO and EMT signature expression. (a,b,c) FAO
(a), EMT (b) and MKS (c) signature expression in cells treated with 4ng/mL of TGFβ
for three days. n=2 for both conditions. (d,e,f) FAO (d), EMT (e) and MKS (f)
signature expression in cells treated with 5ng/mL of TGFβ for three days. n=2 for both
conditions. (g,h,i) FAO (g), EMT (h) and MKS (i) signature expression in cells treated
with 4ng/mL of TGFβ for 11 days, or treated and then withdrawn for 13 days. n=2 for
all conditions. FDR-adjusted p **≤0.01.
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4.3.1.2 TGFβ-mediated downregulation of FAO signature observed in other
cell types
To investigate whether the association between EMT and FAO could be extended
to other cell types, gene expression datasets from lung- and pancreatic cancer and
melanoma cell lines treated with TGFβ to induce EMT were analysed. All cell lines
featured in this analysis were treated with 5ng/mL TGFβ for various times, and tran-
scriptome analysis performed (Sartor et al., 2010; Maupin et al., 2010).
Consistent with the findings from mammary epithelial cells, TGFβ-induced EMT in all
three cell lines resulted in significant down regulation of the FAO signature, compared
to controls (Fig4.2a,d,g). No significant difference in the MKS signature expression was
observed in these cell lines in response to TGFβ treatment (Fig 4.2c,d,f,i). Furthermore,
in another dataset that analysed the transcriptome of three lung cancer cell lines after
TGFβ treatment, the FAO signature expression was down regulated in all cell lines (Fig
4.3) (Sun et al., 2014).
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Figure 4.2: TGFβ treatment of A549 lung cancer, Panc1 pacreatic cancer or
M-BE bronchoepithelial cells induces alterations in FAO and EMT signature
expression. (a,b,c) FAO (a), EMT (b) and MKS (c) signature expression in A549
cells that were serum-starved for 24 hours and then treated with 5ng/mL of TGFβ for
three days. n=3 for both conditions. (d,e,f) FAO (d), EMT (e) and MKS (f) signature
expression in Panc1 cells treated with 5ng/mL of TGFβ for two days. n=3 for both
conditions. (g,h,i) FAO (g), EMT (h) and MKS (i) signature expression in M-BE cells
treated with 5ng/mL TGFβ for six days. n=3 for all conditions. FDR-adjusted p
**≤0.01, *≤0.05.
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Figure 4.3: Alterations in FAO and EMT signature expression upon TGFβ-
induced EMT in a panel of lung cancer cells. FAO (a) and EMT (b) signature
expression in cells treated with or without 2ng/mL of TGFβ for 3 weeks. n=3 for all
conditions. FDR-adjusted p **≤0.01.
4.3.1.3 2-hydroxyglutarate-induced EMT decreases FAO signature expres-
sion
Accumulation of metabolites due to altered activity levels of the citric cycle enzymes
isocitrate dehydrogenase (IDH) and fumarate hydratase have been shown to induce EMT
(Grassian et al., 2012; Sciacovelli et al., 2016). Introducing heterozygous mutations in
IDH1, but not IDH2, by genome editing in HCT116 colorectal cancer cells induced
EMT via the transcription factor ZEB1 and miR-200 microRNA family (Grassian et al.,
2012). Of note, mutations in IDH1/2 result in a gain-of-function neomorphic activity
115
that results in the accumulation of 2-hydroxyglutarate (2-HG). To explore whether EMT
induced by accumulation of 2-HG alters the FAO signature expression, gene expression
data generated from HCT116 cells with IDH1 R123H and IDH1 R132C mutations and
mouse bone marrow cells transduced with IDH1 mutants or treated with 2-HG were
analysed (Grassian et al., 2012; Chaturvedi et al., 2016).
As shown in Fig 4.4a, the FAO signature was decreased in IDH1 R123H and IDH1
R132C clones, compared to parental or non-targeting controls (blue bars). As expected,
the EMT geneset was upregulated in the IDH1 mutants, relative to controls (orange
bars). This finding was also observed in mouse bone marrow cells transduced with wild
type or mutant IDH1, or treated with 2-HG (Fig 4.4b). Taken together, these findings
indicate that the FAO signature is down regulated in response to the oncometabolite
2-HG induced EMT.
4.3.1.4 EMT associated transcription factors and FAO signature expres-
sion in cell systems
Activity of transcription factors such as SNAI1 and SNAI2 are key to effect EMT (De
Craene and Berx, 2013). To gain insight on how modulating such transcription factors
affects the association between EMT and FAO signature expression, gene expression
datasets from studies that transgenically expressed these factors in MCF7 and human
mammary epithelial (HMEC) cell lines were analysed (Tam et al., 2013; Gras et al.,
2014; Dhasarathy et al., 2011). As shown in Fig (4.5a-c), increased SNAI1, SNAI2
and TWIST1 expression in mammary epithelial cells down regulated expression of the
FAO signature. Of note, upregulation of SNAI1 potently induced EMT and decreased
expression of the FAO signature, compared to SNAI2 and TWIST1.
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Figure 4.4: IDH1/2 mutations or 2-HG treatment induces alterations in
FAO and EMT signature expression. (a) Parental and stable isogenic clones of
non-edited and different IDH1/2 were grown for 6 days before RNA was harvested.
n=2 for all conditions (GSE41802). (b) Immortalised bone marrow cells from C57BJ/6
were retrovirally transduced with empty vector, IDH1 wildtype or mutant constructs,
and then transplated into mouse bone marrow. Half of the recipients of bone marrow
cells transduced with empty vector were treated with R-2HG (1mg/day) for four weeks.
Four weeks post transplantation, cells from bone marrow were flow sorted based on GFP
expression, and RNA harvested. n=3 for all conditions (GSE77594). Error bars = SEM.
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This finding was supported by analysis of an independent dataset that overexpressed
SNAI1, SNAI2 and SNAI3 (Fig 4.5d-f). In this instance, SNAI1 overexpression de-
creased FAO signature expression the most compared to the other two factors (Fig 5d).
This is consistent with the findings reported by the authors that generated this dataset
who reported weaker EMT induction by SNAI2 and SNAI3, compared to SNAI1. Impor-
tantly, this finding was also observed in a breast cancer cell system when overexpression
of SNAI1 in MCF7 cells decreased the FAO signature expression (Fig 4.5g). In all
instances, the MKS signature was either significantly lower when SNAI1/2 was overex-
pressed (Fig 4.5i) or showed no difference, compared to control.
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Figure 4.5: Overexpression of EMT transcription factors in mammary epithe-
lial or breast cancer cells alter FAO and EMT signature expression. (a,b,c)
FAO (a), EMT (b) and MKS (c) signature expression in cells stably transduced with con-
trol or TWIST, SNAI1, SNAI2 overexpression vectors. n=3 for all conditions. (d,e,f)
FAO (d), EMT (e) and MKS (f) signature expression in cells stably transduced with
control, SNAI1, SNAI2, SNAI3 overexpression vectors. n=2 for control and SNA1, n=3
for SNAI2 and SNAI3. (g,h,i) FAO (g), EMT (h) and MKS (i) signature expression
in cells transduced with control, SNAI1 or SNAI2 overexpression adenoviral vectors for
four days. n=3 for both conditions. FDR-adjusted p **≤0.01; NS = non-significant.
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Figure 4.6: SNAI1 overexpression decreases FAO signature expression in
three lung cancer cell lines. H292, H1437 and H441 non-small cell lung cancer cell
lines were stably transduced with control or SNAI1 overexpression retroviral vectors
(GSE16194, Yanagawa et al., 2009). n=1 for all conditions.
To investigate whether this finding could also be observed in other cancer cell type, gene
expression datasets from two independent studies that overexpressed SNAI1 in several
lung cancer cell lines were analysed (Shirogane et al., 2010; Yanagawa et al., 2009).
Consistent with the findings in MCF7 and HMEC cell lines, SNAI1 overexpression re-
sulted in the down regulation of the FAO signature expression in most of the lung cancer
cell lines (Figs 4.6 and 4.7, blue bars). Taken together, these findings provide robust
evidence for alteration in the FAO signature expression in response to manipulating
various EMT associated transcription factors in different cell systems.
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Figure 4.7: SNAI1 overexpression in II-18 lung cancer cell line decreases
FAO signature expression. (a) FAO and (b) EMT signature expression in cells
transduced with control or SNAI1 overexpression retroviral vectors for 5 days. n=3 for
both conditions. FDR-adjusted p **≤0.01.
4.3.1.5 FAO signature expression and EMT in organoid systems
To investigate whether the association between the FAO signature and EMT in cell sys-
tems could be extended to organoid cultures, gene expression datasets from studies that
analysed the transcriptome of normal mouse colon or adenoma with or without TGFβ
treatment were analysed (Fischer et al., 2016; Fessler et al., 2016). The FAO signature
expression was decreased in mouse intestinal organoids treated with TGFβ for 5 days,
compared to control and TGFβ inhibitor treated organoids (Fig 4.8a). The MKS prolif-
eration signature expression was similar between control and TGFβ-treated organoids.
Similarly, in patient-derived colorectal tubular adenoma organoids treated with TGFβ,
the FAO signature was down regulated compared to untreated control (Fig 4.8d), while
the MKS signature expression was higher in the treated, compared to control. Taken
together, data from this analyses suggests that FAO is downregulated in response to
TGFβ-induced EMT in different cell types and culture systems.
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Figure 4.8: TGFβ treatment of mouse normal intestinal, colon or tubular
adenocarcinoma organoids alter expression of FAO and EMT signatures.
(a-c) FAO (a), MKS (b) and EMT (c) gene signature expression in mouse intestinal
organoids treated with 0.04 ng/mL TGFβ, 20 µM of LY2109761 TGFβ inhibitor, or
untreated control for 5 days. n=3 for all conditions. (d-f) FAO (d), MKS (e), and
EMT (f) gene signature expression in human patient derived normal colon or adenoma
organoids treated with A83-01 (TGFβ inhibitor) or 5 ng/mL TGFβ inhibitor for 5
days. Normal colon untreated n=2, normal colon treated n=2, adenoma untreated n=6,
adenoma treated n=6. FDR-adjusted p **≤0.01; NS = non-significant.
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4.3.1.6 FAO signature expression not correlated with EMT signature in
primary breast tumours
In light of the correlation between the FAO signature expression and TGFβ-induced
EMT, this association was investigated in primary breast tumour datasets. As shown
in Table 1, analysis of three independent datasets found no evidence of an inverse rela-
tionship between the FAO and EMT gene signatures.
Table 4.1: Spearman correlation analysis of FAO and EMT signatures on
breast cancer datasets.
Dataset n Spearman rho p
METABRIC (training) 973 -0.02 0.53
METABRIC (complete) 1981 -0.05 0.03
GSE25066 508 0.06 0.21
BC2116 2116 0.08 0.0004
4.4 FAO signature expression and cellular differentiation
4.4.1 FAO signature expression increases during mammary epithe-
lial cell differentiation
The degree of cellular differentiation is one component of tumour grade, and patients
with poorly differentiated tumours have a worse prognosis. Since high tumour grade in
breast cancer was observed to have low FAO signature expression, one may ask: how
does the FAO signature expression tracks, across different stages of normal mammary
epithelial cell differentiation?
To investigate this, gene expression datasets of different stages of MEC differentiation
(stem cell, luminal progenitor, and mature ductal luminal cells) were accessed. Of note,
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Figure 4.9: FAO signature expression increases from mammary stem to dif-
ferentiated ductal cell.(a-d). GSE19446 n=5 for all conditions; GSE20402 n=4 for
all conditions; GSE47376 n=3 for all conditions; GSE16997 n=3 for all conditions.
FDR-adjusted p **≤0.01; *≤0.05; NS = non-significant.
in all datasets used in this analysis, the different sub-populations of cells were sorted
based on established cell surface markers (e.g., CD49f, EPCAM) by flow cytometry.
As shown in Fig 4.9, in four independent datasets, the FAO signature was expressed
higher in the mature luminal ductal cells, relative to the undifferentiated mammary stem
cells. This observation was consistent in both mouse and human mammary cells.
4.4.2 Correlation analysis between FAO, MKS and mammary lumi-
nal/stem gene signatures
Molecular signatures have been established for the different cell populations during MEC
differentiation (Lim et al., 2010). In support of Figure 4.9, correlation analysis found a
strong positive association between the FAO and differentiated mammary luminal cell
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signatures, and a negative correlation with a mammary stem cell signature (Tables 4.2
to 4.5). Importantly, the association between FAO and stem or mature luminal cells
in all four datasets analysed was independent of proliferation. Taken together, these
findings provide evidence that genes involved in FAO are differentially expressed during
different stages of mammary cell differentiation.
Table 4.2: Spearman’s correlation matrix of indicated signatures on
GSE47376 (mouse). FDR-adjusted p-values are in parenthesis. n=3 for all con-
ditions.
Signature FAO MKS Luminal Mammary stem
FAO 1 (0) - - -
MKS 0.47 (0.21) 1 (0) - -
Luminal 0.80 (0.01) 0.18 (0.64) 1 (0) -
Mammary stem -0.83 (0.01) -0.52 (0.15) -0.72 (0.03) 1 (0)
Table 4.3: Spearman’s correlation matrix of indicated signatures on
GSE19446 (mouse). FDR-adjusted p-values are in parenthesis. n=5 for all con-
ditions.
Signature FAO MKS Luminal Mammary stem
FAO 1 (0) - - -
MKS 0.25 (0.37) 1 (0) - -
Luminal 0.94 (0) 0.12 (0.67) 1 (0) -
Mammary stem -0.82 (0) -0.34 (0.22) -0.85 (0) 1 (0)
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Table 4.4: Spearman’s correlation matrix of indicated signatures on
mouse mammary stem and luminal progenitor enriched cell populations
(GSE20402). FDR-adjusted p-values are in parenthesis. n=4 for all conditions.
Signature FAO MKS Luminal Mammary stem
FAO 1 (0) - - -
MKS 0.03 (0.96) 1 (0) - -
Luminal 1 (0) 0.03 (0.96) 1 (0) -
Mammary stem -0.77 (0.07) -0.09 (0.87) -0.77 (0.07) 1 (0)
Table 4.5: Spearman’s correlation matrix of indicated signatures on hu-
man mammary stem and luminal progenitor enriched cell populations
(GSE16997). FDR-adjusted p-values are in parenthesis. n=3 for all conditions.
Signature FAO MKS Luminal Mammary stem
FAO 1 (0) - - -
MKS 0.27 (0.49) 1 (0) - -
Luminal 0.73 (0.02) 0.33 (0.38) 1 (0) -
Mammary stem -0.78 (0.01) -0.48 (0.19) -0.82 (0.01) 1 (0)
4.4.3 FAO signature expression and confluence-induced differentia-
tion
The relationship between FAO signature expression and mammary stem cell differenti-
ation is supported from analysis of a dataset with a different experimental design: two
independent human mammary epithelial cell lines (HMT 3552-S1 and HMEC 184) were
cultured in three-dimensional, laminin-rich extracellular matrix to study the temporal
molecular changes over 7 days of differentiation (Fournier et al., 2006).
Analysis of transcriptome data from this study found that the FAO signature was in-
creased at later time points when cells are differentiated, compared to less differentiated
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cells at earlier time points (Fig 4.10). In this instance, however, the increase in the
FAO signature expression was negatively correlated with proliferation (Spearman’s rho
= -0.61, p=0.03).
4.4.4 FAO signature increased in butyrate-induced colorectal cancer
cell differentiation
Treatment of colorectal cancer cells with the short-chain fatty acid butyrate has been
shown to induce cellular differentiation (Orchel et al., 2005; Tanaka et al., 1989). To de-
termine whether the relationship between differentiation and FAO observed in mammary
epithelial cell could be extended to other cell types and mechanisms of differentiation,
gene expression datasets from colorectal cancer cells treated with butyrate were anal-
ysed (Tabuchi et al., 2006, GSE41113 not published).
Dose response and time course treatments of HCT116 colorectal cancer cell line (Fig
4.11a,b) and mouse colon epithelial MCE301 cell line with butyrate (Fig 4.11c,d) re-
sulted in increased expression of the FAO signature. In these datasets however, the
MKS signature expression was decreased in the presence of butyrate, which is consis-
tent with the reported anti-proliferative effect of this molecule (Siavoshian et al., 2000).
In CC531 colon cancer cells treated with butyrate over a 24 hour time course, the inverse
expression levels of FAO and MKS signature expression was stronger at 2- to 16 hour
post treatment, but both signatures were decreased at 24 hours (Fig 4.12) (Germann
et al., 2003).
127
Figure 4.10: FAO signature expression increases during HMEC differentia-
tion. HMEC1S and HMEC184 cells were seeded in laminin-rich extracellular matrix
and gene expression analysed at days 3, 5, and 7 post-seeding. (a) FAO and (b) MKS
signature expression over differentiation time course. FDR-adjusted p **≤0.01; *≤0.05;
NS = non-significant. n=2 for all time points.
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Figure 4.11: FAO signature expression increases upon treatment with
sodium butyrate. (a,b) FAO (a) and MKS (b) signature expression in MCE301
cells treated with 2 mM sodium butyrate over a time course. n=2 for all concentra-
tions. (c,d) FAO (c) and MKS (d) signature expression in HCT116 cells treated with
increasing concentration of sodium butyrate over a 24 hour time course. n=3 for all
time points. FDR-adjusted p **≤0.01; *≤0.05; NS = non-significant.
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Figure 4.12: FAO signature expression increases in CC-531 rat colon carci-
noma cells at earlier time points of sodium butyrate treatment. Cells treated
with 4.5mM sodium butyrate for up to 24 hours (GSE424). n=1 for all time points.
4.5 Discussion
4.5.1 What is known about FAO and EMT?
EMT is an extensive process that facilitates tumour metastasis, and TGFβ signalling
and transcription factors such as SNAI1 and SNAI2 regulate this process (Moustakas
and Heldin, 2007; Nieto et al., 2016; Ye and Weinberg, 2015). Recently, Gaude et.al.
analysed gene expression data from 20 cancers available from TCGA and observed that
decreased expression of genes involved in mitochondrial metabolism was associated with
poor prognosis (Gaude and Frezza, 2016). Intriguingly, this general decrease in mito-
chondrial metabolism genesets was inversely correlated with expression of genes involved
in TGFβ signalling and EMT induction. A study by Marro et. al. compared the tran-
scriptome of MCF10A cells cultured under sparse and confluent densities (Marro et al.,
2014). MCF10A cells exhibit an epithelial or mesenchymal morphology when cultured
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at confluent or sparse densities, respectively. Gene set enrichment analysis found genes
involved in fatty acid metabolism to be upregulated in the confluent compared to sparse
densities. As expected, genesets involved in EMT were downregulated in the confluent
density. While these studies suggest some indication between epithelial-mesenchymal
cellular states and genes involved in mitochondrial metabolism, whether genes involved
in FAO are altered in response to deliberate induction of EMT by pharmacologic or
genetic mechanisms remains unclear.
4.5.2 Association of EMT and FAO signatures in cell and organoid
systems
4.5.2.1 TGFβ-treatment and transgenic expression of EMT transcription
factors
TGFβ-treatment or overexpression of EMT transcription factors lead to a consistent
down regulation in the FAO signature expression, as compared to respective controls.
This observation was not limited to mammary epithelial, but also lung, pancreatic and
colorectal cell or organoid systems. TGFβ is a pleiotropic cytokine: some of its functions
include context-dependent induction or repression of cell proliferation (Massague, 2012).
Analyses in this chapter found that EMT induced by either TGFβ or EMT transcription
factor expression resulted in either decreased or, for most part, no significant differences
in the MKS proliferation signature expression. This suggests that metabolic rewiring
in cells undergoing the morphological transition is independent of proliferation. In this
context, it is not unreasonable to posit that most of the cellular resources would be
channelled to effect the epithelial-mesenchymal transition rather than proliferate, and
thus, may explain the decreased expression of the MKS signature in some instances.
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4.5.2.2 Mutations in IDH1/2
Loss-of-function mutations in IDH and fumarate hydratase lead to the accumulation
of metabolites that are substrates of these enzymes, or generation of other metabo-
lites due to gain-of-function neomorphic activity. Fumarate, for example, accumulates
when FH is inactivated, and downregulates the anti-metastatic miR-200ba429 by epige-
netic mechanisms (Sciacovelli et al., 2016). Heterozygous mutations in IDH1 generates
2-hydroxyglutarate, and induces EMT in SW480 colorectal cancer and MCF10A mam-
mary cell lines (Grassian et al., 2012). Similar to findings from the analysis of TGFβ
treatment and transgenic expression of EMT-associated transcription factor datasets,
the FAO signature was also down regulated in 2HG-induced EMT. The differences in
EMT and FAO signature expression were stronger in IDH1 mutants, compared to IDH2.
Since IDH3 is the primary enzyme that catalyses the conversion of isocitrate to alpha-
ketoglutarate in the citric acid cycle, it is possible that IDH1/2 mutations associated
with a decrease in FAO signature expression are due to aberrant accumulation of 2-HG
and consequent EMT induction, rather than alterations in mitochondrial metabolism
resulting in negative feedback to lower FAO. Taken together, the analyses presented in
this chapter suggest that regardless of how EMT is triggered, the FAO signature expres-
sion is down regulated when cells undergo a morphological transition from an epithelial
to a mesenchymal state.
4.5.3 EMT and FAO in primary breast tumours
In breast cancer, EMT is associated with clinical factors associated with poor prognosis.
Since the FAO signature expression is prognostic in breast cancer; why, then, was there
no correlation observed between the FAO and EMT signatures in primary breast tu-
mours? EMT is not a one-step, binary process, but rather, occurs in discrete, stepwise
stages (Zhang et al., 2013). While the FAO signature is correlated with epithelial or
mesenchymal states, it is not clear what the relationship is like during the intermediate
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stages of EMT. In other words, genes involved in FAO could be downregulated early, in
the midst, or after completion of EMT.
Secondly, it is likely that at any one time, most tumour cells in a primary tumour are
not undergoing EMT. Should most tumour cells undergo EMT and metastasise, then
the prognosis of a patient cohort would be particularly dismal. This was not apparent in
the datasets used for survival analysis in this chapter. Additionally, if there were indeed
a small number of cells undergoing EMT, their gene expression profile could be ’diluted’
by other epithelial and stromal cells from the biopsy. Ergo, the focal and innately low
EMT activity exhibited by tumour cells, together with the discrete stages involved, may
account for its lack of association with the FAO signature. This admixture of cell types,
however, is less pervasive in cell and organoid culture systems. As such, the relative
homogeneity of these systems allows the relationship between the FAO and MKS to be
gleaned with greater clarity.
The lack of correlation between EMT and FAO signature expression in primary breast
tumours can also be explained from another perspective. While EMT induction de-
creases the FAO signature expression, the inverse (i.e. decrease in FAO results in EMT)
is not necessarily true. Given the protean nature of EMT, it is unlikely that alterations
in a single process alone is sufficient to facilitate morphological transitions.
4.5.4 Can activating FAO rescind EMT?
Since EMT is an important process for cells to metastasise, and the FAO signature was
observed to decrease during this process, can increasing FAO abate EMT? This question
was partly answered, albeit in a different context and system, by Kang et. al. (Kang et
al., 2015). EMT has a role in fibrosis; and treatment of primary tubular renal epithelial
cells (TEC) with TGFβ induced a profibrotic phenotype, with increased expression of
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mesenchymal markers such as VIM and FN1. Furthermore, TGFβ treatment decreased
mRNA expression of key oxidative metabolism regulators PPARA, PPARGC1A, as well
as its targets CPT1A and CPT2. Oxygen consumption analysis of TGFβ-treated TEC
revealed decreased baseline OCR, and reduced OCR elevation in response to exogenous
palmitate, compared to untreated control. Importantly, overexpression of PPARGC1A
or treatment with fenofibrate (PPARA agonist) - both inducers of FAO - suppressed
the expression of mesenchymal markers in response to TGFβ treatment. The clinical
significance of this study is that pharmacologic activation of FAO can negate this pro-
cess; and further investigation of such agents in in vivo cancer models may identify a
promising anti-metastasis treatment.
4.5.5 Cellular differentiation and FAO signature expression
Characterising the metabolic adaptation during differentiation has been an ongoing ef-
fort, and much of this has been focused on stem cells (Zheng et al., 2016; Yanes et al.,
2010; Zhang et al., 2011). The inner cell mass of pluripotent blastocysts have lower mi-
tochondrial membrane potential, which suggests reduced mitochondrial potential (Van
Blerkom, 2009). Furthermore, cells reprogrammed from a differentiated to a pluripo-
tent state were associated with a metabolic switch from mitochondrial respiration to
glycolysis (Folmes et al., 2011). While oxidative metabolism has been shown to be up-
regulated in differentiated cells, it is not clear which pathways, and to what extent, they
contribute to the increased citric acid cycle activity in mature cells (Teslaa and Teitell,
2015). Since pertubations in cellular differentiation is a common phenomena in cancer
cells and is a component of tumour grade assessment, it may serve well to understand
the metabolic idiosyncrasies associated with the differentiation status of a cell. This
knowledge may identify potentially druggable pathways to supplement standard adju-
vant treatment regimes.
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Analyses in this chapter present evidence for increased expression of genes involved in
FAO with cellular differentiation. This finding was observed in normal human and mice
mammary cells at different stages of differentiation, as well as in normal colon and col-
orectal cancer cells treated with sodium butyrate. This observation agrees, to an extent,
with increased expression of genes involved in oxidative metabolism, and fatty acid oxi-
dation in particular, and decreased expression of glycolytic genes during cardiomyocyte
stem cell differentiation. A study by Doria et.al. found an enrichment of genes involved
in lipid metabolic processes as mice MEC matures from the stem, or basal, state to
a differentiated ductal cell (Doria et al., 2014). Notably, a geneset involved in fatty
acid beta oxidation that increased as the MEC matures was observed to be prognostic
in breast cancer. However, how the signature cut-off for stratifying patients into ’low’
or ’high’ groups was not clearly indicated, and was not reproduced in an independent
dataset.
In mouse mammary stem and progenitor cells, there was no correlation between the
MKS proliferation and the FAO signature expression. In contrast, mammary epithelial
cells grown three dimensionally in extracellular matrix, and normal colon or cancerous
colorectal cells treated with sodium butyrate were observed to have a negative corre-
lation between the two signatures. What could account for these inconsistencies? A
salient explanation is that the context of studying differentiation varies between the
studies. All three datasets from the human and mouse mammary cell differentiation
isolated stem, luminal progenitor and ductal cells from mammary glands by flow cy-
tometry based on specific lineage marker expression. The differentiation course in vivo
starts from a single mammary stem cell to luminal progenitor and ends with a single
mature ductal cell, and thus, no cell division occur (Visvader and Stingl, 2014). In con-
trast, in the confluence-induced differentiation model, in vitro cultured cells seeded at
low density proliferate and mature, and tend to stop growing due to contact inhibition.
Cells seeded at low confluency have been described to acquire a less differentiated or
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mesenchymal features, and regain their epithelial status after several days of culture or
increased confluency (Marro et al., 2014; Fournier et al., 2006). As such, it is possible
that the confluence-induced lowered proliferation may have a role in the increased ex-
pression of the FAO signature. Taken together, the findings from this chapter suggests
that differentiated cells have higher expression of genes involved in FAO as compared to
their less differentiated counterparts.
4.6 Summary, strengths and limitations
This chapter has presented evidence that the FAO signature is:
(i) down regulated in response to various forms of EMT induction in in vitro and in
vivo systems
(ii) up regulated during mammary stem cell differentiation, as well as during confluence-
induced differentiation in breast cancer cells, and butyrate treatment of colorectal cancer
cells.
The strength of this chapter is that the analyses presented have endeavoured to provide
several independent lines of evidence for the relationship between FAO, EMT and cellular
differentiation. However, short of experimental validation, the association demonstrated
in this chapter is limited only a correlation. Experiments to delineate this association
may identify potential therapeutic opportunity to limit EMT, and possibly metastasis,
or promote tumour cell differentiation.
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Chapter 5
Activation of key oncogenic
signalling pathways alters FAO
signature expression
5.1 Background
Genetic abberations in oncogenes or tumour suppressor genes have a profound impact
on cellular metabolism. For instance, activation of MYC and RAS oncogenes, and PI3K
signalling pathway, as well as loss of TP53 function and LKB1-AMPK pathway all af-
fect glucose and glutamine metabolism (Boroughs and DeBerardinis, 2015). Two of the
most frequently activated pathways in cancer are the mitogen activated protein kinase
(MAPK) and the Wnt signalling cascades (Burotto et al., 2014; Polakis, 2012).
Hitherto, the known metabolic consequence of activation of the Wnt and MAPK path-
ways largely revolve around glycolysis, and very little is known how these pathways
affect FAO (Thompson, 2014; Munoz-Pinedo, El Mjiyad, and Ricci, 2012). This chapter
explores how the FAO signature is affected by genetic or pharmacologic manipulation
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of the MAPK and Wnt signalling pathways.
5.2 Objectives
The objectives of this chapter are to use published gene expression datasets to:
i. investigate how modulation of different Wnt signalling in cell and mouse models
affect FAO signature expression
ii. explore whether the FAO signature is altered in response to BRAF inhibition or
modulation of other MAPK pathway components
iii. gain insight on how modulating microphthalmia-associated transcription factor
(MITF) expression affects expression of the FAO signature
5.3 Results
5.3.1 Alteration of Wnt signalling members in vivo alters FAO signa-
ture expression
5.3.1.1 Knockout, knockdown or single allele inactivation of APC decreases
FAO signature expression
To investigate how alterations in adenomatous polyposis coli (APC) activity influences
the FAO signature expression, gene expression datasets from studies that knockdown or
knockout APC expression were analysed (Reed et al., 2015; Dow et al., 2015; Gaspar
et al., 2008).
As shown in Fig 5.1, Apc deletion in mouse small intestine or colon polyps with Apc
knock down decreased FAO signature expression, compared to respective controls. A
similar observation was made in mice with Apc+/1638N genotype (neomycin gene intro-
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duced into codon 1638 in a transcriptionally opposite orientation to Apc). The expres-
sion of the MKS signature was increased when wild type Apc expression was abrogated,
or in Apc+/1638N mice. This is consistent with the role of β-catenin transcriptionally
activating genes involved in proliferation, such as CCND1 and MYCN (He, Nakada,
and Morrison, 2009; Tetsu and McCormick, 1999; Shtutman et al., 1999).
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Figure 5.1: APC knockout, knockdown, or single allele inactivation decreases
FAO signature expression. (a,b) FAO (a) and MKS (b) signature expression in
mouse small intestine after Apc deletion for 5 days. n=3 for both conditions. (c,d) FAO
(c) and MKS (d) signature expression in colon polyps of six week old mice fed chow
containing doxycycline to induce shRNA expression against Apc or Renilla (control)
and polyps isolated 4-6 weeks later. n=4 for APC shRNA, n=2 for Renilla control.
(e,f) FAO (e) and MKS (f) signature expression in eight month old C57/Bl6/J mice
were kept ad libitium under specific pathogen-free condition until sacrificed for analysis.
n=2 for control, n=4 for Apc+/1638N. FDR-adjusted p **≤0.01; *≤0.05.
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5.3.1.2 Knockout of Bcl9 increases FAO signature expression
The Wnt signalling pathway is also positively regulated by Bcl9 (Moor et al., 2015;
Takada et al., 2012; Roche, Worm, and Bienz, 2008). To understand whether modula-
tion of this gene alters the FAO signature expression, transcriptome data from a study
that assessed the effect of Bcl9 knockout in healthy and tumour colon tissues was anal-
ysed (Moor et al., 2015).
Knockout of Bcl9 - a key positive regulator of β-catenin activity (Takada et al., 2012)
- in mouse tumour resulted in increased expression of the FAO signature (Fig 5.2a,c).
However, no significant difference was observed in the signature expression in normal
colon tissues with Bcl9 knockout. Notably, no statistically significant difference in ex-
pression of the MKS proliferation signature was observed between endogenous and Bcl9
knockout tissues, which is consistent with the finding from the study that generated this
dataset (Fig5.2b,d) (Moor et al., 2015).
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Figure 5.2: Bcl9 knockout increases FAO signature expression. (a,b) FAO (a)
and MKS (b) signature expression in normal colon tissue (EDTA-dissociated) or tumours
(laser microdissected) obtained from 129SvEv/C57BL/6/DBA/2 mice with or without
Bcl9 knock out. n=5 for all conditions. (c,d) FAO (c) or MKS (d) signature expression
in wildtype or knockout Bcl9 normal or colon tumour tissues obtained from Apc-Kras
or mice treated with azoxymethane and dextran sulphate sodium to chemically-induce
Wnt-driven colorectal tumours. n=4-6. FDR-adjusted p *≤0.05; NS = non-significant.
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5.3.1.3 Altering Wnt signalling components in vitro influences FAO signa-
ture expression
The effect of modulating different Wnt signalling components on the FAO signature
expression in cells systems was also explored using published datasets (Azzolin et al.,
2012; Herbst et al., 2014; Mokry et al., 2012, GSE35272 and GSE28467 not published).
In the SW480 colorectal cancer cell line, reintroduction of APC increased the expres-
sion of the FAO signature (Fig 5.3a). Furthermore, knockdown of CTNNB1 - the gene
encoding β-catenin - also increased the FAO signature expression in SW480, DLD-1 and
Ls174T colorectal cancer cells (Figs 5.3a, 5.3c and 5.4a).
In the Ls174T cell line, transgenic expression of dominant negative (dn) T cell factor 4
(TCF4) - which antagonises endogenous TCF4 function - increased the expression of the
FAO signature (Figs 5.4a and 5.4c). In DLD1 cells, overexpression of Dickkopf-related
protein 1 (DKK1) - a negative regulator of Wnt signalling - increased expression of the
FAO signature (Fig 5.4e). In all but one experiment (Fig 4B, SW480 β-catenin siRNA),
the FAO signature expression in response to alterations of the Wnt signalling pathway
was inversely correlated with the MKS proliferation signature.
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Figure 5.3: APC or DKK-1 overexpression, or β-catenin knockdown in-
creases FAO signature expression. (a) SW480 cells were transfected with siRNA
against β-catenin or a construct with APC transgene. n=4 for all conditions. (b) Cells
were transfected with siRNA against β-catenin in SW480 or DLD-1 cells for 48 hrs.
n=2-3. FDR-adjusted p * ≤0.05, **≤0.01, NS = non-significant.
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Figure 5.4: β-catenin knockdown or dnTCF4 expression alters FAO signature
expression in Ls174T cells. (a,b) FAO (a) and MKS (b) signature expression in cells
induced with 1 µg/mL doxycycline for 24 hours to induce dnTCF4 expression, or 72
hours for β-catenin knockdown. n=3 for all conditions. (c,d) FAO (c) and MKS (d)
signature expression in cells induced with 1 µg/mL doxycycline for 20 hours to induce
dnTCF4 expression. n=3 for both conditions. (e,f) FAO (e) and MKS (f) signature
expression in DLD-1 cells lentivirally transduced with control or DKK-1 transgene and
induced with 10 µg/mLdoxycycline for 24 hrs. FDR-adjusted p **≤0.01, NS = non-
significant.
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5.3.1.4 Constitutive Wnt signalling in mouse mammary glands decreases
FAO signature expression
Activation of Wnt signalling has been observed in basal-like breast cancers and is asso-
ciated with metastasis and poor prognosis (Khramtsov et al., 2010; Dey et al., 2013). To
explore the relationship between constitutive Wnt signalling in mammary glands and
the FAO signature expression, transcriptome data from mice with healthy mammary
glands expressing wild type β-catenin, and mammary neoplasia or tumours with consti-
tutively active N-terminal truncated β-catenin expression was analysed (Moumen et al.,
2013).
As shown in Fig 5.5a, the FAO signature expression was gradually decreased from nor-
mal mammary gland to hyperplasia, and was lowest in tumours. Conversely, the MKS
proliferation signature was highest in tumours, while no difference was observed between
small and large neoplasia (Fig 5b).
Taken together, these analyses provide strong in vivo and in vitro evidence that the
FAO signature expression is altered in response to altering different components of the
Wnt signalling pathway.
5.3.1.5 FAO signature expression is not associated with prognosis in col-
orectal cancer
Given the association between Wnt signalling and FAO signature expression in differ-
ent experimental systems, the relationship between the FAO signature expression and
prognosis in colorectal cancer was explored. As shown in Table 5.1, in two independent
datasets, there was no association observed between FAO signature expression and out-
come.
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Figure 5.5: Constitutive Wnt signalling decreases FAO signature expression
across different stages of mammary tumour development. FAO (a) and MKS
(b) signature expression in C57BL6 mice with transgenic N-terminal truncation in β-
catenin in mammary basal/myoepithelial cells sacrificed at different stages of tumour
development. n=4-11. FDR-adjusted p **≤0.01, NS = non-significant.
Table 5.1: FAO signature expression is not associated with survival in col-
orectal cancer cohorts. DFS, disease-free survival; RFS, relapse-free survival; DSS,







GSE39582 557 0.878 (RFS) 0.98 0.88
GSE39582 562 0.501 (OS) 1.1 0.5
GSE17536 177 0.242 (DFS) 1.48 0.245
GSE17536 177 0.169 (DSS) 1.45 0.17
GSE17536 177 0.749 (OS) 1.08 0.75
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5.4 FAO signature expression is associated with MAPK
pathway and MITF status in melanoma
5.4.1 Pharmacological inhibition of mutant BRAF increases FAO
signature expression
BRAF is the most commonly mutated oncogene in melanoma (Hodis et al., 2012; Davies
et al., 2011). To investigate whether the FAO signature expression is altered in response
to BRAF V600E inhibition, gene expression datasets from three studies that performed
transcriptome analysis on two melanoma cell lines treated with vemurafenib were anal-
ysed (Parmenter et al., 2014; Hoeflich et al., 2009; Seip et al., 2016). As shown in Fig 5.6
in three independent datasets, treatment of A375 and Melmet5 cells with vemurafenib
increased the FAO signature expression, compared to controls (5.6a,c,e). Conversely, the
MKS proliferation signature expression was down regulated as compared to untreated
controls (Fig 5.6b,d,f). Furthermore, as shown in Fig 5.7, treatment of a melanoma cell
line panel with PLX4032 (BRAF inhibitor) increased expression of the FAO signature,
consistent with the observation in Fig 5.6 (Joseph et al., 2010).
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Figure 5.6: Vemurafenib treatment of BRAF mutant melanoma cell lines
decreases FAO signature expression. (a,b) FAO (a) and MKS (b) signature ex-
pression in A375 cells treated with DMSO or 1 µM vemurafenib for 24 hours. n=3 both
for conditions. (c,d) FAO (c) and MKS (d) signature expression in A375 cells treated
with DMSO or 10 µM vemurafenib for 24 hours. (e,f) FAO (e) and MKS (f) signature
expression Melmet15 cells were treated with DMSO or 1 µM vemurafenib for 24 hours.
n=3 both for conditions. FDR-adjusted p **≤0.01.
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.
Figure 5.7: BRAF inhibition increases FAO signature expression in a panel
of melanoma cell lines. Indicated melanoma cell lines were treated with DMSO or
250- or 1000 nM PLX4032 for 8 hrs (GSE20051). n=1 for all measurements
5.4.2 BRAF mutant expression alters FAO signature expression
To understand how modulation of mutant BRAF expression affects the FAO signature
expression, gene expression datasets from studies that either overexpress or knockdown
mutant BRAF expression in different cell systems were analysed (Capell et al., 2016;
Hoeflich et al., 2009). Overexpression of BRAF in neonatal epidermal melanocytes de-
creased expression of the FAO signature, and a similar trend was observed in primary
human melanocytes with transgenic BRAF expression (Figs 5.8a,b). Interestingly, the
MKS proliferation signature was down regulated when BRAF V600E was overexpressed
in melanocytes (Fig 5.8b). In the second dataset (Fig 5.8b,c), statistical significance was
not achieved for either signature, which is most likely due to small sample size (n=2).
Furthermore, similar to vemurafenib treatment, shRNA knockdown of mutant BRAF
in A375 melanoma cells increased expression of the FAO signature (Fig 5.8d,e). Taken
together, these findings suggest that modulation of BRAF V600E expression levels af-
fects proliferation and alters expression of genes involved in FAO.
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Figure 5.8: Transgenic mutant BRAF expression in melanocytes decreases
FAO signature expression. (a,b) FAO (a) and MKS (b) signature expression in
primary human melanocytes that were lentivirally transduced with control or BRAF
V600E transgene for two weeks. n=3 for all conditions. (c,d) FAO (c) and MKS (d)
signature expression in low passage primary human melanocytes that were lentivirally
transduced with GFP as control or BRAF V600E transgene for 5 days. (e,f) FAO (e)
and MKS (f) signature expression in A375 cells treated with 1 µg/mL doxycycline for
48 hours to induce shRNA expression against GFP control or BRAF. FDR-adjusted p
* ≤0.05; **≤0.01; NS = non-significant.
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5.4.3 RAS mutant expression alters FAO signature expression
Next, whether different RAS mutants affect the FAO signature to different degree was
investigated. To achieve this, gene expression datasets that overexpress different RAS
mutants in primary human melanocytes, or a mouse model injected with doxycycline-
inducible melanoma cells with NRAS Q61K were analysed (Gupta et al., 2016; Eskan-
darpour et al., 2009; Kwong et al., 2012).
Immortalised human melanocytes stably expressing NRAS Q61K, HRAS V12 or KRAS
V12 mutants resulted in decreased expression of the FAO signature (Fig 5.9a). Of all
RAS mutants, NRAS Q61K expression induced the largest decrease in the FAO sig-
nature. Furthermore, knockdown of NRAS in two independent melanoma cell lines
increased the FAO signature expression (Fig 5.9c). However, the MKS proliferation was
only significantly down regulated in 224, but not BL cells (Fig 5.9d).
Additionally, in an inducible NRAS Q61K melanoma cell line grown in mice, removal
of doxycycline from the diet resulted in the up regulation of the FAO signature, com-
pared to control (continued NRAS Q61K induction) (Fig 5.9e). Treatment with MEK
inhibitor also increased expression of the FAO signature expression, albeit to a weaker
extent compared to mutant RAS depletion (Fig 5.9e, blue bar). As expected, the MKS
proliferation signature was significantly decreased when mutant RAS expression was
depleted (Fig 5.9f). MEK inhibition did not decrease the MKS signature expression,
which is consistent with the findings from the authors that generated this dataset, who
showed poor anti-proliferative response of the NRAS Q61K allograft to MEK inhibitor
(Kwong et al., 2012).
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Figure 5.9: Mutant RAS expression in melanocyte or melanoma cell lines in-
fluences FAO signature expression. (a,b) FAO (a) and MKS (b) signature expres-
sion in primary human melanocytes transduced with control or BRAF V600E transgene
lentiviruses for two weeks. n=3 for all conditions. (c,d) FAO (c) and MKS (d) signature
expression in 224 or BL melanoma cell lines transfected with siRNAs against RAS or
scramble control for up to 72 hours. n=4 for all conditions. (e,f) FAO (e) and MKS (f)
signature expression in melanona cells injected into mice and tumours grown for 6 weeks.
Mice were then treated with vehicle control, MEK inhibitor AZD6244 (100mg/kg) or
doxycycline withdrawn to deplete mutant NRAS expression for four days. FDR-adjusted
p *≤0.05, **≤0.01; NS = non-significant.
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5.4.4 BRAF or MEK inhibition in other cancer types increases FAO
signature expression
To investigate whether the previous findings can be extended to BRAF mutant colorec-
tal cancer, as well as upon MEK inhibition, gene expression datasets of HT29 colorectal
cancer cells treated with a BRAF inhibitor, wildtype BRAF SW480 colorectal cancer
and a panel of pancreatic cancer cell lines treated with a MEK inhibitor, were analysed
(Herr et al., 2015; Schoumacher et al., 2014; Gysin, Paquette, and McMahon, 2012).
Consistent with findings from melanoma cell lines, BRAF inhibition in HT29 cells re-
sulted in increased expression of the FAO signature (Fig 5.10a). Inhibition of MEK
- a kinase downstream of RAF - in SW480 colorectal cancer cell line and pancreatic
cancer cell lines consistently increased the expression of the FAO signature, compared
to untreated controls (Figs 5.10c and 5.11).
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Figure 5.10: BRAF or MEK inhibition in colorectal cancer cell lines increases
FAO signature expression. (a,b) FAO (a) and MKS (b) signature expression in cells
seeded into Matrigel matrix and treated with either 3 µM PLX4720 (BRAF inhibitor)
or DMSO for indicated time points. n=2 for all conditions. (c,d) FAO (c) and MKS
(d) signature expression in cells treated with 1 µM AZD6244 (MEK inhibitor) or DMSO
for 16 hours. n=2 for both conditions. FDR-adjusted p *≤0.05, **≤0.01; NS = non-
significant.
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Figure 5.11: MEK inhibition increases FAO signature expression in a panel
of pancreatic cancer cell lines. Indicated pancreatic cancer cell lines were treated
with 2 mM CI-1040 (MEK inhibitor) for 24 hours (GSE45757). n=3, error bars =
standard error of mean.
5.4.5 MITF expression is associated with FAO signature expression
As mentioned earlier, the transcription factor MITF has varied functions depending on
its expression level, and has been shown to promote oxidative metabolism in response to
BRAF V600E inhibition (Haq et al., 2013). However, how FAO is affected by MITF ex-
pression status remains to be determined. To explore for an association between MITF
expression and FAO signature expression, gene expression datasets from different cell
systems that genetically modulate MITF levels were analysed (Haq et al., 2013; Scholer
et al., 2015).
As shown in Fig 5.12a, the FAO signature expression was upregulated in primary
melanocytes overexpressing both BRAF V600E and MITF, compared to BRAF V600E
alone. MITF overexpression also resulted in decreased proliferation, evident from de-
creased expression of the MKS signature (Fig 5.12b). In another dataset, siRNA against
MITF in Malmet15 melanoma cell line decreased expression of the MKS proliferation
signature (Fig 5.12d) and showed a trend towards increased FAO signature expression
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(Fig 5.12c). The slight deviation from statistical significance could be explained by the
small sample size in this experiment (n=2). Lastly, overexpression of MITF in BS149
glioblastoma cell line was observed to increase the FAO signature expression (Fig 5.12e),
in agreement with the finding in the melanocyte system. Taken together, these findings
reveal an hitherto unrecognised association between MITF expression and expression of
genes involved in FAO.
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Figure 5.12: MITF overexpression or knockdown increases FAO signature
expression. (a,b) FAO (a) and MKS (b) signature expression in immortalised, isogenic
melanocytes overexpressing either BRAF V600E or BRAF V600E and MITF. n=3 for
both lines. (c,d) FAO (c) and MKS (d) signature expression in MaMel15 cells transfected
with control or MITF siRNA for 48 hours. n=2 for both lines. (e,f) FAO (e) and MKS
(f) signature expression in BS149 cells transfected with plasmid expressing the HA tag
as control or MITF for 24 hours. FDR-adjusted p *≤0.05, **≤0.01.
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5.5 Discussion
5.5.1 Wnt signalling and FAO signature expression
The Wnt signalling pathway is dysregulated in approximately 80% of colorectal cancers
(Muzny et al., 2012b). While alterations in glycolysis in response to modulation of Wnt
signalling have been reported (Pate et al., 2014), the analysis presented in this chapter
is the first to demonstrate that FAO is down regulated when Wnt signalling is active.
Analysis of gene expression data from in vivo or in vitro systems that studied the alter-
ations in various Wnt signalling effectors or regulators (e.g., APC, β-catenin, DKK-1,
Bcl9) found a significant association between this pathway and expression of the FAO
signature. It should be emphasised here that for most of these analyses, the FAO and
MKS proliferation signature expression were inversely correlated. However, while knock
out of Bcl9 (wildtype Bcl9 activates Wnt signalling) in mouse colon resulted in increased
FAO signature, no significant difference in MKS proliferation signature expression was
observed, compared to wild type Bcl9 expression. This suggests that the FAO regulation
can be uncoupled from proliferation, depending on which member of the Wnt signalling
pathway is altered. Notably, the association between Wnt signalling and FAO signature
expression was not limited to colon tissues or tumours, but also observed in mammary
tissues across different stages of tumourigenesis.
A gene signature derived from Bcl9 knock out mouse colon was observed to be associated
with better survival in multiple colorectal cancer datasets (Moor et al., 2015). There-
fore, it is not unreasonable to expect the FAO signature to be prognostic in colorectal
cancer. However, this assumption was not true: survival analysis of two colorectal co-
horts found no association between the FAO signature and survival outcomes. Since the
FAO signature was observed to be prognostic in multiple cancers previously, why was
this not observed in colorectal cancer? A plausible explanation is that the FAO activity
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in colorectal cancer is very low, and therefore, survival risk stratification based on this
pathway is not practicable.
5.5.2 MAPK pathway activity and FAO signature expression
Metabolic flux analysis in a panel of melanoma cell lines found that the majority of
glucose is converted to lactate, which is consistent with the Warburg effect, as well
as anaplerotic contribution of glutamine to fatty acid synthesis, compared to normal
melanocyte lines (Scott et al., 2011). In another study, Seahorse extracellular flux anal-
ysis found that normal melanocytes had lower basal oxygen consumption compared to
melanoma cell lines (Hall et al., 2013). However, the coupling of ATP synthesis efficiency
to oxygen consumption was significantly higher in melanocytes, compared to melanoma
cell lines. Furthermore, mitochodrial proton leak was higher in melanoma cell lines,
compared to normal melanocytes (Hall et al., 2013). This is indicative of mitochondrial
metabolism dysfunction in melanoma cell lines. Despite the efforts in characterising the
metabolic correlates associated with the MAPK signalling pathway, very little is known
as to how alterations in this pathway alters FAO in cancer cells.
5.5.2.1 BRAF activity and FAO signature expression
Treatment of melanoma cell lines with vemurafenib was shown to increase the expres-
sion of genes involved in citric acid cycle and oxidative phosphorylation (Haq et al.,
2013), but how this intervention affects FAO is unclear. In this chapter, analysis of gene
expression datasets from BRAF mutant melanoma cell lines treated with vemurafenib
found an increase in the expression of the FAO signature. This increase in FAO would be
expected to result in increased acetyl-CoA generation, which is then further metabolised
in the mitochondria. As such, this pathway could contribute to the increased mitochon-
drial respiration reported in melanoma cells in response to BRAF inhibition (Parmenter
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et al., 2014).
To gain insight on the role of BRAF expression on FAO signature expression, gene ex-
pression datasets from melanocytes with transgenic BRAF expression were analysed.
This analysis found that the FAO signature was down regulated upon transgenic BRAF
V600E expression in melanocytes. Interestingly, the MKS proliferation signature was
not increased in cells with constitutive BRAF activity. This is most likely attributed
to oncogene-induced senescence, a tumour suppressive mechanism that prevents pro-
gression of benign growths (Dhomen et al., 2009). Indeed, one of the datasets analysed
(GSE46801) was generated from a study that focused on elucidating the role between
BRAF-induced senescence and Wnt signalling (Pawlikowski et al., 2013). Assuming
that the melanocytes do not carry additional mutations, these findings suggest that
constitutive BRAF activation per se is sufficient to alter expression of genes involved in
FAO, independently of proliferation.
The association between the FAO signature and BRAF inhibition described in this chap-
ter complement the findings by Hall et. al., who reported that genetic or pharmacologic
inhibition of BRAF V600E in two melanoma cell lines decreased expression of genes
involved in glycolysis such as PGAM1, GAPDH, and LDHA, while oxygen consump-
tion was increased 72-96 hours post-BRAF inhibition (Hall et al., 2013). Importantly,
FM55-M2 and SK-MEL-28 melanoma cell lines showed 3 fold lower coupling of oxygen
consumption to ATP synthesis compared to normal melanocytes. Consequently, the
switch to mitochondrial respiration could not maintain sufficient ATP production to
meet the energetic needs of the melanoma cells. Remarkably, overexpression of GAPDH
in SK-MEL-28 cells was sufficient to significantly increase cell viability, and decrease
the number of detached or senesced cells in response to BRAF inhibition, compared to
empty vector control cells. Findings from this chapter build on the work of Hall et.al.
(Hall et al., 2013) by presenting evidence that genes involved in FAO are significantly
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altered in response to modulation of the RAS-RAF-MEK/ERK signalling pathway.
5.5.2.2 MAPK pathway modulation and FAO signature expression
Expression of three different RAS mutants in melanocytes significantly decreased ex-
pression of the FAO signature. This decrease was particularly stark in melanocytes
with NRAS Q61K expression, which is the second most frequent oncogenic mutation
in cutaneous melanoma, and occurs in a mutually exclusive manner to BRAF muta-
tion (Hodis et al., 2012; Akbani et al., 2015). Together, this suggests that activation of
upstream members of the MAPK pathway can alter expression of genes involved in FAO.
Since RAS mutations remain a challenge for small molecule inhibition, tumours with
RAS-induced MAPK pathway activation can be targeted with MEK inhibitors. Phar-
macological MEK inhibition in colorectal and melanoma cell lines resulted in increased
expression of the FAO signature, compared to untreated control cells. Conversely, the
MKS proliferation signature was decreased in the MEK inhibitor-treated cells. Fur-
thermore, the increase in FAO signature expression was also observed in a panel of
pancreatic cancer cell lines treated with a MEK inhibitor, which altogether, suggests
that the association between MAPK pathway status and FAO signature expression is a
feature of multiple cancers.
5.5.3 Extreme ends of MITF expression decreases proliferation and
upregulates FAO signature
The regulation of MITF protein, and its functional consequence is abstruse; and as such,
a rheostat model was proposed to explain various reports on MITF expression level and
the associated phenotype. Adding to this complexity, Muller et.al. reported that in-
creased, as well as loss of MITF expression was observed in a panel of melanoma cell
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lines that acquired resistance to ERK- or BRAF inhibitor treatment (Muller et al., 2014).
The transcription factor MITF has also been implicated in regulating oxidative metabolism
in melanoma (Haq et al., 2013). Analysis reported in this chapter found that melanocytes
overexpressing MITF showed an increased FAO signature expression. This is consistent
with the rheostat model of high MITF levels inducing differentiation and thereby, de-
creasing proliferation. In MaMel 15 melanoma cells, siRNA against MITF increased
FAO signature expression, which is in line with low MITF levels inducing cell cycle
arrest proposed by the rheostat model. In short, MITF expression at either extreme
results in increased FAO signature expression.
Haq et. al. proposed that the MITF-induced increase in oxidative metabolism could
compensate for decreased glycolysis from BRAF inhibition, and promote treatment re-
sistance (Haq et al., 2013). However, over 75% of resistance to vemurafenib or dabrafenib
treatment is due to reactivation of the MAPK pathway, which is expected to repress
MITF and PGC1A expression (Rizos et al., 2014). Therefore, the proposed logic of the
association between increased oxidative metabolism and BRAF inhibition resistance is
somewhat dissonant. Rather, as Fig 5.12 demonstrates, overexpression of MITF in
the presence of BRAF V600E decreased the expression of the MKS proliferation and in-
creased the expression of the FAO signatures, compared to BRAF V600E overexpression
alone. Since the rheostat model suggests that high expression level of MITF promotes
differentiation and inhibits proliferation, one can propose an alternative notion: MITF-
PGC1A mediated increase in oxidative metabolism upon BRAF inhibition is a desirable
outcome, and therapies that promote FAO offer a mechanism of achieving this. In
support of this argument to an extent, co-treatment of BRAF-mutant melanoma cell
lines that are vemurafenib-resistant via an NRAS mutation with dichloroacetate - an
inhibitor of PDK which activates PDH to oxidise pyruvate in the mitochondria - resulted
in a greater degree of cell death, compared to high dose vemurafenib alone (Parmenter
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et al., 2014).
5.6 Summary, strenghts and limitations
Analysis in this chapter has shown that the FAO gene signature is:
1. altered in response to transgenic expression of Apc or DKK-1, or knock down of
CTNNB1 and Bcl9
2. decreased in response to constitutive Wnt signalling in a mammary tumour model
3. up regulated upon pharmacologic BRAF and MEK inhibition
4. inversely correlated with activity of MAPK components
5. up regulated when MITF expression is either low or high
This chapter describe novel associations between expression of genes involved in FAO
and MAPK and Wnt signalling. Importantly, the analyses conducted included datasets
that modulated different components of these pathways, which was performed to demon-
strate that the association observed is attributable to the activity of the pathways, rather
than effects of individual genes within the MAPK or Wnt signalling cascade.
Since proliferation is a strong component of the activity of these two pathways, it is
likely that expression of the FAO signature is strongly intertwined with the proliferation
status of the cancer cell. These findings, however, were based only on computational
analysis of published gene expression datasets. Nonetheless, they provide compelling
basis for experimental characterisation in pre-clinical systems, and potential questions
at hand include:
(i) can genetic or pharmacologic manipulations that promote FAO drive BRAF mutant
melanoma cell lines, and colorectal cancer cell lines with constitutive Wnt signalling
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away from glycolysis?
(ii) how do manipulations in (i) affect proliferation, invasion, migration of melanoma
and colorectal cancer cells?
(iii) what are the global molecular changes that occur in response to (i)?
Addressing these questions may contribute to our understanding of the intersection be-
tween oncogenic signalling and metabolism; and may identify novel therapeutic targets
to complement current standard care for patients with tumours that exhibit alterations
in MAPK and Wnt signalling.
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Chapter 6
Analysis of CPT1A modulation
in in vitro breast cancer cell
systems
6.1 Background
The previous chapters have described an association between the FAO signature expres-
sion and prognosis in certain cancers. The consistent downregulation of the signature in
several different tumour types, compared to normal tissues suggests that this pathway
is downregulated during disease progression. Importantly, the FAO signature is signifi-
cantly negatively correlated with the MKS proliferation signature.
One mechanism of regulating metabolic pathway flux is through the activity of rate-
limiting enzymes. As mentioned in the Introduction, in FAO, the rate-limiting enzyme
is CPT1A (Bruce et al., 2009; Henique et al., 2010). Importantly, CPT1A is a member
of the 19-gene FAO signature. Pharmacologic and genetic modulation of this enzyme
has been shown to affect beta-oxidation flux (Sousa et al., 2005; Pike et al., 2011). Over-
expression of CPT1A in haematopoietic or skeletal muscle cells resulted in increased ox-
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idation of radiolabelled palmitate or oleate, while shRNA-mediated CPT1A knockdown
of CPT1A in LNCaP prostate cancer cells reduced palmitate oxidation rates (Deberardi-
nis, Lum, and Thompson, 2006; Henique et al., 2010; Schlaepfer et al., 2014). Therefore,
it stands to reason that CPT1A expression level is associated with cellular FAO activity.
Two questions arise from these findings: (i) why is the FAO signature expression down-
regulated in tumours, compared to normal tissues; and (ii) can, and, how does modu-
lating FAO affect cancer cells? This chapter will attempt to answer the second question
using experimental systems. Obviously, modulating the expression of all 19 genes in the
FAO signature is not practical in terms of time and budget available for this project.
Therefore, the second question raised above will be addressed by generating and char-
acterising transgenic cell lines that modulate CPT1A expression for reasons explained
above, and its effect on different cellular characteristics investigated using various func-
tional assays.
6.2 Objectives
The objectives of this chapter are to:
(i) generate and characterise CPT1A overexpression and knockdown systems using nor-
mal breast and breast cancer cell lines
(ii) characterise growth rates between CPT1A transgenic and control lines
(iii) characterise migration rates between CPT1A overexpression and control line
(iv) compare anchorage-indepent growth in transgenic and control lines
(v) functionally validate transgenic lines with CPT1A modulation using extracellular
flux technology
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6.3 CPT1A expression higher in ER-positive compared to
ER-negative breast tumours and cell lines
First, the expression of CPT1A was analysed using gene expression data from breast tu-
mours. In five of six datasets with tumour ER status available analysed, CPT1A mRNA
expression was significantly higher in ER-positive, compared to ER-negative tumours
(Fig 6.1).
Figure 6.1: ER-positive tumours have higher CPT1A mRNA expression
compared to ER-negative tumours. Microarray gene expression datasets from
primary breast tumours with ER status were analysed for expression of CPT1A. Wilcox
rank sum test p **≤0.01; *≤0.05; NS, non-significant.
To determine which cell systems to modulate CPT1A, transcriptome datasets from a
panel of breast cancer cell lines were analysed for CPT1A mRNA expression. As shown
from the waterfall plot in Fig 6.2, a striking enrichment of higher CPT1A expression in
ER-positive, compared to ER-negative cell lines in the first dataset (Neve et al., 2006),
which was also observed in two other independent datasets (Supp Figs A.3, A.4). In-
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triguingly, in the second dataset, an adriamycin-resistant, oestrogen-independent variant
of the MCF7 cell line previously established was observed to have lower CPT1A mRNA
expression levels, compared to the parental line (Fig 6.3, black arrow) (Vickers et al.,
1988).
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Figure 6.2: ER-positive cell lines have higher CPT1A mRNA expression compared to ER-negative cell lines.
Neve et.al. dataset (n=54) (Neve et al., 2006).
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Figure 6.3: ER-positive cell lines have higher CPT1A mRNA expression compared to ER-negative cell lines.
(AstraZeneca dataset (n=38), E-GEOD-57083).
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6.4 Generation of CPT1A overexpression in MDA-MB231
cell line
To investigate the functional consequence of modulating CPT1A expression in cell sys-
tems, tetracycline (Tet) inducible cell lines were generated to overexpress and knockdown
CPT1A in different cell systems.
The TetOn system is based on the transcriptional activation of a transgene downstream
of a Tet response element promoter by the reverse tetracycline transactivator (rtTA) in
the presence of doxycycline (Dox). The levels of induction can be optimised to achieve
the optimal induction based on the dosage of Dox. In in vitro systems, this is achieved
by transfecting cells with plasmid/s that expresses rtTA and the transgene of interest,
followed by adding Dox to the culture medium. This inducible system allows the circum-
vention of potential cytotoxic or non-relevant effects of long-term continual expression
of a transgene.
Since the MDA-MB231 cell line has low CPT1A expression, a double stable Tet system
was generated to overexpress this gene in this cell line. Conversely, the MCF7 cell line,
which has high CPT1A expression, was used to generate a stable shRNA-based knock-
down cell system.
6.4.1 Luciferase assay for Tet induction in MDA-MB231 single, sta-
ble transfectant clones
To generate a double stable system using the MDA-MB231 cells, an initial transfec-
tion with pTetOn was performed. Cells were then seeded into 10- and 15 cm dishes
at various densities and selected for stable transfectants with 1 mg/mL of G418. After
172
approximately 3 weeks of selection, colonies were lifted into 24 well plates and expanded.
To determine which G418-resistant clones demonstrated satisfactory Tet transcriptional
activity in response to doxycycline treatment, clones were plated in duplicates and trans-
fected the following day with a plasmid that expresses firefly luciferase downstream of
a Tet response element (TRE). One of the two transfected wells was induced with 2
µg/mL Dox for 48 hours, and protein lysates were prepared and assayed for luciferase
activity. Control wells were treated with 2 µL of milliQ water. Clones with at least 20
fold induction were taken further for repeated screens. As shown in Fig 6.4, of 29 clones
screened, two clones (10 and 19) showed at least 20 fold induction of luminescence signal
compared to non-induced cells (Fig 6.4a). Upon further screens, clone 10 was selected
to generate the second stable, CPT1A transgenic MDA-MB231 cell line (Fig 6.4b).
6.4.2 Generation of double, stable transfectant clones overexpressing
CPT1A
To generate a double stable cell line, pTetOn MDA-MB231 cell line was co-transfected
with pTRE-CPT1A and pBabe-puro, a plasmid that confers puromycin resistance. Cells
were selected for approximately 2-3 weeks with 1 µg/mL puromycin, and single clones
lifted into 24 well plates. Single clones were screened for pTRE-CPT1A integration by
PCR and positive clones were screened by qPCR for CPT1A mRNA induction upon 2
µg/mL Dox treatment (Fig 6.5).
Based on the qPCR screen, clones with ≥ 8-fold mRNA induction by qPCR were
screened further by immunoblot analysis (Fig 6.6). Clones 3, 5 and 17 were seeded
and induced for 48 hours with 2 µg/mL Dox. Total protein was harvested, resolved
by SDS-PAGE and immunoblotted for CPT1A. As shown in Fig 6.6, all clones showed
increased CPT1A expression after 48 hours induction. Further screens found clone 5 to
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Figure 6.4: Luciferase assay to measure rtTA inducibility in MDA-MB231
TetOn clones. (a) 29 putative TetOn clones were screened and (b) clones 10 and 19
were taken further for repeated screens. n=1 for all conditions.
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Figure 6.5: CPT1A mRNA overexpression screen after 48 hr induction in
putative MDA-MB231 pTRE-CPT1A clones. Cells were seeded in 6 well plates
in duplicates and one well induced with Dox for 48 hours. Control wells were treated
with 2 µL of milliQ water. Total RNA was prepared and expression of CPT1A measured
by qPCR, normalised to GAPDH. Fold changes are presented relative to -Dox. n=1 for
all conditions.
express CPT1A in the absence of Dox (Supp Fig A.5.5) and hence, clones 3 and 17 were
further characterised.
6.4.3 Dose- and time course optimisation of CPT1A induction in
MDA-MB231 double transfectants
To determine the optimal induction of CPT1A expression, dose- and time-course ex-
periments were performed. For Dox dose-response experiment, cells were seeded into 6
well dishes and induced with 0.5- to 5 µg/mL of Dox for 48 hours. As shown in Fig 6.7,
there was a dose-dependent increase in CPT1A expression in cells induced with increas-
ing doses of Dox. Since high Dox concentrations may have a negative impact on cells
(Ahler et al., 2013), 2 µg/mL was selected as the dose for further experiments. Next,
a time course analysis was performed to determine the time point at which optimal
CPT1A expression occurred. Cells were seeded and induced with 2 µg/mL of Dox for
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Figure 6.6: CPT1A overexpression screen after 48 hr induction in selected
MDA-MB231 pTRE-CPT1A clones. Cells were seeded in 6 well plates and in-
duced with Dox for 48 hours. Control wells were treated with 2 µL of milliQ water.
Total lysates were resolved by SDS-PAGE and immunoblotted for CPT1A expression.
Expression of alpha-tubulin (TUBA) was used to estimate loading accuracy. CPT1A 88
kDa; TUBA 50 kDa.
up to 96 hours. The immunoblot shown in Fig 6.7 indicates increased CPT1A expression
over time, starting at 36 hours, with strong expression observed from 48 hours onwards.
6.5 Generation of CPT1A knockdown system in MCF7
cell line
To generate MCF7 cell lines stably expressing inducible shRNA against CPT1A, lentivi-
ral particles were prepared and cells transduced, as described in Methods.
To determine extent of CPT1A knockdown in the single clones, cells were seeded in
duplicates in 6 well dishes and induced for 5 days. qPCR was performed to compare
CPT1A mRNA expression levels between uninduced and induced cells. Based on the
normalised CPT1A expression depicted in Fig 6.8, clone 7 for shRNA1 (57) and clone
2 for shRNA2 (72) were selected for further analysis. Additionally, clone 6 from the
non-silencing construct (green bars) was selected as the control clone for Dox-specific
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Figure 6.7: Dose response and time course characterisation of CPT1A over-
expression in MDA-MB231 cells. Top panel: Cells were treated with indicated
doses of Dox for 48 hours. The 0 µg/mL Dox well was treated with 2 µL of milliQ
water. Bottom panel: Cells were treated with 2 µg/mL Dox for indicated times. Time
0h and Tet parental control wells were treated with 2 µL of milliQ water. CPT1A 88
kDa; TUBA 50 kDa.
effects in further analysis.
To determine Dox dose required for optimal CPT1A protein knockdown in the MCF7
clones, non-silencing and shRNA clones were treated with 0.5- to 6 µg/mL of Dox for
one week. Total protein was harvested, resolved by SDS-PAGE and immunoblotted for
CPT1A. As shown in Fig 6.9, one week of CPT1A mRNA knockdown resulted between
40- to 60% decreased expression at the protein level.
6.6 Generation of CPT1A knockdown system in MCF10A
cell line
To generate MCF10A cell lines stably expressing inducible shRNA, cells were transduced
with viral particles as described in Methods. Puromycin selection was commenced the
following day, and polyclones were generated for non-silencing and the two CPT1A
shRNAs. In this context, polyclone refers to a mixed population of cells that had stably
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Figure 6.8: CPT1A mRNA knockdown screen after 5 days induction in
putative MCF7 shRNA clones. MCF7 shRNA1 (blue bars) and shRNA2 (brown
bars) clones were induced with Dox for 5 days. Controls were treated with milliQ water.
Total RNA was prepared and expression of CPT1A measured by qPCR, normalised to
GAPDH. Fold changes are presented relative to -Dox. Each clone was screened once
(n=1) as a first pass, and selected clones were taken further for analysis of knockdown
at protein level.
Figure 6.9: Characterising CPT1A knockdown in MCF7 cells. MCF7 shRNA1
and shRNA2 clones were induced with indicated doses of Dox for one week. Lysates
were resolved by SDS-PAGE and immunoblotted for CPT1A expression. For shRNA
clone 1, 6 µg/mL of Dox was observed to be toxic to the cells, and insufficient lysates
precluded the analysis of this condition. The 0 µg/mL of Dox wells were treated with 2
µL of milliQ water. CPT1A 88 kDa; TUBA 50 kDa.
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Figure 6.10: CPT1A mRNA knockdown screen in MCF10A shRNA poly-
clones. MCF10A shRNA1 and shRNA2 polyclones with 2 µg/mL Dox for 3 days and
assayed CPT1A expression. Percentage knockdown is relative to -Dox (treated with 2
µL milliQ, normalised to GAPDH. n=1 for all conditions.
integrated the lentiviral construct into the genome and were viable after puromycin se-
lection. This differs to the monoclonal system generated using MDA-MB231 and MCF7
cell lines, where cells were seeded sparsely and individual colonies picked. A mixed,
polyclonal population was generated to save time that would have been required to gen-
erate monoclonal lines with stable shRNA expression.
Four polyclones from each CPT1A shRNAs were screened by qPCR after an initial 3
day knockdown (Fig 6.10). From the qPCR screen, selected polyclones were analysed
for protein expression after 5 days of CPT1A knockdown. Based on the immunoblot
analysis, shRNA clones 1.1 and 2.1 were selected for further experiments.
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Figure 6.11: Characterising CPT1A knockdown in MCF10A cells. MCF10A
shRNA clone 1.1 and shRNA clone 2.1 were induced with 2- or 4 µg/mL Dox for 5 days
and 20 µg of lysates resolved by SDS-PAGE and immunoblotted for CPT1A expression.
Control wells were treated with 2 µL milliQ. CPT1A 88 kDa; TUBA 50 kDa.
Figure 6.12: Characterising CPT1A knockdown in MCF10A cells. MCF10A
shRNA clones 2.1 to 2.4 were induced with 2- or 4 µg/mL Dox for 5 days and 20 µg
of lysates resolved by SDS-PAGE and immunoblotted for CPT1A expression. Control
wells were treated with 2 µL milliQ. CPT1A 88 kDa; TUBA 50 kDa.
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6.7 Characterisation of stable cell systems modulating CPT1A
expression
6.7.1 Real time growth assay in response to CPT1A modulation
6.7.1.1 CPT1A overexpression decreases growth rate of MDA-MB231 cells
To determine how overexpression of CPT1A in the MDA-MB231 cell line affects prolif-
eration rate, cells were pre-induced with 2 µg/mL of Dox for 48 hours prior to seeding
into 96 well plates. Real time growth was monitored for one week using the Incucyte
live imaging system, and phase contrast scans of confluency as a measure of prolifera-
tion were automatically generated every 2 hours. In two independent clones (3 and 17)
of CPT1A overexpression, the growth rate was reduced by approximately 25-35%, as
compared to the Tet parental control (Fig 6.13).
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Figure 6.13: CPT1A overexpression in MDA-MB231 decreases proliferation
rate, compared to Tet parental. (a) A representative growth curve of MDA-MB231
TetOn and pTRE-CPT1A clone 3. Error bars = standard deviation. Real time growth
kinetics of (b) clones 3 and (c) 17 CPT1A were monitored using the Incucyte imaging
system for approximately one week. Confluency at 140 hours is presented. Error bars
= SEM, paired t-test p *≤0.05.
182
6.7.1.2 CPT1A overexpression decreases wound closure rate of MDA-MB231
cells
Next, the effect of CPT1A overexpression in MDA-MB231 cells on the rate of wound
closure as a surrogate of cell migration was investigated. CPT1A expression in MDA-
MB231 cells was induced with 2 µg/mL Dox for 5 days before seeding into Essen Image-
Lock 96 well plate at a density to achieve full confluency the following day. A scratch
through the middle of each well was performed using the Essen WoundMaker, and mi-
gration rate of the wound was monitored using the Incucyte live imaging system. A
representative wound healing profile is shown in Fig 6.14a. In two independent clones,
CPT1A overexpression reduced migration rate between 20-25%, compared to the Tet
parental (Fig 6.14b,c).
6.7.1.3 CPT1A overexpression does not affect transwell migration rate of
MBA-MB231 cells
To further investigate a potential role for CPT1A in migration, the migration rates be-
tween basal and CPT1A overexpression in MDA-MB231 cells were investigated using
the Boyden chamber. Cells were pre-induced with 2 µg/mL Dox for 5 days and seeded
into transwell inserts in serum-free media supplemented with BSA-conjugated palmitic
acid and carnitine (concentrations based on conditions used for Seahorse XF flux anal-
ysis). The migration experiment was conducted for 48 hours. Cells were fixed and
stained with 1 µg/mL DAPI nuclear dye in PBS with 0.25% (v/v) paraformaldehyde
and 0.075% (v/v) saponin, and cells that migrated and attached to the bottom well were
counted using the Cytation. As shown in Fig 6.15, no significant difference in migra-
tion rates were observed between basal and CPT1A overexpression in MDA-MB231 cells.
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Figure 6.14: CPT1A overexpression in MDA-MB231 decreases wound heal-
ing rate, compared to Tet parental. (a) Representative real-time wound confluency
profile of MDA-MB231 TetOn and pTRE-CPT1A clones. Error bars = standard devia-
tion. Wound confluency at 30 hours of (b) clones 3 and (c) 17 CPT1A were monitored
using the Incucyte imaging system for approximately one week. n=3 biological repli-
cates. Error bars = SEM, paired t-test p *≤0.05.
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Figure 6.15: CPT1A overexpression does not affect transwell migration rate
of MDA-MB231 cells. MDA-MB231 Tet parental and CPT1A overexpression clone
3 were induced for 5 days, seeded on transwell inserts and migration rates compared
after 48 hours. n=3 biological replicates, with 2 technical replicates per condition per
experiment. Error bars = SEM, both conditions non-statistically signficant.
6.7.1.4 CPT1A overexpression does not affect anchorage-independent growth
of MDA-MB231 cells
Anchorage-independent growth measures the ability of cells to proliferate without at-
tachment to a surface, and mimics the early events of metastasis. Using gas chromatog-
raphy and mass spectrometry, Hunnewell et.al reported pathways that were active or
inactive in proliferating compared to quiscent spheroid cultures of Ras transformed
mouse embryonic fibroblast cells (Hunnewell and Forbes, 2010). Synthesis of several
amino acids including alanine, glycine, and serine were found to be upregulated in pro-
liferating, compared to quiescent spheroids. Additionally, the citric acid cycle was active
in both proliferating and quiescent spheroids. However, the role of FAO in anchorage-
independent growth remains poorly understood.
To investigate the effect of CPT1A overexpression in MDA-MB231 on anchorage-independent
growth, soft agar assays were performed. MDA-MB231 cells were seeded in agar and
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Figure 6.16: CPT1A overexpression does not affect anchorage-independent
growth in MDA-MB231 cells. 50,000 MDA-MB231 Tet parental, clones 3 and 17
were seeded in 0.3% agar above a 0.6% base agar. Media was replaced every 2-3 days
for 3 weeks, and colonies counted. n=3 biological replicates. Error bars = SEM, both
conditions non-statistically significant.
cultured for approximately 3 weeks in 2 µg/mL Dox or milliQ as control, following which
colonies were counted under a phase contrast microscope. Counts were verified by an
independent observer blinded to the conditions. As shown in Fig 6.16, after 3 weeks of
growth, there were no significant differences observed between basal and overexpression
of CPT1A in MDA-MB231 cells.
6.7.1.5 CPT1A knockdown does not affect proliferation rate of MCF7 cells
If knockdown of CPT1A induces cells to engage in glycolysis, one may postulate that
it could alter the cellular proliferation rate. This is possible through the generation of
anabolic metabolites from glycolytic intermediates to facilitate macromolecule synthe-
sis required for cell division (Lunt and Vander Heiden, 2011). To understand how the
growth rate of MCF7 cells is affected by CPT1A knockdown, cells were pre-induced
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with 2 µg/mL of Dox for one week, and seeded into a 96 well plate. Real-time growth
rate was measured as mentioned in Section 6.7.1.1. As shown in Fig 6.17a, knockdown
of CPT1A using two independent shRNA did not affect the proliferation rate of MCF7
cells. A representative growth curve is shown in Fig 6.17b. Of note, the expression of
red fluorescent protein - which is driven by the same promoter with that of the shRNA
- was routinely monitored to infer the shRNA expression is induced in response to Dox
induction.
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Figure 6.17: CPT1A knockdown does not affect proliferation in MCF7 cells.
Cells were pre-induced for one week, before seeding into 96-well plates. Real time growth
kinetics of CPT1A knockdown was using the Incucyte imaging system for approximately
one week. (a) Representative growth curve profile of MCF7 non-silencing and shRNA
clones. Error bars = standard deviation. (b) Confluency presented at 140 hours is
presented. Error bars = SEM, differences are non-statistically signficant. n=3 biological
replicates, 5 technical replicates per experiment.
188
Figure 6.18: CPT1A knockdown does not affect anchorage-independent
growth in MCF7 cells. 5,000 MCF7 non-silencing, and two shRNAs clones were
seeded in 0.3% agar above a 0.6% base agar. Media was replaced every 2-3 days for
3 weeks, and colonies counted. No statistically significant differences were observed
between the conditions. Error bars = SEM. n=3 biological replicates.
6.7.1.6 CPT1A knockdown does not affect anchorage-independent growth
rate of MCF7 cells
To investigate whether CPT1A knockdown in MCF7 cells affects anchorage-independent
growth, CPT1A shRNA clones were seeded in soft agar and cultured as described in
methods. After 3 weeks, cells were fixed, stained, and colonies counted. As shown in
Fig 6.18, there were no significant differences in the number of colonies between basal
and CPT1A knockdown in MCF7 cells.
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6.8 FAO flux analysis of breast normal and cancer cell lines
with CPT1A modulation
To determine whether overexpression and knockdown of CPT1A in breast cell lines
corresponds with FAO flux, the Seahorse XF extracellular flux assay was performed
to determine oxygen consumption in response to exogenous palmitate. This assay is
a variant of the standard MitoStress test which measures various components of mi-
tochondrial metabolism based on oxygen consumption and extracellular acidification
rate, surrogates of respiration and aerobic glycolysis, respectively (See Section 2.7.2 for
method details). This assay was performed on all three transgenic cell lines generated
in this study.
6.8.1 Real time FAO flux in MDA-MB231 cells with CPT1A over-
expression
To investigate whether increased CPT1A levels are associated with increased FAO flux
in MDA-MB231 cells, real-time oxygen consumption was analysed in response to exoge-
nous palmitate. Except for CPT1A overexpression clone 17, oligomycin and antimycin
treatments decreased the oxygen consumption rate (OCR) in MDA-MB231. In response
to carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCPO treatment, presence
or absence of Dox in the Tet parental control line did not alter OCR when treated with
either BSA-only (blue and orange lines), or BSA-palmitate (yellow and grey lines). Sur-
prisingly, in CPT1A overexpression clone 3, there was no apparent difference in OCR
observed in Dox treated cells with exogenous palmitate (orange line), compared to con-
trol (yellow line) (Fig 6.19b). Furthermore, at time=0, there were no differences in OCR
observed, which suggests that there was no difference in endogenous mitochondrial res-
piration between the conditions.
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Figure 6.19: Real time oxygen consumption analysis in CPT1A overexpress-
ing MDA-MB231 cells. Cells were pre-induced for 5 days, before seeding into XF24
well plates in substrate-limited media overnight. Error bars = standard deviation from
2 technical replicates from one experiment. Oxygen consumption analysis in (a) TetOn
parental, (b) pTRE-CPT1A clone 3 and (c) pTRE-CPT1A clone 17. Arrows indicate
when mitochondrial inhibitors (oligomycin, FCCP and antimycin A) were introduced
into the assay.
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Next, the effect of CPT1A knockdown on palmitate metabolism was analysed in MCF7
cells. Cells were induced for one week prior to oxygen consumption analysis. As ex-
pected, in the non-silencing and CPT1A shRNA clones, oligomycin and antimycin A
treatments decreased oxygen consumption. Interestingly, addition of exogenous palmi-
tate resulted in a more marked increase in OCR in the non-silencing (blue line, 6.20a;
yellow line, 6.20b), compared to CPT1A knockdown (grey line, 6.20a; orange line, 6.20b)
when treated with FCCP. This suggests that decreased CPT1A expression associated
with decreased oxygen consumption. However, it should be noted that some variation
was observed in the basal, endogenous OCR at time=0.
6.8.2 Real time FAO flux in MCF7 cells with CPT1A knockdown
The effect of CPT1A knockdown was also analysed in MCF10A cells. Cells were induced
for one week prior to oxygen consumption analysis. Overall, the oxygen consumption
profile in response to different ETC inhibitors were as expected, with decreased OCR
in response to oligomycin and antimycin A, and maximal OCR observed with FCCP
treatment. However, in these polyclonal non-silencing and CPT1A shRNA lines, no
differences in OCR was observed in response to exogenous palmitate, compared to BSA-
only control, upon treatment with FCCP.
6.8.3 Real time FAO flux in MCF10A cells with CPT1A knockdown
6.9 Discussion
This chapter sought to investigate the functional consequences of CPT1A modulation
in breast normal and cancer cell lines. While extracellular flux rates have been re-
ported on a panel of breast cancer cell lines measuring the glycolytic and mitochondrial
respiration rates, very little is known about the FAO rate in cancer cells (Pelicano et
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Figure 6.20: Real time oxygen consumption analysis in MCF7 cells after
CPT1A knockdown. CPT1A expression was knocked down for one week, before
seeding into XF24 well plates in substrate-limited media overnight. Error bars = stan-
dard deviation from 2 technical replicates from one experiment. Oxygen consumption
analysis in (a) shRNA clone 1 and (b) shRNA clone 2. Arrows indicate when various
mitochondrial inhibitors (oligomycin, FCCP and antimycin A) were introduced into the
assay.
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Figure 6.21: Real time oxygen consumption analysis in MCF10A cells af-
ter CPT1A knockdown. CPT1A expression was knocked down for one week, before
seeding into XF24 well plates in substrate-limited media overnight. Error bars = stan-
dard deviation from 2 technical replicates from one experiment. Oxygen consumption
analysis in (a) shRNA clone 1 and (b) shRNA clone 2. Arrows indicate when various
mitochondrial inhibitors (oligomycin, FCCP and antimycin A) were introduced into the
assay.
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al., 2014). This is important as there are several ways mitochondrial respiration can
be promoted, including glutamine oxidation, conversion of pyruvate to oxaloacetate by
pyruvate carboxylase, and pyruvate and fatty acid oxidation. The standard Seahorse XF
assay measures mitochondrial oxygen consumption from all sources mentioned. There-
fore, it is possible that the contribution of each source may differ within and between
cancer cell lines. Indeed, the oxidation rate of radiolabelled palmitate in MCF7 cells
has been shown to be over 5 fold higher compared to MDA-MB231 cells (Balaban et al.,
2017). Importantly, the protein expression of CPT1A is significantly higher in MCF7-
compared to MDA-MB231 cells, which is consistent with the mRNA expression levels
between these two cell lines (Figs 6.3, 6.2). In another study, CPT1A overexpression in
interleukin-3 dependent cells resulted in approximately 9 fold increase in the oxidation
of radiolabelled palmitate (Deberardinis, Lum, and Thompson, 2006). The implications
of these findings are twofold: (i) FAO flux may vary between different cancer cell lines
and (ii) CPT1A expression is associated with cellular FAO flux in these studies.
6.9.1 CPT1A modulation decreases growth and wound closure rates
in MDA-MB231, but not MCF7 cells
Overexpression of CPT1A in MDA-MB231 cells was observed to decrease the prolif-
eration rate by up to 30%, compared to Tet parental line. This suggests that in this
genetic background, forced FAO can alter the growth kinetics of these cells. This find-
ing is supported by that of DeBerardinis et. al., who found that CPT1A overexpression
in interleukin-3 dependent cells decreased the proliferation rate by approximately 33%,
compared to empty vector control. MDA-MB231 has been shown to be highly glycolytic,
and have low respiration capacity (Pelicano et al., 2014). Therefore, by upregulating
FAO via CPT1A overexpression, it is likely that glycolytic rates would be reduced in
this cell line. Given the central role of glycolysis for anabolic precursors and energetic
needs for cellular growth, it could explain the cytostatic effect brought about by CPT1A
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overexpression, compared to basal expression control.
However, the difference in proliferation observed was relatively modest. A possible ex-
planation for this is that it may require more time for the metabolic rewiring to fully
take effect. Oncogenic mutations can promote a glycolytic phenotype, and MDA-MB231
cells harbour mutations in RAS and TP53, both of which are key to activate glycolysis
(Bryant et al., 2014; Ying et al., 2012; Berkers et al., 2013). Thus, competition between
expression and activity of glycolytic enzymes driven by oncogenic mutations, and the
transgenic expression of CPT1A and increased FAO flux could occur. Consequently,
more time may be required before the molecular phenotype of CPT1A overexpression
manifests.
Overexpression of CPT1A in MDA-MB231 was also observed to decrease the wound
closure rate of by approximately 20%. However, validation of this finding using the
transwell migration assay revealed no difference in migration between Tet and clone 3
overexpression lines. As such, it is possible that the differences observed in the scratch
assay are due to differences in proliferation, rather than the direct effect of CPT1A
overexpression on migration.
In MCF7 cells, no difference was observed in the proliferation rates of non-silencing
control and CPT1A knockdown cells. The knockdown between the two shRNAs ranges
between 40-60%, which indicates that substantial levels of CPT1A protein are still ex-
pressed in these cells. It is not clear what levels of CPT1A knockdown are required
to effectively induce cells to switch to glycolysis. Furthermore, the MCF7 cells with
shRNA knockdown may also increase pyruvate or glutamine oxidation to compensate
for decreased acetyl-CoA to drive the citric acid cycle. It is also possible that assessing
the effect of CPT1A knockdown in different cell lines could reveal stronger effects as
other genetic changes in MCF7 cells could be masking the effect of decreased CPT1A
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expression. This is supported by the findings of Chaneton et. al., who reported de-
creased proliferation in HT29 and SW620, but not HCT116 colorectal cell lines when
PKM2 expression was knocked down (Chaneton et al., 2012). Taken together, more ef-
fective CPT1A knockdown in MCF7, or assaying other cell lines could reveal a potential
effect of modulating CPT1A expression levels on cancer cell proliferation.
6.9.1.1 Culture media constituents and concentrations are key in metabolism
experiments
The RPMI 1640 media used for experiments in this chapter has 11 mM of glucose,
roughly twice the normoglycemic levels in human circulation. Therefore, it may be pos-
sible that repeating these experiments in 5.5 mM glucose may widen the difference in
the basal and CPT1A overexpression isogenic MDA-MB231 cell line. Furthemore, many
other nutrients, amino acids in particular, in standard commercial media are present in
higher concentration than in human plasma or serum (Mayers and Vander Heiden, 2015).
For instance, glutamine, an important anaplerotic substrate, is present at a concentra-
tion of 2 mM, approximately 2.5-5 fold higher compared to human circulation which
ranges from 0.45 to 0.8 mM (Mayers and Vander Heiden, 2015). This is also true for
several other amino acids, and is significant because amino acids has been shown to
contribute to the majority of proliferating cell mass (Hosios et al., 2016). Serine and
glycine, two other important amino acids for cancer cell proliferation, are present be-
tween 2-8 fold higher in RPMI media, compared to human plasma or serum. Hence, in
using commercial media solutions, cells are cultured in pro-proliferative nutrient milieu
which may confound the investigation of specific metabolic pathways.
In addition, while CPT1A expression can be manipulated, it is important that there is
sufficient substrate available for the activity of this enzyme. The concentrations of fatty
acids in fetal bovine serum that cells are routinely cultured in is unknown, although re-
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cent analysis indicates a concentration of 260 µM (Mayers and Vander Heiden, 2015). Of
note, this may be subject to variations between different commercial batches, although
the same batch of serum was used for all experiments in this study. This potential
lack of consistency in concentrations of the different lipid species in serum may result
in lipotoxicity when experiments are supplemented with exogenous palmitic acid. Of
note, in a small cohort of Canadian adults (n=826), analysis of serum lipids by gas
chromatography determined the concentration of free fatty acids to be 474 ±275 µM
(Abdelmagid et al., 2015). This highlights potential interspecies differences in serum
lipid profiles, which may affect interpretation of in vitro metabolism experiments.
6.9.2 CPT1A modulation does not affect anchorage-independent growth
The soft agar assay performed in this chapter on CPT1A overexpression or knockdown
in MDA-MB231 or MCF7 cells, respectively, did not reveal any differences in the num-
ber of colonies, compared to controls. The lack of effect on three-dimensional growth
is inconsistent with the observation that CPT1A overexpression resulted in decreased
monolayer growth of MDA-MB231 cells. A straightforward explanation for this finding
is that CPT1A overexpression may have different effects between monolayer, compared
to anchorage-independent growth in MDA-MB231 cells. It is worth mentioning that the
isogenic MDA-MB231 cell lines used in this experiments were observed to form small
colonies, which could not be counted visually without the assistance of a microscope.
This contrasts with several reports in the literature that reported this cell line to form
sizeable colonies visible to the naked eye. One plausible explanation for this is that in
generating these stable transgenic lines, the passages over time could have selected for
cells that do not form colonies efficiently in soft agar. Furthermore, the soft agar assay
may not be sensitive enough to detect small, but significant differences in colony size,
and hence, modest decreases in CPT1A overexpressing MDA-MB231 cells may not be
captured by the quantitation method utilised in this experiment. In MCF7 cells, knock-
down of CPT1A did not result in significant difference in number of colonies, compared
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to basal expression. Similar to the growth curve analysis, this could be explained by the
possibility that the knockdown achieved in these clones were insufficient to trigger some
form of metabolic or signalling pathway alterations that could affect colony formation.
The soft agar assay, which assesses how well single cells form colonies in response to an
intervention, may reflect the efficiency of colony establishment after metastasis of tu-
mour cells. While the FAO signature expression has been shown to be lower in primary
and metastasis tumour tissues (Chapter 3, Figs 3.13d and 3.14d), how FAO functions
during the early events of dissemination is not well understood. This question was at-
tempted by Pascual et.al. who observed that overexpression of the lipid uptake receptor
CD36 in patient-derived or established oral carcinoma cell lines with low metastatic
propensity significantly promoted the ability of these cells to spread to the lymph nodes
in mice (Pascual et al., 2017). The authors observed several genes involved in alpha
and beta-oxidation to be upregulated in the CD36 overexpressing, compared to basal
expression cells. Additionally, three enzymes involved in FAO - ACADM, ACADVL,
HADHA - were upregulated based on flow cytometry analysis. Based on this, the au-
thors concluded that CD36-mediated fatty acid uptake promotes FAO and facilitates
oral squamous cell carcinoma metastasis.
However, there are several concerns that were apparent in the Pascual study. First, 4 of
9 genes (44%) that were observed to be involved in FAO also featured in another geneset
involved in fatty acid synthesis. Two of these enzymes catalyse reversible reactions, and
two were involved in steroid and lipid modification reactions. This highlights the im-
portance of understanding the biology of curated genesets, and as such, the alpha/beta
oxidation geneset should be interpreted cautiously. Secondly, the flow cytometry analy-
sis of FAO enzymes did not quantify and provide a measure of certainty in the differences
in expression between basal and CD36 overexpression. Interestingly, it is not clear why
CPT1A expression or activity was not assessed in this study, even though the Taqman
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qPCR probe sequence for this gene was listed in their supplementary material. Never-
theless, the authors provided compelling evidence in in vitro and in vivo systems of the
role of CD36 per se in metastasis, although one should be wary of the conclusion that
fatty acid uptake equates to oxidation to promote metastasis of cancer cells.
6.9.2.1 Varied roles of metabolic pathways during anchorage-independent
growth
In light of the findings from the soft agar clonogenic assay in this chapter, it is worth-
while mentioning that metabolic pathways may serve different roles when cultured in
adherent or non-adherent conditions. For instance, in H460 lung cancer cells, IDH1
and IDH2 have different functions when cultured as a monolayer or spheroids (Jiang,
Deberardinis, and Boothman, 2015). Culture of cells under non-adherent conditions
limits spheroid growth due to increased reactive oxygen production (ROS), which was
mitigated by NAPDH generated from the oxidation of isocitrate by IDH2 in the mito-
chondria. The increased supply of citrate is provided by the reductive carboxylation of
alpha-ketoglutarate by IDH1 in the cytosol. Importantly, knockout of IDH1/2 activity
decreased spheroid size but had no effect on cells cultured as a monolayer. Based on
this finding, one should be aware that modulating metabolic pathways, such as FAO,
under non-adherent conditions may not necessarily reflect the findings observed from
adherent setting.
6.9.3 Seahorse XF analysis of transgenic lines
Using the Seahorse XF extracellular flux technology, the FAO flux of cells in the trans-
genic cells was analysed. In all three cell lines with overexpression or knockdown of
CPT1A, there was no apparent evidence of changes in oxygen consumption in response
to exogenous palmitate. Notably, the OCR in response to different mitochondrial poi-
200
sons were in agreement with the expected output from a standard MitoStress assay.
For instance, the ATP synthase inhibitor decreased oxygen consumption, while the
mitochondrial uncoupler increased cellular oxygen consumption in all three cell lines
assayed. Futhermore, MCF7 cells had higher basal OCR, compared to MDA-MB231
cells, which is consistent with the findings reported in the literature. Notwithstanding
genetic differences between these two cell lines, differences in CPT1A expression per
se reflects the approximately 5 fold difference in FAO flux between them. Why, then,
was there negligible difference in OCR in the transgenic lines? This may be due to
the cells being seeded overnight in media with higher concentration of glucose than rec-
ommended by the manufacturers, which was to avoid stressing cells. Furthermore, the
recommended supplementation of glutamine may also allow another route of mitochon-
drial metabolism, which together with glucose, could meet the nutritional need of the
cells, and hence, be less receptive of exogenous palmitic acid. Furthermore, some cell
types may have endogenous lipid stores to utilise when under nutritional stress, and
therefore, may not require exogenous palmitate.
Indeed, the manufacturer suggests that the constituents of the substrate-limited me-
dia and length of time cells are incubated in the substrate-limited media are potential
variables amenable to optimisation for this assay. Of note, in the knockdown lines,
strong RFP expression was observed in the presence of Dox during the pre-induction
period prior to seeding into XF24 plates. Nonetheless, potential variations in knockdown
between experiments cannot be eliminated, which may also contribute to the results ob-
served from the Seahorse XF oxygen consumption analysis. On a more positive note,
the increase in OCR in MCF7 non-silencing compared to CPT1A shRNA suggests that
there is some evidence that knockdown of CPT1A does alter mitochondrial respiration
in these cells.
201
Two potential experiments can be suggested from the preliminary Seahorse XF ex-
tracellular flux analysis. Firstly, it is imperative that the best knockdown of CPT1A
is achieved to confidently observe the impact on FAO flux and oxygen consumption.
An alternative option is to genetically knockdown CPT1A is through transient siRNA
transfection which may achieve higher levels of knockdown before oxygen consumption
analysis in response to exogenous palmitate is performed. Secondly, the Seahorse Mito
Fuel Flex Test could be performed, which would allow the measurement of real time de-
pendency of cells on three metabolic pathways: glycolysis, and glutamine- and fatty acid
oxidation. This is more meaningful as it may identify adaptations in fluxes in response
to modulating FAO in cell systems. For instance, by increasing FAO in MDA-MB231
(highly glycolytic), it may force the cells to respire and possibly rely less on glycolysis
and glutamine oxidation. This information may complement findings from other exper-
iments, such as differential expression of genes encoding enzymes from transcriptome
analysis. Since this assay measures metabolic flux real time, it gives a good indicator of
metabolic adaptation in response to genetic or pharmacologic manipulations, compared
to end point assays (e.g., mRNA or protein expression, enzyme activity, metabolomics).
6.10 Summary, strengths and limitations
This chapter sought to experimentally characterise the association between FAO and
cancer cell biology, in light of findings made in Chapter 3. Expression of CPT1A was
higher in ER-positive, compared to ER-negative tumours and cell lines. Overexpres-
sion of CPT1A in MDA-MB231 was observed to significantly decrease proliferation and
wound healing migration rates. In contrast, no significant differences were observed
in proliferation rate of MCF7 cells with moderate CPT1A knockdown. Unexpectedly,
modulation of CPT1A expression did not alter cellular oxygen consumption in response
to exogenous palmitate in MDA-MB231, MCF7 and MCF10A cell lines.
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The cell systems generated in this chapter was based on Dox induction, which allows
controlled expression of transgenes. This helps to minimise potential artefacts that may
arise from constitutive expression or knockdown of CPT1A. Importantly, the decrease in
proliferation when CPT1A was inducibly overexpressed in MDA-MB231 was observed
in two independent clones, which strengthens this finding. Of note, the MDA-MB231
cells have a mesenchymal morphology. It could be worthwhile studying the effects of
CPT1A modulation on other ER-negative cell lines with epithelial morphology to verify
whether the findings made in this chapter stand in other cell systems. Similarly, it is
also possible that other ER-positive cell lines with a different genetic background, such
as T47D, may be more amenable to genetic knockdown, and as such could facilitate
studying the effects of altering FAO in this system.
This chapter also has a few limitations. The knockdown of CPT1A in MCF7 cells was
not complete, which may explain some of the findings observed using this system. A
potential experiment that may be performed in MCF7 cell line is highlighted in Chapter
8. The Seahorse XF technology may require further optimisation to establish conditions
prior to formally measuring oxygen consumption in response to exogenous palmitate.
This study was limited with regards to time, budget, and logistics to fully undertake
this analysis to completion.
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Chapter 7
Transcriptome analysis of breast
cancer cell systems in response to
CPT1A modulation
7.1 Background
In the previous chapter, the functional assays described revealed that increased CPT1A
expression in MDA-MB231 cell line resulted in decreased proliferation and wound healing
rates. As these assays analyse specific cellular characteristics, the information gleaned
is rather limited. A more global approach to assess the molecular changes in response to
CPT1A modulation may be more informative in understanding how alterations in FAO
features in cancer cell biology.
Pharmacological activation of fatty acid oxidation in a lung cancer cell line has been
shown to induce transcriptional changes, and activation of proteins involved in cell cycle
arrest (Srivastava et al., 2014). However, the signalling pathways and cellular processes
that are altered in response to FAO modulation to affect proliferation is poorly under-
stood. To investigate this, RNA-sequencing analysis was performed to identify global
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transcriptomic changes in MDA-MB231 and MCF7 cell systems in response to CPT1A
modulation.
7.2 Results
This experiment compared the transcriptomes of:
(i) MDA-MB231 TetOn parental with and without Dox induction for 5 days (two bio-
logical duplicates per condition)
(ii) MDA-MB231 pTRE-CPT1A clones 3 and 17 with and without Dox induction for 5
days (two biological duplicates per condition)
(iii) MCF7 non-silencing, shRNA1 and shRNA2 clones induced with Dox for 5 days (two
biological duplicates per condition)
Of note, qPCR was performed on samples to verify that knockdown and overexpression
in the transgenic cell systems indeed occured prior to submitting for sequencing. RNA-
Seq and alignment of raw reads was performed by New Zealand Genomics Limited, and
a matrix of counts for each gene provided. Genes with zero counts across all samples
were removed using the RowSums() function.
7.2.1 Differential expression analysis in MDA-MB231 cells with CPT1A
overexpression
To identify genes that were differentially expressed between basal and CPT1A overex-
pression in the MDA-MB231 cell line, the ’limma’ package and its associated functions
were applied to the expression matrix (Ritchie et al., 2015; Phipson et al., 2016; Liu et
al., 2015). After fitting a linear model using the lmfit() function, the eBayes() function
was applied to determine the log odds of differential expression for each particular gene.
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Multiple hypothesis testing was adjusted for by the false discovery rate method, and
genes with an adjusted p-value threshold of 0.2 were considered significantly differen-
tially expressed. This relatively liberal threshold was defined a priori, based on the pos-
sibility that this RNA-Seq analysis may be under-powered to detect small, biologically
meaningful fold changes. This threshold does increase the possibility of false-positives
in this analysis; and genes identified to be significantly, differentially expressed would
require validation by alternative methods (e.g., qPCR).
Tables 7.1 and 7.2 provide a summary of the differentially expressed genes from the
toptable() function from the limma package. As expected, CPT1A expression was sig-
nificantly increased in pTRE-CPT1A overexpressing clones 3 and 17, but not in the
TetOn parental line. However, only one gene in clone 3 (RP11-563J2.2 ) was differen-
tially expressed with an adjusted p-value of 0.01. This gene encodes a long noncoding
RNA, and very little is reported about this gene apart from the study by Drummond
et. al., who found the expression of this gene to be downregulated in three- compared
to two-dimensional cultures of Caco-2 cells infected with coxsackie virus (Drummond,
Nickerson, and Coyne, 2016).
Three other genes - LAD1, C22orf15 and LPAR4 - had an adjusted p-value of < 0.2
in pTRE-CPT1A clone 3. The gene LAD1 (log2 fold change 1.11; adjusted p=0.205)
encodes an anchoring filament as a component of the basement membrane (Groger et al.,
2012). This gene was reported to be downregulated during EMT, and low expression
was correlated with low rates of pathological complete response from a cohort of breast
cancer patients (Hess et al., 2006). Furthemore, promoter methylation was associated
with poorer outcome in ccRCC (Vlodrop et al., 2017). The LPAR4 gene (log2 fold
change -0.99; adjusted p=0.205) encodes a lysophospatidic acid receptor, and its role in
cancer is not well characterised, apart from a mutation reported in a cohort of Chinese
patients with papillary thyroid carcinoma (Pan et al., 2016). However, none of these
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Table 7.1: Top 20 genes differentially expressed in CPT1A overexpression
clone 3. The ID column represents the gene symbol, logFC indicates the log2 fold
change between pTRE-CPT1A clone 3 +Dox and -Dox clone, the AveExpr column cor-
responds to the average log2 expression of genes, the t column represents the moderated
t-statistic, the P.Value column denotes nominal, unadjusted p-value, the adj.P.Val indi-
cates the FDR-adjusted p-value, and B is the Bayes factor, which indicates the log-odds
that the gene is differentially expressed. Table is sorted according to adjusted p value.
ID logFC AveExpr t P.Value adj.P.Val B
CPT1A 3.562 5.864 34.879 2.05E-10 4.09E-06 2.214
RP11-563J2.2 -1.535 -2.502 -11.936 1.43E-06 0.014 1.356
C22orf15 -0.761 -2.782 -8.026 3.15E-05 0.203 0.483
LAD1 1.112 -2.622 7.763 4.05E-05 0.203 0.391
LPAR4 -0.998 -2.362 -7.522 5.13E-05 0.205 0.301
TFF1 1.548 -2.581 6.790 0.0001 0.312 -0.008
SPON2 1.037 0.960 6.787 0.0001 0.312 -0.009
RP11-440G9.1 -0.889 -2.725 -6.164 0.0002 0.533 -0.321
SOWAHB -1.147 -2.035 -6.077 0.0002 0.533 -0.368
ZMYND10 1.110 -1.795 5.846 0.0003 0.575 -0.500
AP4B1-AS1 0.738 -2.754 5.668 0.0004 0.575 -0.607
CCER2 -0.889 -2.529 -5.381 0.0006 0.575 -0.790
MIR10A -0.586 -2.811 -5.326 0.0006 0.575 -0.826
LOC101928870 -0.586 -2.744 -5.326 0.0006 0.575 -0.826
RP11-486A14.2 -1.045 -2.301 -5.041 0.0009 0.575 -1.024
ZSWIM8-AS1 -1.031 -0.541 -4.967 0.0009 0.575 -1.077
LOC100132815 -0.646 2.375 -4.960 0.0009 0.575 -1.082
C4orf47 -1.030 -2.292 -4.899 0.0010 0.575 -1.127
GBGT1 1.373 -0.398 4.863 0.0011 0.575 -1.154
RERGL 0.575 -2.813 4.857 0.0011 0.575 -1.159
were observed to be significant in pTRE-CPT1A clone 17, and hence may possibly be
unique to pTRE-CPT1A clone 3, and are potentially false-positives.
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Table 7.2: Top 20 genes differentially expressed in CPT1A overexpression
clone 17. The ID column represents the gene symbol, logFC indicates the log2 fold
change between pTRE-CPT1A clone 17 +Dox and -Dox clone, the AveExpr column
corresponds to the average log2 expression of genes, the t column represents the moder-
ated t-statistic, the P.Value column denotes nominal, unadjusted p-value, the adj.P.Val
indicates the FDR-adjusted p-value, and B is the Bayes factor, which indicates the log-
odds that the gene is differentially expressed. Table is sorted according to adjusted p
value.
ID logFC AveExpr t P.Value adj.P.Val B
CPT1A 3.728 5.864 36.497 1.40E-10 2.80E-06 0.678
DUOXA1 -0.718 -2.720 -7.827 3.81E-05 0.234 -0.517
RP11-178C3.2 0.691 -2.724 7.457 5.48E-05 0.234 -0.615
ANGPT2 1.228 -1.936 7.338 6.17E-05 0.234 -0.648
RP11-392P7.6 1.440 -1.566 7.274 6.58E-05 0.234 -0.667
LOC101928117 -0.901 -0.804 -7.210 7.02E-05 0.234 -0.685
RP5-1057J7.6 1.526 -0.731 7.002 8.70E-05 0.249 -0.749
RP11-60I3.5 1.247 -2.537 6.630 0.0001 0.323 -0.872
ZNF599 1.077 -0.747 5.706 0.0004 0.784 -1.239
SLC27A5 0.813 -1.422 5.428 0.0005 0.784 -1.370
CCDC78 0.983 -0.874 5.312 0.0006 0.784 -1.428
FBXO16 -1.245 -0.471 -5.301 0.0006 0.784 -1.434
LOC101928126 0.813 -2.615 5.293 0.0006 0.784 -1.437
LOC101927374 -0.938 -1.639 -5.100 0.0008 0.784 -1.538
NAPB 0.887 2.752 4.976 0.0009 0.784 -1.606
LOC102724642 0.998 0.191 4.964 0.0009 0.784 -1.613
LINC01011 0.989 -0.205 4.925 0.0010 0.784 -1.635
CD81-AS1 -1.250 -2.239 -4.855 0.0011 0.784 -1.675
ZNF793 -0.809 -1.200 -4.850 0.0011 0.784 -1.677
RPP21 -0.809 -1.993 -4.823 0.0011 0.784 -1.694
7.2.1.1 Gene set enrichment analysis
To identify the pathways and processes significantly differentially expressed in response
to CPT1A overexpression, gene set enrichment analysis was performed using the En-
richr online software. Up- and downregulated genes were analysed individually, sorted
ascendingly according to their adjusted p-value (i.e., most to least significant) and the
pre-ranked gene list was provided for enrichment analysis. Four different databases -
KEGG, Reactome, WikiPathways, and Panther - were utilised to identify pathways that
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were enriched in this analysis.
Genes that were upregulated in clone 3 in response to CPT1A overexpression compared
to basal expression showed enrichment of genesets involved in mitochondrial metabolism
(Fig 7.1a,c; yellow arrows). Downregulated genes in this clone showed enrichment of
cell cycle-related genesets in all four databases (Fig 7.1e-h). However, while the nominal
p-values of these genesets were significant, none of these enrichments were statistically
significant after adjustment. All statistical values for enrichment analysis in this chapter
are provided in Supp Tables B.3 to B.58.
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Figure 7.1: Genesets enriched in pTRE-CPT1A clone 3 overexpressing
CPT1A, relative to basal expression. (a,b,c,d) Genesets that were upregulated
from (a) KEGG, (b) Reactome, (c) WikiPathways and (d) Panther databases from the
Enrichr analysis. (e,f,g,h) Genesets that were downregulated from (e) KEGG, (f) Reac-
tome, (g) WikiPathways and (h) Panther databases. The length and brightness of the
bars are positively correlated with how statistically significant the enrichments were. In
panels (b) and (c), yellow arrows indicate the upregulated genesets involved in citric acid
cycle, and the navy blue arrows in panels (e-h) indicate the genesets involved in cell cycle
that were downregulated in response to CPT1A overexpression. Pink and red/brown
coloured bars indicate genesets with nominal p-value of < 0.05. Length and brightness
of coloured bars are correlated with lower p-values. Genesets represented with grey bars
are not statistically significant.
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Genes that were downregulated in clone 17 with CPT1A overexpression compared to
basal expression showed a significant, concordant enrichment for processes involved in
mRNA processing (Fig 7.2e,f,g; yellow arrows). Genes upregulated in clone 17 with
CPT1A overexpression showed enrichment in genesets associated with proliferation (Fig
7.2b-d, yellow arrows). This is in contrast with the findings observed in clone 3, where
proliferation genesets were enriched in genes downregulated in response CPT1A overex-
pression.
211
Figure 7.2: Genesets enriched in pTRE-CPT1A clone 17 overexpressing
CPT1A, relative to basal expression. (a,b,c,d) Genesets that were upregulated
from (a) KEGG, (b) Reactome, (c) WikiPathways and (d) Panther databases from the
Enrichr analysis. (e,f,g,h) Genesets that were downregulated from (e) KEGG, (f) Re-
actome, (g) WikiPathways and (h) Panther databases. Yellow arrows in panels (b-d)
indicate the upregulated genesets involved in cell cycle, and the navy blue arrows in
panels (e-g) indicate downregulated genesets involved in ribosomal processes in response
to CPT1A overexpression. Pink and red/brown coloured bars indicate genesets with
nominal p-value of < 0.05. Length and brightness of coloured bars are correlated with
lower p-values. Genesets represented with grey bars are not statistically significant.
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Next, to explore whether combining the clones together to perform differential analysis
may improve the power to detect significant pathway enrichment, the analysis was re-
peated with the four combined pTRE-CPT1A -Dox and +Dox replicates. Genes that
were upregulated when CPT1A was overexpressed did not show consistent pathway en-
richment across all four databases (Fig 7.3a-d).
Genes downregulated in response to CPT1A overexpression, however, were enriched for
ribosomal and RNA processing associated processes (Fig 7.3e-h, yellow arrows). Of note,
the enrichment of these genesets were also observed in genes that were downregulated
in response to Dox treatment in the TetOn parental line (Supp Fig A.11, yellow arrows).
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Figure 7.3: Genesets enriched in pTRE-CPT1A clones 3 and 17 overexpress-
ing CPT1A, relative to basal expression. (a,b,c,d) Genesets that were upregulated
from (a) KEGG, (b) Reactome, (c) WikiPathways and (d) Panther databases from the
Enrichr analysis. (e,f,g,h) Genesets that were downregulated from (e) KEGG, (f) Reac-
tome, (g) WikiPathways and (h) Panther databases. Navy blue arrows in panels (e-g)
indicate the genesets involved in ribosomal processes that were downregulated in pTRE-
CPT1A clones treated with Dox. Pink and red/brown coloured bars indicate genesets
with nominal p-value of < 0.05. Length and brightness of coloured bars are correlated
with lower p-values. Genesets represented with grey bars are not statistically significant.
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Table 7.3: Top 20 genes differentially expressed in shRNA clone 1.The ID col-
umn represents the gene symbol, logFC indicates the log2 fold change between shRNA
clone 1 and non-silencing clone, the AveExpr column corresponds to the average log2 ex-
pression of genes, the t column represents the moderated t-statistic, the P.Value column
denotes nominal, unadjusted p-value, the adj.P.Val indicates the FDR-adjusted p-value,
and B is the Bayes factor, which indicates the log-odds that the gene is differentially
expressed. Table is sorted according to adjusted p value. CPT1A log2 fold change =
-1.03, adjusted p= 0.2.
ID logFC AveExpr t P.Value adj.P.Val B
TRPM2 -6.805 1.871 -18.366 1.14E-06 0.004 5.184
KCND1 -6.531 1.467 -11.878 1.62E-05 0.021 3.487
PKIA -5.347 -0.207 -17.697 1.44E-06 0.004 5.063
TRPM2-AS -4.277 -0.357 -21.009 5.01E-07 0.003 5.583
CACNA2D1 -3.803 3.295 -6.586 0.000501 0.085 0.487
MSH5-SAPCD1 -3.798 0.125 -5.561 0.001256 0.113 -0.421
PCDH10 -3.786 1.796 -19.594 7.69E-07 0.004 5.384
ARMCX1 -3.651 -1.643 -18.963 9.41E-07 0.004 5.285
ASCL1 -3.571 -0.884 -5.582 0.001231 0.113 -0.400
MAGEA4 -3.476 -0.082 -5.621 0.001186 0.111 -0.363
LEF1 -3.463 0.148 -6.333 0.000622 0.090 0.276
ELOVL2 -3.453 3.470 -8.936 8.77E-05 0.046 2.102
PCDH19 -3.299 2.310 -11.571 1.90E-05 0.022 3.367
C1orf168 -3.291 0.363 -6.244 0.000672 0.092 0.200
PGR -3.268 4.482 -8.105 0.000155 0.053 1.594
SLC4A10 -3.196 0.840 -6.415 0.000579 0.087 0.345
SGCG -3.135 0.207 -10.602 3.20E-05 0.026 2.954
SCNN1G -3.076 1.058 -4.882 0.002475 0.144 -1.105
VWDE -2.967 0.468 -6.435 0.000569 0.086 0.362
PKDCC -2.952 -0.376 -11.716 1.76E-05 0.021 3.424
7.2.2 Differential expression analysis in MCF7 cells with CPT1A knock-
down
To identify genes that were differentially expressed between basal and CPT1A knock-
down in MCF7 cells, the differential analysis pipeline described earlier was applied to
the MCF7 CPT1A knockdown versus non-silencing expression data.
Tables 7.3 and 7.4 summarises the output from the toptable() function from the limma
package. Of note, CPT1A expression was downregulated by 50% in shRNA1 (adjusted
p = 0.19) and 67% in shRNA2 (adjusted p = 0.17), compared to non-silencing control.
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Table 7.4: Top 20 genes differentially expressed in shRNA clone 2. The ID col-
umn represents the gene symbol, logFC indicates the log2 fold change between shRNA
clone 2 and non-silencing clone, the AveExpr column corresponds to the average log2 ex-
pression of genes, the t column represents the moderated t-statistic, the P.Value column
denotes nominal, unadjusted p-value, the adj.P.Val indicates the FDR-adjusted p-value,
and B is the Bayes factor, which indicates the log-odds that the gene is differentially
expressed. Table is sorted according to adjusted p value. CPT1A log2 fold change =
-1.43, adjusted p= 0.17.
ID logFC AveExpr t P.Value adj.P.Val B
ATP6V1G3 6.112 -0.823 28.359 7.84E-08 0.002 5.388
NCMAP 3.913 -0.400 19.283 8.49E-07 0.005 4.679
ARMCX1 -3.651 -1.643 -18.963 9.41E-07 0.005 4.639
PKIA -5.651 -0.207 -18.702 1.02E-06 0.005 4.605
PCDHGB5 3.044 0.220 12.388 1.26E-05 0.046 3.320
UNC13D -2.704 3.160 -12.153 1.41E-05 0.046 3.247
CALB2 -2.310 -0.715 -11.614 1.86E-05 0.052 3.071
PCDH10 -2.089 1.796 -10.810 2.85E-05 0.068 2.780
KCND1 -5.790 1.467 -10.531 3.33E-05 0.068 2.670
CABYR -2.600 -0.624 -10.458 3.47E-05 0.068 2.640
ST3GAL5 2.076 2.261 10.220 3.98E-05 0.071 2.542
RORC 2.133 3.383 9.488 6.18E-05 0.082 2.215
SP100 -2.426 -0.844 -9.372 6.64E-05 0.082 2.160
MAST4 -1.978 1.853 -9.365 6.67E-05 0.082 2.156
LINC00458 2.998 -1.861 9.207 7.37E-05 0.082 2.079
SH3BGRL -2.301 1.279 -9.133 7.73E-05 0.082 2.042
KCNJ8 -2.145 0.298 -8.943 8.74E-05 0.082 1.945
NBPF13P -1.843 -0.821 -8.874 9.14E-05 0.082 1.910
BRINP2 2.282 -0.740 8.849 9.29E-05 0.082 1.897
FAXDC2 1.652 -1.603 8.834 9.38E-05 0.082 1.889
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Since there were more genes that were significantly differentially expressed between the
CPT1A knockdown in MCF7- compared to overexpression in MDA-MB231 cells, gene
ontology analysis was performed to identify cellular processes that may be enriched in
MCF7 cells in response to CPT1A knockdown. In shRNA1 clone, there were 541 genes
that were differentially expressed below the adjusted p-value threshold of 0.2. These
genes were sorted into up- and downregulated, and gene ontology analysis using the
GATHER online software was conducted to investigate for enriched biological processes
(Chang and Nevins, 2006). Genes that were upregulated were enriched for functions
associated with metabolism, antigen presentation and processing, and cell-to-cell com-
munication (Fig 7.4a). Downregulated genes were enriched for processes involved in
developmental processes, including neurogenesis, organ development, cell adhesion and
morphogenesis (Fig 7.4b).
In shRNA2 clone, there were 197 genes that were differentially expressed below the ad-
justed p-value threshold of 0.2. Gene ontology analysis of the upregulated genes found
enrichment for processes involved in vitamin, ganglioside and sphingolipid metabolism
(Fig 7.5a). Genes that were downregulated were enriched for localisation, ion transport,
frizzled-2 signalling and hepatocyte growth factor biosynthesis (Fig 7.5b).
7.2.2.1 Gene set enrichment analysis
To determine pathways that are differentially expressed between CPT1A basal and
knockdown MCF7 cells, a pre-ranked gene set enrichment analysis was performed as
previously.
Genes that were downregulated in shRNA1 and shRNA2 clones with CPT1A knock-
down compared to non-silencing control showed an enrichment for ribosomal and RNA
processing genesets (Fig 7.6e-h, yellow arrows). Genes that were upregulated in shRNA1
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Figure 7.4: Processes enriched in MCF7 shRNA1 clone compared to non-
silencing basal expression. Processes that were (a) upregulated and (b) downreg-
ulated in response to CPT1A knockdown in shRNA1 clone relative to non-silencing
control.
218
Figure 7.5: Processes enriched in MCF7 shRNA2 clone compared to non-
silencing basal expression. Processes that were (a) upregulated and (b) downreg-
ulated in response to CPT1A knockdown in shRNA2 clone relative to non-silencing
control.
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clone were over-represented for signalling pathways, including EGF signalling (Fig 7.6b-
d, yellow arrows). Partly consistent with shRNA1 clone, genes upregulated in shRNA2
in response to CPT1A knockdown were also enriched for EGF signalling pathway. How-
ever, for this clone, the enrichment was only seen in the Panther database (Fig 7.7d,
yellow arrow).
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Figure 7.6: Genesets enriched in MCF7 shRNA1 CPT1A knockdown, rela-
tive to basal non-silencing cells. (a,b,c,d) Genesets that were upregulated from (a)
KEGG, (b) Reactome, (c) WikiPathways and (d) Panther databases from the Enrichr
analysis. (e,f,g,h) Genesets that were downregulated from (e) KEGG, (f) Reactome,
(g) WikiPathways and (h) Panther databases. Yellow arrow in panels (b-d) indicate the
genesets associated with signalling pathways that were upregulated, while the navy blue
arrows in panels (e-g) indicate ribosomal-associated processes that were downregulated
in shRNA clone 1, relative to non-silencing control. Pink and red/brown coloured bars
indicate genesets with nominal p-value of < 0.05. Length and brightness of coloured
bars are correlated with lower p-values. Genesets represented with grey bars are not
statistically significant.
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Figure 7.7: Genesets enriched in MCF7 shRNA2 CPT1A knockdown, rela-
tive to basal non-silencing cells. (a,b,c,d) Genesets that were upregulated from (a)
KEGG, (b) Reactome, (c) WikiPathways and (d) Panther databases from the Enrichr
analysis. (e,f,g,h) Genesets that were downregulated from (e) KEGG, (f) Reactome,
(g) WikiPathways and (h) Panther databases. Yellow arrows in panel (d) indicate the
genesets involved signalling pathways that were upregulated, while navy blue arrows in
panels (e-g) indicate the ribosomal processes that were downregulated in shRNA clone
2, relative to non-silencing control. Pink and red/brown coloured bars indicate genesets
with nominal p-value of < 0.05. Length and brightness of coloured bars are correlated
with lower p-values. Genesets represented with grey bars are not statistically significant.
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Next, the two knockdown clones were combined to explore for genesets enriched with
larger sample size. Genes that were upregulated in this analysis were enriched for sig-
nalling associated genesets, in agreement with the individual differential analysis (Fig
7.8a-d, yellow arrows). Consistent with the findings from analysis of individual shRNA
clones, ribosomal and RNA processing genesets were enriched in genes downregulated
in response to CPT1A knockdown (Fig 7.8e-h, yellow arrows).
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Figure 7.8: Genesets enriched in MCF7 shRNA1 and shRNA2 combined
CPT1A knockdown, relative to basal non-silencing cells. (a,b,c,d) Genesets
that were upregulated from (a) KEGG, (b) Reactome, (c) WikiPathways and (d) Pan-
ther databases from the Enrichr analysis. (e,f,g,h) Genesets that were downregulated
from (e) KEGG, (f) Reactome, (g) WikiPathways and (h) Panther databases. Gene-
sets that were downregulated from (e) KEGG, (f) Reactome, (g) WikiPathways and (h)
Panther databases. Yellow arrows in panels (b-d) indicate the signalling pathways that
were upregulated, while the navy blue arrows in panels (e-h) indicate the ribosomal as-
sociated processes that were downregulated when both shRNA clones were combined,
compared to non-silencing control. Pink and red/brown coloured bars indicate genesets
with nominal p-value of < 0.05. Length and brightness of coloured bars are correlated
with lower p-values. Genesets represented with grey bars are not statistically significant.
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7.2.3 Targeted pathway analysis
Chapters 4 and 5 in this thesis demonstrated a correlation between EMT, Wnt and
MAPK pathways and the FAO signature expression. To explore whether alterations in
CPT1A expression in MDA-MB231 and MCF7 cell lines affect these pathways, a tar-
geted pathway analysis between the FAO and gene signatures corresponding to each of
the pathways were conducted.
7.2.3.1 Wnt, MAPK and EMT signature expression in MDA-MB231 trans-
genic systems
7.2.3.1.1 Wnt signature expression The Wnt signature showed a trend of in-
creased expression in the TetOn parental cells treated with Dox, albeit not statistically
significant (Fig 7.9a). However, no clear trend could be deduced when CPT1A was
overexpressed in pTRE-CPT1A clones 3 and 17. Furthermore, combination of both
overexpression clones together did not reveal a significant difference in the Wnt signa-
ture expression between pTRE-CPT1A clones with and without Dox treatment (t-test
p=0.79).
7.2.3.1.2 MAPK signature expression The MAPK signature showed a trend of
increased expression in TetOn and pTRE-CPT1A clone 3, but not pTRE-CPT1A clone
17 cells in response to Dox, although none of these were statistically significant (Fig
7.9b). Combination of both overexpression clones together did not reveal a significant
difference in the MAPK signature expression between pTRE-CPT1A clones with and
without Dox treatment (t-test p=0.68).
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7.2.3.1.3 EMT signature expression As with the earlier two signatures, the
TetOn parental cells were observed to have a non-significant trend of increased ex-
pression of the EMT signature in response to Dox treatment (Fig 7.9c). However, the
EMT signature was not significantly differentially expressed in either pTRE-CPT1A
overexpression clone. The EMT signature was also not significantly differentially ex-
pressed abetween pTRE-CPT1A clones with and without Dox treatment when the two
overexpression clones were combined (t-test p=0.91).
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Figure 7.9: Wnt, MAPK and EMT signature expression analysis in MDA-
MB231 TetOn and pTRE-CPT1A clones. (a) Wnt, (b) MAPK, and (c) EMT
signature expression in TetOn and pTRE-CPT1A in the presence or absence of Dox.227
7.2.3.2 Wnt, MAPK and EMT signature expression in MCF7 transgenic
systems
7.2.3.2.1 Wnt signature expression In both shRNA knockdown clones, the Wnt
signature expression was higher than the non-silencing control, but these differences
were not significant.(Fig 7.10a). When the two different shRNA knockdown clones were
combined (n=4 total) and expression of the Wnt signature was compared to the non-
silencing control, the difference was not significant (t-test p = 0.18). However, when
one outlier value from shRNA1 clone was removed, the Wnt signature showed a trend of
increased expression in the CPT1A knockdown combined clones (p = 0.063) (Fig 7.10d).
7.2.3.2.2 MAPK signature expression The MAPK signature expression was
higher in both shRNA knockdown clones compared to the non-silencing control, but
these differences were not significant.(Fig 7.10b). Furthermore, the MAPK signature
expression also showed no evidence of being significantly differentially expressed when
the two knockdown clones were combined, compared to the non-silencing control (t-test
p = 0.23). However, when the same outlier value from the Wnt signature expression
analysis was removed, the MAPK signature was expressed higher in the CPT1A knock-
down line, with a favourable statistical trend (p = 0.09) (Fig 7.10e).
7.2.3.2.3 EMT signature expression The EMT signature expression was higher
than the non-silencing control, but these differences were not significant (Fig 7.10c).
Additionally, when the two knockdown clones were combined and EMT signature ex-
pression compared to the non-silencing control, the differences were not significant (t-
test p = 0.16). Removal of the outlier value from the combined clones as above resulted
in increased EMT signature expression when CPT1A was knocked down, which was
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marginally close to statistical significance (p value of 0.073) (Fig 7.10f).
7.2.4 Analysis of publicly available datasets that modulate FAO in
different cell systems
To explore molecular changes that occur in response to alterations in FAO in other cell
systems by different means investigated in this thesis, two publicly available datasets
were analysed. The first dataset was generated by Torrano et. al., who reported that
increased expression of PGC1A - a key co-regulator of fatty acid oxidation - increased
FAO flux and mitochondrial respiration, which resulted in decreased proliferation rates
of prostate cancer cell lines in vitro, and decreased metastasis in xenograft mice stud-
ies (Torrano et al., 2016). The authors performed microarray analysis to compare the
transcriptome of PC3 prostate cancer cells with basal and PGC1A overexpression. The
second dataset analysed was generated by Srivastava et. al., who reported that treat-
ment of NCI-H2347 lung cancer cell line with pioglitazone - a PPARG agonist - resulted
in increased FAO and cell cycle arrest, both in in vitro and in vivo settings (Srivastava
et al., 2014). The authors performed transcriptome analysis of NCI-H2347 cells treated
with pioglitazone for 12-, 24- and 48 hours.
7.2.4.1 Wnt, MAPK and EMT signature expression in PC3 cells with
PGC1A overexpression and NCI-H2347 cells treated with piogli-
tazone
PGC1A overexpression in PC3 cells resulted in decreased expression of the Wnt sig-
nature, and showed a trend towards decreased expression of the MAPK signature (Fig
7.11a,b). Notably, the EMT signature was significantly downregulated in response to
PGC1A overexpression (Fig 7.11c).
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Figure 7.10: Wnt, MAPK and EMT signature expression analysis in MCF7
non-silencing and CPT1A shRNA1 and shRNA2 clones. (a) Wnt, (b) MAPK,
and (c) EMT signature expression in non-silencing and shRNA clones. (d) Wnt, (e)
MAPK, and (f) EMT signature expression in non-silencing and combined shRNA clones
after removal of one outlier value.
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Treatment of NCI-H2347 cells with pioglitazone over a time course led to significant
decreases in the Wnt signature expression across all time points. However, no signifi-
cant differences in MAPK signature expression were observed (Fig 7.11d,e). The EMT
signature showed no evidence of being differentially expressed at the earlier time points,
but pioglitazone treatment at 48 hrs increased the expression of this signature, albeit
with a fairly large variation, compared to vehicle treatment (Fig 7.11f).
7.2.4.2 Differential expression analysis of transcriptome data from PC3
cells with PCG1A overexpression
Differential and enrichment analysis between basal and PGC1A overexpressing PC3
cells was performed as for MDA-MB231 and MCF7 RNA-seq analysis. Genesets that
are upregulated were concordant with those reported by the authors and presented in
the supplementary for brevity (Supp Fig A.14. Briefly, as expected, genesets that were
involved in oxidative metabolism were significantly enriched in genes that were upregu-
lated by PGC1A overexpression in PC3 cells. All of the curated databases consistently
identified enrichment of genesets involved in oxidative phosphorylation and electron
transport chain, while only the WikiPathways database was observed to have a geneset
involved in FAO enriched (Supp Fig A.14c).
In agreement with the findings of the authors that generated this dataset, genesets that
were significantly downregulated in PC3 cells with PGC1A overexpression were primar-
ily involved in cell proliferation. However, this analysis also identified several immune- or
inflammation-related genesets that were downregulated when PGC1A was overexpressed
in PC3 cells (Supp Fig A.13, blue arrows).
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Figure 7.11: Wnt, MAPK and EMT signature expression analysis in PC3
cells with PGC1A overexpression or NCI-H2347 cells treated with pioglita-
zone. (a-c) (a) Wnt, (b) MAPK, and (c) EMT signature expression in PC3 cells with
PGC1A overexpression. (d-f) (d) Wnt, (e) MAPK, and (f) EMT signature expression
in NCI-H2347 cells treated with pioglitazone. Veh = vehicle, Piog = pioglitazone.
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7.2.4.3 Differential expression analysis of transcriptome data from NCI-
H2347 cells treated with pioglitazone
To identify genes involved in signalling pathways that were enriched in NCI-H2347 cells
in response to pioglitazone, differential and enrichment analysis was performed on the
Srivastava et. al. dataset. At 12 hours post-treatment, genesets involved in fatty acid
metabolism were upregulated (Supp Fig A.18, yellow arrows). This was also true at
24 hours post-treatment (Supp Fig A.19, yellow arrows); while at 48 hours, genesets
involved in glycolysis were enriched in genes upregulated in response to PGC1A expres-
sion, presumably to generate NADPH via the pentose phosphate pathway to neutralise
increased free radical species from enhanced mitochondrial respiration (Supp Fig A.20,
cyan arrows).
As shown by the authors, genesets involved in proliferation were also significantly down-
regulated by 12 hours (Supp Fig A.15, cyan arrows). Similar to the observations made
in analysis of Torrano et. al. dataset, genesets associated with immune function were
downregulated in response to pioglitazone treatment (blue arrows). However, at 24- and
48 hours post-treatment, the immune-related genesets were no longer enriched, and over-
representation of other signalling pathways was not observed (Supp Figs A.16, A.17).
Notably, proliferation genesets continued to be downregulated in treated cells over these
time points.
7.3 Discussion
This chapter sought to characterise the transcriptomic features that were differentially
regulated in response to CPT1A modulation in MDA-MB231 and MCF7 cells. In par-
ticular, this hypothesis-generating exercise was focused on identifying the signalling
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pathways that may be altered between the conditions.
7.3.1 Differential and gene set enrichment analysis
7.3.1.1 MDA-MB231 CPT1A overexpression
In MDA-MB231 pTRE-CPT1A clones, apart from CPT1A, no other genes were sig-
nificantly differentially expressed. Gene set enrichment analysis suggests that genes
downregulated in pTRE-CPT1A clone 3 were enriched for cell cycle processes, which
is consistent with the results from the growth curve analysis performed in Chapter 6.
In contrast, cell cycle genesets were enriched in genes that were upregulated in clone
17. Given that the growth curve analysis of this clone also showed slower growth when
CPT1A was overexpressed, it is not entirely clear why genes involved in proliferation
were higher in basal compared to CPT1A overexpression in clone 17. Additionally, there
were no other genesets that were commonly enriched between these two clones. Differen-
tial analysis by combining the two overexpression clones together did not show consistent
enrichment for genes that were upregulated. In contrast, genesets that were commonly
identified to be downregulated were involved in ribosomal processes. Two studies have
documented that doxycycline can affect mitochondrial ribosomal processes, which may
account for the enrichment of these processes in the pTRE-CPT1A and TetOn parental
cell lines (Ahler et al., 2013; Moullan et al., 2015). Another possible reason why genes
involved in signalling pathways are not enriched in this analysis could be that CPT1A
may indirectly induce an increased activity of one or a few key tumour suppressor pro-
teins, such as pRb, and destabilisation of cell cycle-related proteins, thereby leading to
decreased proliferation rates observed in the growth curves of these clones.
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7.3.1.2 MCF7 CPT1A knockdown
In MCF7 cells with CPT1A knockdown relative to basal non-silencing expression, cell
signalling genesets were enriched in the knockdown clones. In particular, an EGF sig-
nalling geneset was a common geneset enriched in both knockdown clones. Notably, this
enrichment was also observed when both knockdown clones were combined for differen-
tial analysis. This supports the trend observed from the targeted analysis, where the
MAPK signature was trending towards increased expression upon CPT1A knockdown.
However, the growth curve analysis performed on this cell system did not suggest dif-
ferences in proliferation rates between CPT1A knockdown and basal expression. This
raises the possibility that there may be other signalling pathways that drive MCF7 cell
proliferation that are not affected by CPT1A knockdown. Another plausible explana-
tion is that under the experimental conditions for this analysis, the magnitude of EGF
signalling downregulation may not be sufficient to alter the cell division rates in MCF7
cells. Perhaps stronger or longer knockdown of CPT1A in MCF7 cells may amplify its
effect on EGF signalling. As for genes that were downregulated by CPT1A knockdown,
genesets involved in ribosomal processes were enriched for, in line with the observation
in MDA-MB231 cells. Hence, this could be attributed to the effect of Dox on mitochon-
drial RNA metabolism.
7.3.1.3 Public datasets
The geneset enrichment analysis was also performed on two publicly available datasets
that modulated FAO in different cell systems. Between both datasets, enriched genesets
that were commonly downregulated were associated with immune function. Of note,
in NCI-H2347 cells treated with pioglitazone, this enrichment was only observed at the
12h, but not later time points. Validation of these genesets on other datasets which
may be available in future should be a priority, before investing experimental resources
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to pursue this finding.
7.3.2 Targeted analysis
7.3.2.1 MDA-MB231 CPT1A overexpression
The expression of specific pathways were also analysed in the MDA-MB231 and MCF7
transgenic systems. In pTRE-CPT1A MDA-MB231 cells, no significant differences were
found in the expression of gene signatures that represent the EMT, Wnt and MAPK
signalling pathways, compared to TetOn parental line. The most obvious explanation
for this observation is that these genesets are not altered by potential metabolic rewiring
brought about by CPT1A overexpression.
While the targeted analysis conducted was exploratory, it is possible that the cell lines
used in this study may not be entirely suitable to observe changes in the three targeted
pathways in response to CPT1A modulation. Due to the crosstalk between pathways,
cancer cells may also activate several signalling cascades that may feed into the MAPK
pathway en route to the nucleus to activate transcriptional programs for proliferation
(Mendoza, Er, and Blenis, 2011). Hence, the linear enrichment of genes, from say, the
MAPK pathway (i.e, RAS - RAF - MEK - ERK) may not be strongly enriched in cer-
tain cell types. Alternatively, certain cell lines may prefer to activate other signalling
pathways independently of the MAPK cascade to proliferate. These two points taken
together may explain the lack of association between CPT1A overexpression and ex-
pression of the Wnt and MAPK gene signatures in the MDA-MB231 cell system. One
suggestion could be to modulate FAO in cell systems with activation in these pathways
- such as BRAF V600E mutant melanoma cell lines, or colorectal cancer cell lines with
mutation in APC or some other Wnt signalling components. As for the EMT gene
signature, it is possible that CPT1A overexpression alone is sufficient to reverse the
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mesenchymal features of MDA-MB231 cells.
7.3.2.2 MCF7 CPT1A knockdown
In MCF7 cells with CPT1A knockdown, analysis of individual clones compared to non-
silencing control suggests a trend of increased expression of the EMT, Wnt, and MAPK
signatures, particularly in shRNA2 clone, which had stronger CPT1A knockdown (67%
knockdown in shRNA2 clone vs 50% in shRNA1 clone). However, these differeces were
not statistically significant. After combining the knockdown clones and removing one
outlier value, the p-values obtained were trending towards significance for all three sig-
natures analysed. Hence, it is possible that stronger CPT1A inhibition may further
enhance the increased expression of these signatures in this cell line. These increased
proliferation and migration associated signatures in response to CPT1A knockdown may
be accounted for by increased glycolytic flux, which on top of ATP, is key to generate
metabolites for proliferation (Lunt and Vander Heiden, 2011; Hay, 2016).
Notably, while the MAPK and Wnt signatures were upregulated, no difference in growth
rates between basal and CPT1A knockdown in MCF7 were observed as described in
Chapter 6. A potential explanation for this is that while these pathways were activated
at the transcript level under the experimental conditions conducted for this RNA-Seq
analysis, it may take longer for the complete metabolic and molecular reprogramming
to manifest and impact cell division rates.
The level of CPT1A knockdown observed in this RNA-Seq analysis is consistent with
multiple, previous experiments. Therefore, this warrants verification of the findings from
the targeted analysis by alternative methods such as using small interfering RNA knock-
down, or CPT1A inhibition with etomoxir. Key genes from each of the three signatures
analysed can then be measured by qPCR. Taken together, this analysis, while prelimi-
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nary, suggests that altering CPT1A expression in MCF7 cells can affect key oncogenic
pathways. It may also be worthwhile to advance these findings using cancer cell lines
with pathway activation of the signatures analysed, such as selected melanoma and lung
(MAPK), and colorectal (Wnt) cancer cell lines.
7.3.2.3 Public datasets
The analysis of published gene expression data from PC3 cells with PGC1A overex-
pression revealed a significant difference in the expression of the EMT geneset. This
supports the decreased lung and bone metastasis in vivo of PGC1A overexpressing PC3
cells, compared to basal expression, reported by the authors. However, even though the
authors of this dataset demonstrated significant decrease in proliferation when PGC1A
was overexpressed, the MAPK and Wnt signalling signatures showed no evidence of
significant differential expression between the two conditions. This suggests that the
PC3 cells utilised in this study may not be reliant on Wnt or MAPK signalling for
proliferation.
In the second dataset analysed, NCI-H2347 cells treated with pioglitazone over a time
course were observed to downregulate Wnt signalling signature expression. The MAPK
signature expression, however, showed no evidence of differential expression over the time
point. Interestingly, the EMT signature was observed to be significantlyupregulated in
pioglitazone treated cells at 48 hours post-treatment, compared to earlier time points,
which suggests that pioglitazone can induce EMT in this cell system. However, the vari-
ation observed in the vehicle-treated cells between time points suggest that one should
be cautious to interpret this finding and more in-depth analysis is required to verify this
observation. In summary, analysis of the two publicly available datasets did not reveal
any outstanding signalling pathway members that were altered at the transcript level.
238
7.3.3 Conclusions and limitations
This chapter sought to identify enriched processes at the transcriptome level in MDA-
MB231 cells with CPT1A overexpression and MCF7 cells with CPT1A knockdown. No
genesets were reproducibly up- or downregulated in the MDA-MB231 pTRE-CPT1A
clones 3 and 17. Consistent enrichment in ribosomal and RNA processing genesets were
found between pTRE-CPT1A and TetOn cell lines, as well as between non-silencing and
CPT1A shRNA MCF7 cell lines. Some enrichment in EGF signalling was observed in
genes upregulated by CPT1A knockdown, which may be worth further investigation.
The ability to detect small differences in gene expression in this study may have been
limited by the number of replicates assayed. From the growth curve analysis described
in Chapter 6, the modest decrease in proliferation (33%) in pTRE-CPT1A cells after
one week suggests a fairly small effect size. The budget of this project allowed the
sequencing of biological duplicates for each condition. Sequencing 2-3 more biological
replicates may possibly identify smaller, but biologically meaningful, fold changes, while
meeting the predefined statistical threshold. Hence, one cannot discount the possibility
that transcriptional changes may be occurring in these systems in response to CPT1A
modulation. Alternatively, this work could be followed up with panel-based gene expres-
sion analysis of selected pathways by either qPCR or the NanoString nCounter platform.
The analysis performed on the public datasets are also subject to some caveats. While
PGC1A is a key transcriptional co-regulator of genes involved in FAO, one cannot dis-
count other processes directly or indirectly activated or inhibited by this protein. Hence,
it is possible that the downregulation of the EMT geneset by PGC1A overexpression
is not due to activation of FAO and overall mitochondrial respiration, but also other
cues modulated by PGC1A. Similarly, given that the pioglitazone concentration used to
treat NCI-H2347 cells was in the micromolar range, the effect of this drug may not be





Conclusions and future directions
8.1 General discussion
This thesis sought to identify and investigate the metabolic correlates of prognosis in
ER-positive breast cancer patients. Analysis of a large training dataset from a cohort
of primary breast tumours identified high expression of a 19-gene signature involved in
FAO that is significantly associated with better disease-specific survival. This finding
was validated in multiple, independent datasets from breast, and other cancer types.
Additionally, analysis of the FAO signature expression in tumour-normal tissues from
different tissues revealed downregulation of the signature in tumour, relative to normal
tissues. This finding suggests that expression of genes involved in FAO is downregulated
during tumourigenesis, and may be part of a larger metabolic rewiring that occurs in a
cancer cell.
Since low expression of the FAO signature is associated with disease recurrence, a re-
lationship between the FAO signature expression and EMT - a process implicated in
metastasis - was explored. Different modalities of EMT induction - a process under-
stood to be important for metastasis - resulted in the decreased expression of the FAO
signature in different cell and organoid systems. This may potentially explain why
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patients with low FAO signature expression have a poorer outcome. Importantly, as
demonstrated by Kang et. al., expression of EMT markers in kidney fibrosis model was
reduced in response to activation of FAO by treatment with fenofibrate (Kang et al.,
2015). These findings warrant further investigation into how activation of FAO may
alter EMT-induced migration and/or invasion in cancer cell systems.
Understanding how oncogenic signalling affects cancer cell metabolism is an ongoing
effort in the field of tumour metabolism (Nagarajan, Malvi, and Wajapeyee, 2016). In
Chapter 5, the association between the FAO signature expression and two key signalling
pathways frequently altered in cancer - MAPK and Wnt - was explored. Activation of
both signalling pathways in cell and organoid systems resulted in the significant down-
regulation of the FAO signature expression. Since both pathways induce cancer cell
proliferation, and Chapter 3 has shown a negative correlation between a proliferation
gene signature and the FAO signature expression, it is possible that the finding above
may be an indirect consequence of activating the MAPK and Wnt pathways. Interest-
ingly, the two oncogenic signalling pathways - MAPK and Wnt - explored in Chapter 5
have also been shown to be involved in EMT induction (Lamouille, Xu, and Derynck,
2014). However, the studies that generated the gene expression datasets analysed in
Chapter 5 did not focus on analysing EMT in response to modulation of the two onco-
genic signalling pathways in different systems. Furthermore, as suggested by the findings
of Mitra et. al. (Mitra and Roy, 2017), the simultaneous activation of TGFβ and Wnt
signalling pathways can negate EMT induction in ovarian cancer cells. Hence, this sug-
gests that the relationship between EMT and oncogenic signalling is complex, and while
this thesis has shown that activation of the Wnt, MAPK and EMT signalling converge
on decreased FAO signature expression, a mechanistic relationship between these three
processes require experimental investigation.
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Based on the computational findings, the effect of experimentally modulating FAO was
investigated in two breast cancer cell systems. Due to the impracticalities of modulating
all the 19 genes in the FAO signature, this thesis generated cell systems that modulate
CPT1A - the rate-limiting enzyme in FAO. Overexpression of CPT1A in MDA-MB231
breast cancer cells decreased the proliferation and wound healing rates. In contrast,
CPT1A knockdown in MCF7 cells did not alter proliferation rates, compared to basal
expression control. A single attempt at measuring oxygen consumption rates in response
to CPT1A expression did not reveal significant differences in oxygen consumption in re-
sponse to exogenous palmitate. Global transcriptome analyses did not reveal pathways
that were significantly altered in response to modulation of CPT1A expression in either
cell systems. However, targeted analysis of EMT, MAPK and Wnt pathways in MCF7
cells with CPT1A knockdown suggests a trend towards increased transcriptional activity
of these pathways in this cell system. Taken together, while this thesis has provided
novel evidence on how modulating FAO in cell systems can alter cancer cell prolifera-
tion, future efforts should focus on analysing other cell lines using different means of
modulating FAO.
8.1.1 Conclusion
In conclusion, this thesis has highlighted the novel association between expression of a
gene signature involved in FAO and prognosis in some cancers. What are potential clin-
ical implications of these findings? Firstly, this study suggests that having an estimate
of how FAO status in a primary tumour may provide useful prognostic information.
One possible avenue of achieving this in presented in the future directions section below
(Section 8.3.1). Tumours identified with low FAO could be treated with agents that can
upregulate FAO, which may improve survival for some cancers.
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8.1.2 Overall strengths and limitations
The basis of this thesis is based on compelling, robust data from computational analy-
ses of publicly available gene expression datasets. These data sets the scene for future
experimental work to dissect the molecular underpinnings described in Chapters 3 to 5.
Some of these findings are in agreement of recent literature, which lends support to pur-
sue them further experimentally. While this thesis has contributed significant findings
as to the relationship between the FAO signature expression and EMT and activation of
oncogenic signalling, due to time constraints, it was limited by the lack of experimental
analysis to further characterise these findings in cell systems. Nevertheless, this thesis
has presented a novel perspective into the role of FAO in cancer biology and prognosis.
Further work, some of which is proposed below, is required to better appreciate the
significance of this metabolic pathway.
8.2 Future directions
This chapter proposes several conceptual applications of how the FAO pathway can be
studied in various different contexts, which could enhance our understanding of tumour
metabolism. This will be followed by suggestions on how the FAO pathway can be
studied at a different scale by harnessing technologies to image and actively monitor
this metabolic pathway in the management of cancer patients.
8.2.1 siRNA knockdown of CPT1A in ER-positive breast cancer cell
lines
This thesis investigated the effects of knocking down CPT1A expression in MCF7 cells
using the shRNA system. However, after one week of knockdown, substantial CPT1A
expression could still be detected by immunoblot analysis. Hence, it is possible that
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there was not sufficient knockdown of CPT1A to alter cellular characteristics such as
proliferation. Hence, future work could explore an alternative method of CPT1A knock-
down such as siRNA. It is worthwhile noting that this method, unlike the stable shRNA
expression performed in this thesis, would be more suitable to study the short term
effects of knocking down the expression of a gene. If the cellular effects of knocking
down CPT1A requires time to manifest, siRNA may not be capture them.
8.2.2 Pharmacologic activation or inhibition of FAO in cancer cell
lines
For experiments that involved looking at the effects of CPT1A knockdown in MCF10A
and MCF7 cells, there was substantial protein expression even after 5-7 days of shRNA
expression, which suggests that the protein has a long half-life. Future work could
use small interfering RNAs against CPT1A or the small molecule etomoxir to inhibit
CPT1A enzyme, and observe whether this intervention affects proliferation, migration
and anchorage-independent growth in breast cancer cell lines. Additionally, the de-
creased proliferation observed when CPT1A was overexpressed in MDA-MB231 cells
could be followed up with pharmacologic activation of FAO in other ER-negative cell
lines.
The drugging exercise can also be extended to other cancer types, which may inform
whether findings from this experiment can be applied to different cancers. Furthermore,
because the genomic profile of most these cell lines have been characterised, observations
from the drugging experiments can be associated with particular genetic profiles, which
may identify genomic correlates of FAO.
Moving away from breast cancer, this thesis found that the FAO signature expression
was expressed lower in several cancers compared to normal tissues. This suggests that
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there may be common feature/s associated with FAO regulation across different can-
cers. ccRCC is particularly intriguing, as the inactivation of VHL which occurs in
approximately 90% of cases, results in the stabilisation of HIF1A, which drives a gly-
colytic phenotype. The use of dichloroacetate (DCA) reversed the Warburg effect and
increased oxidative metabolism, resulting in increased p53 activation and apoptosis, and
decreased proliferation in 786-O ccRCC cell line (Kinnaird et al., 2016). Additionally,
DCA inhibited angiogenesis and tumour growth in vivo. Using ccRCC cell lines with
VHL inactivation, one can ask: what is the effect of enforcing FAO in these cell lines?
Findings from this experiment may provide an understanding of how altered FAO fea-
tures in HIF1A metabolic rewiring in VHL-mutant ccRCCs.
8.2.3 Analysis of other platforms to identify novel regulators and
correlates of FAO
This thesis primarily focused on the computational analysis of mRNA expression data.
Pathways can also be regulated by other means, such as at the post-transcriptional
and epigenetic levels. The TCGA database has microRNA and DNA methylation data
available for most cancer types. By first separating patients into low and high FAO
gene signature expression groups using RNAseq data, differential analysis of miRNA
and DNA methylation can be conducted to identify novel regulators of FAO, as well as
other pathways whose activity are correlated with FAO. As with the drugging exper-
iment, this analysis ought to be performed in several cancers to identify the common
molecular denominators, and unique findings can be further pursued separately, taking
into account the genetics of each cancer.
Assuming a particular miRNA is enriched in the high FAO group, the expression of this
miRNA could be analysed by qPCR in several cancer cell lines. This miRNA could then
be overexpressed in cell lines with low expression, and transcriptome analysis performed
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to identify genes and pathways regulated by the transgenic expression of this miRNA.
Conversely, enriched miRNAs in the low FAO group could be overexpressed in cell lines
with low expression of this miRNA (which presumably, has high FAO). The FAO flux
in response to transgenic expression of this miRNA can be measured using the Seahorse
XF system. Transcriptome analysis after overexpression of this miRNA may identify
genes and pathways that are correlated with, or possibly drive, the decrease in FAO in
cancer cells.
8.2.4 How does hypoxia affect FAO flux?
The diffusion limit for oxygen ranges between 100-200 microns, and cells must be within
this radius for adequate oxygenation (Eales, Hollinshead, and Tennant, 2016). As cancer
cells proliferate, regions of the tumour will be spatially withdrawn from the vasculature,
hence, affecting the supply of oxygen and nutrients. This triggers activation of HIF1A,
which drives a slew of molecular changes, including upregulation of genes that facili-
tate glycolysis. Of note, the electron transport chain (ETC) has been shown to still be
functional at 0.5% oxygen levels, and hypoxic (< 2% oxygen) tumour cells can oxidise
glutamine to generate ATP through the ETC (Chandel et al., 1997; Fan et al., 2013; Le
et al., 2012; Le et al., 2014). Therefore, low oxygen tension does not necessarily imply
the complete ablation of mitochondrial metabolism. However, how FAO is affected dur-
ing hypoxia is poorly understood.
In hepatocellular carcinoma, HIF2A repressed the mRNA expression of two key FAO
genes: ACADM and ACADL, resulting in decreased palmitate and oleate oxidation
(Huang et al., 2014). Whether this finding can be extended to other cancer types re-
mains unclear. Short of culturing cells under hypoxic conditions, treatment with cobalt
chloride or desferrioxamine has been used to mimic hypoxia, which functions by either
displacing or chelating iron atoms that are required for prolyl hydroxylase activity (Xia
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et al., 2009). This enzyme serves to initiate the proteosomal degradation of HIF1A
under normoxic condition. Therefore, these agents may be a good starting point to
study the effect of hypoxia on FAO. Selected cancer cell lines can be treated with cobalt
chloride, and gene expression of key FAO genes such as CPT1A, and the ACAD gene
family measured by qPCR. This information is important because much emphasis has
been placed on the role glycolysis and glutamine oxidation in hypoxic adaptation, but
less is known about FAO. Findings from this experiment may add another piece to the
puzzle as to the overall metabolic adaptations during decreased oxygen tension in cancer
cells.
Recently, the efficacy of a small molecule inhibitor against HIF2A - PT2399 in ccRCC
was reported by two independent groups (Cho et al., 2016; Chen et al., 2016). These
initial studies focused on the pharmacokinetics and dynamics of the molecule, and iden-
tifying biomarkers of response. This presents an opportunity to compare the global
metabolic adaptations and flux of pseudohypoxic ccRCC cell lines treated with PT2399
and vehicle control.
8.2.5 Targeting co-dependencies in tumours with low FAO
Altered cellular metabolism is now considered a hallmark of cancer (Ward and Thomp-
son, 2012). In his commentary in Lancet, Professor Douglas Hanahan proposes that one
solution to overcome the disheartening, inevitable resistance acquired to monotherapy
against one hallmark is to target other hallmarks where possible:
”If one accepts the premise that most cancers acquire a similar armamentarium of ca-
pabilities, then a logical strategy is to remove as many of these capabilities as possible,
rather than merely to target a single mechanism. Such a strategic shift can be thought
of as a plan, of co-targeting of multiple capabilities, especially co-targeting of hallmarks
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that can provide cross-support, whereby the power of one hallmark capability can help
compensate for the therapeutic impairment of another.” (Hanahan, 2014)
Since deregulated cellular metabolism is a hallmark of cancer, targeting metabolic vul-
nerabilities, in tandem with other hallmarks may provide more efficacious for the treat-
ment of certain cancers. The FAO signature expression has been shown to be lower
in several cancers, compared to normal tissues. The first, obvious strategy is to treat
cancers with agents that upregulate FAO. This can be achieved using a PPAR alpha
agonist such as fenofibrate, which has been shown to activate FAO in kidney epithelial
cells (Kang et al., 2015). Additionally, Zeng et.al. described a molecule (Yhhu981) syn-
thesised in-house that increased FAO in the C2C12 skeletal muscle cell line and ob/ob
mice, an in vivo model of obesity (Zeng et al., 2015). Hence, these two molecules provide
a starting point to study the effects of pharmacologically upregulating FAO in cancer
cell lines.
Another option would be to identify other metabolic or signalling pathways correlated
with low FAO. The conceptual framework has also been applied, at least in the pre-
clinical setting, to other aspects of cancer metabolism. Some examples include co-
administration of 2-deoxyglucose and metformin in mouse xenograft models; whereby
inhibiting glycolysis induces cells to adopt oxidative metabolism, and this dependency
can be targeted with metformin (Cheong et al., 2011). In lymphoma, therapy-induced
senescence resulted in increased glycolysis and ATP production, and inhibition of gly-
colysis or autophagy further improved treatment outcome in vivo (Dorr et al., 2013).
Based on these findings, it is possible that other dependencies will emerge in response
to different tumour FAO flux. For example, when FAO is high, cancer cells may be less
dependent on glycolysis. Consequently, flux through the pentose phosphate pathway
would be lower, which results in lesser reducing equivalents available to buffer against
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acute oxidative stress. A small molecule screen performed on normal and cancer lines
by Raj et. al. identified piperlongumine to be selectively cytotoxic to cancer cells via
generation of reactive oxygen species (Raj et al., 2011). Based on this, one may postu-
late that the combination of agents that increase FAO (e.g., fenofibrate, Yhhu981) and
induces oxidative stress (e.g., piperlongumine) may be cytotoxic to high glycolysis/low
FAO tumours.
8.2.6 Elucidating the interaction between tumour metabolism and
microenvironment
This thesis has considered the FAO signature expression in tumours as a cell autonomous
process. Indeed, laser capture microdissected colorectal tumour tissue was found to
have lower FAO signature expression, compared to bulk tumour tissues (Supp Fig A.2).
Nevertheless, there are several studies that suggest the tumour microenvironment can
influence the metabolism of tumour cells (Anastasiou, 2017).
Altering metabolic flux through pharmacologic interventions in the tumour may make
substrates available for the stromal components such as infiltrating immune cells. For
instance, decreasing glycolytic flux in cancer cells may make more glucose available for
T lymphocyte cell function (Chang et al., 2013; Ho et al., 2015). Arginine promotes T
lymphocyte cell anti-tumour activity, and consequently, arginine deprivation may bring
about an immune-suppressive effect (Fletcher et al., 2015). Excess lactate secreted from
tumour cells can blunt natural killer cell and T lymphocyte cell function (Brand et al.,
2016).
Taken together, targeting the metabolic pathways in tumours may have a positive or
negative collateral effect on its immediate environment. This presents an opportunity
to develop metabolic therapies that have a negative impact on the tumour, but also pro-
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mote anti-tumour stromal activity that may further potentiate its treatment efficacy.
8.2.7 Xenopus laevis appendage regeneration as a model system to
understand metabolic correlates of cancer initiation and pro-
gression
The use of model organisms has led to the characterisation of several processes that are
key in tumourigenesis. The nematode Caenorhabditis elegans was key in understanding
apoptosis and hypoxia, and the fruitfly Drosophila melanogaster was integral in eluci-
dating the Notch and Hippo pathways - all highly relevant pathways and processes in
several human cancers (Potts and Cameron, 2011; Epstein et al., 2001; Gonzalez, 2013).
The tadpole Xenopus laevis has a remarkable ability to regenerate its appendages (fins,
tails and limbs), and is a model organism to study regeneration (Beck, Izpisua Bel-
monte, and Christen, 2009; Beck, Christen, and Slack, 2003). Love et. al. investigated
the molecular alterations in response to regeneration of Xenopus tail appendage, and
observed genes such as leptin, proinsulin, hif1a - all of which regulate the activity of
glucose transporters and glycolysis - to be up regulated upon tail amputation. Further-
more, tail regeneration also activates pathways often implicated in cancer such as Wnt,
FGF and leptin-mediated PI3K/Akt signalling (Lin and Slack, 2008; Donato, Frazao,
and Elias, 2010).
The regeneration of Xenopus can be divided into three phases: early, intermediate, and
late. This regenerative process involves proliferation, migration and differentiation - pro-
cesses involved in cancer initiation and progression. While Love et. al. has reported the
importance of the Warburg effect in Xenopus tail regeneration, the global metabolic cor-
relates associated with each regenerative phase remains to be defined. Since the Xenopus
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model is amenable to genetic modification procedures such as genetic editing and devel-
opment of transgenic lines, expression of key, rate-limiting enzymes can be modulated
and their effect on the different phases of regeneration monitored (Ishibashi, Cliffe, and
Amaya, 2012; Love et al., 2011). The power of this system lies in the linear, continuum
regenerative process, which allows identification of the metabolic shifts between the pro-
liferation and migration- (pro-tumourigenic), and differentiation (tumour-suppressive)
phases. Since Xenopus are unlikely to be mired by various genomic aberrations observed
in cancers, the metabolic correlates of regeneration can be attributed to these processes
per se. The findings from this analysis can then be further explored in cancer cell sys-
tems with progressive malignant features, such as the commercially available RWPE1
prostate cell line series.
8.3 Potential translational relevance of FAO in oncology
8.3.1 Radiolabelled fatty acid to image tumours
In oncology, fluoro-deoxyglucose positron emission tomography (FDG-PET) has been
utilised for over 35 years to diagnose and stage tumours (Kelloff et al., 2005). FDG-
PET takes advantage of the avidity for glucose displayed in many tumour types. Upon
uptake via glucose transporters, FDG is phosphorylated to form 2-FDG-phosphate by
hexokinase. The subsequent isomerisation to fructose-6-phosphate is inhibited due to
the absence of an oxygen atom at the C2 position. Hence, it is trapped in the cell and
its accumulation is correlated with the cellular glycolytic rate. The decay of 18-fluorine
in FDG can then be detected by a PET scanner. Apart from diagnosing and staging
tumours, FDG-PET has also been used to monitor therapy response in advanced and
metastatic breast cancers (Lewis, Soloviev, and Brindle, 2015; Brindle, 2008). Another
highly consumed nutrient in cancer is glutamine, and imaging of labelled glutamine has
been reported to be superior compared to FDG to delineate tumour and normal brain
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tissue in glioma patients (Venneti et al., 2015).
8.3.1.1 PET imaging of FAO in cancer
This thesis has shown that genes involved in FAO are downregulated in many cancers,
and is supported by several other studies examining the protein levels and FAO flux of
cancer cells. However, currently, no assays are utilised as part of standard clinical prac-
tise to estimate the FAO status in primary tumours. Several radiolabelled FAO probes
such as fluoro-thia-palmitate (FTP) and fluoro-thio-oleate (FTO) have been developed
and studied in a mouse model (DeGrado et al., 2010). This provides an opportunity
to glean the FAO status of tumours in vivo. By imaging FDG, glutamine and thio-
palmitate/oleate uptake, one may non-invasively infer the metabolic ’score’ based on
the ratios of the uptake values for a particular tumour. With follow up data, one could
correlate the metabolic score with outcome, and potentially establish a novel prognostic
or predictive variable of clinical significance.
8.3.2 Using genomic correlates of tumour metabolism to actively tar-
get metabolic dependencies
The relationship between key oncogenes and tumour metabolism is well documented.
Furthermore, apart from synthetic lethal approaches, there are little therapeutic op-
tions available to treat tumours with tumour suppressor (e.g., CDH1, TP53 ) inactiva-
tion. Hence, targeting specific metabolic dependencies in this instance would provide
another therapeutic avenue for cancer treatment. For example, metformin was shown to
selectively suppress the growth of p53-null, compared to wildtype expression HCT116
isogenic colon cancer cell lines (Buzzai et al., 2005). Mutations in the tumour suppressor
LKB1, which activates AMPK, have been shown to be susceptible to phenformin treat-
ment in non-small cell lung cancer cell lines (Shackelford et al., 2013). Interestingly, in
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mice, mutations in Lkb1 and Kras, but not Kras and p53, were susceptible to phen-
formin treatment, resulting in increased survival. Taken together, these data suggests
clinically actionable metabolic dependencies associated with particular mutations.
Based on this, patients can be administered inhibitors or activators of specific metabolic
pathways, according to the mutational profile of their tumour. Using liquid biopsies,
the efficacy of the treatment can be monitored based on quantity of these mutations
in the circulation (Wan et al., 2017). During the course of treatment, emergence of
other mutations that drive resistance or disease progression may correlate with some
other metabolic dependencies, which could then be targeted. Experimental analyses
described in Chapter 6 suggest that CPT1A modulation in MDA-MB231 and MCF7
cell lines, subject to the discussed limitations, does not consistently converge on influ-
encing the cell cycle. In other words, the cell systems studied in this thesis suggest
that overexpression or knockdown on CPT1A expression does not affect proliferation in
an opposing manner. Furthermore, in silico analysis of CPT1A mRNA expression in
a panel of breast cancer cell lines suggest that while ER-positive cell lines have higher
CPT1A expression compared to ER-negative cell lines, there were substantial differ-
ences in CPT1A expression within these two groups. Hence, it is possible that other
genomic aberrations, in addition to ER status, may be associated with CPT1A expres-
sion in these cell lines. This highlights the need to characterise the genomic correlates
associated with CPT1A expression, which may assist identifying mutations that best
explain the variation observed within the two ER subgroups. To summarise, future
efforts could focus on refining our knowledge regarding mutations and their metabolic
correlates, which may be translated in the clinic with potential therapies and active,




Figure A.1: FAO signature is expressed higher in lung adenocarcinoma com-
pared to squamous cell carcinoma. t-test p * ≤0.05.
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Figure A.2: FAO signature is expressed lower in laser capture microdissected
(LCM) compared to bulk biopsy colon tumours and normal colon tissue. t-
test p ** ≤0.01.
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Figure A.3: ER-positive cell lines have higher CPT1A mRNA expression compared to ER-negative cell lines (GSE41313 dataset).
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Figure A.4: ER-positive cell lines have higher CPT1A mRNA expression compared to ER-negative cell lines (Cancer Cell Line
Encyclopedia dataset).
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Figure A.5: Leaky CPT1A expression in pTRE-CPT1A clone 5 in the absence of Dox induction.
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Figure A.6: Growth curves of pTRE-CPT1A clone 3 with basal and CPT1A
overexpression. Error bars = standard deviation. Blue cirles: Tet -Dox; Navy squares:
Tet +Dox; Red squares: pTRE-CPT1A clone 3 -Dox; Pink triangles: pTRE-CPT1A
clone 3 +Dox.
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Figure A.7: Growth curves of pTRE-CPT1A clone 17 with basal and CPT1A
overexpression. Error bars = standard deviation. Blue cirles: Tet -Dox; Navy squares:
Tet +Dox; Red squares: pTRE-CPT1A clone 17 -Dox; Pink triangles: pTRE-CPT1A
clone 17 +Dox.
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Figure A.8: Would healing rate of pTRE-CPT1A clone 3 with basal and
CPT1A overexpression. Error bars = standard deviation. Blue cirles: Tet -Dox;
Navy squares: Tet +Dox; Red squares: pTRE-CPT1A clone 3 -Dox; Pink triangles:
pTRE-CPT1A clone 3 +Dox.
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Figure A.9: Would healing rate of pTRE-CPT1A clone 17 with basal and
CPT1A overexpression. Erro bars = standard deviation. Blue cirles: Tet -Dox;
Navy squares: Tet +Dox; Red squares: pTRE-CPT1A clone 17 -Dox; Pink triangles:
pTRE-CPT1A clone 17 +Dox.
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Figure A.10: Growth curves of MCF7 non-silencing, shRNA clones 1 and 2.
Error bars = standard deviation. Blue cirles: Non-silencing -Dox; Navy squares: Non-
silencing +Dox; Red squares: shRNA1 -Dox; Pink triangles: shRNA1 +Dox; golden
crosses: shRNA2 -Dox,; green line: shRNA2 +Dox.
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Figure A.11: Geneset enrichment analysis of TetOn cells with Dox treatment.
(a,b,c,d) Genesets that were downregulated in Dox-treated TetOn cells from (a) KEGG,
(b) Reactome, (c) WikiPathways and (d) Panther databases from the Enrichr analysis.
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Figure A.12: Geneset enrichment analysis of TetOn cells with Dox treatment.
(a,b,c,d) Genesets that were upregulated in Dox-treated TetOn cells from (a) KEGG,
(b) Reactome, (c) WikiPathways and (d) Panther databases from the Enrichr analysis.
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Figure A.13: Geneset enrichment analysis of PC3 cells with basal or PGC1A
overexpression. (a,b,c,d) Genesets that were downregulated in PGC1A overexpressing
cells from (a) KEGG, (b) Reactome, (c) WikiPathways and (d) Panther databases from
the Enrichr analysis.
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Figure A.14: Geneset enrichment analysis of PC3 cells with basal or PGC1A
overexpression. (a,b,c,d) Genesets that were upregulated in PGC1A overexpressing
cells from (a) KEGG, (b) Reactome, (c) WikiPathways and (d) Panther databases from
the Enrichr analysis.
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Figure A.15: Genesets enriched in NCI-H2347 cells 12 hrs after pioglitazone
treatment. (a,b,c,d) Genesets that were downregulated in pioglitazone-treated cells
from (a) KEGG, (b) Reactome, (c) WikiPathways and (d) Panther databases from the
Enrichr analysis.
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Figure A.16: Genesets enriched in NCI-H2347 cells 24 hrs after pioglitazone
treatment. (a,b,c,d) Genesets that were downregulated in pioglitazone-treated cells
from (a) KEGG, (b) Reactome, (c) WikiPathways and (d) Panther databases from the
Enrichr analysis.
270
Figure A.17: Genesets enriched in NCI-H2347 cells 48 hrs after pioglitazone
treatment. (a,b,c,d) Genesets that were downregulated in pioglitazone-treated cells
from (a) KEGG, (b) Reactome, (c) WikiPathways and (d) Panther databases from the
Enrichr analysis.
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Figure A.18: Genesets enriched in NCI-H2347 cells 12 hrs after pioglitazone
treatment. (a,b,c,d) Genesets that were upregulated in pioglitazone-treated cells from
(a) KEGG, (b) Reactome, (c) WikiPathways and (d) Panther databases from the Enrichr
analysis.
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Figure A.19: Genesets enriched in NCI-H2347 cells 24 hrs after pioglitazone
treatment. (a,b,c,d) Genesets that were upregulated in pioglitazone-treated cells from
(a) KEGG, (b) Reactome, (c) WikiPathways and (d) Panther databases from the Enrichr
analysis.
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Figure A.20: Genesets enriched in NCI-H2347 cells 48 hrs after pioglitazone
treatment. (a,b,c,d) Genesets that were upregulated in pioglitazone-treated cells from






Table B.1: Clinical information of METABRIC training data.
Median age at diagnosis (years) 61.84 (51.45-70.64)













































Median Nottingham Prognostic Index 4.04 (1.02-6.03)
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Table B.2: Cell lines with CCND1 and CPT1A co-amplification.
Cell lines Tissue
143B, G292CLONEA141B1, HOS, RDES, SJSA1 Bone
BT474, CAMA1, HCC1395, HDQP1, MDA-MB134VI,
MDA-MB175VII, MDA-MB415, MDA-MB453, ZR751, EVSAT
Breast
ME1, OCIM1, REC1 Haematopoetic
HUH7, JHH5, JHH7, SNU387, SNU475, SNU878, SNU886 Liver
DMS114, EPLC272H, NCI1395, NCIH1437, NCIH1573, NCIH1975,
NCIH211, NCIH23, NCIH441, HCIH838
Lung
COLO680N, KYSE140, KYSE180, KYSE510, OE19, TE11, TE15, TE8,
TE9, TT
Oesphagus
COV362, JHM1, OVKATE Ovary
YAPC Pancreas
HS852T, MELHO, MEWO, SKMEL30, SKMEL5 Skin
HS746T, KE39, SNU668, Stomach
CGTHW1 Thyroid
277











Cell cycle Homo sapiens hsa04110 0.044028997 1 0.003235071 0.927158974 -1.733198335 5.412616937
DNA replication Homo sapiens
hsa03030 0.073517601 1 0.042440959 0.927158974 -1.935236309 5.051412699
RNA polymerase Homo sapiens
hsa03020 0.11023229 1 0.060979109 0.927158974 -1.746633355 3.851615457
Biosynthesis of unsaturated fatty acids
Homo sapiens hsa01040 0.086307178 1 0.070731211 0.927158974 -1.507461721 3.693043803
p53 signaling pathway Homo sapiens
hsa04115 0.126380809 1 0.025963106 0.927158974 -1.633457981 3.378735368
Nucleotide excision repair Homo sapiens
hsa03420 0.156176381 1 0.051438651 0.927158974 -1.662043401 3.086031098
Proteasome Homo sapiens
hsa03050 0.178298172 1 0.061072645 0.927158974 -1.428779059 2.463640885
Ribosome biogenesis in eukaryotes
Homo sapiens hsa03008 0.330687642 1 0.041842766 0.927158974 -1.614194189 1.786236664
Base excision repair Homo sapiens
hsa03410 0.253114053 1 0.104298692 0.927158974 -1.178095782 1.618603571
Circadian rhythm Homo sapiens
hsa04710 0.291313663 1 0.125216534 0.927158974 -1.185944072 1.462689708
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HIV Infection Homo sapiens
R-HSA-162906 0.000486535 0.369036917 4.42602E-05 0.022380906 -2.376987336 2.369520256
Host Interactions of HIV factors
Homo sapiens R-HSA-162909 0.000387008 0.369036917 0.00033183 0.083897787 -2.275378521 2.268230636
Cell Cycle, Mitotic Homo sapiens
R-HSA-69278 0.006449666 0.404969749 3.50651E-06 0.002659689 -2.323067069 2.099920003
APC/C:Cdh1 mediated degradation
of Cdc20 and other APC/C:Cdh1
targeted proteins in late mitosis/early
G1 Homo sapiens R-HSA-174178
0.002399061 0.404969749 0.003776443 0.229154539 -2.248536738 2.032548838
SUMOylation of DNA replication
proteins Homo sapiens R-HSA-4615885 0.00257268 0.404969749 0.008923074 0.317916072 -2.248491597 2.032508034
Regulation of mitotic cell cycle
Homo sapiens R-HSA-453276 0.003580122 0.404969749 0.003164282 0.229154539 -2.237066269 2.02218019
DNA Replication Homo sapiens
R-HSA-69306 0.003658523 0.404969749 0.001958131 0.198032266 -2.234778521 2.020112196
APC/C-mediated degradation of cell
cycle proteins Homo sapiens
R-HSA-174143
0.003580122 0.404969749 0.003164282 0.229154539 -2.228739112 2.014652915
M/G1 Transition Homo sapiens
R-HSA-68874 0.004051093 0.404969749 0.003639741 0.229154539 -2.205359518 1.993519097
DNA Replication Pre-Initiation
Homo sapiens R-HSA-69002 0.004051093 0.404969749 0.003639741 0.229154539 -2.194796457 1.983970693
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P-value Z-score Combined Score
DNA Replication Homo sapiens WP466 0.005222081 1 0.014265782 0.913978164 -2.185699155 3.17111E-10
DNA Replication Mus musculus WP150 0.010302767 1 0.020320329 0.913978164 -2.020056622 2.93078E-10
TNF-alpha NF-kB Signaling Pathway
Mus musculus WP246 0.221551491 1 0.012917743 0.913978164 -1.793442026 2.602E-10
Parkin-Ubiquitin Proteasomal System
pathway Homo sapiens WP2359 0.023797604 1 0.014422241 0.913978164 -1.792263771 2.60029E-10
Cell Cycle Homo sapiens WP179 0.017278528 1 0.005962476 0.913978164 -1.79008958 2.59714E-10
Cholesterol Biosynthesis
Homo sapiens WP197 0.007516368 1 0.046654349 0.913978164 -1.762215697 2.5567E-10
Eukaryotic Transcription Initiation
Homo sapiens WP405 0.062249762 1 0.044378143 0.913978164 -1.74801357 2.53609E-10
G1 to S cell cycle control
Mus musculus WP413 0.075442072 1 0.035207801 0.913978164 -1.707844746 2.47781E-10
Proteasome Degradation
Mus musculus WP519 0.036126732 1 0.024911558 0.913978164 -1.703574558 2.47162E-10
Eukaryotic Transcription Initiation
Mus musculus WP567 0.037075337 1 0.036207816 0.913978164 -1.702185739 2.4696E-10
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Cell cycle Homo sapiens P00013 0.020467664 0.999895948 0.076948172 0.882298466 -1.281527657 0.000133353
Oxytocin receptor mediated signaling
pathway Homo sapiens P04391 0.11583907 0.999895948 0.095635256 0.882298466 -1.222159907 0.000127175
5HT2 type receptor mediated signaling
pathway Homo sapiens P04374 0.118821009 0.999895948 0.086369505 0.882298466 -1.209273718 0.000125834
Ubiquitin proteasome pathway
Homo sapiens P00060 0.042571799 0.999895948 0.052698239 0.882298466 -1.19612574 0.000124466
Mannose metabolism Homo sapiens
P02752 0.022899884 0.999895948 0.129913711 0.882298466 -0.479838756 4.9931E-05
Plasminogen activating cascade
Homo sapiens P00050 0.095785002 0.999895948 0.143365747 0.882298466 -0.295053675 3.07027E-05
Thyrotropin-releasing hormone receptor
signaling pathway Homo sapiens P04394 0.303846683 0.999895948 0.170179799 0.882298466 -0.005802686 6.03815E-07
Histamine H1 receptor mediated signaling
pathway Homo sapiens P04385 0.260284061 0.999895948 0.19124416 0.882298466 0.275258882 -2.86429E-05
p53 pathway feedback loops 2
Homo sapiens P04398 0.326165482 0.999895948 0.170219374 0.882298466 0.286631442 -2.98263E-05
Cortocotropin releasing factor receptor
signaling pathway Homo sapiens P04380 0.291313663 0.999895948 0.193108418 0.882298466 0.299677459 -3.11838E-05
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Cell cycle Homo sapiens
hsa04110 0.044028997 1 0.003235071 0.927158974 -1.733198335 5.412616937
DNA replication Homo sapiens
hsa03030 0.073517601 1 0.042440959 0.927158974 -1.935236309 5.051412699
RNA polymerase Homo sapiens
hsa03020 0.11023229 1 0.060979109 0.927158974 -1.746633355 3.851615457
Biosynthesis of unsaturated fatty acids
Homo sapiens hsa01040 0.086307178 1 0.070731211 0.927158974 -1.507461721 3.693043803
p53 signaling pathway Homo sapiens
hsa04115 0.126380809 1 0.025963106 0.927158974 -1.633457981 3.378735368
Nucleotide excision repair Homo sapiens
hsa03420 0.156176381 1 0.051438651 0.927158974 -1.662043401 3.086031098
Proteasome Homo sapiens hsa03050 0.178298172 1 0.061072645 0.927158974 -1.428779059 2.463640885
Ribosome biogenesis in eukaryotes
Homo sapiens hsa03008 0.330687642 1 0.041842766 0.927158974 -1.614194189 1.786236664
Base excision repair Homo sapiens
hsa03410 0.253114053 1 0.104298692 0.927158974 -1.178095782 1.618603571
Circadian rhythm Homo sapiens
hsa04710 0.291313663 1 0.125216534 0.927158974 -1.185944072 1.462689708
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HIV Infection Homo sapiens R-HSA-162906 0.000486535 0.369036917 4.42602E-05 0.022380906 -2.376987336 2.369520256
Host Interactions of HIV factors Homo sapiens
R-HSA-162909 0.000387008 0.369036917 0.00033183 0.083897787 -2.275378521 2.268230636
Cell Cycle, Mitotic Homo sapiens R-HSA-69278 0.006449666 0.404969749 3.50651E-06 0.002659689 -2.323067069 2.099920003
APC/C:Cdh1 mediated degradation of Cdc20 and other
APC/C:Cdh1 targeted proteins in late mitosis/early G1
Homo sapiens R-HSA-174178
0.002399061 0.404969749 0.003776443 0.229154539 -2.248536738 2.032548838
SUMOylation of DNA replication proteins
Homo sapiens R-HSA-4615885 0.00257268 0.404969749 0.008923074 0.317916072 -2.248491597 2.032508034
APC/C-mediated degradation of cell cycle proteins
Homo sapiens R-HSA-174143 0.003580122 0.404969749 0.003164282 0.229154539 -2.238062993 2.023081171
DNA Replication Homo sapiens R-HSA-69306 0.003658523 0.404969749 0.001958131 0.198032266 -2.234778521 2.020112196
Regulation of mitotic cell cycle Homo sapiens
R-HSA-453276 0.003580122 0.404969749 0.003164282 0.229154539 -2.227747576 2.013756623
DNA Replication Pre-Initiation Homo sapiens
R-HSA-69002 0.004051093 0.404969749 0.003639741 0.229154539 -2.204440342 1.992688214
M/G1 Transition Homo sapiens R-HSA-68874 0.004051093 0.404969749 0.003639741 0.229154539 -2.195702879 1.984790046
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DNA Replication Homo sapiens WP466 0.005222081 1 0.014265782 0.913978164 -2.185699155 3.17111E-10
DNA Replication Mus musculus WP150 0.010302767 1 0.020320329 0.913978164 -2.020056622 2.93078E-10
TNF-alpha NF-kB Signaling Pathway
Mus musculus WP246 0.221551491 1 0.012917743 0.913978164 -1.793442026 2.602E-10
Parkin-Ubiquitin Proteasomal System pathway
Homo sapiens WP2359 0.023797604 1 0.014422241 0.913978164 -1.792263771 2.60029E-10
Cell Cycle Homo sapiens WP179 0.017278528 1 0.005962476 0.913978164 -1.79008958 2.59714E-10
Cholesterol Biosynthesis Mus musculus WP103 0.007516368 1 0.046654349 0.913978164 -1.752329034 2.54235E-10
Eukaryotic Transcription Initiation
Homo sapiens WP405 0.062249762 1 0.044378143 0.913978164 -1.74801357 2.53609E-10
G1 to S cell cycle control Mus musculus WP413 0.075442072 1 0.035207801 0.913978164 -1.707844746 2.47781E-10
Proteasome Degradation Mus musculus WP519 0.036126732 1 0.024911558 0.913978164 -1.703574558 2.47162E-10
Eukaryotic Transcription Initiation
Mus musculus WP567 0.037075337 1 0.036207816 0.913978164 -1.702185739 2.4696E-10
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Cell cycle Homo sapiens P00013 0.020467664 0.999895948 0.076948172 0.882298466 -1.281527657 0.000133353
Oxytocin receptor mediated signaling pathway
Homo sapiens P04391 0.11583907 0.999895948 0.095635256 0.882298466 -1.222159907 0.000127175
5HT2 type receptor mediated signaling pathway
Homo sapiens P04374 0.118821009 0.999895948 0.086369505 0.882298466 -1.209273718 0.000125834
Ubiquitin proteasome pathway Homo sapiens
P00060 0.042571799 0.999895948 0.052698239 0.882298466 -1.19612574 0.000124466
Mannose metabolism Homo sapiens P02752 0.022899884 0.999895948 0.129913711 0.882298466 -0.479838756 4.9931E-05
Plasminogen activating cascade Homo sapiens P00050 0.095785002 0.999895948 0.143365747 0.882298466 -0.295053675 3.07027E-05
Thyrotropin-releasing hormone receptor signaling
pathway Homo sapiens P04394 0.303846683 0.999895948 0.170179799 0.882298466 -0.005802686 6.03815E-07
Histamine H1 receptor mediated signaling pathway
Homo sapiens P04385 0.260284061 0.999895948 0.19124416 0.882298466 0.275258882 -2.86429E-05
p53 pathway feedback loops 2 Homo sapiens P04398 0.326165482 0.999895948 0.170219374 0.882298466 0.286631442 -2.98263E-05
Cortocotropin releasing factor receptor signaling
pathway Homo sapiens P04380 0.291313663 0.999895948 0.193108418 0.882298466 0.299677459 -3.11838E-05
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Ribosome Homo sapiens hsa03010 89/137 0.000649568 0.190323372 0.000514486 0.15074431 -1.746138049 2.89689662
Base excision repair Homo sapiens hsa03410 25/33 0.003215776 0.471111128 0.015799542 0.679562894 -1.626543214 1.224236085
Spliceosome Homo sapiens hsa03040 83/134 0.006878816 0.671831062 0.002124723 0.311271983 -1.747319798 0.694993593
RNA polymerase Homo sapiens hsa03020 23/32 0.01343285 0.983956234 0.029471814 0.679562894 -1.746633355 0.028249804
Legionellosis Homo sapiens hsa05134 34/55 0.07020851 1 0.039922133 0.679562894 -1.709516338 4.93928E-10
Epstein-Barr virus infection




107/193 0.121965076 1 0.007386161 0.541036272 -1.628205797 4.70435E-10
Pyrimidine metabolism Homo sapiens
hsa00240 61/105 0.086954367 1 0.019431436 0.679562894 -1.571024109 4.53914E-10
Neurotrophin signaling pathway
Homo sapiens hsa04722 66/120 0.216241679 1 0.03374291 0.679562894 -1.539869748 4.44913E-10
Non-small cell lung cancer
Homo sapiens hsa05223 32/56 0.216318549 1 0.084558063 0.72160196 -1.513766213 4.3737E-10
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Homo sapiens R-HSA-5389840 62/84 1.58985E-05 0.02149842 0.000540715 0.11093287 -2.079555632
Mitochondrial translation termination
Homo sapiens R-HSA-5419276 61/84 4.27121E-05 0.02149842 0.000796536 0.11093287 -2.073160826
Mitochondrial translation initiation
Homo sapiens R-HSA-5368286 61/84 4.27121E-05 0.02149842 0.000796536 0.11093287 -2.045413922
Mitochondrial translation
Homo sapiens R-HSA-5368287 64/90 8.03486E-05 0.030331602 0.000881586 0.11093287 -2.083609973
rRNA processing Homo sapiens
R-HSA-72312 116/180 0.000177018 0.039929015 0.000190545 0.095907895 -1.996434028
Eukaryotic Translation Initiation
Homo sapiens R-HSA-72613 77/114 0.00024792 0.039929015 0.000832051 0.11093287 -1.93903209
Eukaryotic Translation Elongation
Homo sapiens R-HSA-156842 62/89 0.000264431 0.039929015 0.001503239 0.118327548 -1.937632272
Major pathway of rRNA processing in the
nucleolus Homo sapiens R-HSA-6791226 107/166 0.000305804 0.041978491 0.000329529 0.11093287 -1.966950476
Cap-dependent Translation Initiation
Homo sapiens R-HSA-72737 77/114 0.00024792 0.039929015 0.000832051 0.11093287 -1.931661151
Selenocysteine synthesis Homo sapiens
R-HSA-2408557 61/87 0.000222583 0.039929015 0.001463194 0.118327548 -1.896405961
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Homo sapiens R-HSA-5389840 62/84 1.58985E-05 0.02149842 0.000540715 0.11093287 -2.079555632
Mitochondrial translation termination
Homo sapiens R-HSA-5419276 61/84 4.27121E-05 0.02149842 0.000796536 0.11093287 -2.073160826
Mitochondrial translation initiation
Homo sapiens R-HSA-5368286 61/84 4.27121E-05 0.02149842 0.000796536 0.11093287 -2.045413922
Mitochondrial translation
Homo sapiens R-HSA-5368287 64/90 8.03486E-05 0.030331602 0.000881586 0.11093287 -2.083609973
rRNA processing Homo sapiens
R-HSA-72312 116/180 0.000177018 0.039929015 0.000190545 0.095907895 -1.996434028
Eukaryotic Translation Initiation
Homo sapiens R-HSA-72613 77/114 0.00024792 0.039929015 0.000832051 0.11093287 -1.93903209
Eukaryotic Translation Elongation
Homo sapiens R-HSA-156842 62/89 0.000264431 0.039929015 0.001503239 0.118327548 -1.937632272
Major pathway of rRNA processing in the
nucleolus Homo sapiens R-HSA-6791226 107/166 0.000305804 0.041978491 0.000329529 0.11093287 -1.966950476
Cap-dependent Translation Initiation
Homo sapiens R-HSA-72737 77/114 0.00024792 0.039929015 0.000832051 0.11093287 -1.931661151
Selenocysteine synthesis Homo sapiens
R-HSA-2408557 61/87 0.000222583 0.039929015 0.001463194 0.118327548 -1.896405961
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Glycolysis Homo sapiens P00024 14/17 0.007965496 0.876204516 0.065198289 0.901647286 -1.291884483 0.170729962
Mannose metabolism Homo sapiens P02752 6/6 0.017604311 0.968237109 0.131498607 0.901647286 -0.479838756 0.015488367
Huntington disease Homo sapiens P00029 69/124 0.172205038 0.998686368 0.076022202 0.901647286 -0.977492555 0.00128491
Axon guidance mediated by semaphorins
Homo sapiens P00007 12/17 0.083793761 0.998686368 0.151495636 0.901647286 -0.411028002 0.000540295
Salvage pyrimidine ribonucleotides
Homo sapiens P02775 8/10 0.062108649 0.998686368 0.15931664 0.901647286 -0.385744902 0.00050706
Ras Pathway Homo sapiens P04393 38/69 0.289599375 0.998686368 0.169485459 0.901647286 -0.328050215 0.000431221
Pentose phosphate pathway
Homo sapiens P02762 7/8 0.039774248 0.998686368 0.147449453 0.901647286 -0.009071811 1.19249E-05
Integrin signalling pathway
Homo sapiens P00034 82/156 0.378740481 0.998686368 0.119852308 0.901647286 0.129320763 -0.000169992
Nicotine pharmacodynamics pathway
Homo sapiens P06587 17/28 0.201149592 0.998686368 0.196202219 0.901647286 0.16834715 -0.000221292
p38 MAPK pathway
Homo sapiens P05918 19/32 0.220950709 0.998686368 0.197741402 0.901647286 0.173593209 -0.000228188
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hsa03010 89/137 0.000649568 0.190323372 0.000514486 0.15074431 -1.746138049 2.89689662
Base excision repair Homo sapiens
hsa03410 25/33 0.003215776 0.471111128 0.015799542 0.679562894 -1.626543214 1.224236085
Spliceosome Homo sapiens
hsa03040 83/134 0.006878816 0.671831062 0.002124723 0.311271983 -1.747319798 0.694993593
RNA polymerase Homo sapiens
hsa03020 23/32 0.01343285 0.983956234 0.029471814 0.679562894 -1.746633355 0.028249804
Legionellosis Homo sapiens
hsa05134 34/55 0.07020851 1 0.039922133 0.679562894 -1.709516338 4.93928E-10
Epstein-Barr virus infection
Homo sapiens hsa05169 112/202 0.115620096 1 0.006221447 0.541036272 -1.701033337 4.91477E-10
Huntington’s disease Homo sapiens
hsa05016 107/193 0.121965076 1 0.007386161 0.541036272 -1.628205797 4.70435E-10
Pyrimidine metabolism Homo sapiens
hsa00240 61/105 0.086954367 1 0.019431436 0.679562894 -1.571024109 4.53914E-10
Neurotrophin signaling pathway
Homo sapiens hsa04722 66/120 0.216241679 1 0.03374291 0.679562894 -1.539869748 4.44913E-10
Non-small cell lung cancer
Homo sapiens hsa05223 32/56 0.216318549 1 0.084558063 0.72160196 -1.513766213 4.3737E-10
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Homo sapiens R-HSA-5419276 61/84 4.27121E-05 0.02149842 0.000796536 0.11093287 -2.082500048 7.996333396
Mitochondrial translation elongation
Homo sapiens R-HSA-5389840 62/84 1.58985E-05 0.02149842 0.000540715 0.11093287 -2.079555632 7.985027497
Mitochondrial translation initiation
Homo sapiens R-HSA-5368286 61/84 4.27121E-05 0.02149842 0.000796536 0.11093287 -2.036255914 7.818766286
Mitochondrial translation Homo sapiens
R-HSA-5368287 64/90 8.03486E-05 0.030331602 0.000881586 0.11093287 -2.083609973 7.28339438
rRNA processing Homo sapiens R-HSA-72312 116/180 0.000177018 0.039929015 0.000190545 0.095907895 -1.996434028 6.429819304
Eukaryotic Translation Initiation
Homo sapiens R-HSA-72613 77/114 0.00024792 0.039929015 0.000832051 0.11093287 -1.93903209 6.244947635
Eukaryotic Translation Elongation
Homo sapiens R-HSA-156842 62/89 0.000264431 0.039929015 0.001503239 0.118327548 -1.937632272 6.240439307
Major pathway of rRNA processing in the nucleolus
Homo sapiens R-HSA-6791226 107/166 0.000305804 0.041978491 0.000329529 0.11093287 -1.966950476 6.236409091
Cap-dependent Translation Initiation Homo sapiens
R-HSA-72737 77/114 0.00024792 0.039929015 0.000832051 0.11093287 -1.931661151 6.221208406
Selenocysteine synthesis Homo sapiens
R-HSA-2408557 61/87 0.000222583 0.039929015 0.001463194 0.118327548 -1.896405961 6.107663706
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Mus musculus WP163 50/70 0.000399101 0.173608941 0.004502397 0.821667801 -2.034709977 3.562675385
Cytoplasmic Ribosomal Proteins
Homo sapiens WP477 60/89 0.001240039 0.269708474 0.0049864 0.821667801 -1.982224342 2.597533795
TNF-alpha NF-kB Signaling Pathway
Mus musculus WP246 102/179 0.062714727 1 0.013923321 0.881128797 -2.147111963 6.6542E-10
Translation Factors Mus musculus
WP307 30/46 0.03660629 1 0.050987836 0.881128797 -1.918584981 5.94597E-10
TOR Signaling Homo sapiens
WP1471 24/36 0.04234669 1 0.065278922 0.881128797 -1.917167782 5.94157E-10
mRNA Processing Homo sapiens
WP411 74/127 0.060022229 1 0.023370443 0.881128797 -1.861148938 5.76796E-10
Apoptosis-related network due to altered
Notch3 in ovarian cancer
Homo sapiens WP2864
33/53 0.065812912 1 0.061880935 0.881128797 -1.793382185 5.55794E-10
MicroRNAs in Cardiomyocyte
Hypertrophy Mus musculus WP1560 47/79 0.080643871 1 0.04927221 0.881128797 -1.713925724 5.3117E-10
Differentiation Pathway Homo sapiens WP2848 30/48 0.073023164 1 0.070507674 0.881128797 -1.650855231 5.11623E-10
Cytokines and Inflammatory Response
(BioCarta) Mus musculus WP222 17/25 0.065748844 1 0.099304487 0.881128797 -1.643670211 5.09397E-10
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Glycolysis Homo sapiens P00024 14/17 0.007965496 0.876204516 0.065198289 0.901647286 -1.291884483 0.170729962
Mannose metabolism Homo sapiens P02752 6/6 0.017604311 0.968237109 0.131498607 0.901647286 -0.479838756 0.015488367
Huntington disease Homo sapiens P00029 6/6 0.172205038 0.998686368 0.076022202 0.901647286 -0.977492555 0.00128491
Axon guidance mediated by semaphorins
Homo sapiens P00007 12/17 0.083793761 0.998686368 0.151495636 0.901647286 -0.411028002 0.000540295
Salvage pyrimidine ribonucleotides
Homo sapiens P02775 8/10 0.062108649 0.998686368 0.15931664 0.901647286 -0.385744902 0.00050706
Ras Pathway Homo sapiens P04393 38/69 0.289599375 0.998686368 0.169485459 0.901647286 -0.328050215 0.000431221
Pentose phosphate pathway
Homo sapiens P02762 7/8 0.039774248 0.998686368 0.147449453 0.901647286 -0.009071811 1.19249E-05
Integrin signalling pathway
Homo sapiens P00034 82/156 0.378740481 0.998686368 0.119852308 0.901647286 0.129320763 -0.000169992
Nicotine pharmacodynamics pathway
Homo sapiens P06587 17/28 0.201149592 0.998686368 0.196202219 0.901647286 0.16834715 -0.000221292
p38 MAPK pathway
Homo sapiens P05918 19/32 0.220950709 0.998686368 0.197741402 0.901647286 0.173593209 -0.000228188
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Circadian rhythm Homo sapiens
hsa04710 22/30 0.032270794 1 0.02778209 0.738789204 -1.972723766 6.82952E-11
Cell cycle Homo sapiens hsa04110 76/124 0.098320076 1 0.003619894 0.530314447 -1.682638698 5.82525E-11
Propanoate metabolism Homo sapiens
hsa00640 21/32 0.155124276 1 0.06332509 0.738789204 -1.637436576 5.66876E-11
Renal cell carcinoma Homo sapiens
hsa05211 40/66 0.22166039 1 0.032469873 0.738789204 -1.632964146 5.65328E-11
Ubiquitin mediated proteolysis
Homo sapiens hsa04120 86/137 0.042532691 1 0.001239755 0.363248099 -1.62124378 5.61271E-11
Fatty acid metabolism Homo sapiens
hsa01212 30/48 0.18988777 1 0.045639782 0.738789204 -1.596357117 5.52655E-11
Histidine metabolism Homo sapiens
hsa00340 16/24 0.1766657 1 0.090017508 0.738789204 -1.584602029 5.48585E-11
Fanconi anemia pathway Homo sapiens
hsa03460 33/53 0.183179506 1 0.038648303 0.738789204 -1.575371809 5.4539E-11
Sphingolipid metabolism Homo sapiens
hsa00600 29/47 0.225232391 1 0.053897066 0.738789204 -1.524343129 5.27724E-11
Valine, leucine and isoleucine
egradation Homo sapiens hsa00280 29/48 0.279179444 1 0.063216129 0.738789204 -1.425205952 4.93403E-11
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Resolution of D-loop Structures through Synthesis-
Dependent Strand Annealing (SDSA) Homo sapiens
R-HSA-5693554
22/26 0.001549312 1 0.016869381 1 -2.121040787 13.72301632
E2F-enabled inhibition of pre-replication complex
formation Homo sapiens R-HSA-113507 10-Oct 0.002598126 1 0.051521677 1 -2.15552297 12.8317528
Mitotic Prometaphase Homo sapiens R-HSA-68877 74/107 0.002089202 1 0.001567034 0.512216497 -2.040727035 12.59327132
Homologous DNA Pairing and Strand Exchange
Homo sapiens R-HSA-5693579 32/42 0.003966061 1 0.012606959 1 -2.110628714 11.67173851
Presynaptic phase of homologous DNA pairing and
strand exchange Homo sapiens R-HSA-5693616 30/39 0.004093873 1 0.014132866 1 -2.061851432 11.33660329
Resolution of Sister Chromatid Cohesion
Homo sapiens R-HSA-2500257 68/99 0.004047488 1 0.00266868 0.673397014 -2.055766103 11.32657006
Nuclear Pore Complex (NPC) Disassembly
Homo sapiens R-HSA-3301854 26/34 0.008520672 1 0.022415359 1 -2.131943316 10.15926432
Resolution of D-loop Structures through
Holliday Junction Intermediates
Homo sapiens R-HSA-5693568
24/32 0.016861236 1 0.031711902 1 -2.007564692 8.196360665
Synthesis of PIPs at the early endosome membrane
Homo sapiens R-HSA-1660516 Dec-14 0.017443534 1 0.065134982 1 -1.794672654 7.266245924
Sphingolipid de novo biosynthesis
Homo sapiens R-HSA-1660661 24/33 0.029735483 1 0.039411741 1 -2.011389469 7.070867154
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Integrated Breast Cancer Pathway
Homo sapiens WP1984 94/155 0.096407157 1 0.003626549 0.953513783 -2.127329909 4.15732E-10
Integrated Cancer Pathway
Homo sapiens WP1971 32/48 0.070814326 1 0.031532034 0.953513783 -2.009492422 3.92704E-10
Interactome of polycomb repressive
complex 2 (PRC2) Homo sapiens WP2916 Dec-16 0.087109788 1 0.097098961 0.953513783 -1.952583354 3.81582E-10
TGF-beta Signaling Pathway
Homo sapiens WP366 80/132 0.11934912 1 0.006995534 0.953513783 -1.906446959 3.72566E-10
EGF/EGFR Signaling Pathway
Homo sapiens WP437 96/163 0.187874277 1 0.006093841 0.953513783 -1.87418167 3.66261E-10
DNA Damage Response Homo sapiens WP707 42/68 0.16447303 1 0.034736318 0.953513783 -1.870598454 3.6556E-10
Retinoblastoma (RB) in Cancer
Homo sapiens WP2446 54/90 0.20622926 1 0.026683119 0.953513783 -1.646304923 3.21728E-10
miRNA regulation of DNA
Damage Response Mus musculus
WP2087
39/64 0.210506177 1 0.046288023 0.953513783 -1.611742187 3.14974E-10
Signaling Pathways in Glioblastoma
Homo sapiens WP2261 48/83 0.352700157 1 0.052068364 0.953513783 -1.51338035 2.95751E-10
EGFR1 Signaling Pathway
Mus musculus WP572 97/171 0.368334943 1 0.01231713 0.953513783 -1.447872511 2.83E-10
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Hypoxia response via HIF activation
Homo sapiens P00030 18/24 0.03751418 0.999921119 0.07386194 0.825188466 -1.475088254 0.000116361
p53 pathway feedback loops 2
Homo sapiens P04398 29/45 0.134231595 0.999921119 0.08801102 0.825188466 -1.292571313 0.000101964
EGF receptor signaling pathway
Homo sapiens P00018 66/109 0.149039656 0.999921119 0.036149254 0.825188466 -1.27730461 0.000100759
Hedgehog signaling pathway Homo sapiens P00025 15/18 0.012347547 0.999921119 0.06001324 0.825188466 -1.273353241 0.000100448
Metabotropic glutamate receptor group II
pathway Homo sapiens P00040 20/30 0.138475226 0.999921119 0.11795991 0.825188466 -1.179608412 9.30527E-05
PI3 kinase pathway Homo sapiens P00048 27/42 0.149885392 0.999921119 0.098950557 0.825188466 -0.815089955 6.42979E-05
Axon guidance mediated by netrin
Homo sapiens P00009 19/30 0.237606658 0.999921119 0.160970229 0.825188466 0.021768899 -1.71723E-06
Ubiquitin proteasome pathway
Homo sapiens P00060 26/43 0.293371619 0.999921119 0.150802686 0.825188466 0.263729867 -2.08042E-05
Adrenaline and noradrenaline biosynthesis
Homo sapiens P00001 16/25 0.246985848 0.999921119 0.180200431 0.825188466 0.268674917 -2.11943E-05
5-Hydroxytryptamine degredation
Homo sapiens P04372 5/5 0.050997743 0.999921119 0.172276188 0.825188466 0.446757952 -3.52422E-05
299












Ribosome Homo sapiens hsa03010 101/137 5.23703E-12 1.52921E-09 1.08251E-06 0.000316093 -1.746138049 35.44400421
Spliceosome Homo sapiens hsa03040 89/134 3.44946E-07 5.03621E-05 7.77281E-05 0.011348299 -1.77196951 17.53589228
Fructose and mannose metabolism
Homo sapiens hsa00051 25/32 0.000125783 0.012242902 0.00762193 0.370933912 -1.55094245 6.828503249
Huntington’s disease
Homo sapiens hsa05016 110/193 0.000419006 0.030587457 0.000959826 0.093423109 -1.826574114 6.369565818
Oxidative phosphorylation
Homo sapiens hsa00190 76/133 0.002751738 0.160701494 0.005204621 0.366420156 -1.724055636 3.151930079
Pyrimidine metabolism
Homo sapiens hsa00240 61/105 0.004137115 0.180640379 0.008923645 0.372243492 -1.652908426 2.828534718
TNF signaling pathway
Homo sapiens hsa04668 62/110 0.009576391 0.279630609 0.013287333 0.484987638 -1.672329193 2.131025345
Epstein-Barr virus infection
Homo sapiens hsa05169 107/202 0.011613617 0.308288747 0.006274318 0.366420156 -1.701033337 2.001637304
Proteasome Homo sapiens hsa03050 28/44 0.009137396 0.279630609 0.030335664 0.555387316 -1.37701027 1.754704634
Base excision repair
Homo sapiens hsa03410 22/33 0.009327733 0.279630609 0.037348407 0.555387316 -1.178095782 1.501230727
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Infectious disease Homo sapiens
R-HSA-5663205 210/348 3.06872E-09 7.03286E-07 2.62789E-07 0.00039576 -2.368730796 33.55899794
Eukaryotic Translation Elongation
Homo sapiens R-HSA-156842 68/89 1.17069E-09 7.03286E-07 2.4763E-05 0.003818097 -2.008387964 28.45384019
rRNA processing Homo sapiens
R-HSA-72312 120/180 2.38445E-09 7.03286E-07 3.6581E-06 0.002754552 -2.004201911 28.39453428
Peptide chain elongation Homo sapiens
R-HSA-156902 65/84 1.06954E-09 7.03286E-07 2.82233E-05 0.003818097 -1.965461354 27.84567736
Formation of a pool of free 40S subunits
Homo sapiens R-HSA-72689 72/96 1.62274E-09 7.03286E-07 2.23632E-05 0.003818097 -1.941052342 27.49986265
Cap-dependent Translation Initiation
Homo sapiens R-HSA-72737 82/114 3.73592E-09 7.03286E-07 1.84552E-05 0.003818097 -1.939670905 27.48029114
Eukaryotic Translation Initiation
Homo sapiens R-HSA-72613 82/114 3.73592E-09 7.03286E-07 1.84552E-05 0.003818097 -1.931022481 27.35776457
Major pathway of rRNA processing in the
nucleolus Homo sapiens R-HSA-6791226 111/166 7.23614E-09 1.21085E-06 7.59972E-06 0.00381506 -1.982525455 27.0103036
Eukaryotic Translation Termination
Homo sapiens R-HSA-72764 66/87 3.44592E-09 7.03286E-07 3.77586E-05 0.003818097 -1.879954752 26.63426243
Nonsense Mediated Decay (NMD)
independent of the Exon Junction
Complex (EJC) Homo sapiens
R-HSA-975956
66/89 1.68554E-08 1.63909E-06 6.13216E-05 0.00486054 -1.862683657 24.81350144
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Ribosome Homo sapiens hsa03010 101/137 5.23703E-12 1.52921E-09 1.08251E-06 0.000316093 -1.746138049 35.44400421
Spliceosome Homo sapiens hsa03040 89/134 3.44946E-07 5.03621E-05 7.77281E-05 0.011348299 -1.77196951 17.53589228
Fructose and mannose metabolism
Homo sapiens hsa00051 25/32 0.000125783 0.012242902 0.00762193 0.370933912 -1.55094245 6.828503249
Huntington’s disease
Homo sapiens hsa05016 110/193 0.000419006 0.030587457 0.000959826 0.093423109 -1.826574114 6.369565818
Oxidative phosphorylation
Homo sapiens hsa00190 76/133 0.002751738 0.160701494 0.005204621 0.366420156 -1.724055636 3.151930079
Pyrimidine metabolism
Homo sapiens hsa00240 61/105 0.004137115 0.180640379 0.008923645 0.372243492 -1.652908426 2.828534718
TNF signaling pathway
Homo sapiens hsa04668 62/110 0.009576391 0.279630609 0.013287333 0.484987638 -1.672329193 2.131025345
Epstein-Barr virus infection
Homo sapiens hsa05169 107/202 0.011613617 0.308288747 0.006274318 0.366420156 -1.701033337 2.001637304
Proteasome
Homo sapiens hsa03050 28/44 0.009137396 0.279630609 0.030335664 0.555387316 -1.37701027 1.754704634
Base excision repair
Homo sapiens hsa03410 22/33 0.009327733 0.279630609 0.037348407 0.555387316 -1.178095782 1.501230727
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Huntington disease Homo sapiens
P00029 69/124 0.009678337 0.358098456 0.032565816 0.99580555 -1.459003251 1.498319468
Glycolysis
Homo sapiens P00024 13/17 0.00821785 0.358098456 0.075444228 0.99580555 -1.056996395 1.085479608
Mannose metabolism
Homo sapiens P02752 06-Jun 0.008077308 0.358098456 0.110722342 0.99580555 -1.008891743 1.036078665
Parkinson disease
Homo sapiens P00049 45/81 0.033334402 0.41112429 0.075903745 0.99580555 -0.714215843 0.634837682
De novo purine biosynthesis
Homo sapiens P02738 17/26 0.02789128 0.386991515 0.103273668 0.99580555 -0.09669066 0.091793521
Apoptosis signaling pathway
Homo sapiens P00006 53/102 0.087507397 0.883029192 0.114861677 0.99580555 -0.676005058 0.084093014
Cytoskeletal regulation by Rho
GTPase Homo sapiens P00016 37/70 0.108200266 0.92386381 0.147399165 0.99580555 -0.190407529 0.015078488
Integrin signalling pathway
Homo sapiens P00034 74/156 0.279126566 0.99992324 0.203683171 0.99580555 0.606925854 -4.65894E-05
Blood coagulation
Homo sapiens P00011 20/38 0.209021966 0.99992324 0.244374558 0.99580555 0.89060768 -6.83657E-05
Toll receptor signaling pathway
Homo sapiens P00054 25/49 0.231290334 0.99992324 0.246989832 0.99580555 0.97075554 -7.45181E-05
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Huntington disease Homo sapiens
P00029 69/124 0.009678337 0.358098456 0.032565816 0.99580555 -1.459003251 1.498319468
Glycolysis
Homo sapiens P00024 13/17 0.00821785 0.358098456 0.075444228 0.99580555 -1.056996395 1.085479608
Mannose metabolism
Homo sapiens P02752 06-Jun 0.008077308 0.358098456 0.110722342 0.99580555 -1.008891743 1.036078665
Parkinson disease
Homo sapiens P00049 45/81 0.033334402 0.41112429 0.075903745 0.99580555 -0.714215843 0.634837682
De novo purine biosynthesis
Homo sapiens P02738 17/26 0.02789128 0.386991515 0.103273668 0.99580555 -0.09669066 0.091793521
Apoptosis signaling pathway
Homo sapiens P00006 53/102 0.087507397 0.883029192 0.114861677 0.99580555 -0.676005058 0.084093014
Cytoskeletal regulation by Rho
GTPase Homo sapiens P00016 37/70 0.108200266 0.92386381 0.147399165 0.99580555 -0.190407529 0.015078488
Integrin signalling pathway
Homo sapiens P00034 74/156 0.279126566 0.99992324 0.203683171 0.99580555 0.606925854 -4.65894E-05
Blood coagulation
Homo sapiens P00011 20/38 0.209021966 0.99992324 0.244374558 0.99580555 0.89060768 -6.83657E-05
Toll receptor signaling pathway
Homo sapiens P00054 25/49 0.231290334 0.99992324 0.246989832 0.99580555 0.97075554 -7.45181E-05
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Homologous DNA Pairing and Strand
Exchange Homo sapiens
R-HSA-5693579
33/42 1.35786E-05 0.012268241 0.002214407 0.256360162 -2.150062576 9.461869426
Presynaptic phase of homologous DNA
pairing and strand exchange
Homo sapiens R-HSA-5693616
31/39 1.63033E-05 0.012268241 0.002626843 0.28238563 -2.116898092 9.315921104
Mitotic Prometaphase
Homo sapiens R-HSA-68877 70/107 2.94451E-05 0.014771646 0.000589317 0.159346453 -2.032383599 8.566589857
Resolution of Sister Chromatid Cohesion
Homo sapiens R-HSA-2500257 65/99 4.73832E-05 0.017827915 0.000848069 0.159346453 -2.064423139 8.313410887
Nuclear Pore Complex (NPC) Disassembly
Homo sapiens R-HSA-3301854 26/34 0.00025457 0.067761606 0.007901028 0.503811279 -2.161900365 5.819315901
Resolution of D-loop Structures through
Synthesis-Dependent Strand Annealing
(SDSA) Homo sapiens R-HSA-5693554
21/26 0.000270146 0.067761606 0.010797081 0.541653561 -2.023745338 5.447435791
Generic Transcription Pathway Homo sapiens
R-HSA-212436 419/812 0.000321913 0.069211402 7.80122E-07 0.001174084 -2.21539766 5.916418073
NS1 Mediated Effects on Host Pathways
Homo sapiens R-HSA-168276 28/39 0.000860423 0.161866993 0.010681099 0.541653561 -2.128454739 3.875874173
Branched-chain amino acid catabolism
Homo sapiens R-HSA-70895 18/23 0.001502051 0.251176373 0.021472843 0.719285486 -2.049153276 2.831109969
Transport of Ribonucleoproteins into the
Host Nucleus Homo sapiens R-HSA-168271 22/30 0.001991403 0.272390972 0.018959846 0.711796498 -1.961893148 2.551475094
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Homo sapiens WP1971 32/48 0.002707704 0.809187378 0.006865658 0.739774697 -2.009492422 0.425459324
Retinoblastoma (RB) in Cancer
Homo sapiens WP2446 54/90 0.00436095 0.809187378 0.003050389 0.657358867 -1.925101836 0.407591746
Integrated Breast Cancer Pathway
Homo sapiens WP1984 87/155 0.005632395 0.809187378 0.000975001 0.420225539 -2.127329909 0.450408439
Sphingolipid Metabolism
Homo sapiens WP1422 14/20 0.02475276 1 0.048798684 0.86872574 -1.583707823 3.13571E-10
miRNA regulation of DNA Damage
Response Mus musculus WP2087 37/64 0.034208996 1 0.01891683 0.86872574 -1.861744519 3.68622E-10
DNA Damage Response
Homo sapiens WP707 39/68 0.035150165 1 0.017754816 0.86872574 -1.900460742 3.76288E-10
TGF-beta Signaling Pathway
Homo sapiens WP366 71/132 0.037178195 1 0.005902796 0.739774697 -1.852717473 3.66835E-10
Apoptosis Modulation by HSP70
Homo sapiens WP384 13/19 0.03902709 1 0.062750749 0.86872574 -1.414082763 2.79986E-10
Amino Acid metabolism
Mus musculus WP662 48/92 0.125725356 1 0.029986198 0.86872574 -1.386201539 2.74466E-10
EGF/EGFR Signaling Pathway
Homo sapiens WP437 81/163 0.170358418 1 0.014947435 0.86872574 -1.331331993 2.63601E-10
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pathway Homo sapiens P00035 19/28 0.014974154 0.842985146 0.045082357 0.942152799 -1.454104809 0.248369741
p53 pathway feedback loops 2
Homo sapiens P04398 28/45 0.018846605 0.842985146 0.035472243 0.942152799 -1.535525583 0.262276893
Vasopressin synthesis
Homo sapiens P04395 8/10 0.030263436 0.842985146 0.102598617 0.942152799 -0.414769187 0.070845041
Ubiquitin proteasome pathway
Homo sapiens P00060 26/43 0.03653362 0.842985146 0.051722883 0.942152799 -1.074471106 0.183526049
DNA replication Homo sapiens
P00017 13/19 0.03902709 0.842985146 0.085879676 0.942152799 -0.207873651 0.035506055
FAS signaling pathway Homo sapiens
P00020 19/31 0.058948927 0.890199843 0.081752291 0.942152799 -0.692757605 0.080574151
p53 pathway Homo sapiens P00059 39/71 0.07418332 0.890199843 0.05273086 0.942152799 -0.717019375 0.08339602
Transcription regulation by bZIP
transcription factor Homo sapiens
P00055
23/42 0.152219512 0.999985854 0.120096529 0.942152799 -0.084844636 1.20018E-06
PDGF signaling pathway
Homo sapiens P00047 55/112 0.262609674 0.999985854 0.091242135 0.942152799 -0.218250058 3.08729E-06
EGF receptor signaling pathway
Homo sapiens P00018 53/109 0.300505988 0.999985854 0.10608284 0.942152799 0.09503699 -1.34436E-06
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Homo sapiens hsa04120 89/137 4.01689E-06 0.00117695 2.17262E-05 0.006365782 -1.645025777 11.09541754
Valine, leucine and isoleucine
degradation Homo sapiens hsa00280 33/48 0.001045435 0.114032247 0.004389122 0.336001534 -1.973149212 4.284247578
Lysosome Homo sapiens hsa04142 73/123 0.001556754 0.114032247 0.000807335 0.118274636 -1.699249096 3.689535378
Protein export Homo sapiens hsa03060 18/23 0.001502051 0.114032247 0.013439873 0.366851759 -1.479036126 3.211392682
Propanoate metabolism Homo sapiens
hsa00640 23/32 0.002440072 0.119156838 0.011168218 0.366851759 -1.505727714 3.203156686
Glycosylphosphatidylinositol(GPI)-anchor
biosynthesis Homo sapiens hsa00563 19/25 0.002036014 0.119156838 0.013772592 0.366851759 -1.275723187 2.713864676
Fanconi anemia pathway Homo sapiens
hsa03460 34/53 0.00516358 0.216132715 0.008259153 0.366851759 -1.53066026 2.344761261
Sphingolipid metabolism Homo sapiens
hsa00600 30/47 0.009301728 0.340675795 0.013212076 0.366851759 -1.627989953 1.753058655
FoxO signaling pathway Homo sapiens
hsa04068 72/133 0.030583504 0.814633342 0.005032849 0.336001534 -1.572113954 0.322310329
Ubiquinone and other terpenoid-quinone
biosynthesis Homo sapiens hsa00130 09-Nov 0.016589164 0.540069436 0.061384329 0.72793414 -0.271127945 0.167030421
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Homologous DNA Pairing and Strand
Exchange Homo sapiens R-HSA-5693579 33/42 1.35786E-05 0.012268241 0.002214407 0.256360162 -2.150062576 9.461869426
Presynaptic phase of homologous DNA
pairing and strand exchange Homo
sapiens R-HSA-5693616
31/39 1.63033E-05 0.012268241 0.002626843 0.28238563 -2.116898092 9.315921104
Mitotic Prometaphase Homo sapiens
R-HSA-68877 70/107 2.94451E-05 0.014771646 0.000589317 0.159346453 -2.032383599 8.566589857
Resolution of Sister Chromatid Cohesion
Homo sapiens R-HSA-2500257 65/99 4.73832E-05 0.017827915 0.000848069 0.159346453 -2.064423139 8.313410887
Generic Transcription Pathway Homo sapiens
R-HSA-212436 419/812 0.000321913 0.069211402 7.80122E-07 0.001174084 -2.21539766 5.916418073
Nuclear Pore Complex (NPC) Disassembly
Homo sapiens R-HSA-3301854 26/34 0.00025457 0.067761606 0.007901028 0.503811279 -2.161900365 5.819315901
Resolution of D-loop Structures through
Synthesis-Dependent Strand Annealing
(SDSA) Homo sapiens R-HSA-5693554
21/26 0.000270146 0.067761606 0.010797081 0.541653561 -2.023745338 5.447435791
NS1 Mediated Effects on Host Pathways
Homo sapiens R-HSA-168276 28/39 0.000860423 0.161866993 0.010681099 0.541653561 -2.128454739 3.875874173
Branched-chain amino acid catabolism
Homo sapiens R-HSA-70895 18/23 0.001502051 0.251176373 0.021472843 0.719285486 -2.049153276 2.831109969
Transport of Ribonucleoproteins into the
Host Nucleus Homo sapiens R-HSA-168271 22/30 0.001991403 0.272390972 0.018959846 0.711796498 -1.97866224 2.573283581
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Integrated Breast Cancer Pathway
Homo sapiens WP1984 87/155 0.005632395 0.809187378 0.000975001 0.420225539 -2.127329909 0.450408439
Integrated Cancer Pathway
Homo sapiens WP1971 32/48 0.002707704 0.809187378 0.006865658 0.739774697 -2.009492422 0.425459324
Retinoblastoma (RB) in Cancer
Homo sapiens WP2446 54/90 0.00436095 0.809187378 0.003050389 0.657358867 -1.925101836 0.407591746
DNA Damage Response
Homo sapiens WP707 39/68 0.035150165 1 0.017754816 0.86872574 -1.900460742 3.76288E-10
miRNA regulation of DNA Damage
Response Mus musculus WP2087 37/64 0.034208996 1 0.01891683 0.86872574 -1.861744519 3.68622E-10
TGF-beta Signaling Pathway
Homo sapiens WP366 71/132 0.037178195 1 0.005902796 0.739774697 -1.852717473 3.66835E-10
Sphingolipid Metabolism
Homo sapiens WP1422 14/20 0.02475276 1 0.048798684 0.86872574 -1.583707823 3.13571E-10
Apoptosis Modulation by HSP70
Homo sapiens WP384 13/19 0.03902709 1 0.062750749 0.86872574 -1.414082763 2.79986E-10
Amino Acid metabolism
Mus musculus WP662 48/92 0.125725356 1 0.029986198 0.86872574 -1.386201539 2.74466E-10
EGF/EGFR Signaling Pathway
Homo sapiens WP437 81/163 0.170358418 1 0.014947435 0.86872574 -1.331331993 2.63601E-10
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p53 pathway feedback loops 2
Homo sapiens P04398 28/45 0.018846605 0.842985146 0.035472243 0.942152799 -1.535525583 0.262276893
Interferon-gamma signaling pathway
Homo sapiens P00035 19/28 0.014974154 0.842985146 0.045082357 0.942152799 -1.454104809 0.248369741
Ubiquitin proteasome pathway
Homo sapiens P00060 26/43 0.03653362 0.842985146 0.051722883 0.942152799 -1.074471106 0.183526049
p53 pathway Homo sapiens P00059 39/71 0.07418332 0.890199843 0.05273086 0.942152799 -0.717019375 0.08339602
FAS signaling pathway
Homo sapiens P00020 19/31 0.058948927 0.890199843 0.081752291 0.942152799 -0.692757605 0.080574151
Vasopressin synthesis
Homo sapiens P04395 8/10 0.030263436 0.842985146 0.102598617 0.942152799 -0.414769187 0.070845041
DNA replication
Homo sapiens P00017 13/19 0.03902709 0.842985146 0.085879676 0.942152799 -0.207873651 0.035506055
PDGF signaling pathway
Homo sapiens P00047 55/112 0.262609674 0.999985854 0.091242135 0.942152799 -0.218250058 3.08729E-06
Transcription regulation by bZIP
transcription factor Homo sapiens P00055 23/42 0.152219512 0.999985854 0.120096529 0.942152799 -0.084844636 1.20018E-06
EGF receptor signaling pathway
Homo sapiens P00018 53/109 0.300505988 0.999985854 0.10608284 0.942152799 0.09503699 -1.34436E-06
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Ribosome Homo sapiens hsa03010 96/137 4.95032E-06 0.001450443 1.36084E-05 0.003987267 -1.746138049 11.41255979
Spliceosome Homo sapiens hsa03040 87/134 0.000863141 0.126450192 0.000229518 0.033624441 -1.77196951 3.664267773
Non-alcoholic fatty liver disease (NAFLD)
Homo sapiens hsa04932 86/151 0.088857304 1 0.004353338 0.31888203 -1.83402353 5.3371E-11
RNA polymerase Homo sapiens hsa03020 22/32 0.033692559 1 0.033331699 0.65107919 -1.81944086 5.29466E-11
Ribosome biogenesis in eukaryotes
Homo sapiens hsa03008 51/89 0.145710455 1 0.022244928 0.538657626 -1.804099388 5.25002E-11
Huntington’s disease Homo sapiens
hsa05016 109/193 0.078943834 1 0.00178487 0.174322302 -1.801778075 5.24326E-11
Proteasome Homo sapiens hsa03050 29/44 0.034502412 1 0.023284581 0.538657626 -1.584085426 4.60977E-11
Chronic myeloid leukemia Homo sapiens
hsa05220 41/73 0.230260077 1 0.045619066 0.74257702 -1.544697267 4.49515E-11
Oxidative phosphorylation Homo sapiens
hsa00190 73/133 0.219421874 1 0.014971049 0.538657626 -1.542795911 4.48961E-11
Aminoacyl-tRNA biosynthesis Homo sapiens
hsa00970 37/66 0.250588619 1 0.056326156 0.849889713 -1.5388376 4.47809E-11
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rRNA processing Homo sapiens R-HSA-72312 131/180 2.27506E-09 3.45354E-06 5.26191E-07 0.000399379 -2.027505558 25.49813675
Major pathway of rRNA processing in the
nucleolus Homo sapiens R-HSA-6791226 120/166 2.03308E-08 1.54311E-05 1.97863E-06 0.001001185 -2.037037884 22.56860138
Processing of Capped Intron-Containing
Pre-mRNA Homo sapiens R-HSA-72203 129/193 6.85401E-06 0.002601099 1.37825E-05 0.005230441 -2.13325627 12.69676025
Formation of a pool of free 40S subunits
Homo sapiens R-HSA-72689 71/96 3.98195E-06 0.002014865 0.000142834 0.018418939 -1.941052342 12.04850649
Influenza Viral RNA Transcription and
Replication Homo sapiens R-HSA-168273 89/128 1.76486E-05 0.002726863 0.000107584 0.01814589 -2.01559186 11.90127049
Influenza Infection Homo sapiens
R-HSA-168254 100/147 2.36978E-05 0.003214243 7.62964E-05 0.016738192 -2.001151063 11.48693394
mRNA Splicing - Major Pathway Homo sapiens
R-HSA-72163 93/134 1.29894E-05 0.002726863 7.99621E-05 0.016738192 -1.940469769 11.45770434
Peptide chain elongation Homo sapiens
R-HSA-156902 62/84 1.79635E-05 0.002726863 0.000379598 0.026045385 -1.884299625 11.12604192
Selenocysteine synthesis Homo sapiens
R-HSA-2408557 64/87 1.58412E-05 0.002726863 0.000328614 0.024941768 -1.879014764 11.09483691
Nonsense-Mediated Decay (NMD)
Homo sapiens R-HSA-927802 76/106 1.26674E-05 0.002726863 0.000169872 0.018418939 -1.870115837 11.04229227
316










mRNA processing Mus musculus WP310 243/398 3.84669E-05 0.01665616 1.36293E-06 0.000590147 -2.13612911 8.747395616
Cytoplasmic Ribosomal Proteins
Homo sapiens WP477 63/89 0.000126924 0.01831931 0.001056719 0.152519803 -1.953073984 7.811904515
mRNA Processing Homo sapiens WP411 86/127 0.000110455 0.01831931 0.000405397 0.087768357 -1.941057273 7.763840078
Cytoplasmic Ribosomal Proteins
Mus musculus WP163 48/70 0.0023339 0.252644628 0.006058257 0.524645064 -1.940461432 2.669631364
Estrogen signalling Mus musculus WP1244 50/75 0.004704345 0.407396275 0.007567885 0.546149015 -1.900182655 1.706304963
PluriNetWork Mus musculus WP1763 160/284 0.044704656 1 0.001428018 0.154582935 -1.846398794 2.9766E-11
TNF-alpha NF-kB Signaling Pathway
Mus musculus WP246 101/179 0.090133597 1 0.009746518 0.60289176 -1.820647406 2.93508E-11
Eukaryotic Transcription Initiation
Mus musculus WP567 28/41 0.019822993 1 0.03218215 0.972118652 -1.793666737 2.89159E-11
RANKL/RANK Signaling Pathway
Homo sapiens WP2018 35/55 0.042263909 1 0.035290413 0.972118652 -1.775492764 2.86229E-11
TOR Signaling Homo sapiens WP1471 25/36 0.02024715 1 0.036687478 0.972118652 -1.768534897 2.85107E-11
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29/43 0.02274452 0.999998914 0.041532694 0.835048813 -1.439435008 1.56307E-06
Alpha adrenergic receptor signaling pathway
Homo sapiens P00002
15/23 0.126762421 0.999998914 0.140788295 0.835048813 -1.036031797 1.12502E-06
p53 pathway Homo sapiens P00059 39/71 0.303044048 0.999998914 0.131116039 0.835048813 -0.920706371 9.99785E-07
Oxytocin receptor mediated signaling
pathway Homo sapiens P04391
22/39 0.310711232 0.999998914 0.190410543 0.835048813 -0.851255657 9.2437E-07
Thyrotropin-releasing hormone receptor
signaling pathway Homo sapiens P04394
23/41 0.317610873 0.999998914 0.188897352 0.835048813 -0.828333458 8.99479E-07
p53 pathway by glucose deprivation
Homo sapiens P04397
15/21 0.049011697 0.999998914 0.094254695 0.835048813 -0.795947666 8.64311E-07
Parkinson disease Homo sapiens P00049 44/81 0.323850574 0.999998914 0.125440002 0.835048813 -0.612006508 6.64571E-07
p53 pathway feedback loops 2
Homo sapiens P04398
24/45 0.444080264 0.999998914 0.236001463 0.835048813 -0.199277098 2.16393E-07
mRNA splicing Homo sapiens P00058 5/5 0.035047544 0.999998914 0.152895645 0.835048813 -0.11767251 1.27779E-07
Apoptosis signaling pathway
Homo sapiens P00006
53/102 0.475645266 0.999998914 0.151536452 0.835048813 0.141395881 -1.5354E-07
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Ribosome Homo sapiens hsa03010 96/137 4.95032E-06 0.001450443 1.36084E-05 0.003987267 -1.746138049 11.41255979
Spliceosome Homo sapiens hsa03040 87/134 0.000863141 0.126450192 0.000229518 0.033624441 -1.77196951 3.664267773
Non-alcoholic fatty liver disease (NAFLD)
Homo sapiens hsa04932
86/151 0.088857304 1 0.004353338 0.31888203 -1.83402353 5.3371E-11
RNA polymerase Homo sapiens hsa03020 22/32 0.033692559 1 0.033331699 0.65107919 -1.81944086 5.29466E-11
Ribosome biogenesis in eukaryotes
Homo sapiens hsa03008
51/89 0.145710455 1 0.022244928 0.538657626 -1.804099388 5.25002E-11
Huntington’s disease Homo sapiens hsa05016 109/193 0.078943834 1 0.00178487 0.174322302 -1.801778075 5.24326E-11
Proteasome Homo sapiens hsa03050 29/44 0.034502412 1 0.023284581 0.538657626 -1.584085426 4.60977E-11
Chronic myeloid leukemia
Homo sapiens hsa05220
41/73 0.230260077 1 0.045619066 0.74257702 -1.544697267 4.49515E-11
Oxidative phosphorylation
Homo sapiens hsa00190
73/133 0.219421874 1 0.014971049 0.538657626 -1.542795911 4.48961E-11
Aminoacyl-tRNA biosynthesis
Homo sapiens hsa00970
37/66 0.250588619 1 0.056326156 0.849889713 -1.5388376 4.47809E-11
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rRNA processing Homo sapiens R-HSA-72312 131/180 2.27506E-09 3.45354E-06 5.26191E-07 0.000399379 -2.027505558 25.49813675
Major pathway of rRNA processing in the
nucleolus Homo sapiens R-HSA-6791226 120/166 2.03308E-08 1.54311E-05 1.97863E-06 0.001001185 -2.037037884 22.56860138
Processing of Capped Intron-Containing
Pre-mRNA Homo sapiens R-HSA-72203 129/193 6.85401E-06 0.002601099 1.37825E-05 0.005230441 -2.13325627 12.69676025
Formation of a pool of free 40S subunits
Homo sapiens R-HSA-72689 71/96 3.98195E-06 0.002014865 0.000142834 0.018418939 -1.941052342 12.04850649
Influenza Viral RNA Transcription and
Replication Homo sapiens R-HSA-168273 89/128 1.76486E-05 0.002726863 0.000107584 0.01814589 -2.01559186 11.90127049
Influenza Infection Homo sapiens
R-HSA-168254 100/147 2.36978E-05 0.003214243 7.62964E-05 0.016738192 -2.001151063 11.48693394
mRNA Splicing - Major Pathway
Homo sapiens R-HSA-72163 93/134 1.29894E-05 0.002726863 7.99621E-05 0.016738192 -1.940469769 11.45770434
Peptide chain elongation Homo sapiens
R-HSA-156902 62/84 1.79635E-05 0.002726863 0.000379598 0.026045385 -1.884299625 11.12604192
Selenocysteine synthesis Homo sapiens
R-HSA-2408557 64/87 1.58412E-05 0.002726863 0.000328614 0.024941768 -1.879014764 11.09483691
Nonsense-Mediated Decay (NMD)
Homo sapiens R-HSA-927802 76/106 1.26674E-05 0.002726863 0.000169872 0.018418939 -1.870115837 11.04229227
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mRNA processing Mus musculus
WP310 243/398 3.84669E-05 0.01665616 1.36293E-06 0.000590147 -2.13612911 8.747395616
Cytoplasmic Ribosomal Proteins
Homo sapiens WP477 63/89 0.000126924 0.01831931 0.001056719 0.152519803 -1.953073984 7.811904515
mRNA Processing Homo sapiens WP411 86/127 0.000110455 0.01831931 0.000405397 0.087768357 -1.941057273 7.763840078
Cytoplasmic Ribosomal Proteins
Mus musculus WP163 48/70 0.0023339 0.252644628 0.006058257 0.524645064 -1.940461432 2.669631364
Estrogen signalling Mus musculus WP1244 50/75 0.004704345 0.407396275 0.007567885 0.546149015 -1.900182655 1.706304963
PluriNetWork Mus musculus WP1763 160/284 0.044704656 1 0.001428018 0.154582935 -1.846398794 2.9766E-11
TNF-alpha NF-kB Signaling Pathway
Mus musculus WP246 101/179 0.090133597 1 0.009746518 0.60289176 -1.820647406 2.93508E-11
Eukaryotic Transcription Initiation
Mus musculus WP567 28/41 0.019822993 1 0.03218215 0.972118652 -1.793666737 2.89159E-11
RANKL/RANK Signaling Pathway
Homo sapiens WP2018 35/55 0.042263909 1 0.035290413 0.972118652 -1.775492764 2.86229E-11
TOR Signaling Homo sapiens WP1471 25/36 0.02024715 1 0.036687478 0.972118652 -1.768534897 2.85107E-11
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Homo sapiens P00060 29/43 0.02274452 0.999998914 0.041532694 0.835048813 -1.439435008 1.56307E-06
Alpha adrenergic receptor signaling
pathway Homo sapiens P00002 15/23 0.126762421 0.999998914 0.140788295 0.835048813 -1.036031797 1.12502E-06
p53 pathway Homo sapiens P00059 39/71 0.303044048 0.999998914 0.131116039 0.835048813 -0.920706371 9.99785E-07
Oxytocin receptor mediated signaling
pathway Homo sapiens P04391 22/39 0.310711232 0.999998914 0.190410543 0.835048813 -0.851255657 9.2437E-07
Thyrotropin-releasing hormone receptor
signaling pathway Homo sapiens P04394 23/41 0.317610873 0.999998914 0.188897352 0.835048813 -0.828333458 8.99479E-07
p53 pathway by glucose deprivation
Homo sapiens P04397 15/21 0.049011697 0.999998914 0.094254695 0.835048813 -0.795947666 8.64311E-07
Parkinson disease Homo sapiens P00049 44/81 0.323850574 0.999998914 0.125440002 0.835048813 -0.612006508 6.64571E-07
p53 pathway feedback loops 2
Homo sapiens P04398 24/45 0.444080264 0.999998914 0.236001463 0.835048813 -0.199277098 2.16393E-07
mRNA splicing Homo sapiens P00058 5/5 0.035047544 0.999998914 0.152895645 0.835048813 -0.11767251 1.27779E-07
Apoptosis signaling pathway
Homo sapiens P00006 53/102 0.475645266 0.999998914 0.151536452 0.835048813 0.141395881 -1.5354E-07
5HT2 type receptor mediated signaling
pathway Homo sapiens P04374 24/46 0.504681112 0.999998914 0.262239554 0.835048813 0.30674461 -3.33091E-07
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Homo sapiens hsa03010 126/137 6.91217E-28 2.01144E-25 1.73597E-12 5.05167E-10 -1.746138049 99.29549519
Spliceosome
Homo sapiens hsa03040 93/134 7.21871E-07 0.000105032 1.04478E-05 0.001013441 -1.77196951 16.23344317
RNA transport
Homo sapiens hsa03013 113/172 3.68639E-06 0.000343204 7.65662E-06 0.001013441 -1.818646653 14.50768105
Cell cycle
Homo sapiens hsa04110 85/124 4.71758E-06 0.000343204 3.41195E-05 0.002482194 -1.65735888 13.22105862
DNA replication
Homo sapiens hsa03030 28/36 0.000312529 0.018189207 0.004386834 0.208830265 -1.737606889 6.96246373
Parkinson’s disease
Homo sapiens hsa05012 85/142 0.004169887 0.188152262 0.000885631 0.051543725 -1.648540408 2.75389292
Basal transcription factors
Homo sapiens hsa03022 31/45 0.004525999 0.188152262 0.009667627 0.281327937 -1.588514154 2.653618839
Nucleotide excision repair
Homo sapiens hsa03420 31/47 0.01185013 0.431048489 0.01468285 0.356059106 -1.562454789 1.314859908
Pyrimidine metabolism
Homo sapiens hsa00240 62/105 0.019106127 0.617764785 0.005152126 0.208830265 -1.571024109 0.756679837
Ribosome biogenesis in eukaryotes
Homo sapiens hsa03008 52/89 0.038113023 1 0.011322068 0.299520152 -1.709146788 2.16099E-10
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GTP hydrolysis and joining of the
60S ribosomal subunit Homo sapiens
R-HSA-72706
100/107 7.97753E-24 3.34581E-21 3.01917E-09 4.31302E-07 -2.009041336
Eukaryotic Translation Elongation
Homo sapiens R-HSA-156842 86/89 1.25722E-23 3.34581E-21 1.38372E-08 1.23314E-06 -1.999543502
Formation of a pool of free 40S subunits
Homo sapiens R-HSA-72689 92/96 2.4287E-24 3.34581E-21 5.70686E-09 5.76393E-07 -1.957868628
Peptide chain elongation Homo sapiens
R-HSA-156902 82/84 1.3589E-23 3.34581E-21 2.22101E-08 1.68241E-06 -1.929389474
3’ -UTR-mediated translational regulation
Homo sapiens R-HSA-157279 99/106 1.54592E-23 3.34581E-21 3.70094E-09 4.31302E-07 -1.920146677
L13a-mediated translational silencing of
Ceruloplasmin expression Homo sapiens
R-HSA-156827
99/106 1.54592E-23 3.34581E-21 3.70094E-09 4.31302E-07 -1.912399155
Viral mRNA Translation Homo sapiens
R-HSA-192823 82/84 1.3589E-23 3.34581E-21 2.22101E-08 1.68241E-06 -1.891750904
Translation Homo sapiens R-HSA-72766 130/151 2.76224E-22 3.80436E-20 5.03854E-10 1.52668E-07 -1.958454231
Eukaryotic Translation Initiation
Homo sapiens R-HSA-72613 104/114 1.60554E-22 2.43239E-20 3.4968E-09 4.31302E-07 -1.923012872
Cap-dependent Translation Initiation
Homo sapiens R-HSA-72737 104/114 1.60554E-22 2.43239E-20 3.4968E-09 4.31302E-07 -1.915641643
325











Homo sapiens WP477 83/89 8.18475E-20 3.51944E-17 4.54913E-08 1.95613E-05 -2.0113747 76.20222514
Cytoplasmic Ribosomal Proteins
Mus musculus WP163 67/70 6.16048E-18 1.3245E-15 4.82532E-07 6.9163E-05 -2.003293795 68.62831615
mRNA processing Mus musculus WP310 243/398 2.52258E-07 3.61569E-05 1.75486E-07 3.77294E-05 -2.085306546 21.32776806
G1 to S cell cycle control
Mus musculus WP413 45/60 2.53034E-05 0.002720119 0.001446587 0.119065727 -1.940011093 11.45979987
DNA Replication Mus musculus WP150 32/40 4.2154E-05 0.003094645 0.003396209 0.171748397 -1.969978797 11.38269947
DNA Replication Homo sapiens WP466 33/42 6.26473E-05 0.003581782 0.003594734 0.171748397 -1.897031669 10.68388286
mRNA Processing Homo sapiens WP411 84/127 4.31811E-05 0.003094645 0.000357236 0.038402881 -1.834512826 10.59996595
G1 to S cell cycle control Homo sapiens WP45 49/68 6.66378E-05 0.003581782 0.001661382 0.119065727 -1.840388461 10.36487426
Eukaryotic Transcription Initiation
Mus musculus WP567 32/41 0.000102539 0.004899086 0.004401732 0.189274472 -1.65644524 8.810146393
Eukaryotic Transcription Initiation
Homo sapiens WP405 33/44 0.000307395 0.013217998 0.005890253 0.230255351 -1.74801357 7.562214112
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De novo purine biosynthesis
Homo sapiens P02738
21/26 0.000746254 0.081341683 0.014467927 0.788502013 -1.358444089
General transcription regulation
Homo sapiens P00023
21/28 0.00395651 0.215629787 0.024367679 0.885358993 -1.172366804
Parkinson disease Homo sapiens P00049 50/81 0.011280384 0.307390454 0.011833181 0.788502013 -1.225262519
DNA replication Homo sapiens P00017 15/19 0.00671703 0.244052075 0.040747569 0.938002313 -0.783523762
p53 pathway by glucose deprivation
Homo sapiens P04397
15/21 0.028789294 0.523005512 0.067355288 0.938002313 -0.20233436
Transcription regulation by bZIP
transcription factor
Homo sapiens P00055
25/42 0.100797916 0.999970119 0.081674827 0.938002313 -0.569379066
p53 pathway Homo sapiens P00059 38/71 0.232919593 0.999970119 0.097854295 0.938002313 -0.513332379
p53 pathway feedback loops 2
Homo sapiens P04398
24/45 0.308331551 0.999970119 0.166980689 0.938002313 -0.199277098
Cytoskeletal regulation by Rho GTPase
Homo sapiens P00016
35/70 0.447181621 0.999970119 0.177949311 0.938002313 0.550919768
Ubiquitin proteasome pathway
Homo sapiens P00060
22/43 0.421474418 0.999970119 0.221645709 0.938002313 0.750348403
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Ribosome Homo sapiens hsa03010 126/137 6.91217E-28 2.01144E-25 1.73597E-12 5.05167E-10 -1.746138049 99.29549519
Spliceosome Homo sapiens hsa03040 93/134 7.21871E-07 0.000105032 1.04478E-05 0.001013441 -1.77196951 16.23344317
RNA transport Homo sapiens
hsa03013
113/172 3.68639E-06 0.000343204 7.65662E-06 0.001013441 -1.818646653 14.50768105
Cell cycle Homo sapiens
hsa04110
85/124 4.71758E-06 0.000343204 3.41195E-05 0.002482194 -1.65735888 13.22105862
DNA replication Homo sapiens
hsa03030
28/36 0.000312529 0.018189207 0.004386834 0.208830265 -1.737606889 6.96246373
Parkinson’s disease Homo sapiens
hsa05012
85/142 0.004169887 0.188152262 0.000885631 0.051543725 -1.648540408 2.75389292
Basal transcription factors
Homo sapiens hsa03022
31/45 0.004525999 0.188152262 0.009667627 0.281327937 -1.588514154 2.653618839
Nucleotide excision repair
Homo sapiens hsa03420
31/47 0.01185013 0.431048489 0.01468285 0.356059106 -1.562454789 1.314859908
Pyrimidine metabolism
Homo sapiens hsa00240
62/105 0.019106127 0.617764785 0.005152126 0.208830265 -1.571024109 0.756679837
Ribosome biogenesis in eukaryotes
Homo sapiens hsa03008
52/89 0.038113023 1 0.011322068 0.299520152 -1.709146788 2.16099E-10
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P-value Z-score Combined Score
GTP hydrolysis and joining of the 60S ribosomal
subunit Homo sapiens R-HSA-72706 100/107 7.97753E-24 3.34581E-21 3.01917E-09 4.31302E-07 -2.009041336 94.71942382
Eukaryotic Translation Elongation Homo sapiens
R-HSA-156842 86/89 1.25722E-23 3.34581E-21 1.38372E-08 1.23314E-06 -1.999543502 94.27163347
Formation of a pool of free 40S subunits
Homo sapiens R-HSA-72689 92/96 2.4287E-24 3.34581E-21 5.70686E-09 5.76393E-07 -1.957868628 92.30680578
Peptide chain elongation Homo sapiens
R-HSA-156902 82/84 1.3589E-23 3.34581E-21 2.22101E-08 1.68241E-06 -1.929389474 90.96411111
L13a-mediated translational silencing of
Ceruloplasmin expression Homo sapiens
R-HSA-156827
99/106 1.54592E-23 3.34581E-21 3.70094E-09 4.31302E-07 -1.920612299 90.55029736
3’ -UTR-mediated translational regulation
Homo sapiens R-HSA-157279 99/106 1.54592E-23 3.34581E-21 3.70094E-09 4.31302E-07 -1.911927886 90.14085698
Viral mRNA Translation Homo sapiens
R-HSA-192823 82/84 1.3589E-23 3.34581E-21 2.22101E-08 1.68241E-06 -1.891750904 89.18958133
Translation Homo sapiens R-HSA-72766 130/151 2.76224E-22 3.80436E-20 5.03854E-10 1.52668E-07 -1.958454231 87.57336671
Eukaryotic Translation Initiation
Homo sapiens R-HSA-72613 104/114 1.60554E-22 2.43239E-20 3.4968E-09 4.31302E-07 -1.923012872 86.84869966
Cap-dependent Translation Initiation
Homo sapiens R-HSA-72737 104/114 1.60554E-22 2.43239E-20 3.4968E-09 4.31302E-07 -1.915641643 86.51579411
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83/89 8.18475E-20 3.51944E-17 4.54913E-08 1.95613E-05 -2.0113747
Cytoplasmic Ribosomal Proteins
Mus musculus WP163
67/70 6.16048E-18 1.3245E-15 4.82532E-07 6.9163E-05 -2.003293795
mRNA processing
Mus musculus WP310
243/398 2.52258E-07 3.61569E-05 1.75486E-07 3.77294E-05 -2.085306546
G1 to S cell cycle control
Mus musculus WP413
45/60 2.53034E-05 0.002720119 0.001446587 0.119065727 -1.940011093
DNA Replication
Mus musculus WP150
32/40 4.2154E-05 0.003094645 0.003396209 0.171748397 -1.969978797
DNA Replication
Homo sapiens WP466
33/42 6.26473E-05 0.003581782 0.003594734 0.171748397 -1.897031669
mRNA Processing
Homo sapiens WP411
84/127 4.31811E-05 0.003094645 0.000357236 0.038402881 -1.834512826
G1 to S cell cycle control
Homo sapiens WP45
49/68 6.66378E-05 0.003581782 0.001661382 0.119065727 -1.840388461
Eukaryotic Transcription Initiation
Mus musculus WP567
32/41 0.000102539 0.004899086 0.004401732 0.189274472 -1.65644524
Eukaryotic Transcription Initiation
Homo sapiens WP405
33/44 0.000307395 0.013217998 0.005890253 0.230255351 -1.74801357
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De novo purine biosynthesis
Homo sapiens P02738 21/26 0.000746254 0.081341683 0.014467927 0.788502013 -1.358444089
General transcription regulation
Homo sapiens P00023 21/28 0.00395651 0.215629787 0.024367679 0.885358993 -1.172366804
Parkinson disease
Homo sapiens P00049 50/81 0.011280384 0.307390454 0.011833181 0.788502013 -1.225262519
DNA replication
Homo sapiens P00017 15/19 0.00671703 0.244052075 0.040747569 0.938002313 -0.783523762
p53 pathway by glucose deprivation
Homo sapiens P04397 15/21 0.028789294 0.523005512 0.067355288 0.938002313 -0.20233436
Transcription regulation by bZIP
transcription factor Homo sapiens P00055 25/42 0.100797916 0.999970119 0.081674827 0.938002313 -0.569379066
p53 pathway Homo sapiens P00059 38/71 0.232919593 0.999970119 0.097854295 0.938002313 -0.513332379
p53 pathway feedback loops 2
Homo sapiens P04398 24/45 0.308331551 0.999970119 0.166980689 0.938002313 -0.199277098
Cytoskeletal regulation by Rho GTPase
Homo sapiens P00016 35/70 0.447181621 0.999970119 0.177949311 0.938002313 0.550919768
Ubiquitin proteasome pathway
Homo sapiens P00060 22/43 0.421474418 0.999970119 0.221645709 0.938002313 0.750348403
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Lysosome Homo sapiens hsa04142 88/123 2.24603E-07 6.58087E-05 3.10185E-05 0.009088432 -1.774614657 17.08733556
Amino sugar and nucleotide sugar metabolism
Homo sapiens hsa00520 36/48 0.000187944 0.02753385 0.003805048 0.185813188 -1.81131231 6.506848047
Phosphatidylinositol signaling system
Homo sapiens hsa04070 63/98 0.001373239 0.13411963 0.002682742 0.185813188 -1.810830966 3.638001271
AGE-RAGE signaling pathway in diabetic
complications
Homo sapiens hsa04933
64/101 0.002149576 0.157456456 0.003186436 0.185813188 -1.97638418 3.653556298
Vibrio cholerae infection Homo sapiens
hsa05110 35/51 0.003232521 0.189425719 0.011139313 0.293053561 -1.793071285 2.983237258
Pancreatic cancer Homo sapiens hsa05212 43/66 0.005271749 0.257437075 0.010004555 0.293053561 -1.826072629 2.477943958
Peroxisome Homo sapiens hsa04146 52/83 0.007455075 0.312048134 0.008587533 0.279571907 -1.537014262 1.790003471
Inositol phosphate metabolism Homo sapiens
hsa00562 45/71 0.009181836 0.33628474 0.012002194 0.293053561 -1.710345558 1.863929521
Glycosphingolipid biosynthesis - ganglio series
Homo sapiens hsa00604 Dec-15 0.013806674 0.449483929 0.059285871 0.468820253 -0.760944033 0.608492837
Steroid biosynthesis Homo sapiens hsa00100 15/20 0.015732393 0.460959108 0.05167766 0.458834978 -0.683126195 0.529044309
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159/259 2.64668E-05 0.040070706 1.76172E-05 0.026672516 -2.121468661 6.824997503
Synthesis of substrates in N-glycan biosythesis
Homo sapiens R-HSA-446219 46/63 7.66923E-05 0.058056094 0.001688897 0.426164972 -1.81102872 5.154813632
Biosynthesis of the N-glycan precursor
(dolichol lipid-linked oligosaccharide, LLO)
and transfer to a nascent protein
Homo sapiens R-HSA-446193
53/78 0.000467013 0.171322453 0.002436081 0.449360023 -1.768125582 3.119340958
XBP1(S) activates chaperone genes
Homo sapiens R-HSA-381038 38/53 0.000584691 0.171322453 0.005052062 0.640277931 -2.161209424 3.812822542
IRE1alpha activates chaperones
Homo sapiens R-HSA-381070 39/55 0.000710411 0.171322453 0.005182695 0.640277931 -2.167447676 3.823828115
Transferrin endocytosis and recycling
Homo sapiens R-HSA-917977 23/29 0.000736701 0.171322453 0.012012344 0.739952057 -2.442618736 4.309287046
PLC-gamma1 signalling Homo sapiens
R-HSA-167021 26/34 0.000905271 0.171322453 0.010747191 0.739952057 -2.139727618 3.774924171
EGFR interacts with phospholipase C-gamma
Homo sapiens R-HSA-212718 26/34 0.000905271 0.171322453 0.010747191 0.739952057 -2.063635305 3.640681519
PI Metabolism Homo sapiens
R-HSA-1483255 41/60 0.001686787 0.283755137 0.006630028 0.640277931 -1.873583396 2.360047348
DAG and IP3 signaling Homo sapiens
R-HSA-1489509 24/32 0.002270693 0.342169387 0.01622033 0.739952057 -2.025093153 2.171809897
334










PodNet: protein-protein interactions in
the podocyte Mus musculus WP2310 175/305 0.001446818 0.627918834 5.49766E-05 0.022844647 -2.162864775 1.006476939
Signaling Pathways in Glioblastoma
Homo sapiens WP2261 51/83 0.013482129 1 0.009771762 0.521287956 -2.237669845 1.18228E-10
Sphingolipid Metabolism Homo sapiens
WP1422 15/20 0.015732393 1 0.047859089 0.654261852 -1.583707823 8.36757E-11
EGF/EGFR Signaling Pathway Homo sapiens
WP437 93/163 0.020180071 1 0.003355621 0.398186745 -1.951731624 1.0312E-10
MicroRNAs in Cardiomyocyte Hypertrophy
Mus musculus WP1560 48/79 0.021232808 1 0.013740501 0.521287956 -1.884983292 9.95936E-11
B Cell Receptor Signaling Pathway
Homo sapiens WP23 57/97 0.030338356 1 0.01252088 0.521287956 -1.850270788 9.77596E-11
Alzheimers Disease Mus musculus WP2075 44/73 0.031640665 1 0.01947661 0.603774901 -1.728412911 9.13212E-11
Focal Adhesion Mus musculus WP85 103/185 0.034593957 1 0.003669924 0.398186745 -1.851387356 9.78186E-11
AGE/RAGE pathway Homo sapiens WP2324 40/66 0.035300789 1 0.023647899 0.654261852 -1.704540388 9.00599E-11
IL-6 signaling Pathway Mus musculus WP387 56/97 0.047326409 1 0.016834743 0.562021413 -1.698273366 8.97288E-11
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VEGF signaling pathway Homo sapiens P00056 38/54 0.001048565 0.11534216 0.015208028 0.611135601 -1.793943603 3.874653156
EGF receptor signaling pathway Homo sapiens P00018 68/109 0.002833989 0.155869419 0.010995932 0.611135601 -1.66940221 3.102979127
Endothelin signaling pathway Homo sapiens P00019 48/75 0.005544637 0.203303369 0.022321367 0.613837593 -1.542643749 2.457517862
Histamine H1 receptor mediated signaling pathway
Homo sapiens P04385 19/26 0.010406202 0.280592934 0.059479348 0.883632738 -1.025293151 1.302994101
Integrin signalling pathway Homo sapiens P00034 90/156 0.015305069 0.280592934 0.016667335 0.611135601 -1.303494511 1.65654638
Angiogenesis Homo sapiens P00005 79/142 0.059305476 0.806294591 0.042141354 0.790809024 -1.08684955 0.234005344
CCKR signaling map ST Homo sapiens P06959 90/165 0.078562877 0.806294591 0.043135038 0.790809024 -0.944000829 0.203249142
Angiotensin II-stimulated signaling through G proteins
and beta-arrestin Homo sapiens P05911 21/34 0.088814516 0.806294591 0.130314903 0.883632738 -0.298321917 0.06423053
PDGF signaling pathway Homo sapiens P00047 62/112 0.09576847 0.806294591 0.070794982 0.883632738 -0.599788747 0.129138179
5HT2 type receptor mediated signaling pathway
Homo sapiens P04374 27/46 0.114600182 0.806294591 0.131682467 0.883632738 -0.34297753 0.073845156
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Ribosome Homo sapiens hsa03010 119/137 6.62275E-21 1.9206E-18 4.94538E-11 1.43416E-08 -1.746138049 71.23177309
Spliceosome Homo sapiens hsa03040 93/134 1.06572E-06 0.000154529 7.38312E-06 0.001070552 -1.77196951 15.54925634
Cell cycle Homo sapiens hsa04110 78/124 0.001092335 0.098444481 0.000383934 0.02783518 -1.682638698 3.900798249
Ribosome biogenesis in eukaryotes
Homo sapiens hsa03008 58/89 0.001357855 0.098444481 0.001119012 0.054390246 -1.899051987 4.402501068
RNA transport Homo sapiens hsa03013 101/172 0.00569601 0.33036858 0.00037173 0.02783518 -1.770138112 1.960509985
Parkinson’s disease Homo sapiens hsa05012 83/142 0.013292337 0.642462947 0.001312868 0.054390246 -1.648540408 0.729390331
Proteasome Homo sapiens hsa03050 29/44 0.016722931 0.660771892 0.016172561 0.360772507 -1.428779059 0.592009737
RNA polymerase Homo sapiens hsa03020 22/32 0.01822819 0.660771892 0.02481554 0.439585395 -1.455403339 0.603041417
Aminoacyl-tRNA biosynthesis
Homo sapiens hsa00970 40/66 0.036327753 1 0.014268045 0.344811081 -1.8367639 3.04467E-11
Non-alcoholic fatty liver disease (NAFLD)
Homo sapiens hsa04932 85/151 0.039398097 1 0.002574506 0.093325828 -1.704855833 2.82602E-11
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P-value Z-score Combined Score
rRNA processing Homo sapiens
R-HSA-72312 156/180 9.24433E-27 1.39959E-23 5.32853E-12 4.0337E-09 -2.027505558 106.6939869
Major pathway of rRNA processing in the
nucleolus
Homo sapiens R-HSA-6791226
143/166 4.57439E-24 3.46282E-21 5.53139E-11 2.79151E-08 -2.037037884 95.96934548
Formation of a pool of free 40S subunits
Homo sapiens
R-HSA-72689
91/96 8.87638E-23 4.47961E-20 8.63648E-09 1.42037E-06 -1.941052342 86.47808515
Eukaryotic Translation Elongation Homo sapiens
R-HSA-156842 85/89 5.18054E-22 1.96084E-19 2.11848E-08 2.00461E-06 -1.990699041 85.75084577
Peptide chain elongation Homo sapiens
R-HSA-156902 81/84 6.96612E-22 2.10934E-19 3.43376E-08 2.66682E-06 -1.929389474 82.9690374
Selenocysteine synthesis Homo sapiens
R-HSA-2408557 83/87 1.99879E-21 4.3231E-19 3.19524E-08 2.66682E-06 -1.896405961 80.18980111
3’ -UTR-mediated translational regulation
Homo sapiens R-HSA-157279 97/106 4.55866E-21 7.66868E-19 9.26583E-09 1.42037E-06 -1.903709095 79.40745994
Eukaryotic Translation Termination Homo sapiens
R-HSA-72764 83/87 1.99879E-21 4.3231E-19 3.19524E-08 2.66682E-06 -1.871301154 79.12824073
L13a-mediated translational silencing of
Ceruloplasmin expression Homo sapiens
R-HSA-156827
97/106 4.55866E-21 7.66868E-19 9.26583E-09 1.42037E-06 -1.895972865 79.08476656
GTP hydrolysis and joining of the 60S ribosomal subunit
Homo sapiens R-HSA-72706 97/107 2.53297E-20 3.19577E-18 1.26892E-08 1.42608E-06 -1.926919618 77.62538758
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Homo sapiens WP477 82/89 1.78742E-18 7.70377E-16 1.21592E-07 2.6203E-05 -2.0113747 69.99513845
Cytoplasmic Ribosomal Proteins
Mus musculus WP163 66/70 1.73309E-16 3.7348E-14 1.20356E-06 0.000172912 -2.003293795 61.93883161
mRNA processing Mus musculus WP310 257/398 1.24745E-10 1.79217E-08 4.89349E-09 2.10909E-06 -2.085306546 37.19614645
mRNA Processing Homo sapiens WP411 92/127 5.00037E-08 5.3879E-06 2.61352E-05 0.002816073 -1.887785049 22.90139059
Eukaryotic Transcription Initiation
Mus musculus WP567 32/41 0.000121359 0.010461156 0.005140609 0.349353894 -1.839407237 8.387855786
Eukaryotic Transcription Initiation
Homo sapiens WP405 33/44 0.000361934 0.025998895 0.006870884 0.370168879 -1.921945268 7.014526011
Estrogen signalling Mus musculus WP1244 50/75 0.001358023 0.083615408 0.005673961 0.349353894 -1.843532654 4.574776925
Electron Transport Chain Homo sapiens WP111 65/103 0.002433063 0.131081283 0.004539666 0.349353894 -1.852053079 3.763256411
Electron Transport Chain Mus musculus WP295 57/93 0.010469932 0.410230973 0.011445818 0.411095628 -1.740970174 1.551265234
Parkin-Ubiquitin Proteasomal System pathway
Homo sapiens WP2359 44/70 0.012628775 0.442003101 0.018177901 0.602667343 -1.610054807 1.314510541
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Parkinson disease Homo sapiens P00049 47/81 0.060971067 0.999997287 0.03533651 0.966152793 -1.225262519 3.32358E-06
p53 pathway by glucose deprivation
Homo sapiens P04397 16/21 0.010060774 0.999997287 0.046221371 0.966152793 -1.191689871 3.23252E-06
Ubiquitin proteasome pathway
Homo sapiens P00060 26/43 0.08453118 0.999997287 0.076099785 0.966152793 -0.831161838 2.25457E-06
p53 pathway Homo sapiens P00059 39/71 0.181576217 0.999997287 0.085281711 0.966152793 -0.717019375 1.94495E-06
De novo purine biosynthesis
Homo sapiens P02738 17/26 0.067279119 0.999997287 0.09189801 0.966152793 -0.63744213 1.72909E-06
De novo pyrimidine deoxyribonucleotide
biosynthesis Homo sapiens P02739 08-Oct 0.046951944 0.999997287 0.12194085 0.966152793 -0.572919781 1.55407E-06
General transcription regulation
Homo sapiens P00023 17/28 0.142575263 0.999997287 0.131984363 0.966152793 -0.295620776 8.01885E-07
mRNA splicing Homo sapiens P00058 05-May 0.027774789 0.999997287 0.135392394 0.966152793 -0.11767251 3.19192E-07
Transcription regulation by bZIP
transcription factor Homo sapiens P00055 22/42 0.379960786 0.999997287 0.211518388 0.966152793 -0.084844636 2.30145E-07
p53 pathway feedback loops 2
Homo sapiens P04398 23/45 0.437744233 0.999997287 0.23121077 0.966152793 -0.077799963 2.11036E-07
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Table B.59: Datasets analysed for survival analysis in different cancer types.
Dataset ID Number and brief annotation of samples Platform
METABRIC 1981 breast tumours Illumina HumanWG-6 v3.0
GSE20685 347 breast tumours Affymetrix U133 Plus2
GSE21653 266 breast tumours Affymetrix U133 Plus2
GSE22219 216 breast tumours Illumina humanRef-8 v1.0
GSE25066 508 breast tumours Affymetrix U133A
GSE41313 52 breast cancer cell lines Affymetrix U133 PlusPM
GSE42568 104 breast cancers, 17 normal breast biopsies Affymetrix U133 Plus2
GSE46563 94 breast cancers Illumina HumanWG-6 v3.0
GSE45827 11 normal breast tissues, 130 breast cancers Affymetrix U133 Plus2
GSE65904 177 melanomas Illumina HumanHT-12 V4.0
TCGA breast cancer cohort
(UCSC Cancer Browser)
776 breast tumours with complete clinical data Illumina HiSeq 2000
TCGA clear cell renal cell carcinoma cohort
(UCSC Cancer Browser)
588 kidney tumours with complete clinical data Illumina HiSeq 2000
TCGA melanoma cohort
(UCSC Cancer Browser)
396 melanomas with complete clinical data Illumina HiSeq 2000
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Table B.60: Datasets analysed for neoadjuvant treatment analysis.
Dataset ID Number and brief annotation of samples Platform
Neoadjuvant anti-oestrogen therapy
GSE5462 51 pre- and post letrozole treatment biopsy samples Affymetrix U133A
FAIMoS 102 pre- and post anastrozole treatment biopsy samples Illumina HumanWG-6 v3.0
GSE27473 MCF7 basal vs ESR1 knockdown Affymetrix U133 Plus2
Neoadjuvant chemotherapy
GSE20194 278 breast tumours Affymetrix U133A
GSE23988 61 breast tumours Affymetrix U133A
GSE25066 508 breast tumours Affymetrix U133A
GSE32646 115 breast tumours Affymetrix U133 Plus2
GSE42822 91 breast tumours Affymetrix U133A
Hess et. al. (UCSC Cancer Browser) 133 breast tumours Affymetrix U133A
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Table B.61: Datasets analysed for tumour-normal analysis.
Dataset ID Number and brief annotation of samples Platform
GSE10072 49 normal lung, 58 lung adenocarcinomas Affymetrix U133A
GSE13507
10 normal bladder mucosa, 58 primary bladder tumour stroma,
163 primary bladder tumours, 23 recurrent bladder tumours
Illumina HumanWG-6 v2.0
GSE13911 31 normal adjacent gastric tissues, 39 gastric cancers Affymetrix U133 Plus2
GSE15471 36 normal pancreatic, 36 pancreatic cancers Affymetrix U133 Plus2
GSE17679 18 normal skeletal muscle, 88 Ewing sarcomas Affymetrix U133 Plus2
GSE30784 45 normal oral tissues, 17 oral dysplasia, 167 oral cancers Affymetrix U133 Plus2
GSE44076 50 healthy colorectal mucosa, 98 colorectal cancers Affymetrix U219
GSE53757 72 normal renal tissue, 72 ccRCC tumours Affymetrix U133 Plus2
GSE6631 49 normal head and neck mucosa, 58 head and neck cancers Affymetrix U95v2
GSE6919 81 normal, 65 primary prostate tumours, 25 metastatic prostate tumours Affymetrix U95v2
GSE9750 24 normal pancreas, 33 pancreatic cancers Affymetrix U133A
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GSE16194 Lung cancer cell lines panel with SNAIL1 overexpression Affymetrix U133 Plus2
GSE16997
Mouse mammary stem, luminal progenitor and
mature luminal cells
Illumina MouseWG-6 v3.0
GSE17708 A549 cells treated with TGFB Affymetrix U133 Plus2
GSE19446
Four subpopulations of mammary cells based
on cell surface markers
Illumina MouseWG-6 v2.0
GSE19679 II-18 lung cancer cell lines with SNAIL1 overexpression Illumina HumanWG-6 v2.0
GSE20402 Mouse mammary stem and mature luminal cells Illumina MouseWG-6 v2.0
GSE23952 Panc-1 cells treated wih TGFB Affymetrix U133 Plus2
GSE28569 MCF10A cells treated with TGFB Agilent G4112F
GSE29672
MCF7 cells transduced with SNAIL1 and
SLUG transcription factors
Affymetrix U133 Plus2
GSE40374 M-BE bronchial epithelial cells treated with TGFB Agilent G4112F
GSE40690
HMEC mammary cells transduced with SNAIL1,
SLUG and SNAIL3 transcription factors
Illumina HumanHT-12 v4.0
GSE41113
HCT116 cells treated with increasing doses
of sodium butyrate
Illumina HumanWG-6 v2.0
GSE41802 HCT116 cells with various IDH1/2 mutations Affymetrix U133 Plus2
GSE424 CC-531 rat colon cancer cells treated with sodium butyrate Affymetrix Rat Genome U34
GSE43495
HLME mammary cells transduced with SNAIL1, SLUG
and TWIST transcription factors
Illumina HumanRef-8 v3.0
GSE4410










NMuMG mouse mammary gland cells treated with TGFB,
or treated and then withdrawn
Affymetrix Mouse
Genome 430 2.0
GSE49644 Lung cancer cell lines panel treated with TGFB Affymetrix U133 Plus2
GSE58296




GSE74377 MCF10A cells treated with TGFB Illumina HiSeq 2500
GSE77594
Mouse bone marrow cells with IDH1 mutation
or treated with 2-HG
Affymetrix Mouse
Genome 430 2.0
GSE79642 Normal colon or adenoma organoids treated with TGFB HT HG-U133 PlusPM
GSE8096 HMECS1 and HMEC184 differentiation time course Affymetrix U133A
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Ls174T cells with dominant-negative
Tcf4 or beta catenin siRNA
Affymetrix U133 Plus2




BL or 224 melanoma cells treated with
siRNA against mutant NRAS
Affymetrix U133A
GSE13487
A375 melanoma cells treated with vemurafenib
or with BRAF knockdown
Affymetrix U133 Plus2
GSE20051 SkMel-5 cells treated with BRAF inhibitor Affymetrix U133A
GSE28467 Ls174T cells with dominant-negative Tcf4 Illumina MouseWG-6 v3.0
GSE35094
Ex vivo mouse intestinal organoid with
Apc wildtype or knockout
Illumina MouseWG-6 v2.0
GSE35272 DLD1 cells transduced with DKK-1 expression vector Affymetrix HuGene 1.0
GSE38007
Human melanoma cells with BRAF V600E,
or BRAF V600E and MITF overexpression
Affymetrix U133A
GSE39904
SW480 cells with APC transgene or
beta catenin siRNA
Affymetrix U133 Plus2
GSE39984 NRAS depletion vs AZD6244 in mouse melanoma
Affymetrix Mouse
Genome 430 2.0
GSE42872 A375 melanoma cells treated with vemurafenib Affymetrix HuGene 1.0
GSE43825
Mouse mammary hyperplasia and tumours tissue
with constitutive beta-catenin activity
Affymetrix Mouse
Genome 430 2.0
GSE44097 SW480 and DLD1 cells with beta catenin siRNA Affymetrix U133 Plus2
GSE45757
Panels of pancreatic cancer cell lines
treated with MEK1/2 inhibitor
Affymetrix U133A2
GSE45757
Panel of pancreatic cancer cell lines
treated with MEK inhibitor
Affymetrix U133A
GSE46801
Human melanocytes transduced with
empty vector or mutant BRAF
Affymetrix U133 Plus2
GSE50791 HT29 DMSO vs vemurafenib Illumina HumanHT-12 v4.0
GSE55624 SW480 colorectal cancer cells treated with MEK inhibitor Affymetrix U133 Plus2
GSE56896 Ls174T cells with dominant-negative TCF4 transgene Affymetrix U133 Plus2
GSE60837
Healthy mouse colon with wildtype or Bcl9 knockout,
Apc/Kras tumour with wildtype and Bcl9 knockout
Illumina HiSeq 2500
GSE61705 BS149 glioblastoma cells with MITF overexpression Affymetrix HuGene 1.0
GSE62827




Mouse small intestine from wild type
or 5 day post Apc knock out
Affymetrix Mouse
Genome 430 2.0
GSE67186 Colon polyps with basal and APC knockdown Illumina HiSeq 2000
GSE67637 Melmet5 melanoma cells treated with vehicle control or
vemurafenib Illumina HumanHT-12 v4.0
GSE71881 MaMel15 melanoma cells with siRNA against MITF Illumina HumanHT-12 v4.0
GSE9580
Normal mouse intestinal epithelial and




Table B.64: Datasets analysed for experimental analysis and RNA-Seq chapters.
Dataset ID Number and brief annotation of samples Platform
E-TABM-157 51 breast cancer cell lines Affymetrix U133A
GSE41313 52 breast cancer cell lines HT HG-U133 PlusPM
GSE57083
AstraZeneca: Cancer cell lines from many tissues,
but only breast cancer cell lines were analysed
Affymetrix U133 Plus2
Cancer Cell Line Encyclopedia
(source code available from cBioPortal)
Broad Institute/Novartis: Cancer cell lines from many tissues,
but only breast cancer cell lines were analysed
Affymetrix U133 Plus2
GSE59735 NCI-H2347 cells treated with pioglitazone over a time course Illumina HumanHT-12 v4.0





Table C.1: Gene members of the MAPK, Wnt and EMT signatures analysed in this thesis.
MAPK signature
DUSP3, DUSP4, DUSP6, DUSP7, ELK1, MAPK1, MAPK11, MAPK14, MAPK3, MAPK7, MEF2A, PPP2CA, PPP2R1A, PPP2R1B,
PPP2R5D, RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA5
Wnt signature
CXCL5, ZIC2, CBX2, GLS2, BAG2, ZNF503, LEF1, NELF, HOXA11, CKLFSF7, LIMS1, SLC19A2, SCLY, HIRA, GPR172A,
DOCK4, AMPD2, MAT2A, TPST2, PPIF, SLC5A19, SLC1A5, TIMM10, POLRMT, ITGB4BP, ZNF275, SFRS7, RBM12, UMPK
EMT signature
ADAM12, CDH2, CDH11, COL1A1, COL3A1, COL6A1, COL6A3, CTGF, CYP1B1, DLC1, FBLN1,
FBLN5, FGF2, FGFR1, FN1, HAS2, LAMC2, LUM, MMP2, MYL9, NID2, NR2F1, NRP1, PLAT, PPA2B, PRKCA, RECK,
SERPINE1, SERPINE2, SPOCK1, TGM2, TNFAIP6, TPM, VCAN, WNT5A, CDKN2C, EMP3, FBN1, IGFBP3, IL1R1, LTBP1,
MME, PMP22, PTGER2, PTX3, SYNE1, TAGLN, TUBA1A, VIM, ZEB1, DCN, ABCA1, GALNT10, SLC22A4, C5ORF13. CDK14,
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